<SEC-DOCUMENT>0000939767-19-000042.txt : 20190222
<SEC-HEADER>0000939767-19-000042.hdr.sgml : 20190222
<ACCEPTANCE-DATETIME>20190222161231
ACCESSION NUMBER:		0000939767-19-000042
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20181228
FILED AS OF DATE:		20190222
DATE AS OF CHANGE:		20190222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		19625834

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel2018123110-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s280978614CF05534B0085A9F356B2AF5"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM 10-K</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For the fiscal year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">or</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo2017aa04.jpg" alt="exellogo2017aa04.jpg" style="height:64px;width:192px;"></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1851 Harbor Bay Parkway</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Alameda, CA 94502</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Registered Pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Common Stock $.001 Par Value per Share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Registered Pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.  </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:21%;"></td><td style="width:4%;"></td><td style="width:25%;"></td><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,531.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(based on the closing sales price of the registrant&#8217;s common stock on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;29, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Excludes an aggregate of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">40.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;shares of the registrant&#8217;s common stock held by persons who were directors and/or executive officers of the registrant at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;29, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;12, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">300,129,630</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;shares of the registrant&#8217;s common stock outstanding.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 27, 2019, in connection with the registrant&#8217;s 2018 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K. </font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD36D0AFB401F5BFC8C2FE43520189BDD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s5F576B93FEF95AC3ACBF50C87228B5AD"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s52557FD36231562EB537B4F3E2631575"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s52557FD36231562EB537B4F3E2631575">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s123F1A4230FD574F9AE4120364651BF5"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s123F1A4230FD574F9AE4120364651BF5">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1B.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2214BBA635F959E1BBBA0EB7A7AAC7CD"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2214BBA635F959E1BBBA0EB7A7AAC7CD">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF6C67EA79C105256834C57AA4E2B4260"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF6C67EA79C105256834C57AA4E2B4260">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s56F486021F185BDEB73A36BAA4A53B33"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s56F486021F185BDEB73A36BAA4A53B33">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF84D951091645315B053F5CB68FA47FF"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF84D951091645315B053F5CB68FA47FF">56</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sC6AACBE7367C583E91F6CBF85BDE4B81"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s32C2946A795C51558F3DA5858775020C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s32C2946A795C51558F3DA5858775020C">56</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s55C17F35F8C85AAF9B55986D5634D97E"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s55C17F35F8C85AAF9B55986D5634D97E">58</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5A6097605FF75AC38F587E503A2A1E54"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDC0589145EF15F89995F8E0C0F60BDBC">59</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s17CB1E4CCF915508BDE957B4B8A840F0"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s17CB1E4CCF915508BDE957B4B8A840F0">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;8.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5F982B3C69785F0AA8E6F73F0FF39CE8"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5F982B3C69785F0AA8E6F73F0FF39CE8">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAB5C97CC76DB5DA1BF096970DF83594C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAB5C97CC76DB5DA1BF096970DF83594C">116</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB34A4B39284524BA37144FFF5C0F775"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDB34A4B39284524BA37144FFF5C0F775">116</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9B.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDD80458EA4A855E88C872CD9C2CED55C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDD80458EA4A855E88C872CD9C2CED55C">118</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s528A9B677330508791F0FC838F07957A"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;10.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1AD932E223ED56488BCF8D2ED870209A"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1AD932E223ED56488BCF8D2ED870209A">118</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;11.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0D9281AA9CB55C81B1983FDA967923C6"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0D9281AA9CB55C81B1983FDA967923C6">118</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;12.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s793A713A5A48568182E7C22B9D2564BA"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s793A713A5A48568182E7C22B9D2564BA">118</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;13.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s793A713A5A48568182E7C22B9D2564BA"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s11DD5CA78D3956E68738D463D94F5DCE">119</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;14.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE91A47D948935612BA2CB6A19E10C027"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE91A47D948935612BA2CB6A19E10C027">119</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sD83AEFDD7BD6507A94A259F73D425733"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;15.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sBE9A48EC4055555585CD8A09CAF6B58C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sBE9A48EC4055555585CD8A09CAF6B58C">120</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;16.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3D9FF744015A55CFA0E8EBFBDD208FD3"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3D9FF744015A55CFA0E8EBFBDD208FD3">125</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s4A6B656B28B5549DB2F6055439D12208"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A6B656B28B5549DB2F6055439D12208">126</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1</font></div></div><hr style="page-break-after:always"><div><a name="s5F576B93FEF95AC3ACBF50C87228B5AD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; fiscal year 2018 ended on December 28, 2018; and fiscal year 2019 will end on January 3, 2020. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, December 28, 2018 and January 3, 2020 are indicated as being as of and for the years ended (or ending, as applicable) December&#160;31, 2016, 2017, 2018 and 2019, respectively. The annual period and quarterly period ending January 3, 2020 are a 53-week fiscal year and a 14-week fiscal quarter, respectively; all other annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div><div><a name="s52557FD36231562EB537B4F3E2631575"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that aims to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development and received regulatory approval; three have a growing commercial presence worldwide, and we expect that the fourth will soon enter the marketplace in Japan. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC);</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Beyond its approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers. The growth that we have experienced in recent years is largely attributable to cabozantinib&#8217;s clinical and commercial success; consistent with our values and legal obligations, we are committed to ensuring that all patients who are prescribed cabozantinib are able to access this essential medicine.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#8482; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Over the course of 2018, revenues from the sales of CABOMETYX and COMETRIQ and from the royalties and milestone payments received pursuant to collaboration agreements with our partners, coupled with disciplined expense management, have fueled the growth of our organization. We believe we can continue to grow in a sustainable manner, supported by a healthy cash position and profitability over the past two fiscal years. We are utilizing our cash and investments to enable future success by expanding the development program for cabozantinib and by building a pipeline of new drug candidates through reinitiated internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug development and commercialization expertise. The following report details the progress we made executing our growth strategy in 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exelixis Marketed Products: CABOMETYX and COMETRIQ</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#160;was first approved by the U.S. Food and Drug Administration (FDA) on April 25, 2016, for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy and by the European Commission (EC) on September 9, 2016, similarly for the treatment of advanced RCC in adults in the European Union (EU) following prior VEGF-targeted therapy. On December 19, 2017, the FDA approved the expanded indication for CABOMETYX to include previously untreated patients with advanced RCC, and the EC approved CABOMETYX on May 17, 2018 as a first-line treatment for adults with intermediate- or poor-risk advanced RCC. Most recently, CABOMETYX was approved by the FDA on January 14, 2019, for the treatment of patients with HCC who have been previously treated with sorafenib, which followed the EC&#8217;s earlier approval of CABOMETYX on November 15, 2018, for the treatment of HCC in adults previously treated with sorafenib. COMETRIQ, our first marketed product, was approved by the FDA on November 29, 2012, for the treatment of patients with progressive, metastatic MTC, and in March 2014, the EC granted COMETRIQ a conditional marketing authorization for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. In 2018 and 2017, we generated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$619.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$349.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in net product revenues from sales of CABOMETYX and COMETRIQ in the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S. and Japan, CABOMETYX and COMETRIQ are marketed by our collaboration partner Ipsen Pharma SAS (Ipsen). Should CABOMETYX and COMETRIQ be approved in Japan, they will be marketed by our collaboration partner Takeda Pharmaceutical Company Limited (Takeda). In 2018 and 2017, we earned $32.3 million and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.8 million, respectively, of gross royalties for net sales of products incorporating cabozantinib outside of the U.S. For additional information on the terms of our collaboration agreements with Ipsen and Takeda, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Commercial Collaborations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Renal Cell Carcinoma - CABOMETYX is Now the Leading Tyrosine Kinase Inhibitor (TKI) Treatment Option for Patients with Advanced RCC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Kidney cancer is among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S., with approximately 30,000 patients requiring systemic treatment. Globally, approximately 68,000 patients require systemic treatment for kidney cancer. A growing number of these patients with RCC have been or will be treated with CABOMETYX, which has become a new standard of care for the treatment of patients suffering from this difficult-to-treat disease; in fact, as of December 2018, CABOMETYX was the TKI of choice among physicians treating these patients in terms of new prescriptions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since CABOMETYX was first approved, our promotional and medical affairs teams have been focused on educating physicians about CABOMETYX&#8217;s unique clinical profile. We believe that the success of CABOMETYX is attributable to this clinical profile, derived from the results of our clinical trials, METEOR and CABOSUN. CABOMETYX is the first and only single-agent therapy approved for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). In addition, in previously untreated patients with advanced RCC, CABOMETYX is the only approved single-agent therapy to improve PFS and ORR compared with sunitinib, a first-generation TKI that was the previous standard of care. It is also noteworthy that on September 7, 2018, the National Comprehensive Cancer Network (NCCN), the nation&#8217;s foremost non-profit alliance of leading cancer centers, updated its Clinical Practice Guidelines to recommend CABOMETYX as the only TKI with preferred status for advanced RCC patients who have progressed on prior therapy and for the treatment of advanced RCC regardless of patient risk status (favorable-, intermediate-, and poor risk). These updated recommendations strengthened the differentiation of CABOMETYX from other TKIs approved for this indication, leading many physicians to consider CABOMETYX a preferred therapeutic option, despite numerous competing products approved to treat advanced RCC. For additional information about CABOMETYX&#8217;s profile as expressed in the METEOR and CABOSUN clinical trial data, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In markets outside the U.S. in 2018, we continued to work closely with our partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX as a treatment for advanced RCC. As a result of the approvals of CABOMETYX for RCC indications in more than ten territories outside of the U.S., including the EU, Canada, Brazil, Taiwan, South Korea and Australia, CABOMETYX has continued to grow both in sales revenue and the number of RCC patients benefiting from its clinical effect. Additionally, with respect to the Japanese market, our partner Takeda is advancing its clinical development activities in Japan support of potential future regulatory filings for CABOMETYX in both RCC and HCC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Hepatocellular Carcinoma - the CABOMETYX Label Expanded to Include Previously Treated HCC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 700,000 deaths and 800,000 new cases each year. In the U.S., the incidence of liver cancer has more than tripled since 1980. Although HCC is the most common form of liver cancer, making up about three-fourths of the estimated nearly 42,000 new </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cases of liver cancer in the U.S. during 2018, this patient population was long underserved. Prior to 2017, there was only one approved systemic therapy for the treatment of HCC. Then, in 2017 and 2018, four new therapies were approved in the U.S. for HCC, one for previously untreated patients and three for patients previously treated with sorafenib. Given the introduction of new and more effective therapies, we believe the second- and later-line HCC market has the potential to grow significantly in coming years, as the new treatment options are expected to result in an increasing number of patients receiving multiple lines of therapy. With the recent approval of CABOMETYX in January 2019 for HCC patients previously treated with sorafenib, we aim to play a key role in the advancement of therapeutic options for these patients.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA&#8217;s approval of CABOMETYX for this HCC indication was based on our phase 3 pivotal study, CELESTIAL. The CELESTIAL study met its primary endpoint, demonstrating that cabozantinib significantly improved OS, as compared to placebo. For additional information on CELESTIAL, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals&#8212;HCC - CELESTIAL.&#8221; Upon FDA approval, we were immediately prepared to offer CABOMETYX to all eligible HCC patients in the U.S. who may benefit from this treatment option. We were able to take action so quickly due to the strength of our existing commercial and medical affairs organizations, in addition to our well-established distribution network and our ability to leverage our RCC commercialization experience. The NCCN&#8217;s inclusion of CABOMETYX in its Clinical Practice Guidelines for Hepatobiliary Cancers as a Category 1 option for the treatment of patients with HCC (Child-Pugh Class A only) who have been previously treated with sorafenib further supports CABOMETYX as an important new treatment option for eligible HCC patients.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S., the EC&#8217;s approval of CABOMETYX provided physicians in the EU with a second approved therapy for the second-line treatment of this aggressive and difficult-to-treat cancer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Medullary Thyroid Cancer - COMETRIQ, the First Commercial Approval of Cabozantinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We estimate that there are between 500 and 700 first-line and second-line patients in the U.S. who will be eligible for COMETRIQ. The FDA&#8217;s approval of COMETRIQ for this MTC indication was based on our phase 3 trial, EXAM. The EXAM trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for cabozantinib, as compared to placebo. For additional information on EXAM, see &#8220;&#8212;Cabozantinib Development Program&#8212;Clinical Trials Supporting Regulatory Approvals&#8212;MTC - EXAM.&#8221; In 2018 and 2017, we generated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$19.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in net product revenues from sales of COMETRIQ in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in more than 20 individual tumor types investigated in phase 1 and 2 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We are currently evaluating cabozantinib, both as a single agent and in combination with immune checkpoint inhibitors (ICIs), in a broad development program comprising over 75 ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of those trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. In addition to co-sponsoring trials with us, our commercial collaboration partners Ipsen and Takeda also conduct trials in their territories through similar independently-sponsored programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following two tables summarize select cabozantinib clinical development activities, one describing studies that evaluate the potential of cabozantinib as a single-agent, and the other describing studies that evaluate the potential of cabozantinib in combination with one or more ICIs:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, SINGLE-AGENT</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Thyroid Cancer</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (EXAM)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Post-marketing study (EXAMINER)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Differentiated thyroid cancer (DTC)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 (COSMIC-311)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Renal Cell Carcinoma (RCC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (METEOR and CABOSUN)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First- or second-line papillary RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Randomized phase 2&#8224; (PAPMET)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Hepatocellular Carcinoma (HCC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. on January 14</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;2019; approved in EU in November 2018 (CELESTIAL)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Small Cell Lung Cancer (NSCLC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EGFR wild-type</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Molecular alterations in RET, ROS1, MET, AXL, or NTRK1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Trials </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic urothelial carcinoma (UC)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (ATLANTIS)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Colorectal cancer (CRC)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">High-grade uterine sarcomas</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#167;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic gastrointestinal stromal tumor</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#167; (CABOGIST)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pancreatic neuroendocrine tumors and carcinoid tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* and Phase 3&#8224; (CABINET)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Plexiform neurofibromas (pediatric and adult cohorts)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Relapsed osteosarcoma or Ewing sarcoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Soft-tissue sarcomas</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21259842519686%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combination Regimen</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Genitourinary Cancers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (CheckMate 9ER)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cisplatin-Ineligible advanced UC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ pembrolizumab</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2* (PemCab)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced or metastatic non-clear cell RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Gastrointestinal Cancers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (COSMIC-312), including a single-agent cabozantinib exploratory arm</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1/2 (Checkmate 040)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Neoadjuvant locally advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b*</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">KRAS wild-type metastatic CRC and cMET amplified metastatic CRC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; panitumumab</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1* (CaboMAb)</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Lung Cancers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NSCLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Gynecologic Cancers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced or metastatic endometrial cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic, triple negative breast cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Breast cancer with brain metastases</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; trastuzumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Head and Neck Cancers</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Recurrent, metastatic squamous cell carcinoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ cetuximab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Recurrent, metastatic squamous cell carcinoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ pembrolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Trials in Multiple Tumor Types</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced solid tumors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b with 18 cabozantinib and atezolizumab expansion cohorts, including RCC, UC, castration-resistant prostate cancer (CRPC), HCC, colorectal adenocarcinoma, DTC, NSCLC, endometrial cancer, ovarian cancer, breast cancer, gastric or gastroesophageal junction adenocarcinoma and head and neck cancer (COSMIC-021), and 2 single-agent cabozantinib exploratory cohorts (UC and NSCLC)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Genitourinary tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b&#8224;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced CRC, HCC, gastric, gastroesophageal or esophageal adenocarcinoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ durvalumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1* (CAMILLA)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trials Supporting Regulatory Approvals</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - METEOR</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. METEOR met its primary endpoint, demonstrating a statistically significant and clinically </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">meaningful increase in PFS for CABOMETYX. The median PFS was 7.4 months for the CABOMETYX arm versus 3.8 months for the everolimus arm. CABOMETYX also significantly improved ORR, a secondary endpoint, compared with everolimus. In September 2015,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">The New England Journal of Medicine (NEJM)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;published the complete, detailed positive results from the primary analysis of METEOR, and these results were also presented at the European Society for Medical Oncology (ESMO) 2015 Congress. After additional follow up, METEOR also met its other secondary endpoint of OS, as presented in June 2016 at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting and published in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Lancet Oncology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The median OS was 21.4 months for patients receiving CABOMETYX versus 16.5 months for those receiving everolimus. The safety profile in the study and in later analyses was consistent with the established profile of cabozantinib and other TKIs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the METEOR trial, the FDA approved CABOMETYX for the treatment of patients with advanced RCC following prior antiangiogenic therapy, and the European Medicines Agency (EMA) approved CABOMETYX for the treatment of advanced RCC in adults following prior VEGF-targeted therapy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - CABOSUN</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2016, we announced positive results from CABOSUN, a randomized, open-label, active-controlled phase 2 trial comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease conducted by The Alliance for Clinical Trials in Oncology under our CRADA with NCI-CTEP. These results were presented at the ESMO 2016 Congress in October 2016 and subsequently published in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Clinical Oncology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in November 2016. CABOSUN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in investigator-assessed PFS compared with sunitinib.&#160;The median PFS for cabozantinib was 8.2 months versus 5.6 months for sunitinib. Investigator-assessed</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ORR, a secondary endpoint, was also significantly improved, at 33% for cabozantinib versus 12% for sunitinib, and median OS, another secondary endpoint, showed a trend favoring cabozantinib with 30.3 months versus 21.8 months for sunitinib. Updated results from CABOSUN were presented at the ESMO 2017&#160;Congress in September 2017 and subsequently published in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">European Journal of Cancer </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in May 2018. The updated results included the analysis from a blinded independent radiology review committee (IRRC), which confirmed the primary efficacy endpoint results of investigator-assessed PFS, as well as an updated investigator-assessed analysis. Per the IRRC analysis, the median PFS for cabozantinib was 8.6 months versus 5.3 months for sunitinib, and both the updated investigator assessment and IRRC analysis demonstrated consistent and statistically significant improvement of PFS with cabozantinib as compared to sunitinib. The updated OS analysis had a data cut-off of&#160;July 1, 2017, and showed a favorable trend for patients randomized to cabozantinib compared to sunitinib that was not statistically significant. Median OS was 26.6 months for patients receiving cabozantinib versus 21.2 months for those receiving sunitinib. The safety profile in the study and in later analyses was consistent with the established profile of cabozantinib and other TKIs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the CABOSUN trial, the FDA approved CABOMETYX for the treatment of patients with previously untreated, advanced or metastatic RCC on December 19, 2017, and we commenced our commercial launch of CABOMETYX for this new indication immediately upon such approval. Additionally, on May 17, 2018, the EC approved cabozantinib as a first-line treatment for adults with intermediate- or poor-risk advanced RCC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">RCC - Retrospective Analyses of CABOSUN and METEOR</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As the advanced RCC treatment landscape continues to evolve and include multiple ICI treatment options, biomarker analyses are of increasing importance to help select for advanced RCC patients who would potentially derive the most clinical benefit from CABOMETYX. Two relevant retrospective analyses were presented at the ESMO 2018 Congress in October 2018 that described the potential utility of CABOMETYX in patients with advanced RCC regardless of their PD-L1 status, as well as in those patients with advanced RCC who progressed on previous ICI monotherapy or combination treatment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The first analysis of data from the CABOSUN and METEOR trials evaluated the effect of PD-L1 expression on clinical outcomes with cabozantinib in advanced RCC and demonstrated that cabozantinib improved clinical outcomes regardless of PD-L1 status, relative to sunitinib or everolimus, the respective comparator arms for each trial. The findings showed that PD-L1 expression was associated with shorter median PFS and OS in both METEOR and CABOSUN. Treatment with cabozantinib, however, improved PFS and OS compared with everolimus (METEOR) and sunitinib (CABOSUN) in both PD-L1 positive and PD-L1 negative patients. An additional retrospective analysis found that cabozantinib was active in patients previously treated with ICIs, either alone or in combination with anti-VEGF or other therapies. At a median follow-up of 12 months, ORR was 33%, disease control rate (DCR) was 79% and the one-year OS rate was 53%. Together, these analyses evaluating data from the CABOSUN and METEOR clinical trials contribute to cabozantinib&#8217;s unique product profile, as well as its value as a treatment option for patients with advanced RCC within an evolving and competitive treatment landscape that includes multiple ICI treatment options.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">HCC </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;CELESTIAL</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, we announced positive results of CELESTIAL, our phase 3 pivotal trial comparing cabozantinib to placebo in patients with HCC who had received previous treatment with sorafenib. The CELESTIAL trial, which we initiated in September 2013, was designed to enroll 760 patients who had received prior systemic therapy with sorafenib, could have received up to two prior systemic therapies for HCC, and must have progressed following at least one prior therapy. The CELESTIAL trial was conducted at more than 100 sites globally in 19 countries and enrollment was completed in September 2017. Patients were randomized 2:1 to receive 60 mg of cabozantinib daily or placebo and were stratified based on etiology of the disease (hepatitis C, hepatitis B or other), geographic region (Asia&#160;or other regions) and presence of extrahepatic spread and/or macrovascular invasion (yes or no). No cross-over was allowed between the study arms.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 16, 2017, we announced that CELESTIAL had met its primary endpoint, with cabozantinib providing a statistically significant and clinically meaningful improvement versus placebo in OS, and that the independent data monitoring committee (IDMC), recommended CELESTIAL be stopped for efficacy. In January 2018,&#160;statistically significant and clinically meaningful positive results from the second interim analysis of CELESTIAL were presented during an oral session at the 2018 ASCO&#8217;s Gastrointestinal Cancers Symposium. In July 2018,&#160;the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;NEJM</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;also published the complete, detailed positive results from CELESTIAL. In the total population of second- and third-line patients, median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (hazard ratio (HR) 0.76; 95% confidence interval (CI) 0.63-0.92; p=0.0049). Median PFS was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44; 95% CI 0.36-0.52; p&lt;0.0001). ORR was 4% with cabozantinib and 0.4% with placebo (p=0.0086). Disease control (partial response (PR) or stable disease (SD)) was achieved by 64% of patients in the cabozantinib group compared with 33% in the placebo group. In a subgroup analysis of patients whose only prior therapy for HCC was sorafenib (70% of patients in the study), median OS was 11.3 months with cabozantinib versus 7.2 months with placebo (HR 0.70; 95% CI 0.55-0.88). PFS in the subgroup was 5.5 months with cabozantinib versus 1.9 months with placebo (HR 0.40; 95% CI 0.32-0.50). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The safety profile of cabozantinib observed in the study was consistent with the established profile of cabozantinib and other TKIs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the CELESTIAL trial, the FDA approved CABOMETYX on January 14, 2019 for the treatment of patients with HCC who have been previously treated with sorafenib, and we commenced our commercial launch of CABOMETYX for this new indication immediately upon such approval. Additionally, on November 15, 2018, our partner Ipsen received EC approval of CABOMETYX as a monotherapy for HCC in adults who have previously been treated with sorafenib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">MTC - EXAM</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2011, we announced positive results from EXAM, a phase 3 international, multi-center, randomized double-blinded controlled trial of COMETRIQ in patients with progressive, metastatic MTC. EXAM met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for COMETRIQ-treated patients compared to those receiving placebo, with median PFS of 11.2 months in the COMETRIQ arm versus 4.0 months in the placebo arm. In addition, the ORR was 27% with PRs observed only among patients in the COMETRIQ arm, and the median duration of objective response was 14.7 months for patients treated with COMETRIQ. These primary results were presented at the ASCO 2012 Annual Meeting in June 2012 and subsequently published in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Clinical Oncology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in October 2013. In November 2014, we announced completion of the OS analysis, a secondary endpoint of the study. Consistent with an earlier interim analysis, there was no statistically significant difference in OS between the treatment arms. The median OS was 26.6 months for the COMETRIQ arm and 21.1 months for the placebo arm. We presented the final results at the ASCO 2015 Annual Meeting and submitted the results to regulatory authorities to satisfy post-marketing commitments. The safety profile in the study was consistent with the established profile of cabozantinib and other TKIs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the EXAM trial, the FDA approved COMETRIQ on November 29, 2012, for the treatment of patients with progressive, metastatic MTC. In March 2014, the EC granted COMETRIQ a conditional marketing authorization for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. COMETRIQ is marketed and commercialized in the EU by Ipsen. In connection with the approval of COMETRIQ for the treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, all of which have been satisfied, other than a requirement to conduct the EXAMINER clinical study, comparing a lower dose of cabozantinib with the labeled dose of 140 mg. EXAMINER is evaluating safety and PFS in progressive, metastatic MTC patients and is ongoing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Late-Stage Exelixis Sponsored Trials Evaluating Cabozantinib as a Monotherapy</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">DTC - COSMIC-311</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Published studies indicate that approximately 54,000 new cases of thyroid cancer will be diagnosed in the U.S. in 2019. With the incidence of thyroid cancer increasing more rapidly than any other type of cancer in the U.S., and limited </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">options available to patients whose disease has progressed following treatment with radioiodine (RAI) and anti-VEGFR therapy, we believe there is an urgent need for new treatment options.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Informed by cabozantinib&#8217;s encouraging clinical activity in phase 1 and 2 studies in patients with RAI-refractory differentiated thyroid cancer (DTC), in October 2018 we initiated COSMIC-311, a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two prior VEGFR-targeted therapies. The co-primary endpoints for the trial are PFS and ORR. The trial aims to enroll approximately 300 patients at approximately 150 sites globally. Patients will be randomized in a 2:1 ratio to receive either cabozantinib 60 mg or placebo once daily.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted Under our Clinical Collaboration Agreements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib has shown clinical anti-tumor activity with objective responses observed in more than 20 forms of cancer in phase 1 and 2 evaluation; we are, therefore, focused on advancing a broad cabozantinib clinical development program to fully investigate its therapeutic potential, both alone and in combination with other therapies. In particular, given that clinical observations from early-stage clinical trials evaluating cabozantinib in combination with ICIs have shown preliminary promising activity across a diverse range of tumors, and that patients have been able to tolerate these drug combinations, we are focused on exploring the potential of cabozantinib in combination with ICI&#8217;s in later-stage settings. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Studies with Bristol-Myers Squibb Company (BMS)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Preclinical data and clinical observations from an ongoing phase 1 trial evaluating cabozantinib in combination with nivolumab, with or without ipilimumab, in patients with previously treated genitourinary tumors suggest that cabozantinib may result in a more immune-permissive tumor environment. In consideration of those results, in February 2017, we entered into a clinical collaboration agreement with BMS for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217; PD-1 ICI, nivolumab, both with or without BMS&#8217; CTLA-4 ICI, ipilimumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of the collaboration, we are evaluating these combinations in a phase 3 pivotal trial in previously untreated or metastatic advanced RCC and in a phase 1/2 trial in both previously treated and previously untreated advanced HCC. We also intend to evaluate these combinations in other phase 3 pivotal trials in various other tumor types, including UC. Pursuant to our agreements with BMS, each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each trial will be determined on a trial-by-trial basis. For additional information on the terms of the clinical trial collaboration agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - CheckMate 9ER</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER is an open-label, randomized, multi-national phase 3 pivotal trial evaluating nivolumab in combination with cabozantinib versus sunitinib in patients with previously untreated, advanced or metastatic RCC. The original trial protocol required patients to be randomized 1:1:1 to one of three arms: cabozantinib and nivolumab; cabozantinib, nivolumab and ipilimumab; or sunitinib. However, following the positive results of CheckMate 214, BMS&#8217;s phase 3 trial evaluating nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic RCC and in an effort to accelerate the development of the cabozantinib and nivolumab combination, the trial protocol was amended to remove the triplet combination. The modified protocol for the trial aims to enroll approximately 580 patients with previously untreated, advanced or metastatic RCC of all risk groups. Patients are being randomized 1:1 to receive either 40 mg of cabozantinib daily and 240 mg of nivolumab every 2 weeks, or 50 mg of sunitinib daily on a 4-weeks-on/2-weeks-off schedule. The primary endpoint for the trial is PFS and the secondary endpoint is OS. The triplet combination continues to be evaluated in an ongoing phase 1b trial in patients with advanced genitourinary malignancies and a separate phase 3 trial evaluating the triplet combination versus nivolumab and ipilimumab is in preparation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - Checkmate 040</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 040 is a large, multi-cohort phase 1/2 trial in patients with previously treated and previously untreated advanced HCC, including a cohort evaluating treatment regimens that include cabozantinib in combination with nivolumab or in combination with both nivolumab and ipilimumab. This cohort containing the cabozantinib combination treatment regimens enrolled approximately 30 patients into each of two groups in accordance with the trial protocol, with one group receiving 40 mg of cabozantinib daily and 3 mg of nivolumab every two weeks, and the other group receiving 40 mg of cabozantinib daily, 3 mg of nivolumab every two weeks and 1 mg ipilimumab every six weeks. The primary objectives for the cohorts are safety and tolerability, ORR and duration of response (DOR) and the secondary objectives include time to progression (TTP), PFS and OS.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Studies with the Roche Group (Roche)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Diversifying our exploration of cabozantinib combinations with ICIs, in February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s anti-PD-L1 ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of the collaboration, we are evaluating this combination in a phase 1b trial in locally advanced or metastatic tumors and a phase 3 pivotal trial in previously untreated advanced HCC. Depending on results from the phase 1b trial, COSMIC-021, we may also evaluate this combination in various other tumor types, including NSCLC. For additional information on the terms of the master clinical supply agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Locally Advanced or Metastatic Solid Tumors - COSMIC-021</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion cohort phase, which is ongoing. The dose-escalation phase of the trial enrolled 12 patients with advanced RCC, and results were presented at the ESMO 2018 Congress</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The primary objective was to determine the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. Cabozantinib doses of 40 mg daily and 60 mg daily were evaluated. All patients received the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks. The dose-escalation phase of the study determined the optimal dose of cabozantinib as 40 mg daily when given in combination with the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks. No dose-limiting toxicities or serious adverse events (AEs) were noted. Dose reductions and higher grade AEs were less frequent with the 40 mg cabozantinib dosing cohort. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Encouraging clinical activity was also observed. The safety profile for the combination in the dose-escalation phase of the trial was consistent with the established profile of each combination agent, and no new safety signals have emerged.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Enrollment in the expansion stage of this study, which is currently ongoing, includes the following eighteen combination tumor expansion cohorts:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with advanced non-squamous NSCLC without a defined tumor genetic alteration (EGFR, ALK, ROS1, or BRAF) who have not received prior therapy with an ICI;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an ICI;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with NSCLC with an EGFR mutation who have progressed following treatment with an EGFR-targeting TKI for metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed following treatment with an ICI;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with CRPC who have previously received enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with RCC with clear cell histology who have not had prior systemic anticancer therapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with RCC with non-clear cell histology who have not had prior systemic anticancer therapy for inoperable, locally advanced, recurrent or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed on or after platinum-containing chemotherapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with triple-negative breast cancer (TNBC) who have progressed following treatment with at least one prior systemic therapy for inoperable, locally advanced, recurrent or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with epithelial ovarian cancer (EOC) who have platinum-resistant or refractory disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with endometrial cancer who have progressed following treatment with at least one prior systemic therapy for inoperable, locally advanced, recurrent or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with advanced HCC who have a Child-Pugh score of A and have not had prior systemic anticancer therapy for inoperable, locally advanced, recurrent or metastatic disease;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with gastric or gastroesophageal junction adenocarcinoma who have progressed following treatment with platinum-containing or fluoropyrimidine-containing chemotherapy for inoperable locally advanced, recurrent or metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with colorectal adenocarcinoma who have progressed following treatment with systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan for metastatic disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with head and neck cancer of squamous cell histology who have progressed following treatment with platinum-containing chemotherapy for inoperable locally advanced, recurrent or metastatic disease; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with DTC who are radio-refractory or deemed ineligible for treatment with iodine-131.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Each expansion cohort will initially enroll approximately 30 patients, and cohorts may be further expanded, including the cohorts of patients with UC or NSCLC who have been previously treated with an ICI, for a total of up to 1,000 patients. In addition, there are two exploratory cohorts that will evaluate cabozantinib as a single-agent therapy in patients with NSCLC without a defined tumor genetic alteration and in patients with UC, in each case who have progressed following treatment with an ICI.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - COSMIC-312</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. The co-primary endpoints of the trial are PFS and OS. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting. The study aims to enroll approximately 640 patients at up to 200 sites globally. Patients will be randomized to one of three arms: cabozantinib and atezolizumab (40 mg); sorafenib; or cabozantinib (60 mg). The co-primary endpoints for the trial are PFS and OS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are sponsoring COSMIC-312, and&#160;Ipsen&#160;will co-fund the trial.&#160;Ipsen&#160;will have access to the results to support potential future regulatory submissions outside of the U.S. and&#160;Japan. Roche is providing atezolizumab free of charge.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted through our CRADA with NCI-CTEP and our IST Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2011, we entered into a CRADA with NCI-CTEP for the clinical development of cabozantinib. Through our CRADA with NCI-CTEP and our IST program we have been able to expand the cabozantinib development program while avoiding over-burdening our internal development resources. Our CRADA reflects a major commitment by NCI-CTEP to support the broad exploration of cabozantinib&#8217;s potential in a wide variety of cancers, each representing a substantial unmet medical need. Through this mechanism, NCI-CTEP provides funding for as many as 20 active clinical trials of cabozantinib each year for a five-year period. The term of the CRADA was extended in October 2016 for an additional five-year period through October 2021, provided that both parties maintain the right to terminate the CRADA for any reason upon sixty days&#8217; notice, for an uncured material breach upon thirty days&#8217; notice and immediately for safety concerns. Investigational New Drug (IND) applications for trials under the CRADA are held by NCI-CTEP. NCI-CTEP also retains rights to any inventions made in whole or in part by NCI-CTEP investigators.&#160;However, for inventions that claim the use and/or the composition of cabozantinib, we have an automatic option to elect a worldwide, non-exclusive license to cabozantinib inventions for commercial purposes, with the right to sublicense to affiliates or collaborators working on our behalf, as well as an additional, separate option to negotiate an exclusive license to cabozantinib inventions.&#160;Further, before any trial proposed under the CRADA may commence, the protocol is subject to our review and approval, and the satisfaction of certain other conditions. We believe our CRADA with NCI-CTEP has and will enable us to continue to expand the cabozantinib development program broadly in a cost-efficient manner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Advanced Genitourinary Tumors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results from a phase 1 trial evaluating cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors being conducted under our CRADA with NCI-CTEP were first presented at the ESMO 2016 Congress in October 2016 and most recently updated at the 2018 ASCO Genitourinary Cancers Symposium in February 2018. The updated data reported results from 78 patients treated with either cabozantinib and nivolumab with or without ipilimumab. Forty-nine patients were treated with the doublet combination of cabozantinib and nivolumab and 29 patients were treated with the triplet combination of cabozantinib, nivolumab and ipilimumab. Among the nineteen patients with metastatic UC who were evaluable for response, the ORR across all treatment groups was 42% (2 complete responses (CRs) and 6 PRs of 19 patients) and the DCR (DCR = CR, PR and SD) was 84%. Seven of eight (88%) metastatic UC patients with an objective response had not progressed at the time of the data cut-off. Median PFS in this patient population was 12.8 months and the OS rate at 12 months was 77%. Among the 13 patients with metastatic RCC who were evaluable for response, ORR was 54 percent (7 PRs of 13 patients) and the DCR was 100%. In the overall study the ORR in 64 evaluable patients was 36% (3 CRs and 20 PRs) with a median DOR of 24 months. 78 patients were included in the safety analysis. No dose-limiting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">toxicity was observed in the study. Based on general tolerability, the recommended cabozantinib dose for the expanded dose cohorts and for future late stage evaluation was determined as cabozantinib at 40 mg daily oral dose combined with nivolumab at 3 mg/kg every 2 weeks and ipilimumab at 1 mg/kg every 3 weeks for 4 doses. The safety profile for the combination in the trial was consistent with the established profile of each combination agent, and no new safety signals have emerged. This phase 1b study supported the choice of dose for the ongoing CheckMate 9ER trial in previously untreated advanced RCC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">DTC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results from a phase 2 single-arm, open-label trial evaluating cabozantinib for the first-line treatment of metastatic RAI-refractory DTC, an IST conducted by the Center for Rare Cancers and Personalized Therapy&#160;at the&#160;Abramson Cancer Center&#160;of the&#160;University of Pennsylvania, were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium in February 2018. The primary endpoint of the trial was ORR. Patients were administered oral cabozantinib 60 mg once daily. Among the 35 patients who were evaluable for response, PR was achieved by 54% of patients (n=19), and SD was reported in 43 percent of patients (n=15) per RECIST 1.1. All but one evaluated patient experienced a decrease in tumor target lesions. Secondary endpoints of the trial included PFS, TTP, DOR and clinical benefit rate (CBR), defined as the number of patients achieving an objective response or stable disease for at least 6 months. The CBR at six months was 80% (n=28). With a median follow up for the study of 35 weeks, the median PFS had not been reached. The median TTP among those patients who progressed was 35 weeks. The safety profile in the study was consistent with the established profile of cabozantinib and other TKIs. It was on the basis of these encouraging trial results and results from earlier phase 1 and 2 trials in RAI-refractory DTC patients who had received prior systemic therapies that we initiated COSMIC-311.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">NSCLC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2014, we announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type NSCLC. This trial (Study E1512) was sponsored through our CRADA with NCI-CTEP and was conducted by the ECOG-ACRIN Cancer Research Group. The positive results from this trial were reported at the ASCO 2015 Annual Meeting in May 2015 and subsequently published online in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Lancet Oncology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in November 2016. The study met its primary endpoint, demonstrating significant increases in PFS for cabozantinib and the combination of cabozantinib plus erlotinib when individually compared to the erlotinib arm. The safety profile for the combination in the trial was consistent with the established profile of other TKI/TKI combination therapies. Informed by these clinical results, we are working with clinical collaborators to explore cabozantinib&#8217;s further development in NSCLC, including potential combination approaches with ICIs, such as within one of the expansion cohorts of COSMIC-021, our phase 1b study with Roche evaluating the combination of cabozantinib and atezolizumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Cancer Indications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are 46 ongoing and 30 planned externally sponsored trials evaluating the clinical and therapeutic potential of cabozantinib, including those administered through our CRADA with NCI-CTEP and our IST program.&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Like our CRADA with NCI-CTEP, our IST program helps us to continue to evaluate cabozantinib across a broad range of tumor types. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These externally sponsored trials include signal seeking studies of single-agent cabozantinib, novel combinations, and randomized trials.&#160;The monotherapy trials are focused on solid tumors including genitourinary neoplasms, gastrointestinal malignancies, lung cancer and a variety of less common tumor types.&#160;The combination studies include trials combining cabozantinib with several different ICIs, as well as studies adding cabozantinib to monoclonal antibodies and small molecules which target specific cellular pathways.&#160;Randomized trials within the CRADA include a phase 3 study in neuroendocrine tumors and phase 2 trials in both endometrial cancer in combination with checkpoint inhibitors and in prostate cancer in combination with docetaxel.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A complete listing of all ongoing cabozantinib trials can be found at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:underline;">www.ClinicalTrials.gov</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">XL092 Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XL092 is the first internally-discovered Exelixis compound to enter the clinic following the company&#8217;s reinitiation of drug discovery activities. XL092 is a next-generation oral TKI that targets VEGF receptors, MET, and other kinases implicated in cancer&#8217;s growth and spread. The molecule is the subject of an active IND that we submitted to the FDA in December 2018, and that the FDA accepted in January 2019. XL092 will initially be studied in a multi-center phase 1 clinical trial designed to evaluate its pharmacokinetics, safety and tolerability. The trial is divided into dose-escalation and expansion phases. The dose-escalation phase of the trial will enroll patients with advanced solid tumors, with the primary objective of determining a dose for daily oral administration of XL092 suitable for further evaluation. Assuming positive data from the initial phase of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the trial, the expansion phase is designed to further explore the selected dose of XL092 in individual tumor cohorts, where safety, tolerability, and initial clinical activity would be evaluated.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Expansion of the Exelixis Pipeline: Drug Discovery and Business Development Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are actively focused on expanding our pipeline through internal drug discovery and targeted business development activities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Drug Discovery</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical, therapeutic and commercial potential of cabozantinib, we are also working to rebuild our product pipeline by discovering and developing new cancer therapies for patients. From 2000 until 2012, we had an active discovery group that advanced 22 compounds to the IND stage, either independently or with collaboration partners, including cabozantinib and cobimetinib. We built significant infrastructure, including a library of 4.6 million compounds, and gained extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In 2016, we resumed internal drug discovery efforts with the goal of identifying novel and promising therapeutic candidates to advance into clinical trials. Furthest along in these efforts is XL092. For additional information on XL092, see &#8220;&#8212;XL092 Development Program</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our new discovery organization is leveraging that history in a focused and measured manner. We are concentrating our in-house work on the most demanding and time-sensitive aspects of lead optimization and use contract research organizations to support more routine activities, thereby minimizing our internal footprint while still maintaining an agile, competitive approach. We are and will continue to be judicious in the selection of targets, focusing on those with robust preclinical validation datasets. We remain focused on oncology as a therapeutic area, and prioritize those targets that we believe, for example, are key components of signaling pathways frequently deregulated in human cancers or are components of mechanisms that contribute to tumor-mediated immune suppression. We anticipate that our experience identifying high quality lead compounds against a variety of target classes through use of our propriety compound library, coupled with our expertise in medicinal chemistry, tumor biology and pharmacology, will permit us to prosecute competitive and productive discovery programs in areas of high potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Development</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also focused on augmenting our pipeline by entering into collaborative relationships or in-licensing agreements for attractive, early-stage oncology assets and then further developing them utilizing our established and validated clinical development infrastructure. As part of this strategy, in January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy Therapeutics, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inc. (StemSynergy) for the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CK1&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">), a component of the Wnt signaling pathway implicated in key oncogenic processes. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, in May 2018,&#160;we entered into a collaboration and license agreement with&#160;Invenra, Inc. (Invenra) which is&#160;focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer. We have already made considerable progress under our collaborations with both StemSynergy and Invenra and believe we will continue to do so in 2019. For additional information on our collaboration with StemSynergy, see &#8220;&#8212;Collaborations&#8212;StemSynergy Collaboration,&#8221; and for additional information on our collaboration with Invenra, see &#8220;&#8212;Collaborations&#8212;Invenra Collaboration.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are seeking additional, external collaborative relationships around assets and technologies that complement our in-house drug discovery and development efforts. These collaborative relationships are aimed at expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, Daiichi Sankyo and BMS for other compounds and programs in our portfolio. Under each of our collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cabozantinib Commercial Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Ipsen Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of December 31, 2018, we achieved aggregate milestone payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$275.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including milestone payments during 2018 of (i) $50.0 million upon the EMA filing and the approval of cabozantinib as a treatment for patients with previously untreated RCC, (ii) $25.0 million upon Ipsen&#8217;s achievement of $100.0 million of net sales cumulatively over four consecutive fiscal quarters, (iii) $50.0 million upon EMA filing and the approval of cabozantinib as a treatment for patients with previously treated HCC, (iv) $5.0 million upon the approval by Health Canada of cabozantinib for the treatment of adults with advanced RCC who have received prior VEGF-targeted therapy and (v) $20.0 million upon the initiation of COSMIC-312.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$84.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$519.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with future sales volume milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. We were initially entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales; this amount was reached in the second quarter of 2018. As of December 31, 2018 and going forward, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales (with separate tiers for Canada); these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD$30.0 million of annual net sales and a tiered royalty thereafter to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers for Canada will also reset each calendar year. As of December 31, 2018, we have earned royalties of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$36.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GlaxoSmithKline (GSK), we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding: CheckMate 9ER; CheckMate 040 (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); the dose escalation phase and first eight expansion cohorts of COSMIC-021; and COSMIC-312.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished and labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a pharmacovigilance agreement, which defines each partner&#8217;s responsibilities for safety reporting. The pharmacovigilance agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;$50.0 million upfront nonrefundable payment from Takeda. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Effective March 2018, we amended the collaboration agreement to modify the milestones we are eligible to receive under this agreement, and as of December 31, 2018, we are eligible to receive</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to both previously treated and previously untreated RCC and previously treated HCC, as well as additional development, regulatory and first-sale milestone payments for potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with sales volume milestones and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and following this initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers will reset each calendar year. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GSK, we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for 20% of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In accordance with the collaboration agreement, Takeda has opted into and is co-funding CheckMate 9ER.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) two years after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application (MAA) in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cabozantinib Development Collaborations </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">BMS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s ICIs, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC and HCC in the CheckMate 9ER and CheckMate 040 trials, respectively. We also intend to evaluate these combinations in other phase 3 pivotal trials in various other tumor types, including UC. For descriptions of the Checkmate 9ER and Checkmate 040 trials, see &#8220;&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with BMS.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination IND application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial and unless otherwise agreed between the parties, costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear two-thirds of the costs for such study treatment arms and we will bear one-third of the costs. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Roche</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021 and in December 2018, we initiated COSMIC-312. We are the trial sponsor, and Roche is providing atezolizumab free of charge. For descriptions of the COSMIC-021 and COSMIC-312 trials, see &#8220;&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with Roche.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">StemSynergy Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and li</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cense agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CK1&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, a component of the Wnt signaling pathway implicated in key oncogenic processes. Activation of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#946;-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">catenin, a key downstream component of the pathway, is increased in multiple tumors, including a majority of colorectal cancers, where mutations in the APC gene that result in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#946;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-catenin stabilization are prevalent. Compounds targeting </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CK1&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;have also been shown to induce degradation of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#946;-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">catenin and pygop</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">us, another member of the pathway, in preclinical CRC models, and to inhibit the growth of tumors. Importantly, their GI-sparing qualities may help overcome limitations of other approaches targeting the Wnt pathway. Under the terms of the agreement,&#160;we&#160;wil</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">l partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CK1&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We paid&#160;StemSynergy an upfront payment of&#160;$3.0 million&#160;in initial research and development funding, and we plan to provide StemSynergy with additional research and development funding of up to $1.2 million during 2019 on an as needed basis. StemSynergy will also be eligible for up to&#160;$56.5 million&#160;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Invenra Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra, which is&#160;focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of&#160;$2.0 million&#160;and a project initiation fee of&#160;$2.0 million.&#160;In January 2019, we initiated our second discovery project, for which we paid an additional project initiation fee of $2.0 million. Invenra is eligible to receive payments of up to&#160;$131.5 million&#160;based on the achievement of specific development and regulatory milestones for a product containing the lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to&#160;$325.0 million&#160;if certain sales thresholds are achieved as well as single-digit tiered royalties on net sales of the approved product. We also have the right to initiate four additional discovery projects for development subject to an upfront payment of&#160;$2.0 million&#160;for each project, as well as additional global milestone payments and royalties for any products that arise from these discovery efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project basis at any time prior to commercialization, for any or no reason, upon thirty days&#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Genentech, Daiichi Sankyo and BMS described below are representative of this historical strategy. We have since evolved and are now a fully-integrated biopharmaceutical company focused on driving the expansion and depth of our product offerings through the continued development of cabozantinib, internal drug discovery and execution of strategic transactions that align with our oncology drug development and commercialization expertise, all to improve care and outcomes for people with cancer around the world. While the historical collaboration agreements described below have the potential to provide future revenue, and while we have already received some collaboration revenues from these arrangements, we do not expect to receive significant revenues from these historical collaboration agreements unless and until our partnered compounds generate substantial sales in the territories and indications where they are approved, or if not yet approved, enter late-stage clinical development. If these events occur, then the milestone payments, royalties or other rights and benefits under our historical collaboration agreements could become substantial.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Genentech - Cobimetinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors.&#160;Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. We received aggregate upfront and milestone payments of&#160;$50.0&#160;million under our collaboration agreement with Genentech and are not eligible for any additional milestone payments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allows for us to provide up to 25% of the total sales force for approved cobimetinib indications in the U.S. Between November 2015 and December 2017, we fielded 25%&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a review of the commercial landscape, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Cobimetinib Profit Sharing and Royalty Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. These tiers will reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. During 2018, we earned royalties of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on net sales of COTELLIC outside the U.S. and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;profit on the profit and loss sharing of U.S. actual sales which are recorded in Collaboration revenues.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Cobimetinib Clinical Development Program </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to its established commercialization of COTELLIC, Genentech continues to make significant progress with respect to the clinical development, regulatory status and commercial potential of cobimetinib. Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech&#8217;s investigator sponsored trial program, including two phase 3 pivotal trials currently underway exploring the combination of cobimetinib with atezolizumab or atezolizumab alone in BRAF wild type melanoma&#160;(IMspire170) and the combination of cobimetinib with atezolizumab and vemurafenib in BRAF V600 mutant melanoma (IMspire150). Additionally, although&#160;IMblaze370, a third phase 3 pivotal trial conducted by Genentech evaluating the combination of cobimetinib with atezolizumab in CRC did not meet its primary endpoint as announced in May 2018, Genentech continues to pursue the cobimetinib development program&#160;and is conducting a series of early-stage clinical trials investigating the combination of cobimetinib and atezolizumab in multiple tumor settings. Should these trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that cobimetinib could provide us with a potentially meaningful source of revenue in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Melanoma - coBRIM. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2014, we announced positive top-line results from coBRIM, the phase 3 pivotal trial conducted by Genentech evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600E or V600K mutation. The primary endpoint was investigator-determined PFS, and secondary endpoints included OS, ORR, IRRC-determined PFS and DOR. coBRIM met its primary endpoint, demonstrating a statistically significant increase in investigator-determined PFS. The median PFS was 9.9 months for the combination of cobimetinib and vemurafenib versus 6.2 months for vemurafenib alone. The median PFS as established by an IRRC, a secondary endpoint, was 11.3 months for the combination arm compared to 6.0 months for the control arm. ORR, another secondary endpoint, was 68% for the combination versus 45% for vemurafenib alone. Data were published in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">NEJM </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and presented at the ESMO 2014 Congress in September 2014.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Updated results for PFS and ORR from coBRIM were then presented at the ASCO 2015 Annual Meeting in June 2015 and showed a median PFS of 12.3 months for the combination of cobimetinib and vemurafenib versus 7.2 months for vemurafenib alone, and an ORR of 70% for the combination of vemurafenib and cobimetinib versus 50% for vemurafenib alone. In November 2015, we announced that the coBRIM trial also met its OS secondary endpoint, demonstrating a statistically significant increase in OS for the combination of cobimetinib and vemurafenib compared to vemurafenib monotherapy. The median OS was 22.3 months for the combination of cobimetinib and vemurafenib versus 17.4 months for vemurafenib alone. The safety profile of the combination was consistent with that observed in a previous study.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CoBRIM served as the basis for the regulatory approval of COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S., Switzerland, the EU, Canada, Australia, Brazil and other countries.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Melanoma - IMspire150. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, Genentech initiated IMspire150, a phase 3 pivotal trial evaluating the combination of cobimetinib, vemurafenib and atezolizumab vs. cobimetinib plus vemurafenib in previously untreated BRAF V600 mutation positive patients with metastatic or unresectable locally advanced melanoma. This trial, which has a primary endpoint of PFS, was based on the results of Genentech&#8217;s ongoing phase 1b trial in the same patient population. The trial completed enrollment of approximately 500 patients in April 2018. Genentech has announced that top-line results are expected during 2019, and should the results prove positive, Genentech also intends to submit regulatory filings for this combination in 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Melanoma - IMspire170. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, Genentech initiated IMspire170, a phase 3 trial comparing cobimetinib plus atezolizumab to pembrolizumab in previously untreated BRAF WT patients with metastatic or unresectable locally advanced melanoma. IMspire170 was based on the results of Genentech&#8217;s ongoing phase 1b trial in the same patient population. This trial, which has a primary endpoint of PFS, is designed to enroll 450 patients; the first patient was enrolled in December 2017. Genentech has announced that top-line results for the trials are expected during 2019, and should the results prove positive, Genentech also intends to submit regulatory filings for this combination in 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Cancer Indications. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to IMspire150 and IMspire170, additional earlier-stage clinical trials are ongoing studying the combination of cobimetinib with a variety of agents in multiple tumor types. These include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the combination of cobimetinib and vemurafenib in additional melanoma patient populations and settings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 2 trial of cobimetinib in combination with taxanes, with or without atezolizumab in first-line TNBC (COLET);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 2 studies of cobimetinib in combination with atezolizumab in RCC, head and neck squamous cell carcinoma, UC and hormone receptor positive, HER2 negative breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 1/2 studies of cobimetinib in combination with atezolizumab in melanoma and NSCLC, in combination with vemurafenib and atezolizumab in melanoma, and in combination with venetoclax in relapsed or refractory acute myeloid leukemia and multiple myeloma;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 1b study evaluating the safety, tolerability and pharmacokinetics of cobimetinib in combination with atezolizumab and bevacizumab in patients with metastatic CRC; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 1b/2 study of cobimetinib in combination with atezolizumab (one arm of a randomized umbrella study) in metastatic pancreatic ductal adenocarcinoma.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A complete listing of all ongoing cobimetinib trials can be found at www.ClinicalTrials.gov. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. During the research term, which concluded in November 2007, we jointly identified drug candidates with Daiichi Sankyo for further development. Esaxerenone is the only remaining drug candidate identified under the collaboration that continues to be developed by Daiichi Sankyo, and we are entitled to receive payments upon attainment of pre-specified development, regulatory and commercialization milestones for esaxerenone</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, Daiichi Sankyo reported positive top-line results from ESAX-HTN, a phase 3 pivotal trial of esaxerenone, and submitted a Japanese regulatory application for esaxerenone for an essential hypertension indication in February 2018, for which we received a $20.0 million milestone payment, which we recorded in the first quarter of 2018. Data from ESAX-HTN were published in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Hypertension </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in June 2018. Daiichi Sankyo&#8217;s application was then approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) in January 2019, and the first commercial sale of the branded esaxerenone product MINNEBRO in Japan will trigger the payment of a $20.0 million milestone payment to us. As of December 31, 2018, and after giving effect to the milestone payment associated with the Japanese regulatory application for esaxerenone, we have achieved an aggregate of $45.5 million in development, regulatory and commercialization milestone payments related to MINNEBRO over the life of the collaboration agreement. We are eligible to receive additional commercialization milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$110.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including the $20.0 million milestone payment associated with the first commercial sale of MINNEBRO in Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon 90 days&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo also continues to advance the development program for esaxerenone, with an ongoing phase 3 pivotal trial evaluating esaxerenone as a treatment option for patients in Japan with diabetic nephropathy. Should this trial prove positive and Daiichi Sankyo obtain regulatory approval based on such positive results, and taking into account the approval of MINNEBRO by the MHLW in January 2019 for the treatment of hypertension, we believe that esaxerenone will provide an additional source of revenue in the future. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">BMS - ROR Collaboration Agreement </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Under the terms of the collaboration agreement, we were responsible for activities related to the discovery, optimization and characterization of the ROR antagonists during the collaborative research period which began on October&#160;8, 2010 and ended on&#160;July 8, 2013. Since the end of the collaborative research period, BMS has and will continue to have sole responsibility for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each product developed by BMS under the collaboration, we will be eligible to receive payments upon the achievement by BMS of development and regulatory milestones. As of December 31, 2017, we have earned aggregate development and regulatory milestones of $12.5 million, including a $2.5 million development milestone payment in February 2017 in connection with the achievement of certain preclinical milestones set forth in the collaboration agreement and a $10.0 million regulatory milestone payment in October 2017 in connection with BMS&#8217;s filing of a Clinical Trial Authorization in Europe for a first in-human study of an </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ROR&#947;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;inverse agonist. We are eligible for additional development and regulatory milestone payment of up to $240.0 million in the aggregate and commercialization milestones of up to $150.0 million in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement was amended and restated in April 2011 in connection with an assignment of patents to a wholly-owned subsidiary. BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Manufacturing and Product Supply</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations who, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations expand due to our development and commercial progress, we expect to enter into new agreements with additional third-party contract manufacturers and suppliers as needed. This will continue for the foreseeable future for all of our product candidates and all of our current and future commercial products. We have selected well-established and reputable global third-party contract manufacturers for our drug substance and drug product manufacturing that have good regulatory standing, large manufacturing capacities and multiple manufacturing sites within their business footprint. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practices, the EC&#8217;s Guidelines on Good Distribution Practice (GDP), as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Through our third-party manufacturers and data service providers, we have implemented product serialization designed to comply with the Drug Supply Chain Security Act (DSCSA), pursuant to which all prescription pharmaceutical products manufactured and distributed in the U.S. were required to be serialized as of November 27, 2018. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis to ensure compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers, and our quality department audits them on a periodic basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia and Europe. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers to ensure they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Within our supply chain, we have established safety stock amounts for both our drug substance and drug products, and store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. In parallel, for business continuity reasons, we expect to establish additional suppliers for our drug substance and drug product manufacturers soon. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved advanced RCC and HCC indications, as well as potential additional indications if trials evaluating CABOMETYX in those indications prove to be successful and gain regulatory approval in the future. Our manufacturing footprint also enables us to fulfill our supply obligations for CABOMETYX and COMETRIQ to our collaboration partners, Ipsen and Takeda, for global development and commercial purposes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Marketing, Sales and Distribution</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. In addition, although we currently do not co-promote COTELLIC alongside Genentech, we have the right to do so and will do so if we, in consultation with Genentech, deem it useful and appropriate to realize COTELLIC&#8217;s commercial objectives. We use customary pharmaceutical company practices to market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses and pharmacists.&#160;Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third-party vendors, such as advertising agencies, market research firms and other sales-support related services as needed. We believe that our commercial team and distribution practices are sufficient to ensure our marketing efforts reach our target audience and deliver our products to patients in a timely and compliant fashion.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we rely on Ipsen and Takeda for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ongoing and further</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S. For COTELLIC, we rely on Genentech, as our collaboration partner, for all current and future commercialization and marketing activities, with the exception of the limited co-promotion activities highlighted above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services (EASE). Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE provides comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Seasonal Operations and Backlog</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our marketed products do not reflect any significant degree of seasonality.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets in which we operate are characterized by short lead times and the absence of significant backlogs. We do not believe that backlog information is material to our business as a whole.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Environment, Health and Safety</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In support of the development and expansion of our product pipeline, we have resumed discovery activities. Our research and development processes involve the controlled use of certain hazardous materials and chemicals. We are subject to federal, state and local environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and may continue to incur, expenditures to ensure we are in compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Government Regulation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, marketing approval, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, post-marketing safety reporting, export, import, record keeping, advertising and promotion of our products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nonclinical laboratory and animal tests, some of which must be conducted in accordance with Good Laboratory Practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">submission of an IND, which must become effective before human clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the investigational drug candidate for its proposed intended use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for drug products, submission of an New Drug Application (NDA) to the FDA for commercial marketing, or generally of a supplemental New Drug Application (sNDA), for approval of a new indication if the product is already approved for another indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for biological products, submission of a Biologics License Application (BLA) to FDA for commercial marketing, or generally a supplemental Biologics License Application (sBLA) for approval of a new indication if the product is already approved for another indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA approval of the NDA or sNDA, or BLA or sBLA.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The testing and approval process requires substantial time, effort and financial resources. Prior to commencing the first human clinical trial with a product candidate, we must submit an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development. Further, an independent institutional review board for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial and provide its informed consent form before the trial commences at that center. Regulatory authorities or an institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 1 - Studies, which involve the initial introduction of a new drug product candidate into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, tolerability, absorption, metabolism, distribution and excretion in healthy humans or patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 2 - Studies are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosage, and common short-term side effect and risks associated with the drug. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. In some cases, a sponsor may decide to run what is referred to as a &#8220;phase 2b&#8221; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluation, which is a second, confirmatory phase 2 trial that could, if positive, serve as a pivotal trial in the approval of a product candidate.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 3 - When earlier phase evaluations provide preliminary evidence suggesting that a dosage range of the product is effective and has an acceptable safety profile, phase 3 trials are performed to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 trials are undertaken in large patient populations to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded patient population at multiple clinical trial sites.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called phase 4 studies may be made a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. The results of phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system. The results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions. Although the FDA is not required to follow the recommendations of an advisory committee, the agency usually does so. The FDA may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data and/or an additional phase 3 pivotal clinical trial. Even if such data are submitted, the FDA may ultimately decide that the NDA or sNDA does not satisfy the criteria for approval. An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Satisfaction of FDA development and approval requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Government regulation may delay or prevent marketing of product candidates for new diseases for a considerable period of time and impose costly procedures upon our activities. The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all. Success in early stage clinical trials does not ensure success in later stage clinical trials. Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Even if a product candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market, including withdrawal of the NDA approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including obtaining prior FDA approval of certain changes to the approved NDA, record-keeping requirements, and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain manufacturing requirements, including procedural and documentation requirements, upon us and our third-party manufacturers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency. Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of the relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which the FDA has approved the drug and that are otherwise consistent with the FDA-approved label for the drug. Failure to comply with these requirements can result in adverse publicity, warning or untitled letters, corrective advertising and potential civil and criminal penalties. Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA generally does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label uses. Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various U.S. federal and state regulatory, investigative, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various U.S. federal and state laws and regulations, including claims asserting antitrust violations, violations of the Federal Food, Drug, and Cosmetic Act (FDCA), false claims laws, the Prescription Drug Marketing Act, anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the Orphan Drug Act of 1983, as amended, is intended to incentivize the development of drugs and biological products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or that affects more than 200,000 persons in the U.S. and for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). If a drug is being developed for a rare disease or condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-designated indication. If the FDA has previously approved another same drug for the same indication, to obtain orphan drug designation, the sponsor of the subsequent drug would be required to provide a plausible hypothesis of clinical superiority over the previously approved drug to obtain an orphan designation. Upon FDA receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 50% for qualified clinical trial expenses, the ability to apply for grant funding, and waiver of the Prescription Drug User Fee Act (PDUFA) application fee. Following the passage of the Tax Cuts and Jobs Act of 2017, for clinical trial expenses incurred in tax years 2018 and going forward, the tax credit is reduced to 25%. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity for the approved orphan-designated indication. Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases or conditions that demonstrate the potential to fill unmet medical needs. Priority review is designed to shorten the review period for drugs that treat serious conditions and that, if approved, would offer significant advances in safety or effectiveness or would provide a treatment where no adequate therapy exists. Under priority review, the FDA aims to take action on application within six months as compared to a standard review time of 10 months. Certain other types of drug applications are also eligible for priority review. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review. Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint, or certain clinical endpoints, reasonably likely to predict clinical benefit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial. In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives: intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review; and rolling review.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">The Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Hatch-Waxman Act established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Abbreviated New Drug Application (ANDA).</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;An ANDA may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug (RLD).&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">previously found to be safe and effective. Furthermore, conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans. In this regard, the FDA has published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active pharmaceutical ingredient in CABOMETYX and COMETRIQ, as it does for many FDA-approved therapeutic products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">505(b)(2)&#160;NDAs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;A 505(b)(2) application is one for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) of the FDCA, an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) applicant establishes that reliance on FDA&#8217;s prior findings of safety and efficacy for an approved product is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of both an ANDA application and a 505(b)(2) application may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides (a) up to five years of exclusivity for the first approval of a new chemical entity (NCE) exclusivity and (b) three years of exclusivity for approval of an NDA or supplemental application for a product that is not an NCE but rather where the application contains new clinical studies considered essential to the approval of the NDA or sNDA (three-year &#8220;changes&#8221; exclusivity). NCE exclusivity runs from the time of approval of the NDA and bars FDA from accepting for review of any ANDA or 505(b)(2) application for a drug containing the same active moiety for five years (or for four years if the application contains a paragraph IV certification that a reference product patent is invalid or not infringed by the ANDA/505(b)(2) product). The three-year &#8220;changes&#8221; exclusivity generally bars the FDA from approving any ANDA or 505(b)(2) application that relies on the information supporting the approval of the drug or the change to the drug for which the information was submitted and the exclusivity granted.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book Listing.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is referred to as the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD&#8217;s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. The ANDA or 505(b)(2) application also will not receive final approval until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. We intend to defend vigorously any patents for our approved products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Regulation Outside of the United States </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The way clinical trials are conducted in the EU will undergo a major change when Regulation (EU) 536/2014 governing clinical trials in the EU, repealing the existing Directive 2001/20/EC comes into application in 2019. This regulation harmonizes the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database. The EMA will set up and maintain the portal and database, in collaboration with the Member States and the EC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under EU regulatory systems, a company may submit MAAs either under centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the Committee for Medicinal </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Products for Human Use (CHMP) so that an opinion is issued on product approvability. The opinion is considered by the EC which is responsible for granting the centralized marketing authorization in the form of a binding EC decision. If the application is approved, the EC grants a single marketing authorization that is valid for all EU member states as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area (EEA). The decentralized and mutual recognition procedures, as well as national authorization procedure are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State (RMS). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state. Under this procedure the applicant can select the member state that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each Concerned Member State must decide whether to recognize the RMS assessment. If a member state does not agree with the assessment, and the disputed points cannot be resolved the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the CHMP for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all member states. If the application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU, or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant for a similar medicinal product can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare Regulation </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate include, but are not limited to: the federal Anti</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. For example, in June 2018, California Governor Jerry Brown signed the California Consumer Privacy Act of 2018 (CCPA), which takes effect on January 1, 2020 and will broadly define personal information, give California residents expanded privacy rights and protections and provide for civil penalties for violations and a private right of action for data breaches. There are similar legislative proposals being advanced in other states, as well as in Congress. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act (HIPAA). Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we obtain and/or disclose individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. These laws could create liability for us or increase our cost of doing business. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. International laws, such as the EU General Data Protection Regulation 2016/679 (GDPR) and Swiss Federal Act on Data Protection, regulate the processing of personal data within the EU and between countries in the EU and countries outside of the EU, including the U.S. On April 27, 2016, the EU legislature adopted the GDPR, which replaced the prior Directive 95/46/EC when it took effect on May 25, 2018, and it is directly applicable in all Member States. The GDPR applies to EU-based organizations engaged in the processing of personal data belonging to EU data subjects. The GDPR has an extra-territorial effect in the sense that it applies to a &#8220;controller&#8221; or &#8220;processor&#8221; who is not established in the EU and is engaged in processing of personal data of EU subjects. Furthermore, in October 2015, the Court of Justice of the EU declared the previous framework, the International Safe Harbor Privacy Principles (the Safe Harbor) invalid for data transfer between the U.S. and the EU. The Safe Harbor has now been replaced by the EU-U.S. Privacy Shield, a framework for transatlantic exchanges of personal data for commercial purposes between the EU and the U.S. in accordance with the principles of the GDPR.&#160; Accordingly, there may be an immediate impact on companies located in the U.S. as they devote resources to comply with these new obligations. &#160;The GDPR establishes a tiered approach to penalties for breach which enables the data protection authorities of the various Member States to impose fines for certain infringements, including the breach of requirements relating to international transfers or the basic principles for processing of personal data (such as conditions for obtaining consent from that individual whose data is being transferred). The severity of these fines may be up to the higher of 4% of annual worldwide revenue or &#8364;20 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the PPACA) created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services annually certain payments and other transfers of value provided to physicians and teaching hospitals made in the previous calendar year. In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Because our products are covered in the U.S. by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require our products be offered at substantial rebates/discounts to Medicaid and certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program). We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate prices, or offer required discounts or rebates could subject us to substantial penalties.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Subject to the application in the EU of the Transparency Directive 89/105/EEC, which aims to ensure the transparency of measures adopted to control pricing and reimbursement, pricing and reimbursement in the EU/EEA is governed by national rules and policy and may vary from Member State to Member State.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Reimbursement </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Patients may be less likely to use our products if coverage is not provided and reimbursement is inadequate to cover a significant portion of the cost of our products. In addition, although to date qualified patients who </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">would not otherwise be able to afford our products have been able to receive financial support from us in some cases, and from independent patient support foundations in other cases, these programs have recently been subject to significant government scrutiny, and in the future these patients may no longer be able to use our products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Additionally, a third-party payer&#8217;s decision to cover a particular drug product does not ensure that other payers will also provide coverage for the drug product, or will provide coverage at an adequate reimbursement rate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering proposals or have enacted legislative and regulatory changes to the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. There has been particular and increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. At the federal level, there have been several U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Also, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, in October 2018, the Centers for Medicare &amp; Medicaid Services (CMS) proposed a rule that would require drug manufacturers to disclose drug prices in television advertisements. While any proposed measure will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. With respect to drug pricing transparency, for example, in October 2017, California Governor Jerry Brown signed legislation known as SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined threshold to certain purchasers and related reports to the government. SB-17 is currently subject to challenge, but in the meantime, manufacturers must comply with its requirements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the pharmaceutical industry has already been significantly affected by major legislative initiatives, including, for example, the PPACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA recently have been enacted. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January 23, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Congress may continue to consider legislation to repeal and replace some or all elements of the PPACA, and in December 2018, a Texas U.S. District </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Court Judge ruled that the PPACA is unconstitutional in its entirety because of the repeal of the &#8220;individual mandate&#8221; that was part of the Tax Cuts and Jobs Act. Although that ruling is being appealed, we cannot predict the outcome of this litigation, including a possible decision by the United States Supreme Court, or whether other healthcare reform initiatives will continue to be pursued or adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing, which could have a negative impact on our revenue or sales of any products or future approved products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other legislative changes have also been proposed and adopted since the PPACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to 2%&#160;per fiscal year, starting in 2013, and the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, in November 2018, CMS proposed a rule that would allow Medicare Part D and Medicare Advantage plans to limit coverage under certain defined circumstances for certain drugs, including cancer medicines, pursuant to exceptions to the existing &#8220;protected classes&#8221; policy. Such laws or regulations, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding for our products. In the future, there will likely continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including our approved products and any future approved products. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU member states may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits the medicinal product generates for the company placing it on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in countries in the EU do not follow the price structures of the U.S. and they generally tend to be priced significantly lower.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Competition </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are many companies focused on the development of small molecules and antibodies for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cabozantinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that our ability to successfully compete will depend on, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">efficacy, safety and reliability of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">timing and scope of regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to complete clinical development and obtain regulatory approvals for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to successfully commercialize cabozantinib and secure coverage and adequate reimbursement in approved indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product acceptance by physicians and other health care providers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib in&#160;territories where it is approved outside of the U.S.;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">skills of our employees and our ability to recruit and retain skilled employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">protection of our intellectual property; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the availability of substantial capital resources to fund development and commercialization activities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets for which we intend to pursue regulatory approval of cabozantinib are highly competitive. We are aware of products in research or development by our competitors that are intended to treat all of the tumor types we are targeting, and should they demonstrate suitable clinical evidence, any of these products may compete with cabozantinib. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. While we have adapted our development strategy for cabozantinib to address the fact that this approach to treating cancer with ICIs, or ICIs in combination with other therapeutic agents, has become highly prevalent in indications for which our products are approved, CABOMETYX may become less marketable if our clinical trials fail to show efficacy in comparison to competing ICI products or ICI product combinations. Furthermore, the complexities of such a strategy has and may continue to require collaboration with some of our competitors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">CABOMETYX - RCC:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;We believe the principal competition for CABOMETYX in advanced RCC includes: BMS&#8217; nivolumab; the combination of BMS&#8217;s ipilimumab and nivolumab; Pfizer&#8217;s axitinib, sunitinib and temsirolimus, each as single-agent therapies; Novartis&#8217; everolimus and pazopanib, each as single-agent therapies; Bayer&#8217;s and Onyx Pharmaceuticals&#8217; (a wholly-owned subsidiary of Amgen) (Onyx&#8217;s) sorafenib; Roche&#8217;s bevacizumab; the combination of Eisai&#8217;s lenvatinib and Novartis&#8217; everolimus; and Prometheus&#8217; aldesleukin. Additionally, there are a variety of therapies being developed for advanced RCC, including: the combination of Roche&#8217;s bevacizumab and atezolizumab; the combination of Merck&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; the combination of Merck&#8217;s pembrolizumab and Pfizer&#8217;s axitinib; the combination of Pfizer&#8217;s avelumab and axitinib; the combination of Calithera&#8217;s CB-938 and Novartis&#8217; everolimus; AVEO Pharmaceutical&#8217;s tivozanib; and generic versions of sorafenib, everolimus and sunitinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;The competitive landscape for RCC is evolving rapidly, especially given the entrance of ICI combination therapies and potential entrance of ICI-TKI combination therapies into the RCC treatment landscape, particularly in the first-line setting. This will lead to new trends in prescribing and sequencing of certain drugs and combinations across different lines of therapy. It is therefore difficult to predict how these changes will affect sales of CABOMETYX during 2019 and going forward.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">CABOMETYX - HCC: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe the principal competition for CABOMETYX in previously treated HCC includes: Bayer&#8217;s regorafenib; Bayer&#8217;s and Onyx&#8217;s sorafenib; BMS&#8217; nivolumab; Eisai&#8217;s levantinib; and Merck&#8217;s pembrolizumab. Additionally, there are a variety of therapies being developed for previously treated HCC, including: Eli Lilly&#8217;s ramucirumab; and generic versions of sorafenib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">COMETRIQ:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;We believe that the principal competing anti-cancer therapy&#160;to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease. We believe that COMETRIQ also faces competition as a treatment for progressive, metastatic MTC from off-label use of certain treatments, including: Bayer&#8217;s and Onyx&#8217;s sorafenib; Pfizer&#8217;s sunitinib; Takeda&#8217;s ponatinib; Novartis&#8217; pazopanib; and Eisai&#8217;s lenvatinib. Additionally, there are a variety of compounds being developed for MTC with early-stage clinical trials in progress, including: Blueprint Medicine Corporation&#8217;s BLU-667 (for certain subsets of MTC patients); and Loxo Oncology, Inc.&#8217;s LOXO-292 (which was recently granted Breakthrough Therapy Designation by the FDA for the treatment of patients with RET-mutant MTC who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Potential Cabozantinib Indications Beyond RCC, MTC and previously treated HCC:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;We have initiated COSMIC-311, a phase 3 pivotal trial evaluating cabozantinib in patients with DTC who have progressed after up to two prior VEGFR-targeted therapies, and COSMIC-312, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with previously untreated HCC. However, we face a rapidly evolving treatment landscape for the treatment of both of these indications, as other therapies have recently received regulatory approval or are in advanced stages of clinical development, which may impair the relative value of CABOMETYX or a combination of CABOMETYX with an ICI in DTC and previously untreated HCC, respectively. Should cabozantinib be approved for this indication of DTC, we believe its principal competition may include: Bayer&#8217;s and Onyx&#8217;s sorafenib; and Eisai&#8217;s lenvatinib. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with previously untreated advanced HCC, we believe its principal competition may include: Eisai&#8217;s levantinib; Bayer&#8217;s and Onyx&#8217;s sorafenib; BMS&#8217;s nivolumab; the combination of Merck&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; BeiGen and Celgene&#8217;s tislelizumab; the combination of Roche&#8217;s bevacizumab and atezolizumab; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">AstraZeneca&#8217;s durvalumab; the combination of AstraZeneca&#8217;s durvalumab and tremelimumab; and generic versions of sorafenib. Examples of potential competition for cabozantinib in other cancer indications include: other VEGF pathway inhibitors, including Genentech&#8217;s bevacizumab and Pfizer&#8217;s axitinib; other RET inhibitors including Eisai&#8217;s lenvatinib and Takeda&#8217;s ponatinib; other MET inhibitors, including Astra Zeneca&#8217;s savolitinib, Pfizer&#8217;s crizotinib and Mirati&#8217;s glesatinib; and ICIs such as BMS&#8217;s ipilimumab and nivolumab, Merck&#8217;s pembrolizumab and Roche&#8217;s atezolizumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cobimetinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that cobimetinib&#8217;s principal competition amongst targeted agents includes: the combination of Novartis&#8217; trametinib and dabrafenib; and the combination of Array&#8217;s encorafenib and binimetinib. Within the class of ICIs, we believe that cobimetinib&#8217;s principal competition includes: the combination of BMS&#8217;s ipilimumab and nivolumab; and Merck&#8217;s pembrolizumab. The second category, ICIs, are of particular competitive importance vis-a-vis cobimetinib in advanced melanoma as they are already FDA approved in melanoma patient populations that overlap with those that may be eligible for cobimetinib, they have been rapidly incorporated into the NCCN treatment guidelines, and they are viewed with a high degree of enthusiasm by physicians and key opinion leaders. Ongoing and future trials incorporating ICIs, including combination trials, may further impact usage of cobimetinib in melanoma and potentially in additional tumor types in which cobimetinib may ultimately gain approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Competition for Esaxerenone</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that esaxerenone&#8217;s principal competition for the treatment of hypertension in Japan will be Bayer&#8217;s MR antagonist, finerenone, if and when it is approved by the MHLW. Finerenone is still in development for this indication, and results from ongoing clinical studies are not expected during 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Significant Customers</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate as a single business segment and have operations solely in the U.S. During the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we derived </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from Ipsen, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from Caremark L.L.C. and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from affiliates of McKesson Corporation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patents and Proprietary Rights </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We actively seek patent protection in the U.S., Europe and selected other foreign countries to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. We own all global patents associated with cabozantinib, cobimetinib and our other drug candidates referenced below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cabozantinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib is covered by 10 issued patents in the U.S., building from U.S. Pat. No.&#160;7,579,473, for the composition-of-matter of cabozantinib and pharmaceutical compositions thereof. This composition of matter patent would expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The following table describes the US patents that cover our marketed cabozantinib products, and which are listed in the Orange Book. Except as otherwise noted, the stated expiration dates include any patent term extensions already granted. In addition to the composition of matter patent referenced above, the table includes patents directed to, among other things, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our cabozantinib products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4251968503937%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:13%;"></td><td style="width:14%;"></td><td style="width:52%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">General Subject Matter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent Expiration</font></div></td></tr><tr><td rowspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,579,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,497,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,877,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,724,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Formulations of cabozantinib</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2033</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,039,757</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2031</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,034,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Methods of treatment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2031</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,579,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,877,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,717,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Formulations of cabozantinib</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2032</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Filed for inclusion in the Orange Book for patients with HCC who have been previously treated with sorafenib</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In Europe, cabozantinib is protected by issued patents covering the composition-of-matter and methods of use. The issued patent would expire in September 2024, but we have applied for and either have obtained, or expect to obtain Supplementary Protection Certificates in Europe to extend the term to 2029. In addition to the composition of matter patent, the table below includes later-expiring patents directed to the commercial product, including, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4251968503937%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:13%;"></td><td style="width:14%;"></td><td style="width:52%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">General Subject Matter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patent Expiration</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2213661</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter and methods of treatment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2387563</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib and methods of treatment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2030</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2213661</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Composition of matter and methods of treatment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2387563</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Salt and polymorphic forms of cabozantinib and methods of treatment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2030</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Similarly in Japan, cabozantinib is protected by an issued patent covering the composition-of-matter, and salts thereof, as well as pharmaceutical compositions and related methods of use. We intend to apply for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European composition of matter patents have been issued in Australia and Canada, and are anticipated to expire in 2024. We have other filed patent applications and issued patents in the U.S. and other selected countries covering certain synthetic methods, salts, polymorphs, formulations, and combinations of cabozantinib that, if issued, are anticipated to expire as late as 2035</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Outside the U.S. and Japan, cabozantinib is licensed to Ipsen; in Japan cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements. A discussion of risks and uncertainties that may affect our patent position and other proprietary rights is set forth in &#8220;Risk Factors,&#8221; contained in Part I, Item 1A of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cobimetinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cobimetinib is covered by three issued patents in the U.S., including U.S. Pat. No 7,803,839 for the composition of matter of cobimetinib and pharmaceutical compositions thereof. U.S. Pat. No 7,803,839 would normally expire in February 2027, but we have applied for a patent term extension to extend the term to November 2029. Cobimetinib is also covered by an issued patent in Europe (covering the composition-of-matter of cobimetinib and certain methods of use), which would normally expire in October 2026, but we have applied for and are obtaining Supplementary Protection Certificates to extend the term to November 2030. Foreign counterparts of the issued U.S. and European patents are issued or pending in Australia, Canada, Japan and selected other foreign countries. We have filed patent applications in the U.S. and other selected countries covering certain salts and polymorphs of cobimetinib that, if issued, are anticipated to expire in approximately 2036. We have filed patent applications in the U.S. and other selected countries covering certain synthetic methods related to making cobimetinib that, if issued, are anticipated to expire in approximately 2033. Cobimetinib is licensed to Genentech in the U.S. and to Roche outside of the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Drug Candidates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also have pending patent applications, and will continue to file new patent applications, in the U.S., Europe and other selected countries covering the composition-of-matter of our other drug candidates in clinical and/or preclinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development. We intend to describe these patents in more detail once it is determined that a particular drug candidate warrants further development.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not believe that&#160;patent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">protection is appropriate or can be obtained. We also require all of our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive proprietary information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all proprietary information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Furthermore, our agreements with employees and, in most circumstances, our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors expressly provide that all inventions, concepts, developments, copyrights, trademarks or other intellectual property developed by an employee during the employment period, or developed by a service provider during the service period or utilizing our proprietary drugs or information, shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Employees</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had 484 full-time equivalent employees, all of which are located in the U.S. None of our employees are represented by a labor union, and we consider our employee relations to be good.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We make available free of charge on or through our website our Securities and Exchange Commission (SEC) filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</font></div><div><a name="s123F1A4230FD574F9AE4120364651BF5"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future our ability to maintain or meaningfully increase unrestricted cash flow to fund our commercial operations and our development and discovery programs is dependent upon the continued successful commercialization of CABOMETYX for the treatment of RCC and HCC, in each case in territories where it has been approved and according to the terms of such regulatory approvals. The commercial opportunity for CABOMETYX as a treatment for RCC and HCC remains subject to a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for these conditions.&#160;If revenue from CABOMETYX decreases or remains flat, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations. Furthermore, as a consequence of our collaboration agreements with Ipsen and Takeda, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaborators dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaborators depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, foreign sales of CABOMETYX by our collaborators could be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions or barriers and changes in tariffs, including as a result of the United Kingdom&#8217;s (UK) pending withdrawal from the EU (commonly referred to as &#8220;Brexit&#8221;), escalating global trade and political tensions, or otherwise. If our collaborators are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX has been approved for the treatment of advanced RCC in the U.S., the EU and other territories, and for the treatment of previously treated HCC in the U.S. and the EU. Following these approvals, our ability to grow our company remains contingent upon, among other things, further success in the clinical development, regulatory approval and market acceptance of cabozantinib, the active pharmaceutical ingredient in CABOMETYX, in potential additional indications. We cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval. Should we prove unsuccessful in advancing the further clinical development and commercialization of cabozantinib beyond its currently approved indications, we may be unable to execute our business plans, which could have a material adverse impact on our business, financial condition and results of operations. Even if we and our partners receive the required regulatory approvals to market cabozantinib for any additional indications or in additional territories, we and our partners may not be able to effectively commercialize CABOMETYX in these additional indications or territories. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to increase revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. If CABOMETYX does not continue to be prescribed broadly for the treatment of advanced RCC and achieve market acceptance for the treatment of previously treated HCC, we may not be able to grow product revenues. The degree of market acceptance of CABOMETYX will depend upon a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of CABOMETYX in comparison to competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the safety of CABOMETYX, including the existence of serious side effects of CABOMETYX and their severity in comparison to those of competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#8217;s relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">potential unexpected results connected with analysis of data from future or ongoing clinical trials of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of CABOMETYX label expansions for additional indications, if any, relative to competitive treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the price of CABOMETYX relative to competitive therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">price increases taken by us and the impact on the net sales price of CABOMETYX as a result of any new laws, regulations or other government initiatives affecting pharmaceutical pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, market access and product distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the sufficiency of commercial and government health insurance coverage and adequacy of reimbursement for CABOMETYX; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to CABOMETYX.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in the event that any of these or other factors cause market acceptance of CABOMETYX to decrease, this could negatively impact our revenues, which could have a material adverse impact on our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are competitive, highly diversified and are characterized by rapid technological change, particularly in the area of novel oncology therapies. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage. Further, our competitors may be more effective at using their technologies to develop commercial products. As a result, our competitors may be able to more easily develop products that would render our products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates that we are not aware of at an earlier stage of development that may compete with our marketed products and product candidates. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Delays in the development of cabozantinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, the indications for which CABOMETYX is approved are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. While we have adapted our development strategy for cabozantinib to address the fact that this approach to treating cancer with ICIs in combination with other therapeutic agents has become highly prevalent in indications for which our products are approved, we cannot ensure that our clinical trials will show efficacy in comparison to competing products or product combinations. Furthermore, the complexities of such a development strategy has and may continue to require collaboration with some of our competitors. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also may face competition from manufacturers of generic versions of our marketed products, and both Congress and the FDA are seeking to promote generic competition, including through proposals that may limit or reduce the term for patent exclusivity or regulatory exclusivity for branded products. Such generic competition often results in very significant decreases in the overall sales or prices at which branded products can be sold.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and product distribution capabilities for our products or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial-stage oncology-focused biotech companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded, and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, we may be unable to maximize the commercial potential of CABOMETYX and COMETRIQ in their approved indications. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly judge the requisite size and experience of our current commercialization teams or the level of distribution necessary to market and sell CABOMETYX successfully in multiple indications. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize our products will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers to handle storage and distribution for our commercial supplies of both CABOMETYX and COMETRIQ in the U.S. Furthermore, we rely on our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration partners for ongoing and further commercialization and distribution of CABOMETYX and COMETRIQ in their respective territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs) with the effect of introducing earlier patient access to CABOMETYX and COMETRIQ.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third-party services related to the distribution of CABOMETYX and COMETRIQ on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or obtain for our products both sufficient health insurance coverage and adequate reimbursement from third-party payers, our business will suffer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and adequate reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients may not be capable of paying for CABOMETYX or COMETRIQ themselves and may rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or adequate reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ. Third-party payers continue to scrutinize and manage the prices charged for pharmaceutical products and services, and many also limit reimbursement for newly-approved products and indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct or inaccurate reporting, the laws that may affect our ability to operate include, without limitation:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute (AKS), which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Among other things, this statute prohibits persons and entities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests, value-added services to customers, and providing anything at less than its fair market value;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the FDCA and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HIPAA and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the PPACA Open Payments program created under the Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities, as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">well as state and local laws requiring the registration of pharmaceutical sales representatives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals) and its foreign equivalents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state and municipal pharmaceutical price and price reporting laws, both existing (e.g., California&#8217;s SB-17) and under consideration, which require or propose to require us to provide notice of price increases and/or file complex ancillary reports concerning prices and pricing and discount practices. The legal and regulatory landscape, and associated compliance obligations imposed on pharmaceutical companies, may increase general and administrative costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;cause revenue fluctuations due to speculative buying practices by purchasers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or diminish our revenues as a result of the imposition of caps on pricing and price increases.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, govern certain marketing practices, including off-label promotion. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. These individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to commercialize our marketed products profitably.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, we may face uncertainties as a result of executive, legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect pending an appeal of the decision, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the PPACA will impact the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not have a material adverse impact on our business financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business. The Trump Administration has also indicated an intention to regulate prescription drug pricing, and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which will reauthorize the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which manufacturers of such products partially pay for the FDA&#8217;s pre-market review of their product candidates. The legislation includes, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals that would limit or reduce the term for patent exclusivity or regulatory exclusivity in the biopharmaceutical industry. While we cannot currently predict the specific outcome or impact on our business of such regulatory actions or legislation, they do have the potential to facilitate the development and future approval of generic versions of our products or otherwise limit or reduce the term for our market exclusivity, which could result in very significant decreases in the overall sales or prices of our marketed products and materially harm our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. Insurers also continue to pursue means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. These policy actions could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs. Requests could originate in various forms, including through a Congressional inquiry (e.g., from the U.S. Senate Finance Committee) or a subpoena from the U.S. Department of Justice. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects. It is possible that these inquiries could result in: negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products; and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing (including requirements for pharmaceutical manufacturers to report price increases and provide a public justification for these increases if they exceed certain benchmarks), review the relationship between pricing and manufacturer patient programs, reduce the price of drugs </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">under Medicare, reform government program reimbursement methodologies for drugs, and facilitate value-based arrangements between manufacturers and payers. Also, the Trump Administration&#8217;s budget proposal for fiscal year 2019 contains drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, both Congress and the Trump Administration have indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, in October 2018, CMS proposed a rule that would require drug manufacturers to disclose drug prices in television advertisements, and in November 2018, CMS proposed a rule that would allow Medicare Part D and Medicare Advantage plans to limit coverage under certain defined circumstances for certain drugs, including cancer medicines, pursuant to exceptions to the existing &#8220;protected classes&#8221; policy. In addition, the U.S. Department of Health and Human Services (HHS) Office of Inspector General has solicited input for proposed rulemaking related to the potential addition of &#8220;safe harbor&#8221; regulations for the AKS. This solicitation aims, among other things, at changes to pharmaceutical contracting and discounting (including potentially encouraging value-based contracting). We cannot know what form any final regulations promulgated by CMS or the HHS Office of Inspector General might look like or how they could affect our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing, including the National Medicaid Pooling Initiative. With respect to drug pricing transparency, for example, in October 2017, California Governor Jerry Brown signed SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined threshold to certain purchasers and related reports to the government. SB-17 is currently subject to challenge, but in the meantime, manufacturers must comply with its requirements. We do not know what form legislative proposals concerning drug prices may take in other states or how they would affect us. It is possible that these laws would encourage federal and state healthcare programs to reduce the amount of reimbursements they provide for prescription drugs, and any reduction in reimbursement from these government healthcare programs may result in a similar reduction in payments from private payers. We also believe that pricing transparency requirements, such as the requirement for us, in certain circumstances, to provide lengthy notices of price increases to purchasers, may influence customer ordering patterns for CABOMETYX and COMETRIQ, and that this, in turn, may increase the volatility of our revenues as a reflection of changes in inventory volumes. Therefore, the implementation of these cost cost</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in some foreign countries, particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to twelve months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner, Ipsen, may be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients in affording pharmaceuticals have become the subject of scrutiny. In recent years, some pharmaceutical manufacturers were named in class action lawsuits challenging the legality of their patient assistance programs and support of independent charitable patient support foundations under a variety of federal and state laws. Our patient assistance program and support of independent charitable foundations could become the target of similar litigation. At least one insurer also has directed its network pharmacies to no longer accept manufacturer co-payment coupons for certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">specialty drugs the insurer identified. In addition, certain state and federal enforcement authorities and members of Congress have initiated inquiries about co-pay assistance programs. Some state legislatures have also been considering proposals that would restrict or ban co-pay coupons.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there has been regulatory review and enhanced government scrutiny of donations by pharmaceutical companies to patient assistance programs operated by charitable foundations. The HHS Office of Inspector General has established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor&#8217;s product. If we are deemed not to have complied with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Further, numerous organizations, including pharmaceutical manufacturers, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support, and certain of these organizations have entered into, or have otherwise agreed to, significant civil settlements with applicable enforcement authorities. In connection with these civil settlements, the U.S. government has and may in the future require the affected companies to enter into complex corporate integrity agreements that impose significant reporting and other requirements on those companies. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to government regulations relating to privacy and data protection that have required us to modify certain of our policies and procedures with respect to the collection and processing of personal data, and future regulations may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to maintain compliance with these regulations could jeopardize certain business transactions and create additional liabilities for us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection in the U.S. continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use and disclosure of personal information. For example, in June 2018, California Governor Jerry Brown signed the CCPA,&#160;which takes effect on January 1, 2020 and will broadly define personal information, give California residents expanded privacy rights and protections and provide for civil penalties for violations and a private right of action for data breaches. There are similar legislative proposals being advanced in other states, as well as in Congress. In addition, most healthcare providers who are expected to prescribe our products, and from whom we obtain patient health information, are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU Data Privacy Directive (95/46/EC) and implementing legislation in the various national Member States of the EU was replaced on May 25, 2018 by the more restrictive GDPR, which now regulates the processing of personal data within the EU and between countries in the EU and countries outside of the EU, including the U.S. Switzerland is updating the Swiss Data Protection Act, and updates to data protection laws in other countries may occur in due course. In connection with these new laws, in particular the CCPA and GDPR, we have modified certain of our policies and procedures with respect to the collection and processing of personal data to the extent necessary given our operations and commensurate with similar companies in our industry. We will continue to review all future privacy and other regulations implemented pursuant to the CCPA, GDPR and other applicable laws to assess whether additional procedural safeguards are warranted, which may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to provide adequate privacy protections and maintain compliance with these laws and regulations could jeopardize certain domestic and cross-border business transactions and create additional liabilities for us, including the imposition of sanctions or other penalties, as well as increase our cost of doing business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">505(b)(2) NDA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail above in &#8220;Item 1. Business&#8221; under the heading "Government Regulation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Hatch-Waxman Act.&#8221; In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our drugs prior to the expiry of one or more listed patents for the drug, we may end up engaging in litigation with the potential generic competitor to protect our patent rights, which would require us to incur significant expense and result in distraction for our management team, and could also have an adverse impact on our stock price. Moreover, if any such ANDAs or 505(b)(2) NDAs were to be approved, and if our listed patents covering cabozantinib were held to be invalid (or if any such competing generic versions of cabozantinib were found not to infringe our patents), we would have generic competitors in the market, and the resulting generic competition would negatively affect our business, financial condition and results of operations. In particular, generic cabozantinib products would be significantly less costly than ours to bring to market. Companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, regardless of the regulatory approval pathway, the introduction of a generic version of any of our marketed products could result in very significant decreases in the overall sales or prices of these marketed products and materially harm our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new potential product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval in a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and later stage clinical trials may fail to confirm the results observed in earlier stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of cabozantinib in new indications</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or of our other product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or a tolerable safety profile;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results may require us to conduct further testing or to abandon projects that we had expected to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lower-than-anticipated patient registration or enrollment in our clinical testing, resulting in the delay or cancellation of clinical testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaborators to provide us on a timely basis with an adequate supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulators or institutional review boards may withhold authorization to commence or conduct clinical trials of cabozantinib or another product candidate, or delay, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their determination that participating patients are being exposed to unacceptable health risks.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of the clinical testing of cabozantinib or our other product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our clinical and commercial collaboration partners to fund a significant portion of the clinical development of cabozantinib and our product candidates. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for the financial obligations associated with the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">characteristics of the product candidate under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of patients who ultimately participate in the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the length of time required to enroll suitable patient subjects.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a MAA to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC, previously treated HCC and MTC, or one of our other product candidates, the approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC, we are subject to a post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet ultimately fail to yield product candidates for clinical development for a number of reasons. For example, potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery effort or if we are unable to successfully obtain rights to suitable product candidates, our business, financial condition and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or inadvertent disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a materially adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image and goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements, Accounting and Financial Results</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to maintain or increase profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$690.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; other collaboration revenues; and the level of our expenses, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We expect to continue to spend significant additional amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the execution of strategic transactions that align with our oncology drug development expertise, which efforts could involve substantial costs. To offset these costs, we will need to generate substantial revenues. If these costs exceed our expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be forced to limit the expansion of our product development programs or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$851.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$850.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations. Our business operations continued to grow substantially during 2018. In order to maintain business growth and maximize the clinical and commercial opportunities for cabozantinib, we plan to continue to execute on the U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib, both alone and in combination with other therapies, research and development activities, as well as through strategic transactions. Our ability to execute on these business objectives will depend on many factors including but not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to control costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including any disruptions resulting from government shutdowns, the UK&#8217;s pending withdrawal from the EU, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets.&#160;Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160; Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to limit the expansion of our product development programs or commercialization efforts, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations, particularly those relating to the way we account for revenues and costs. New pronouncements from the Financial Accounting Standards Board (FASB) and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The recently passed comprehensive tax reform bill could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017 and December 31, 2018, or are expected to be recorded in future periods. Additionally, further guidance may be forthcoming from the FASB and SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts, possibly with retroactive effect. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of earnings and applicable tax rates in the various places that we operate, the accounting for stock options and share based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws such as the passage of the Tax Cuts and Jobs Act, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2018, we had federal and state net operating loss carryforwards of approximately $1.1 billion. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2028 for federal income tax purposes and 2028 for California state income tax purposes. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2018, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The transition away from the London Interbank Offered Rate (LIBOR) could affect the value of certain short-term investments, as well as our ability to seek additional debt financing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Actions by governmental entities may impact certain financial instruments in which we have invested or may invest in the future. For example, some of these financial instruments may rely in some fashion upon LIBOR, which is an average interest rate, determined by the ICE Benchmark Administration, that banks charge one another for the use of short-term money. The UK's Financial Conduct Authority, which regulates LIBOR, has announced plans to phase out the use of LIBOR by the end of 2021. While only a small percentage of our short-term investments include financial instruments subject to LIBOR, and while we do not currently have any outstanding debt that is subject to LIBOR, there remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, and any potential effects of the transition away from LIBOR on certain instruments in to which we may enter in the future are not known. The transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that currently rely on LIBOR. The transition may also result in reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes.&#160; Any such effects of the transition away from LIBOR, as well as other unforeseen effects, result in expenses, difficulties, complications or delays in connection with future financing efforts, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The UK&#8217;s pending withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Brexit has created significant uncertainty concerning the future relationship between the UK and the EU. While discussions between the UK and the EU focused on finalizing withdrawal issues and transition agreements are ongoing, limited progress to date in these negotiations and ongoing uncertainty within the UK government and parliament sustains the possibility of the UK leaving the EU on March 29, 2019 without a withdrawal agreement and associated transition period in place, which is likely to cause significant market and economic disruption. The effects of Brexit will depend on any agreements the UK makes to retain access to EU markets either during a transitional period or more permanently. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the UK and the EU, undermine bilateral cooperation in key policy areas and significantly disrupt trade between the UK and the EU. In addition, Brexit&#160;could lead to legal uncertainty and potentially divergent national laws and regulations as the UK determines which EU laws to replace or adopt. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the UK from the EU would have and how such withdrawal would affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, which are responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU, and any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that result from Brexit may have an adverse impact on this part of our supply chain. In addition, trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaborator Ipsen to market our products in Europe. Furthermore, the announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations, and the pending withdrawal of the UK from the EU may also adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit, among others, could have a material adverse impact on our business, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subject us to a number of risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo and BMS for the development and ultimate commercialization of certain compounds generated from our research and development efforts. Our dependence on our relationships with collaborators for the development and commercialization of compounds subjects us to, a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborators may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, deliver product that fails to meet appropriate quality and regulatory standards and results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes that may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for COTELLIC, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators may experience financial difficulties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; lack of success in their efforts to obtain regulatory approvals in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with the terms of our collaboration agreements and related ancillary agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to GMP, GCP, GDP and Good Pharmacovigilance Practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators could independently move forward with competing drug candidates developed either independently or in collaboration with others, including our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to enter into additional collaboration arrangements with other parties in an area or field of exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of development of our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, our product development efforts could be delayed, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations expand due to our development and commercial progress, we expect to enter into new agreements with additional third-party contract manufacturers and suppliers as needed. This will continue for the foreseeable future for all of our product candidates and all of our current and future commercial products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to ensure compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and have a material adverse impact on our business, financial condition and results of operations. Through our third-party contract manufacturers and data service providers, we have implemented product serialization designed to comply with the DSCSA, pursuant to which all prescription pharmaceutical products manufactured and distributed in the U.S. were required to be serialized as of November 27, 2018. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our collaborators&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientific advisors and collaborators may be subject to restriction and change.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These advisors and collaborators are not our employees and may have other commitments or pursue other opportunities that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as advisors and collaborators or otherwise limit our access to these experts, or that the advisors themselves may now be more reluctant to work with industry partners. In any of these circumstances, we may lose </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">work performed by these advisors and collaborators or be unable to engage them in the first place, and our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Information Technology, Data Privacy and Intellectual Property</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber-attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cyber-security efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our contract manufacturing organizations, contract research organizations or vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees and others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cyber-security systems at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, should any third parties receive FDA approval of an ANDA for a generic version of cabozantinib or an 505(b)(2) NDA with respect to cabozantinib, and if our patents covering cabozantinib were held to be invalid (or if such competing generic versions of cabozantinib were found to not infringe our patents), then they could introduce generic versions of cabozantinib or other such 505(b)(2) products before our patents expire, and the resulting generic competition would negatively affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third-party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to develop or commercialize certain product candidates, which could severely harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, facilities, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial and scientific personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, in the second quarter of 2018, we moved our corporate headquarters from South San Francisco, California to Alameda, California. This relocation may make it more difficult to retain certain employees, and any resulting loss of talent and need to recruit and train new employees could be disruptive to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, a disaster could cause significant delays in our programs and make it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability and have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, any hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as a result of multiple factors, including pricing information required to be disclosed by us pursuant to drug pricing transparency laws</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in the amount of deductions from gross sales, including changes to the discount percentage of rebates and chargebacks mandated by the government programs in which we participate, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and chargebacks and changes in patient demographics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones under our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and business development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third-party vendor relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in the fourth quarter of 2018, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against deferred tax assets was released. Therefore, beginning in 2019, we expect to commence recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which would result in a significant reduction in our net income and net income per share. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the possibility of such fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements related to our or our collaborators&#8217; clinical trials or delays in those clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaborators&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products or clinical trial data by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications seeking a path to U.S. approval of generic versions of our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel or board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the extent to which coverage and adequate reimbursement is available for both CABOMETYX and COMETRIQ from government and health administration authorities, private health insurers, managed care programs and other third-party payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the pending Brexit and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including possible repeal and/or replacement of all or portions of PPACA or increases or changes in tariffs and other trade restrictions stemming from Trump administration and foreign government policies, or future U.S. federal government shutdowns, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a classified Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">limitations on the removal of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div><a name="s2214BBA635F959E1BBBA0EB7A7AAC7CD"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1B. Unresolved Staff Comments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">None.</font></div><div><a name="sF6C67EA79C105256834C57AA4E2B4260"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Properties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We lease a total of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of office and research facilities in the San Francisco Bay Area. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The lease expires in January 2028. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have two five-year options to extend the lease and a one-time option to terminate the lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year of the initial term. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that our existing leased facilities as well as our rights to acquire additional space under our existing lease arrangements are sufficient to accommodate our current and near-term needs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><a name="s56F486021F185BDEB73A36BAA4A53B33"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are not a party to any material legal proceedings. We may from time to time become a party or subject to various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><a name="sF84D951091645315B053F5CB68FA47FF"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sC6AACBE7367C583E91F6CBF85BDE4B81"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II</font></div><div><a name="s32C2946A795C51558F3DA5858775020C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April 11, 2000.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Holders</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">February&#160;12, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were 398 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dividends</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unregistered Sales of Equity Securities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no unregistered sales of equity securities by us during the year ended December&#160;31, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following graph compares, for the five year period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the cumulative total stockholder return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2013 in each of our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="fiveyearchart2018.jpg" alt="fiveyearchart2018.jpg" style="height:353px;width:672px;"></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:29%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Composite Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Biotechnology Index</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><a name="s55C17F35F8C85AAF9B55986D5634D97E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Selected Financial Data</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following Selected Financial Data has been derived from our audited Consolidated Financial Statements and should be read in conjunction with Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part II, Item 8. &#8220;Financial Statements and Supplementary Data&#8221; contained in this Annual Report on Form 10-K. The consolidated financial information as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and for the years ended, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are derived from audited Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K. The consolidated financial information as of December&#160;31, 2016, 2015 and 2014, and for each of the years ended December&#160;31, 2015 and 2014, are derived from audited Consolidated Financial Statements not included in this Annual Report on Form 10-K. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;font-weight:bold;">(In thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,895</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">189,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,829</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">219,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">249,569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">438,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(28,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(121,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(224,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expenses), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, basic </font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">194,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, diluted</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">194,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">851,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">479,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">242,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Working capital (deficit) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">791,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">369,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,422,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">332,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">323,256</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">255,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">420,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(880,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,912,925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,751,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,287,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(140,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(159,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><a name="sDC0589145EF15F89995F8E0C0F60BDBC"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; fiscal year 2018 ended on December 28, 2018; and fiscal year 2019 will end on January 3, 2020. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, December 28, 2018 and January 3, 2020 are indicated as being as of and for the years ended (or ending, as applicable) December&#160;31, 2016, 2017, 2018 and 2019, respectively. The annual period and quarterly period ending January 3, 2020 are a 53-week fiscal year and a 14-week fiscal quarter, respectively; all other annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are an oncology-focused biotechnology company that aims to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development and received regulatory approval; three have a growing commercial presence in markets worldwide, and we expect that the fourth will soon enter the marketplace in Japan. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX tablets approved for advanced RCC and previously treated HCC, and COMETRIQ capsules approved for progressive, metastatic MTC. The two other products resulting from our discovery efforts are: COTELLIC, an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech; and MINNEBRO, an oral, non-steroidal, selective blocker of the MR approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX was first approved by the FDA, for previously treated patients with advanced RCC in April 2016, and then in December 2017, approximately two months ahead of the assigned PDUFA action date, the FDA expanded CABOMETYX&#8217;s approval in this indication to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib. This most recent approval was based on results from CELESTIAL, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which demonstrated a statistically significant and clinically meaningful improvement in OS versus placebo. We are highly focused on optimizing the execution of this commercial launch</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in HCC in the U.S. through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our commercial and medical affairs organizations and established distribution network.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we have entered into license agreements with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda. Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Both partners also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, since the initiation of our collaboration Ipsen has continued to execute on its commercialization plans, most recently receiving regulatory approval from the EC for CABOMETYX </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for HCC in adults who have previously been treated with sorafenib, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda continues to conduct clinical development activities in both RCC and HCC, with the goal of supporting future regulatory filings in Japan. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our partners for rest of world regulatory and commercialization activities, we are also focused on the next wave of cabozantinib&#8217;s clinical development program, pursuing other indications that have the potential to expand the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">therapies, in a broad development program comprising&#160;over </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">75</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our CRADA with NCI-CTEP or our IST program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s late-stage development program. One pivotal trial that has resulted from this effort is COSMIC-311, our phase 3 trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies initiated in October 2018. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with ICIs to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs in multiple clinical trials. The most advanced of these combination studies include Checkmate 9ER, a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated advanced or metastatic RCC, and Checkmate 040, a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with both previously treated and previously untreated advanced HCC. Both trials are in collaboration with BMS. As a further part of our clinical collaboration with BMS, we also plan to evaluate cabozantinib and nivolumab with or without ipilimumab in various other tumor types, including UC. Diversifying our exploration of combinations with ICIs, we have also initiated COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab, versus sorafenib in previously untreated advanced HCC, and COSMIC-021, a phase 1b dose escalation study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The COSMIC-021 study comprises eighteen tumor expansion cohorts, including multiple therapeutic settings of RCC, UC, and NSCLC and single therapeutic settings of HCC, CRPC, TNBC, EOC, endometrial cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, DTC and head and neck cancer of squamous cell histology, and is currently enrolling. Findings from the dose escalation stage of the study demonstrate that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. Depending on the results from COSMIC-021, we may also evaluate this combination in various other tumor types, including NSCLC. COSMIC-021 also includes two exploratory cohorts that will evaluate cabozantinib as a single-agent therapy in NSCLC and UC indications. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical, therapeutic and commercial potential of cabozantinib, we also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we have reinitiated internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Notably, these efforts are led by some of the same experienced scientists responsible for the discovery of cabozantinib and cobimetinib, which have been approved for commercialization by regulatory authorities, as well as other promising compounds we have discovered, many of which are in various stages of clinical, regulatory and commercial development pursuant to our collaborations with Daiichi Sankyo and BMS. Using our expertise in medicinal chemistry, tumor biology and pharmacology, we are advancing drug candidates toward and through preclinical development. Furthest along in these internal drug discovery efforts is XL092, a next-generation oral TKI that is currently the subject of an active IND.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These internal drug discovery activities are augmented by efforts to identify and in-license promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. In furtherance of this strategy, in January 2018, we entered into an exclusive global collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of this agreement,&#160;we&#160;have partnered with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. Additionally, in May 2018, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we entered into a collaboration and license agreement with</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Invenra</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. To date, we have initiated two such discovery projects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018 Business Updates and Financial Highlights</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2018, we continued to execute on our commercial, development and financial objectives, generating significant revenue from operations and enabling the business to maximize the clinical and commercial potential of our CABOMETYX and our other internally discovered, commercially available products and to expand the product pipeline. Significant business updates and financial highlights for 2018 and subsequent to year end include:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January and June 2018, we announced amendments to the protocol for COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, to add new expansion cohorts to the trial (for an aggregate of eighteen cohorts), which now includes patients with RCC, UC, NSCLC, CRPC, HCC, TNBC, EOC, endometrial cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, DTC and head and neck cancer of squamous cell histology. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting CK1&#945;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2018, we announced updated results from the NCI-CTEP-sponsored phase 1 trial of cabozantinib in combination with nivolumab, with or without ipilimumab, in patients with refractory genitourinary tumors. The updated results demonstrated an acceptable tolerability profile and high rates of durable responses in the previously treated metastatic UC and metastatic RCC cohorts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2018, we appointed Maria C. Freire, Ph.D. to our Board of Directors. Dr. Freire serves as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health, an independent 501(c)(3) charitable organization established by Congress to support the National Institutes of Health by raising private funds for biomedical research and fostering partnerships and alliances around the world.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with Invenra to discover and develop multispecific antibodies for the treatment of cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, Ipsen received regulatory approval from the EC for CABOMETYX as a treatment for adult patients with previously untreated, intermediate- or poor-risk advanced RCC. The EC&#8217;s approval of CABOMETYX was based on results from CABOSUN, a randomized phase 2 trial comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease that demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR versus sunitinib.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we announced that IMblaze370, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab in patients with CRC, did not meet its primary endpoint. However, Genentech continues to pursue the cobimetinib development program, either as a single-agent or in combination studies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2018, clinical data from cabozantinib were the subject of fifteen presentations at the ASCO 2018 Annual Meeting, including a poster presentation covering a sub-group analysis of CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, comparing outcomes by duration of sorafenib treatment in patients whose only prior treatment was sorafenib and outcomes based on age. The findings showed that cabozantinib improved OS and PFS compared with placebo irrespective of duration of prior sorafenib treatment or age category.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2018, we were added to Standard &amp; Poor&#8217;s (S&amp;P&#8217;s) MidCap 400 index and are classified under S&amp;P&#8217;s Global Industry Classification Standard Biotechnology Sub-Industry index.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2018, the NEJM published results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC. The data demonstrate that cabozantinib provided a statistically significant and clinically meaningful improvement in OS versus placebo.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2018, NCCN updated its Clinical Practice Guidelines to include favorable new recommendations for CABOMETYX as a treatment for patients with advanced RCC, regardless of patient risk status. As part of this update, NCCN also designated CABOMETYX as the only preferred TKI treatment option for previously untreated patients with poor- or intermediate-risk, and the only preferred TKI treatment option for previously treated patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2018, Ipsen received regulatory approval from Health Canada for CABOMETYX as a treatment in Canada for adult patients with advanced RCC who have received prior VEGF-targeted therapy. Health Canada&#8217;s approval of CABOMETYX was based on results from METEOR, our phase 3 trial in which CABOMETYX provided </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a statistically significant and clinically meaningful improvement in OS, PFS and ORR as compared with everolimus in patients with advanced RCC who have received prior anti-angiogenic therapy.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2018, we initiated COSMIC-311, a phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two VEGFR-targeted therapies. This trial was informed by cabozantinib&#8217;s encouraging clinical activity in patients with RAI-refractory DTC in phase 1 and 2 studies for which updated data was presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium in February 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2018, clinical data from cabozantinib were the subject of thirteen presentations at ESMO, including a poster presentation covering the results from the dose escalation stage of COSMIC-021, our phase 1b study evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Findings from the dose escalation phase of the trial demonstrate that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. In another poster presentation, data were presented from an analysis that evaluated the effect of PD-L1 expression on clinical outcomes with cabozantinib in advanced RCC from the CABOSUN and METEOR trials. This analysis showed that cabozantinib&#8217;s activity was independent of PD-L1 expression. Additionally, a separate retrospective analysis of RCC patients found that cabozantinib was active following prior treatment with immune checkpoint inhibitor therapy either alone or in combination with VEGF-targeted or other prior therapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2018, Ipsen received approvals from both the Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria in Brazil for CABOMETYX as a treatment for both previously treated and previously untreated advanced RCC and from the Taiwan Food and Drug Administration for CABOMETYX as a treatment for patients with advanced RCC who have received prior anti-angiogenic therapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, Ipsen received regulatory approval from the EC for CABOMETYX as a treatment for HCC in adults who have previously been treated with sorafenib. The EC&#8217;s approval of CABOMETYX was based on results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, which demonstrated a statistically significant and clinically meaningful improvement in OS versus placebo.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2018, we initiated COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced HCC. We are sponsoring COSMIC-312, and&#160;Ipsen&#160;will co-fund the trial.&#160;Ipsen&#160;will have access to the results to support potential future regulatory submissions outside of the U.S. and&#160;Japan. Roche is providing atezolizumab free of charge. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2019, we announced that our partner Daiichi Sankyo received approval from the MHLW for MINNEBRO as a treatment for patients with hypertension in Japan. MINNEBRO is a compound identified during our research collaboration with&#160;Daiichi Sankyo, which the companies entered into in&#160;March 2006, and has been subsequently developed by&#160;Daiichi Sankyo.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib.&#160;The FDA&#8217;s approval of CABOMETYX was based on results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, which demonstrated a statistically significant and clinically meaningful improvement in OS versus placebo.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2019, the FDA accepted our IND for XL092, a next-generation oral TKI and the first compound to advance from our new discovery organization. The phase 1 dose escalation trial will evaluate its pharmacokinetics, safety and tolerability in patients with advanced solid tumors, with the primary objective of determining a dose for daily oral administration of XL092 suitable for further evaluation. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2018 Financial Highlights </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for 2018 was </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$690.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$2.32</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$2.21</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, diluted, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$154.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$0.52</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$0.49</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share diluted, for 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$853.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$452.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$619.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$349.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$182.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$112.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$206.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$159.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for 2017.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$851.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the second quarter of 2018, Ipsen reached $150.0 million in cumulative net sales of cabozantinib, which resulted in an increase in the minimum royalty rate earned by us to 22% of net sales by Ipsen. Previously we had been entitled to receive a tiered royalty of 2% to 12%. Since reaching that milestone, we are entitled to receive a tiered royalty of 22% to 26% of annual net sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the fourth quarter of 2018, we released substantially all of our valuation allowance against our deferred tax assets which resulted in a </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$244.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;income tax benefit. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;below for a discussion of the detailed components and analysis of the amounts above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will continue to face a number of challenges and risks to our business that may impact our ability to execute on our 2019 business objectives. In particular, we anticipate that for the foreseeable future our ability to maintain or meaningfully increase unrestricted cash flow to fund our commercial operations and our development and discovery programs will be dependent upon the continued successful commercialization of CABOMETYX for the treatment of RCC and HCC, in each case in territories where it has been approved and according to the terms of such regulatory approvals, and in potential other indications for which we are in late-stage development, such as previously treated RAI-refractory DTC. The commercial opportunity for CABOMETYX as a treatment of RCC and HCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of these conditions. Our ability to maintain or meaningfully increase product revenues from CABOMETYX is also affected by a number of other factors, including the highly competitive markets for which we intend to pursue regulatory approval of cabozantinib and the prospect for new competitive therapies and generic competition, and the extent to which coverage and reimbursement for CABOMETYX is available from government and other third-party payers. Obtaining and maintaining appropriate coverage and reimbursement for CABOMETYX is increasingly challenging due to, among other things, the focus healthcare cost containment and other potential austerity measures being discussed in the U.S. and worldwide, as well as increasing interest amongst legislators and policymakers in the U.S. in restricting drug prices through the imposition of pharmaceutical drug price controls. Our ability to fulfill the commercial potential of cabozantinib also depends on whether data generated by our clinical development activities will support regulatory approval of cabozantinib in additional indications. Achievement of our 2019 business objectives will also depend on the success of our development and commercialization strategy formulated to navigate increased competition, including that from, but not limited to, ICIs, as well as the use of combination therapy to treat cancer. Furthermore, our research and development objectives may be impeded as we work to scale our organization to meet the demands of expanded drug development and discovery activities. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or we may not be able to successfully identify appropriate candidates for in-licensing or acquisition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For a complete discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</font></div><div><a name="s8b9fce0a322b4bf381d352697588addc"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">127</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were impacted by our adoption of Accounting Standards Update No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(Topic 606). For additional information on our adoption of Topic 606, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8212;Recently Adopted </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accounting Pronouncements,&#8221; &#8220;Note 2. Revenues&#8221; and &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">599,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in net product revenues for CABOMETYX for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016, were primarily due to a 72% and 228% increase, respectively, in the number of units of CABOMETYX sold, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and, to a lesser extent,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increases in the average selling price of the product. The increases in CABOMETYX sales volumes </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the continued growth of CABOMETYX in advanced RCC </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following regulatory approvals of CABOMETYX for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy in April 2016 and for previously untreated patients with advanced RCC in December 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in net product revenues for COMETRIQ for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016, were primarily due to a 26% and 53% decline, respectively, in the number of units of COMETRIQ sold. COMETRIQ sales volume has continued to decrease since the launch of CABOMETYX in April 2016. The adoption of Topic 606 did not impact our net product revenues.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K. The increase in the reserve balances for discounts and allowances from December 31, 2017 to December 31, 2018 was primarily the result of an increase in product sales volume, and to a lesser extent, higher discounts and participation in government programs, and an increase in commercial contracting. The increase in the reserve balances for discounts and allowances from December 31, 2016 to December 31, 2017 was the result of an increase in product sales volume, and to a lesser extent, additional reserves for goods in the channel expected to have higher discounts during early 2018, as well as a higher volume in government programs. Those increases were partially offset by payments, the issuance of customer credits and the prior period adjustments for chargebacks and certain rebates. We expect our discounts and allowances as a percentage of gross product revenues to increase during 2019 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as our business evolves and the number of patients participating in government programs increases, the discounts and rebates paid to government payers increase </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and as a result of the engagement in commercial contracting that may result in additional discounts or rebates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">192,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,637</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,858</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,905</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">820</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the full recognition of substantive </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:0px;padding-top:0px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only royalties we paid to pay GSK on Ipsen&#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$234.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$103.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The increases in collaboration revenues were primarily the result of increases in milestones revenues, royalties under our collaboration agreement with Ipsen, development cost reimbursement revenues and profit sharing under our collaboration agreement with Genentech; those increases were partially offset by decreases in the recognition of deferred revenue due to the adoption of Topic 606 and increases in the royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues were $164.4 million, $57.5 million and $40.0 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Milestone revenues related primarily to development, regulatory and commercial achievements under our collaboration agreement with Ipsen. Under our Ipsen collaboration, during the year ended December 31, 2018, we recognized three developmental and regulatory milestones totaling $115.0 million and a commercial milestone for $25.0 million, as compared to two developmental and regulatory milestones totaling $40.0 million during 2017. See &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K for additional information about the timing and amounts of revenue associated with the achievement of these milestones. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from year to year</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">R</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">were</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;$32.3 million, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.8 million and $0.2 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increased demand and approvals of CABOMETYX in additional indications and/or jurisdictions outside of the U.S</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We were initially entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales; this amount was reached in the second quarter of 2018. As of December 31, 2018 and going forward, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales (with separate tiers for Canada); these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD$30.0 million of annual net sales and a tiered royalty thereafter to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers for Canada will also reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For 2019, we expect the royalty revenues to increase as a result of achieving the 22% minimum royalty tier.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">connection with our collaboration arrangements with Ipsen and Takeda were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$24.9 million and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.7 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase for the year ended December&#160;31, 2018, was primarily the result of Ipsen&#8217;s and Takeda&#8217;s participation in the CheckMate 9ER study. There were no such development cost reimbursements during the year ended December&#160;31, 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech totaled $13.6 million </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;collaboration revenues included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on ex-U.S. net sales of COTELLIC of $6.4 million and $2.8 million, respectively. Profits and losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016 were included in Selling, general and administrative expenses. We achieved a profit on the U.S. commercialization of COTELLIC in 2018, as compared to a loss in 2017, as Genentech scaled back the personal promotion of COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;resulting in a reduction in commercial expenditures while revenues from the sale of COTELLIC remained relatively flat.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from the amortization of deferred revenue related to the recognition of a portion of the upfront payments received in connection with our February 2016 collaboration agreement with Ipsen and the upfront payment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">received in connection with our January 2017 collaboration agreement with Takeda. Such revenues were $4.5 million, $28.9 million and $13.3 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The decrease in the recognition of such revenues for the year ended December&#160;31, 2018, as compared to 2017 was a result of the adoption of Topic 606; Upon adopting Topic 606 on January 1, 2018, we recorded a $236.7 million reduction of the unrecognized upfront and non-substantive milestone payments previously received from our collaboration partners that had been included in deferred revenue at December 31, 2017 along with a corresponding reduction of our opening accumulated deficit. For the year ended December 31, 2017, we recognized $18.5 million and $10.4 million of such revenue in connection with the Ipsen collaboration agreement and the Takeda collaboration agreement, respectively. For the year ended December 31, 2016, we recognized $13.3 million of such revenue in connection with the Ipsen collaboration agreement. No such revenue was recognized in connection with the Takeda collaboration agreement during 2016. The increase in such revenues for the year ended December&#160;31, 2017, as compared to 2016, is due to the timing of the execution of those agreements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the years ended December&#160;31, 2018, 2017 and 2016, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration revenues were reduced by $5.4 million, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million and $0.2 million, respectively, for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty we are required to pay GSK on the net sales by Ipsen of any product incorporating cabozantinib. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Cost of goods sold and our gross margins were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">130</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we are required to pay </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">GSK on U.S. net sales by us of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing the product, write-downs related to expiring and excess inventory, and other third-party logistics costs. Portions of the manufacturing costs for inventory were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. Cost of goods sold included a 2%, 3% and 7% reduction related to materials that had been previously expensed during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;amounts remaining related to previously expensed materials in our inventory balances as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Write-downs related to excess and expiring inventory were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Cost of goods sold for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to the growth in sales of CABOMETYX. The increase in Cost of goods sold for the year ended December&#160;31, 2017, as compared to 2016, primarily&#160;reflects the growth in product sales of CABOMETYX following the product&#8217;s launch in late April 2016 and an increase in market share. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not expect our gross margin to change significantly during the year ending December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, consulting and outside services, stock-based compensation, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">license costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in Research and development expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in clinical trial costs, personnel expenses, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">license costs and stock-based compensation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$26.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increase in clinical trial costs was primarily due to increased costs associated with: CheckMate 9ER, COSMIC-311, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COSMIC-312 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and the preparation for further pivotal phase 3 trials that are expected to be initiated in 2019. Personnel expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$21.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to an increase in headcount to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">support our development and discovery efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">License costs increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;f</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of our entry into the collaboration agreements with&#160;Invenra and StemSynergy. Stock-based compensation increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to an increase in headcount. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in Research and development expenses for the year ended December&#160;31, 2017, as compared to 2016, was primarily related to an increase in personnel expenses and clinical trial costs. Personnel expenses increased $8.5 million for the year ended December&#160;31, 2017, as compared to 2016, primarily due to support for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our development efforts and our medical affairs organization.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Clinical trial costs increased $4.4 million for the year ended December&#160;31, 2017, as compared to 2016 primarily due to start-up costs associated with CheckMate 9ER and COSMIC-021, partially offset by decreases in costs related to METEOR.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened Research and development expenses on a project-by-project basis.&#160;We group our Research and development expenses into three categories: Development, Drug discovery and Other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Research and development expenses by category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">137,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">78,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,944</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services and laboratory supplies for all periods presented and license costs for our collaboration and license agreements with&#160;Invenra and StemSynergy during the year ended December 31, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of Research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, preliminary data from and final results of clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound, and as a result, we expect our near-term research and development expenses to primarily relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">75</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ongoing or planned clinical trials across multiple indications. Notable studies of this program include: CheckMate 9ER and CheckMate 040, each in collaboration with BMS; company-sponsored COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; and company-sponsored COSMIC-311. In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we have reinitiated internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. These internal drug discovery activities are augmented by efforts to identify and in-license promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. As a result, for 2019 we expect our Research and development expenses to increase as we continue to expand the cabozantinib development program and our product pipeline. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation, marketing costs and corporate giving. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Selling, general and administrative expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in personnel expenses, consulting and outside services, stock-based compensation, corporate giving and marketing costs. Personnel expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in general and administrative headcount to support our commercial and research and development organizations. Consulting and outside services and marketing costs increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in marketing activities in connection with preparations for the CABOMETYX launch in HCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">were partially offset by a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;decrease in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC. For the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, such losses on the U.S. commercialization of COTELLIC were included in Selling, general and administrative expenses whereas for the year ended December&#160;31, 2018, the profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">included in Collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Stock-based compensation increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount. Corporate giving, consisting predominantly of donations to independent patient support foundations, increased $6.4 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in Selling, general and administrative expenses for the year ended December&#160;31, 2017, as compared to 2016, was primarily related to increases in personnel expenses, consulting and outside services, marketing costs and charitable contribution expenses. Personnel expenses increased $11.3 million for the year ended December&#160;31, 2017, as compared to 2016, primarily due to an increase in general and administrative headcount to support our commercial and research and development organizations. Consulting and outside services increased $10.7 million for the year ended December&#160;31, 2017, as compared to 2016, primarily due to increases in consulting for marketing activities. Marketing costs increased $6.6 million for the year ended December&#160;31, 2017, as compared to 2016, primarily due to an increase in losses recognized under our collaboration agreement with Genentech. In December 2016, Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay certain disputed costs that had been accrued by us; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the year ended December 31, 2016, we offset Selling, general and administrative expenses with a $13.3 million recovery of disputed losses that we had recognized and recorded prior to 2016. Marketing costs also included a loss of $2.1 million for activities during the year ended December&#160;31, 2017 under our collaboration agreement with Genentech, as compared to a loss of $4.5 million for activities during 2016. Corporate giving increased $5.2 million for the year ended December&#160;31, 2017, as compared to 2016. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For 2019, we expect modest growth in Selling, general and administrative expenses in 2019 to support our overall organizational growth.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Income (Expenses), Net</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other income (expenses), net, were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2018 v. 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>2017 v. 2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(33,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expenses), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Interest income for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016, respectively, were the result of both an increase in our investment balances and an increase in the yield earned on those investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in Interest expense for the year ended December&#160;31, 2018, as compared to 2017 and 2016, were due to the repayment of the Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes), in June 2017, the repayment of the our $80.0 million term loan with Silicon Valley Bank in March 2017, and the conversions and the redemption of the 4.25% convertible senior subordinated notes due 2019 (2019 Notes), during the third and fourth quarters of 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The changes in Other, net for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016, were primarily due to a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">loss on extinguishment of debt and gains on the sale of other equity investments that both occurred in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During the years ended December&#160;31, 2017 and 2016 we recognized a $6.2 million and $13.9 million loss on extinguishment of debt, respectively, due to the repayment of the Deerfield Notes in June 2017 and the conversions and the redemption of the 2019 Notes during the third and fourth quarters of 2016. There was no such retirement of debt during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Other, net also included gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, during the years ended December&#160;31, 2018, 2017 and 2016, respectively, related to the August 2016 sale of our 9% interest in Akarna Therapeutics, Ltd. (Akarna) to Allergan Holdco UK Limited (Allergan). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Tax Benefit (Provision)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax benefit (provision) were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income taxes benefit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$244.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;benefit related to the release of substantially all of our valuation allowance against our deferred tax assets. The decision to release the valuation allowance was made after we determined that it was more likely than not that these deferred tax assets, including net operating losses and tax credits, would be realized</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and was based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December 31, 2018 and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the release of the valuation allowance in 2018, starting in 2019, we expect to record a provision for income taxes on our pretax income using an estimated effective tax rate between 21% and 23%. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other than the benefit we recorded for the release of our valuation allowance during the year ended 2018, the provision for income taxes for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;primarily related to taxes in states for which we do not have net operating loss carryforwards due to a limited operating history. Our historical losses were sufficient to fully offset our federal taxable income for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Impact of Duration of Fiscal Years</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. 2019 will be a 53-week fiscal year as compared to 52-week fiscal years for 2018, 2017 and 2016. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accordingly, t</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">he 53-week fiscal year in 2019 may result in a modest increase in revenues and expenses, as compared to 2018, 2017 and 2016.</font></div><div><a name="s3DCE916C6CDD5F56A0C0FB2FFD7C6BB4"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$851.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$850.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements, Accounting and Financial Results,&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.&#160;Our assumptions may prove to be wrong or other factors may adversely affect our sources of cash, and as a result we may not have the cash resources to fund our operations as currently planned, which would have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to rebuild our product pipeline through our reinitiated drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Furthermore, even if we believe we have sufficient funds for our current and future operating plans</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">415,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">210,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(297,850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36,795</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(214,548</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(169,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our operating activities provided cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$415.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$165.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$210.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as depreciation and amortization, share-based compensation charges and the release of our valuation allowance against our deferred tax assets; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Results of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the increase in cash provided by operating activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$270.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in net product revenues and $42.5 million increase in cash received for milestones. These were partially offset by a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$128.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in operating expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and by the impact of the upfront nonrefundable payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;received from Takeda in 2017 in consideration for the exclusive license and other rights contained in our collaboration agreement with Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the decrease in cash provided by operating activities for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, include the upfront nonrefundable payment of $200.0 million received from Ipsen in 2016 in consideration for the exclusive license and other rights contained in our collaboration agreement with Ipsen along with a $67.0 million increase in operating expenses. These were offset by a $213.6 million increase in net product revenues and the upfront nonrefundable payment of $50.0 million received from Takeda in the year ended December&#160;31, 2017 in consideration for the exclusive license and other rights contained in our collaboration agreement with Takeda.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our investing activities used cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$297.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$36.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$214.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash used during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily due to investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$557.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and Property and equipment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$33.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily related to our new corporate headquarters and research facilities in Alameda, California, offset by cash provided from the maturity and sale of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$280.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by investing activities for the year ended December&#160;31, 2017 was primarily due to cash received from the sale and maturity of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$373.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, offset by cash used for investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$319.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During 2017 we also invested $21.1 million in property and equipment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used by investing activities for the year ended December&#160;31, 2016 was primarily due to investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$369.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, offset by cash provided by the maturity and sale of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$153.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our financing activities provided cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$9.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$169.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash used during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$15.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily the result of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in proceeds from the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net share settlements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in financing activities for the year ended December&#160;31, 2017 was primarily the result of $185.8 million paid for all amounts outstanding under the Deerfield Notes and our term loan with Silicon Valley Bank. Those payments were partially offset by $15.9 million of proceeds from the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net share settlements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the year ended December&#160;31, 2016 was primarily the result of $23.4 million of proceeds from the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">share settlements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Those proceeds were partially offset by cash payments from the conversion and redemption of the 2019 Notes totaling $7.7 million.</font></div><div><a name="s3AEC0C995AD555FDAC5C39F4C0F9E28B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have contractual obligations in the form of leases and purchase obligations. The following chart details our contractual obligations as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual Obligations </font><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">1-3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">More than 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating leases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchase and other long-term obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,067</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total contractual cash obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,635</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">In addition to the above, we have committed to make potential future milestone payments to Invenra or StemSynergy as part of our collaboration agreements with those parties. Payments under those agreements generally become due and payable only upon achievement of certain developmental, regulatory and sales-based milestones. Because the achievement of those milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on our Consolidated Balance Sheets and have not been included in the table above. For more information about these obligations, see &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Purchase obligations include firm purchase commitments related to manufacturing and maintenance of inventory, software services and other long term contractual obligations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have any off-balance-sheet arrangements, as defined by applicable SEC regulations.</font></div><div><a name="s7BA320CEC3E95044B746EDC6A44F18CD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock option valuation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Net Product Revenues and Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration to which we are entitled to in exchange for those goods or services</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. Discounts and allowances are complex and require significant judgment by management. Estimates are assessed each period and updated to reflect current information.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the related gross product revenue. Our estimates for the expected utilization are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. For a further description of our discounts and allowances, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. In addition, in recording revenues for our research and development services performance obligation, we use internal development projected cost estimates to determine the amount of revenue to record as we satisfy this performance obligation, known as the inputs method.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues and U.S. profits and losses under the collaboration agreement with Genentech based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical activity, adjusted for any changes in facts and circumstances, as appropriate. We base our estimates on the best information available at the time provided to us by our collaboration partners. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases are generally considered to be changes in estimates and will be reflected in our Consolidated Statements of Operations in the period they become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Accruals</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our clinical trials have been executed with support from contract research organizations and other vendors. We accrue costs for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock Option Valuation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our estimate of compensation expense requires us to determine the appropriate fair value model and a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and related tax effects. The most significant assumptions are our estimates of the expected volatility and the expected term of the stock option. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical volatilities when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to exploit market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. As required under generally accepted accounting principles, we review our valuation assumptions at each grant date and, as a result, from time to time we change the valuation assumptions we use to value stock options granted. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation could be materially different in the future. For additional description of our stock-based compensation, see &#8220;Note&#160;7. Stock-based Compensation&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including net operating losses and tax credits, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 8. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><a name="s17CB1E4CCF915508BDE957B4B8A840F0"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, our exposure to market risk for changes in interest rates relates primarily to our investment portfolio. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had cash and investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$851.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Our investments are subject to interest rate risk, and our interest income may fluctuate due to changes in interest rates. We manage market risk through diversification requirements mandated by our investment policy, which limits the amount of our portfolio that can be invested in a single issuer. We limit our credit risk by limiting purchases to high-quality issuers. For our investments, we obtain the estimated effects of hypothetical interest rate changes from the same third-party pricing sources we use to value our investments. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an increase in the interest rates of one percentage point would have had a net adverse change in the fair value of interest rate sensitive assets of $3.4 million and $1.6 million, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues and sales-based milestones we receive from our collaboration agreements with Ipsen and Genentech are a percentage of the net sales made by those partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro. The royalty payments on these ex-U.S. sales are calculated initially in the currency in which the sale is made and are then converted into the U.S. dollar to determine the amount our partners pay us. Fluctuations in the exchange ratio of the U.S. dollar and these foreign currencies will have the effect of increasing or decreasing our revenues even if the amount of units sold does not change. For example, if the U.S. dollar strengthens against a foreign currency, then our royalty revenues will decrease for the same number of units sold in that foreign currency and the date </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we achieve </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales-based milestones would be delayed. For the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an average 10% strengthening of the U.S. dollar relative to the currencies in which these products are sold would have resulted in revenues being reduced by approximately $3.8 million and $1.0 million, respectively. </font></div><div><a name="s5F982B3C69785F0AA8E6F73F0FF39CE8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 8. Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s75E0A4F2A365512D8CB92F8DBAF608E2"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s75E0A4F2A365512D8CB92F8DBAF608E2">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB451E6DBE0DB5DC689E8C164E91A0A00"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB451E6DBE0DB5DC689E8C164E91A0A00">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAF43F88597E754EC8D9925E06CC7C477"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAF43F88597E754EC8D9925E06CC7C477">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3FF7AC766F605850B64E0764ADBE3BDC"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3FF7AC766F605850B64E0764ADBE3BDC">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s89FB37501CCE51128F1D0CAD5F8A1EFB"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s89FB37501CCE51128F1D0CAD5F8A1EFB">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9B7BDA6506725D089139AE3E70B5334C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9B7BDA6506725D089139AE3E70B5334C">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sED9F8272FF0F587B9B692D63F733A57E"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sED9F8272FF0F587B9B692D63F733A57E">82</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><a name="s75E0A4F2A365512D8CB92F8DBAF608E2"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the &#8220;Company&#8221;) as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity (deficit) and cash flows for each of the three fiscal years in the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and the results of its operations and its cash flows for each of the three fiscal years in the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 28, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Adoption of ASU No. 2014-09 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), effective December 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have served as the Company&#8217;s auditor since 2002.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><a name="sB451E6DBE0DB5DC689E8C164E91A0A00"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">314,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">378,559</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">204,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">162,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">897,016</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">484,874</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">157,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,422,286</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,954</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,825</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">105,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">134,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">370,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 299,876,080 and 296,209,426 at December 31, 2018 and 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,168,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,114,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(701</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(880,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,287,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,422,286</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><a name="sAF43F88597E754EC8D9925E06CC7C477"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">219,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">438,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(28,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(33,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><a name="s3FF7AC766F605850B64E0764ADBE3BDC"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">689,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities. During the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, there was a tax benefit of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;related to other comprehensive income as a result of the release of our valuation allowance for our deferred tax assets; there was </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;income tax benefit or provision related to other comprehensive income (loss) during the remaining periods presented. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><a name="s89FB37501CCE51128F1D0CAD5F8A1EFB"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:41%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Additional<br>Paid-in<br>Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br>Other<br>Comprehensive<br>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br>Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total<br>Stockholders&#8217;<br>Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">227,960,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,772,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,912,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(140,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock in settlement of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,009,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,953,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">289,923,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,072,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Accounting Standards Update (ASU) No. 2016-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#160;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,408,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock on exercise of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">877,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,209,426</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,114,184</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No.&#160;2016-02, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,666,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,626</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,626</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">299,876,080</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,168,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(880,363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,287,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><a name="s9B7BDA6506725D089139AE3E70B5334C"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">4,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">40,626</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">23,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">22,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">401(k) matching contributions made in common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">3,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Amortization of right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Deferred taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(244,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">6,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">13,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Amortization of debt discounts and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">8,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(11,825</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">8,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Gain on other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(2,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(2,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(2,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Trade receivables, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(85,471</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(43,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(38,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(4,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">3,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(3,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(3,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(722</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(3,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,086</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">430</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">3,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">11,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">16,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">5,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(3,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Rebates and fees due customers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">7,389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">4,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">3,866</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Accrued collaboration liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">6,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(10,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">13,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">256,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">14,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Other current and long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(9,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">1,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">415,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">165,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">210,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(33,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(21,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(1,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(557,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(319,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(369,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">280,826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">336,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">151,485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from sale of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">11,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">37,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">209</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(297,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">36,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(214,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">12,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">17,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">25,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Proceeds from employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">5,202</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">4,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">2,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Taxes paid related to net share settlement of equity awards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(7,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(6,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(4,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Principal payments on financing lease obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Principal repayments of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(185,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Payments on conversion of convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(7,135</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">9,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">(169,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">15,696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Net increase in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">127,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">32,478</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">11,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">144,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">315,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Calibri,sans-serif;font-size:9.5pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS - continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosure:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">21,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment deemed to have been acquired in build-to-suit lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred to acquire Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock in settlement of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;include the transition adjustment for the adoption of Topic 842.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><a name="sED9F8272FF0F587B9B692D63F733A57E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="sE49C81E2000B593998767600E8C3C2C8"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">products resulting from our discovery efforts have progressed through clinical development an</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">d received regulatory approval; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;have a growing commercial presence in markets worldwide, and we expect that the fourth will soon enter the marketplace in Japan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other commercially available products resulting from our discovery efforts include COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech), and MINNEBRO&#8482; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, and December 28, 2018 are indicated as being as of and for the years ended (or ending, as applicable) December&#160;31, 2016, 2017 and 2018, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(ASU 2016-18)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash are included with cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in Net cash provided by investing activities for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 4. Cash and Investments&#8212;Cash, Cash Equivalents and Restricted Cash&#8221; for a reconciliation of cash and cash equivalents presented in our previously published Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2016 and Cash, cash equivalents and restricted cash reported in the accompanying Consolidated Statement of Cash Flows for the same periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification (ASC) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(Topic 605)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2018 we early adopted Topic 842. We adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2018 in accordance with ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under previous lease guidance, ASC Topic 840: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(Topic 840). We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2018.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Impact of Adoption of Topic 606 and Topic 842</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 842, with the impact relating to a change in the classification of certain of our buildings in our Lease Agreement (the Lease) with Ascentris 105, LLC (Ascentris) from a build to suit lease to an operating lease. For a description of the Lease, see &#8220;Note 11. Commitments.&#8221; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,635</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,323</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Includes deferred rent and current portion of operating lease liabilities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone from Ipsen&#8217;s filing with the European Medicines Agency (EMA) for cabozantinib as a treatment for patients with previously treated HCC, that was deemed probable under Topic 606 prior to January 1, 2018. Deferred revenue as of January 1, 2018 was related to the up-front, nonrefundable, fees and milestones earned that were allocated to our research and development services performance obligation which had not been satisfied as of that date. Contract assets and liabilities are netted by collaboration agreement in our Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 842 primarily related to the recognition of an operating lease right-of-use asset and operating lease liability for the Lease. In addition, the adoption of Topic 842 resulted in a change in classification of the build-to-suit component of the Lease under Topic 840 to an operating lease under Topic 842 and as a result we derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December 31, 2017, as we had been deemed to own these buildings under Topic 840. For a description of the Lease, see &#8220;Note 11. Commitments&#8221; in these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 606 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 842 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balances Without the Adoption of Topic 606 or 842</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">889,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">205,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">413,767</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,606</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">488,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(48,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(84,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">774,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we had not adopted Topic 606, we would also have recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone in the first quarter of 2018 upon the validation of Ipsen&#8217;s filing with the EMA for cabozantinib as a treatment for patients with previously treated HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously reported deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were nominal. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory-related costs are recognized as Cost of goods sold in the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:200px;"></td><td style="width:5px;"></td><td style="width:200px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Office equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 606.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Topic 808: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(Topic 808). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;amounts remaining related to previously expensed materials in our inventory balances as of December&#160;31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in our Consolidated Balance Sheet at December 31, 2018. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For lease agreements entered into after the adoption of Topic 842 that include lease and non-lease components, such components are generally accounted for separately. For our building leases, as a result of us having elected to adopt the package of practical expedients permitted under the Topic 842 transition guidance, we account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 840</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 842.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) is estimated as the value of the underlying shares of our common stock. The grant date fair value of stock-options is estimated using a Monte Carlo simulation pricing model for stock options that include market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on an accelerated basis over the requisite service period for awards with a market or performance condition and on a straight-line basis over the requisite service period for all other awards. Compensation expense relating to awards subject to performance conditions is recognized when management determines that it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis. We have made an election to record forfeitures when they occur. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 8. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Topic 808 to the unit of account guidance in ASC 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(ASU 2018-15). ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(ASU 2017-04)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div><div><a name="s72e5b629ce9045bea9e8b7545e307b38"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. REVENUES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">402,569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(119,250</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,561</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,124</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">192,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,637</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenue, were recorded in accordance with Topic 808 for all periods presented.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">599,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">110,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">305,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,327</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">46,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">632,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&#8217; headquarters.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(74,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,978</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of Trade receivables, net and the remaining reserve balances are classified as Other current liabilities in the accompanying Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,545</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(46,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,237</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,417</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,428</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$198.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><a name="s85A16A85E8B2508A84040D55B4E91C65"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, Daiichi Sankyo, Merck &amp; Co., Inc. (Merck) and Bristol-Myers Squibb Company (BMS) for other compounds and programs in our portfolio.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of December 31, 2018, we have also achieved aggregate milestones of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$275.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to development, regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$140.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in milestones recognized during 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$84.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$519.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with sales-based milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were initially entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales; this amount was reached in the second quarter of 2018. As of December 31, 2018 and going forward, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales (with separate tiers for Canada); these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of annual net sales and a tiered royalty thereafter to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers for Canada will also reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GSK, we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such costs, provided Ipsen chooses to opt into such trials.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied at our cost, as defined in the agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$48.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets. See &#8220;&#8212;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upfront nonrefundable payment from Takeda. During the year ended December 31, 2018, we also achieved a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;development related milestone.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestone payments, without limit, for additional potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with sales volume milestones and receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and following this initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty tiers will reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Consistent with our historical agreement with GSK, we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:504px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of December&#160;31, 2018, the net contract liability for the collaboration agreement with Takeda was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have allocated the transaction price for each of these collaborations, which are described below, to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The portion of the transaction price allocated to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union (EU) for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on our evaluation of the collaboration agreements as of January 1, 2018, the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone we expected to achieve during the three months ended March 31, 2018. Other than that </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the year ended December&#160;31, 2018, the transaction price increased as a result of the achievement of various milestones described above. We further updated the transaction price based upon the impact of research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December 31, 2018, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">BMS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC and HCC in the CheckMate 9ER and CheckMate 040 trials, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Each party will be responsible for supplying finished drug product for the applicable clinical trial and unless otherwise agreed between the parties, costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear two-thirds of the costs for such study treatment arms and we will bear one-third of the costs. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The Roche Group (Roche) Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b trial evaluating the safety and tolerability of the combination in patients with locally advanced or metastatic tumors, and in December 2018, we initiated COSMIC-312, a phase 3 pivotal trial evaluating the combination versus sorafenib in previously untreated advanced HCC, with an exploratory arm also evaluating cabozantinib monotherapy in previously untreated advanced HCC. We are the trial sponsor, and Roche is providing atezolizumab free of charge.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, GSK continues to be entitled to a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty we are required to pay on all net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">StemSynergy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Therapeutics, Inc. (StemSynergy) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">), a component of the Wnt</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;signaling pathway implicated in key oncogenic processes. Under the terms of the a</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">greement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we paid&#160;StemSynergy an upfront payment of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in initial research and development funding and provided </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in additional research and development funding. StemSynergy is eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in additional such funding on an as needed basis. The research and development funding costs incurred to date were included in Research and development expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy will also be eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Invenra</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, Inc. (Invenra) C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ollaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with Invenra, which is focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and a project initiation fee of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The payments were included in Research and development expenses in the accompanying Consolidated Statements of Operations. As of December 31, 2018, we also have the right to initiate five additional discovery projects for development subject to an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts. Invenra is eligible to receive payments based on the achievement of specific development and regulatory milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for a product containing the lead preclinical asset in the first indication and up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$127.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for a product developed from each addition project we initiate. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$325.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per product if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project, basis at any time prior to commercialization, for any or no reason, upon thirty days&#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC for the year ended December 31, 2018 were included Collaboration revenues and profits and losses on for the years ended December&#160;31, 2017 and 2016 were included in Selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allows for us to provide up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the total sales force for approved cobimetinib indications in the U.S. Between November 2015 and December 2017, we fielded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a review of the commercial landscape, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Profit Sharing and Royalty Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of profits and losses from the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of U.S. actual sales, decreasing to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. These tiers will reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Clinical Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cobimetinib is being evaluated by Genentech in a development program consisting of more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;clinical trials. These trials are being sponsored by Genentech or through Genentech&#8217;s investigator sponsored trial program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. In January 2019, subsequent to our year-end, Daiichi Sankyo received approval from the Japanese Ministry of Health, Labour and Welfare for MINNEBRO as a treatment for patients with hypertension. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional development, regulatory and sales-based milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$110.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under this collaboration agreement, including a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone payment upon the first arm&#8217;s-length sale of MINNEBRO in Japan. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">90 days</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">0.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to Ligand on net sales of MINNEBRO.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Merck</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Merck collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Price for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (PI3K-&#948;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-&#948; program. Subsequent to December 31, 2018, we have been notified by Merck that they will be terminating their PI3K-&#948; program, including their development activities under this collaboration agreement. Upon the termination of the collaboration agreement by Merck, the license granted to Merck will terminate. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">BMS - ROR Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:416px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:9px;"></td><td style="width:66px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">BMS collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Since July 2013, BMS has been solely responsible for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible for additional development and regulatory milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$240.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate and sales-based milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Other Collaborations &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have evaluated our collaborations agreements with Genentech, Daiichi Sankyo, Merck and BMS and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">102</font></div></div><hr style="page-break-after:always"><div><a name="sA4EDA76A66015E768B27ED1B0E3EAAE2"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. CASH AND INVESTMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">314,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">852,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">851,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">zero</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">236,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">275,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">320,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">199</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">674,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Cost Method Equity Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, related to the August 2016 sale of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;interest in Akarna Therapeutics, Ltd. (Akarna) to Allergan Holdco UK Limited (Allergan). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other, net in the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;During 2018, BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that their beneficial ownership increased to more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">104</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">investments managed by BlackRock was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$298.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$141.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;invested in the BlackRock Liquidity Money Market Fund. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We incurred </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in fees for BlackRock advisory services performed during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><a name="sCE1AE5A58CF15EC79DBD2BDFB74B55B0"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory included in Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets in the accompanying Consolidated Balance Sheets. As of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of a portion of our finished goods.</font></div><div><a name="s8A1025D7001A56389EC04E62686BA55A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">68,206</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into the Lease for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet. For a description of the Lease, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">see &#8220;Note 11. Commitments.&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in related Leasehold improvements, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">105</font></div></div><hr style="page-break-after:always"><div><a name="s1D77C9D3CC8655ECBB01730BC231B1D7"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,511</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we granted stock options and RSUs to employees and directors. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">14,693,867</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares were available for grant under our equity incentive plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term, an exercise price equal to the fair market value on the date of grant, and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year life from the date of grant. Stock options issued prior to May 2011 have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year life from the date of grant. RSUs granted to our employees generally vest annually over a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">its outstanding </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">stock options accelerated with the exercise period being extended to no more than one year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">4,722,008</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">330,492</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">434,523</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">559,936</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$15.74</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$11.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$3.91</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. Cash received</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP in the years ended December 31, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">106</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,238,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,466,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(288,197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(18,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,674,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">254,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,463,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">229,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, in connection with our long-term incentive compensation program, we granted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">308,365</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;stock options to our President and Chief Executive Officer that have a market vesting condition (PSOs). In addition to the standard service conditions included in our other stock options, these PSOs </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equal to or greater than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">125%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized over the service period of the award, which commenced on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5,870,303</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;performance-based stock options vested during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and we recognized</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">in stock-based compensation for those</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock option grants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">. We did</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">t have any</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock options outstanding during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and therefore, did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">stock-based compensation for</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">options during that year.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">107</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$48.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to our unvested stock options, including the PSOs described above. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.5 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the stock option holders had all stock option holders exercised their stock options on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of stock options exercised </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the dates of exercise </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$39.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$85.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from option exercises during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Activity for RSUs during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,519,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,081,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(343,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,857,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, in connection with our long-term incentive compensation program, we awarded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">693,131</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). These PSUs are included in the RSU activity table presented above. The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when the attainment of the performance goal is determined </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">by management </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to be probable. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the year ended December 31, 2018, we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not recognize any compensation expense related to these PSUs. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the total unrecognized compensation expense related to the unvested PSUs was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based RSUs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;issued prior to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$81.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">401(k) Retirement Plan</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the Exelixis, Inc. 401(k) Plan (the 401(k) Plan) whereby eligible employees may elect to contribute up to the lesser of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. During 2018, we made matching contributions in the form of our common stock of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$8,500</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of each participant&#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$3.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">571,674</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares were available for issuance under the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">401(k) Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">108</font></div></div><hr style="page-break-after:always"><div><a name="sEE7BB0AD68EA5F01B778AE9A9F361D0A"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income (loss) before income taxes is derived solely from within the U.S. The Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. Our historical net operating losses are sufficient to fully offset any federal taxable income. The Income tax provision for the year ended December 31, 2017, related to state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax (provision) benefit at the statutory federal income tax rates of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2018, 2017 and 2016, respectively, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax (provision) benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(94,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">109</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146,701</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">303,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(58,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">245,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We applied the guidance in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Securities and Exchange Commission&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Staff Accounting Bulletin No. 118</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;when accounting for the enactment-date effects of the Tax Cuts and Jobs Act in 2017 and throughout 2018. At December 31, 2017, we had not completed our accounting for all the enactment-date income tax effects of the Tax Cuts and Jobs Act for Section 162(m) related to the deduction limitation for the remuneration of certain employees. As of December 31, 2018, we have now completed our accounting for all of the enactment-date income tax effects of the Tax Cuts and Jobs Act and the impact was not material.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2018, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;December 31, 2018 and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$244.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are realizable and the valuation allowance was reduced accordingly. As of December 31, 2018, we continue to carry a valuation allowance of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$58.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance decreased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$360.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during 2018 and 2017, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had federal net operating loss carryforwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$614 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2031</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$102 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2021</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2038</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carryforwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$453 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2028</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$34 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which do not expire.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 study through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and concluded that an ownership change, as defined under Section 382, had not occurred. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;will significantly change over the next 12 months. As of December 31, 2018, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$76.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in unrecognized tax benefits, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Operations as a component of income taxes. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2018 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods. </font></div><div><a name="s3804A01580045627AD60216C0EDBD110"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,911</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">111</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potential shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. Warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of our common stock issued in January 2014 (2014 Warrants) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017.</font></div><div><a name="s9A6BF564AF7455D0AF2ECC314A920CE2"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. FAIR VALUE MEASUREMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">780,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">796,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">844,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">453,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Commitments&#8221; regarding the determination of the amount of our operating lease liabilities as of December 31, 2018. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration liabilities, Rebates and fees due to customers and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.</font></div><div><a name="sD68B79A0C7FF5C208B2096BB4E6A53A2"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As described further in &#8220;Note 1. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Organization and Summary of Significant Accounting Policies&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we adopted Topic 842 as of January 1, 2018. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into the Lease with Ascentris for office and research facilities located at the Premises in Alameda, California. The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, following the conclusion of a partial twelve-month rent abatement period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year of the initial term; none of these optional periods have been considered in the determination of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">right-of-use asset or the lease liability for the Lease as we did not consider it </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay to Ascentris certain variable costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space, as that additional space becomes available at 1601, 1701 and 1751 Harbor Bay Parkway, Alameda, California over the remainder of the initial term of the Lease at a market rate determined pursuant to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We had an additional operating lease which expired in July 2018 for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;buildings in South San Francisco, California with a total area of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116,063</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have performed an evaluation of our other contracts with customers and suppliers in accordance with Topic 842 and have determined that, except for the leases described above, a nominal operating lease for space at a data center to house our data servers and a nominal financing lease for office equipment, none of our contracts contain a lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing obligation for build-to-suit lease</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,056</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">113</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and was included in Net cash provided by operating activities in our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,794</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,904</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,187</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9.0 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the weighted average discount rate used to determine the operating lease liability was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;standby letters of credit related to the Lease with Ascentris with a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have also obtained standby letters of credit related to a workers compensation insurance policy with credit limits of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We had also previously obtained a standby letter of credit related to our South San Francisco lease with a credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which was released during 2018. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">none</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit. The certificate of deposits used to collateralize the standby letters of credit were included in short-term and long-term restricted cash and investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were previously required to provide collateral as part of an employee purchasing card program. The collateral requirement for the purchase card program at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we were notified that we had been released from this collateral requirement. The collateral was invested in certificates of deposit which were included in long-term restricted cash and investments. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">114</font></div></div><hr style="page-break-after:always"><div><a name="s20A97ACEB1DF58148446EC17B7840A9E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31, </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">225,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">213,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">168,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">111,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">125,176</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,307</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">360,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See &#8220;Note 3. Collaboration Agreements&#8221; for more information on our collaboration agreement with Genentech.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">115</font></div></div><hr style="page-break-after:always"><div><a name="sAB5C97CC76DB5DA1BF096970DF83594C"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sDB34A4B39284524BA37144FFF5C0F775"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9A. Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the Effectiveness of Controls.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of the end of our 2018 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Internal Control&#160;&#8211; Integrated Framework</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of December 28, 2018 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of December 28, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 28, 2018, based on the COSO criteria.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 28, 2018 and December 29, 2017, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8216; equity (deficit) and cash flows for each of the three fiscal years in the period ended December 28, 2018, and the related notes and our report dated February 22, 2019 expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">117</font></div></div><hr style="page-break-after:always"><div><a name="sDD80458EA4A855E88C872CD9C2CED55C"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9B. Other Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable</font></div><div><a name="s528A9B677330508791F0FC838F07957A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART III</font></div><div><a name="s1AD932E223ED56488BCF8D2ED870209A"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our board of directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Class II Directors&#8221; appearing in our Proxy Statement for our 2019 Annual Meeting of Stockholders to be filed with the SEC within 120 days after </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we refer to as our 2019 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Executive Officers&#8221; appearing in our 2019 Proxy Statement. The information required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; appearing in our 2018 Proxy Statement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Code of Ethics</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media&#8212;Corporate Governance&#8212;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Corporate Governance Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</font></div><div><a name="s0D9281AA9CB55C81B1983FDA967923C6"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 11. Executive Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2019 Proxy Statement.</font></div><div><a name="s793A713A5A48568182E7C22B9D2564BA"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2019 Proxy Statement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Compensation Plan Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which consists of our 2000 Equity Incentive Plan (the 2000 Plan) our 2000 Non-Employee Directors&#8217; Stock Option Plan (the Director Plan) our 2000 Employee Stock Purchase Plan (the ESPP) our 2011 Equity Incentive Plan (the 2011 Plan) our 2014 Equity Incentive Plan (the 2014 Plan) our 2016 Inducement Award Plan (the 2016 Plan) our 2017 Equity Incentive Plan (the 2017 Plan) and our 401(k) Plan:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Plan Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">securities to&#160;be issued upon exercise of outstanding&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants and rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted-average exercise&#160;price of outstanding&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants&#160;and&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(c)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans approved by stockholders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,242,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,415,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans not approved by stockholders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">289,027</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup>&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">571,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,531,396</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,987,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1 )</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Equity plans approved by our shareholders are the 2000 Plan, the 2011 Plan, the 2014 Plan, the Director Plan, the 2017 Plan and the ESPP. As of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, a total of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">4,722,008</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 246,410 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or and the weighted-average exercise&#160;price of such rights as of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, as those numbers are not known.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units (RSUs) which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $8.61.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents shares of our common stock issuable pursuant to the 2016 Plan and our 401(k) Plan.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, no shares of our common stock remained available for issuance under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs, or any other stock award.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">We sponsor a 401(k) Plan whereby eligible employees may elect to contribute up to the lesser of 50% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) Plan permits us to make matching contributions on behalf of all participants. During the year ended </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">, we matched 100% of the first </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$8,500</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;of participant contributions into our 401(k) Plan in the form of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.49.</font></div></td></tr></table><div><a name="s11DD5CA78D3956E68738D463D94F5DCE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 13. Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Class II Directors&#8221; appearing in our 2019 Proxy Statement.</font></div><div><a name="sE91A47D948935612BA2CB6A19E10C027"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 14. Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2019 Proxy Statement. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">119</font></div></div><hr style="page-break-after:always"><div><a name="sD83AEFDD7BD6507A94A259F73D425733"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART IV</font></div><div><a name="sBE9A48EC4055555585CD8A09CAF6B58C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 15. Exhibits, Financial Statement Schedules</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following documents are being filed as part of this report:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:72px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:84%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s75E0A4F2A365512D8CB92F8DBAF608E2"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s75E0A4F2A365512D8CB92F8DBAF608E2">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB451E6DBE0DB5DC689E8C164E91A0A00"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB451E6DBE0DB5DC689E8C164E91A0A00">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAF43F88597E754EC8D9925E06CC7C477"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAF43F88597E754EC8D9925E06CC7C477">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3FF7AC766F605850B64E0764ADBE3BDC"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3FF7AC766F605850B64E0764ADBE3BDC">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s89FB37501CCE51128F1D0CAD5F8A1EFB"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s89FB37501CCE51128F1D0CAD5F8A1EFB">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9B7BDA6506725D089139AE3E70B5334C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9B7BDA6506725D089139AE3E70B5334C">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sED9F8272FF0F587B9B692D63F733A57E"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sED9F8272FF0F587B9B692D63F733A57E">82</a></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following Exhibits are filed as part of this report.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/25/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000036/exhibit31amendedandrestate.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/21/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">S-1,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4/7/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001409/0001012870-00-001409.txt"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Indemnity Agreement</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">S-1,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">as&#160;amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/17/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312507101304/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/3/2007</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904034294/a04-12880_1ex10d2.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Equity Incentive Plan (early exercise permissible)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/8/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904039592/a04-14803_1ex10d1.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Equity Incentive Plan (early exercise may be restricted)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12/15/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000009/exel20131231exhibit106.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/20/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511042330/dex107.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Employee Stock Purchase Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Schedule 14A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4/13/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit108.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2011 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.9</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511210303/dex103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2011 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/4/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.10</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit1010.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/29/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.12</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.13</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.14</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000042/exel20141014exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/16/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit1015.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.16</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.17</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.18</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1020.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.19</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1021.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1022.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.21</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1023.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.22</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1024.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.23</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1025.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-Employee Director Equity Compensation Policy</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/5/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.25</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/10/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">121</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312506135893/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June&#160;20, 2006, between Exelixis, Inc. and Gisela M. Schwab,&#160;M.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6/26/2006</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.27</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.28</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000149/exel20151231exhibit1024.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 11, 2000, between Exelixis, Inc. and Peter Lamb.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/29/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.29</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.30</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510248047/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Resignation Agreement dated July&#160;22, 2010, by and between Exelixis, Inc. and George A. Scangos</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/4/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Annual Cash Bonus Compensation Plan for Executives</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/16/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.32</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit1032.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash Compensation Information for Non-Employee Directors.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.33</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000069/exel20180331exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/2/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1039.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment to Lease Agreement dated October 16, 2017 to Lease Agreement dated May 2, 2017 between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment to Lease Agreement dated June 13, 2018 to Lease Agreement dated May 2, 2017 between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/1/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.37*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1045.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1046.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #1 dated April 16, 2013, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">122</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1047.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #2 dated July 18, 2016, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.40**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit1040.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.41*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit103-ame.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.42*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1049.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.43*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000183/exel20170930exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.44*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1046.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.45*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit104-ame.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.46*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1048.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.47*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1051.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration Agreement dated December&#160;22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.48*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1052.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment, dated March&#160;13, 2008, to the Collaboration Agreement dated December&#160;22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">123</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510179304/dex105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment, dated April&#160;30, 2010, to the Collaboration Agreement dated December 22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/5/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.50 *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment, dated July 19, 2017, to the Collaboration Agreement dated December 22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.51*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000126/exel2017033110-qaexhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/14/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.52*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/1/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.53*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.54*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.55*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated July 6, 2018, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.56*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement dated July 6, 2018, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Takeda Pharmaceutical Company Limited</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.57*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000218/exel20180930exhibit103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ono Territorial Supplemental Agreement dated July 6, 2018, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Ono Pharmaceutical Co., Ltd. and Bristol-Meyers Squibb Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit211.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subsidiaries of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit231.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4A6B656B28B5549DB2F6055439D12208"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Power of Attorney (contained on signature page)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit311.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">124</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit312.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32.1&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20181231exhibit321.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Labels Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Management contract or compensatory plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Confidential treatment granted for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Confidential treatment requested for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8225;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table></div></div><div><a name="s3D9FF744015A55CFA0E8EBFBDD208FD3"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;None provided.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">125</font></div></div><hr style="page-break-after:always"><div><a name="s4A6B656B28B5549DB2F6055439D12208"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">E</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, I</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">NC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">KNOW ALL PERSONS BY THESE PRESENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, that each person whose signature appears below constitutes and appoints </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MICHAEL M. MORRISSEY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">CHRISTOPHER J. SENNER </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#32;JEFFREY J. HESSEKIEL </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director, President and</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Executive&#160;Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Executive&#160;Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Financial&#160;Officer </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Financial and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounting&#160;Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">APADOPOULOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Stelios Papadopoulos, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HARLES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">OHEN&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Charles Cohen, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;B. F</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ELDBAUM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carl B. Feldbaum, Esq.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARIA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;C. F</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">REIRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Maria C. Freire, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:672px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sD36D0AFB401F5BFC8C2FE43520189BDD"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;A</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">LAN</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARBER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Alan M. Garber, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;V</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">INCENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;T. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARCHESI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Vincent T. Marchesi, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">OSTE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George Poste, DVM, Ph.D., FRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">CANGOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George A. Scangos, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ULIE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">MITH&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Julie A. Smith</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;L</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;W</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ILLSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Lance Willsey, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ACK</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;L. W</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">YSZOMIERSKI&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Jack L. Wyszomierski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">127</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>exel20181231exhibit108.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD27B79238775C69CB0A00C8920707C62"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.8</font></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2011 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 16, 2011</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: MARCH 18, 2011</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">APPROVED BY THE STOCKHOLDERS: MAY 18, 2011</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY: APRIL 12, 2018</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TERMINATION DATE: FEBRUARY 15, 2021</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Successor to Prior Plans.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan is intended as the successor to (i) the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which terminated pursuant to its terms on January 26, 2010 and after such termination, no additional stock awards have been or shall be granted under the 2000 Plan and (ii) the Exelixis, Inc. 2010 Inducement Award Plan (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Inducement Plan&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and together with the 2000 Plan, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Prior Plans&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">).  From and after the Effective Date, no additional awards shall be granted under the Inducement Plan and all outstanding stock awards granted under the Prior Plans shall remain subject to the terms of the Prior Plans; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, any shares subject to outstanding stock awards granted under the Prior Plans that expire or terminate for any reason prior to exercise or settlement or are forfeited because of the failure to meet a contingency or condition required to vest such shares or are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award other than a stock option or stock appreciation right (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after the Effective Date of this Plan shall be subject to the terms of this Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The persons eligible to receive Awards are Employees, Directors and Consultants.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company and its Affiliates, by means of the Plan, seek to secure and retain the services of the group of persons eligible to receive Awards as set forth in Section 1(b), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine from time to time (A) which of the persons eligible under the Plan shall be granted Awards; (B) when and how each Award shall be granted; (C) what type or combination of types of Award shall be granted; (D) the provisions of each Award granted (which need not be identical), including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a Stock Award; (E) the number of shares of </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Common Stock with respect to which a Stock Award shall be granted to each such person; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the extent it shall deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable. However, except as provided in Section 9(a) relating to Capitalization Adjustments, to the extent required by applicable law or listing requirements, stockholder approval shall be required for any amendment of the Plan that either (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (D) materially extends the term of the Plan, or (E) expands the types of Awards available for issuance under the Plan. Except as provided above, rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that except with respect to amendments that disqualify or impair the status of an Incentive Stock Option, a Participant&#8217;s rights under any Award shall not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.  Notwithstanding the foregoing, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent if necessary to maintain the qualified status of the Award as an Incentive Stock Option or to bring the Award into compliance with Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Section 162(m) and Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Delegation to an Officer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate to one or more Officers of the Company the authority to do one or both of the following: (i)&#160;designate Employees to be recipients of Options and Stock Appreciation Rights (and, to the extent permitted by applicable law, other Stock Awards) and the terms thereof, and (ii)&#160;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Officers and Employees; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that the Board resolutions regarding such delegation shall specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Notwithstanding the foregoing, the Board may not delegate authority to an Officer to determine the Fair Market Value pursuant to Section&#160;13(w) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Repricing; Cancellation and Re-Grant of Stock Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Neither the Board nor any Committee shall have the authority to: (i) reduce the exercise price of any outstanding Options or Stock Appreciation Rights under the Plan, or (ii) cancel any outstanding Options or Stock Appreciation Rights that have an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Share Reserve.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date shall not exceed 10,000,000 shares </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">plus</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;the Returning Shares, if any, as such shares become available from time to time (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of the Common Stock that may be issued pursuant to the Plan and does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance shall not reduce the number of shares available for issuance under the Plan.  Furthermore, if a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), such expiration, termination or settlement shall not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to subsection 3(c), the number of shares available for issuance under the Plan shall be reduced by: (i) one share for each share of stock issued pursuant to (A) an Option with respect to which the exercise price is at least 100% of the Fair Market Value of the underlying Common Stock on the date of grant, or (B) a Stock </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Appreciation Right with respect to which the strike price is at least 100% of the Fair Market Value of the underlying Common Stock on the date of grant; and (ii) 1.5 shares for each share of Common Stock issued pursuant to a Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Award or Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited shall revert to and again become available for issuance under the Plan.  To the extent (A) there is issued a share of Common Stock pursuant to a Stock Award that counted as</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.5 shares against the number of shares available for issuance under the Plan pursuant to Section 3(b) or (B) any Returning Shares granted under the Prior Plans pursuant to an award other than a stock option or stock appreciation right, and such share of Common Stock becomes available for issuance under the Plan pursuant to Section 1(a), Section 3(a) or this Section 3(c), then the number of shares of Common Stock available for issuance under the Plan shall increase by 1.5 shares.   Also, each share reacquired by the Company pursuant to Section 8(g) in connection with a Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Award or Other Stock Award shall again become available for issuance under the Plan and shall increase the number of shares of Common Stock available for issuance under the Plan by</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.5 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any shares subject to a Stock Award are not delivered to a Participant because the Stock Award is exercised through a reduction of shares subject to the Stock Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;), the number of shares that are not delivered to the Participant shall no longer be available for issuance under the Plan.  Also, any shares reacquired by the Company pursuant to Section 8(g) upon the exercise of an Option or Stock Appreciation Right or as consideration for the exercise of an Option or Stock Appreciation Right shall no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Incentive Stock Option Limit.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding anything to the contrary in this Section 3 and, subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options shall be 30,000,000 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Section 162(m) Limitation on Annual Grants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, a maximum of 1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">shares of Common Stock subject to Options, Stock Appreciation Rights and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted may be granted to any Participant during any calendar year.  Notwithstanding the foregoing, if any additional Options, Stock Appreciation Rights or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Awards are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards shall not satisfy the requirements to be considered &#8220;qualified performance-based compensation&#8221; under Section 162(m) of the Code unless such additional Stock Awards are approved by the Company&#8217;s stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligibility for Specific Stock Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Nonstatutory Stock Options and SARs may not be granted to Employees, Directors, and Consultants who are providing Continuous Services only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405 promulgated under the Securities Act, unless the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code because the Stock Awards are granted pursuant to a corporate </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">transaction (such as a spin off transaction) or unless such Stock Awards comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Ten Percent Stockholders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate.  All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Option Agreement or Stock Appreciation Right Agreement shall conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR shall be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise price (or strike price) of each Option or SAR shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Option or SAR is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise price (or strike price) lower than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR if such Option or SAR is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board shall have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company shall accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, further,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">that (A) shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations;  or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.  The appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right on such date, over (B) the strike price that will be determined by the Board at the time of grant of the Stock Appreciation Right.  The appreciation distribution in respect to a Stock Appreciation Right may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board shall determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs shall apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Participant only by the Participant; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request.  Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, an Option or SAR may be transferred pursuant to a domestic relations order; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, the Participant may, by delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect Option exercises, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, the executor or administrator of the Participant&#8217;s estate shall be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates (other than for Cause or upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) but only within such period of time ending on the earlier of (i) the date three months following the termination of the Participant&#8217;s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement), or (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Stock Award Agreement (as applicable), the Option or SAR shall terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause or upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR shall terminate on the earlier of (i) the expiration of a total period of three months (that need not be consecutive) after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Stock Award Agreement, if the immediate sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR shall terminate on the earlier of (i) the expiration of a period equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), or (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Stock Award Agreement (as applicable), the Option or SAR (as applicable) shall terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement), or (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR is not exercised within the time specified herein or in the Stock Award Agreement (as applicable), the Option or SAR shall terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#8217;s Continuous Service is terminated for Cause, the Option or SAR shall immediately terminate upon such Participant&#8217;s termination of Continuous Service, and the Participant shall be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Non-Exempt Employees</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR. Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, (i) in the event of the Participant&#8217;s death or Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Stock Award Agreement or in another applicable agreement or in accordance </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), any such vested Options and SARs may be exercised earlier than six months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate.  To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common Stock may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&#160;evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Restricted Stock Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividends.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that each Restricted Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Performance Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Performance Stock Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  A Performance Stock Award is a Stock Award that may vest or may be exercised contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion.  The maximum number of shares covered by an Award that may be granted to any Participant in a calendar year attributable to Stock Awards described in this Section 6(c)(i) (whether the grant, vesting or exercise is contingent upon the attainment during a Performance Period of the Performance Goals) shall not exceed 1,000,000 shares of Common Stock. The Board may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Stock Award to be deferred to a specified date or event.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Performance Cash Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  A Performance Cash Award is a cash award that may be paid contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may also require the completion of a specified period of Continuous Service.  At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion.  In any calendar year, the Committee may not grant a Performance Cash Award that  has a maximum value that may be paid to any Participant in excess of  $1,000,000. The Board may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Cash Award to be deferred to a specified date or event.  The Committee may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Board Discretion.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Section 162(m) Compliance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Unless otherwise permitted in compliance with the requirements of Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee shall establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (a) the date 90 days after the commencement of the applicable Performance Period, or (b) the date on which 25% of the Performance Period has elapsed, and in either event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee shall certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such relate solely to the increase in the value of the Common Stock). Notwithstanding satisfaction of any completion of any Performance Goals, to the extent specified at the time of grant of an Award to &#8220;covered employees&#8221; within the meaning of Section 162(m) of the Code, the number of shares of Common Stock, Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further considerations as the Committee, in its sole discretion, shall determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Other Stock Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6.  Subject to the provisions of the Plan, the Board shall have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock reasonably required to satisfy such Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant shall not be eligible for the grant of a Stock Award or the subsequent issuance of Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company shall have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award.  Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall constitute general funds of the Company.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of a Stock Award to any Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Incentive Stock Option $100,000 Limitation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000, the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Electronic Delivery</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any reference herein to a &#8220;written&#8221; agreement or document shall include any agreement or document delivered electronically or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Compliance with Section 409A.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent that the Board determines that any Award granted hereunder is subject to Section 409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code.  To the extent applicable, the Plan and Award Agreements shall be interpreted in accordance with Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount shall be made upon a &#8220;separation from service&#8221; before a date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(d), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Sections 3(e) and 6(c)(i) , and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board shall make such adjustments, and its determination shall be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) shall terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Stock Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution shall be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Current Participants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) shall</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board shall determine (or, if the Board shall not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Stock Awards shall terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) shall</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board shall determine (or, if the Board shall not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Stock Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards shall terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Payment for Stock Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B) any exercise price payable by such holder in connection with such exercise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) shall</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">be accelerated in accordance with the vesting schedule applicable to such </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration shall occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant would receive pursuant to a Change in Control from the Company or otherwise (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then such Payment shall be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a Payment is triggered (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Plan Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may suspend or terminate the Plan at any time.  Unless terminated sooner by the Board, the Plan shall automatically terminate on the day before the 10th anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;No Impairment of Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan shall become effective on the Effective Date.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The law of the State of California shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions shall apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act.  The Board shall have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards No. 123 (revised).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term shall mean, with respect to a Participant, the occurrence of any of the following events:  (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause shall not be made unless and until there shall have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together  with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the  Company  representing  at 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding  the merger, consolidation or similar transaction are  converted  by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing or any other provision of this Plan, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, shall not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register the sale of the Company&#8217;s securities to such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, shall not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service shall be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of (i) any leave of absence approved by the Board or Chief Executive Officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Control Acquisition&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding  the merger, consolidation or similar transaction are  converted  by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Covered Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant,  the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date of the special meeting of stockholders of the Company held in 2011 provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Good Reason&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect  immediately prior to a Change in Control by greater than ten percent, except to the extent the compensation of other similarly  situated  persons are accordingly  reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare  benefit  plans  that,  taken as a whole, provide  substantially  similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s  contributions  may be raised to the extent of any cost  increases imposed by third  parties)  or any action by the  Company or an Affiliate that would  adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices  resulting in diminution  of position,  excluding for this purpose an isolated,  insubstantial  and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly  after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite  that is more than fifty miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material  breach by the Company or an Affiliate of any of the material provisions of an agreement  with such Participant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant shall have &#8220;Good Reason&#8221; for his or her resignation only if: (a) such Participant notifies the Company in writing, within 30 days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b) the Company does not cure such condition within 30 days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c) the Participant resigns from employment within 30 days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a stock option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Outside Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity shall be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Cash Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv) total stockholder return; (v) return on equity or average stockholder&#8217;s equity; (vi) return on assets, investment, or capital employed; (vii) stock price; (viii) margin (including gross margin); (ix) income (before or after taxes); (x) operating income; (xi) operating income after taxes; (xii) pre-tax profit; (xiii) operating cash flow; (xiv) sales or revenue targets; (xv) increases in revenue or product revenue; (xvi) expenses and cost reduction goals; (xvii) improvement in or attainment of working capital levels; (xiii) economic value added (or an equivalent metric); (xix) market share; (xx) cash flow; (xxi) cash flow per share; (xxii) share price performance; (xxiii) debt reduction; (xxiv) implementation or completion of projects or processes; (xxv) customer satisfaction; (xxvi) stockholders&#8217; equity; (xxvii) capital expenditures; (xxiii) debt levels; (xxix) operating profit or net </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">operating profit; (xxx) workforce diversity; (xxxi) growth of net income or operating income; (xxxii) billings; and (xxxiii) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Goals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board shall appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; and (5) to exclude the effects of any &#8220;extraordinary items&#8221; as determined under generally accepted accounting principles.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2011 Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ten Percent Stockholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:25px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.&#160;&#160;&#160;&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>exel20181231exhibit1010.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s757602F88BD8AA88646F0C8B7C68207D"></a></div><div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2014 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 28, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: APRIL 14, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">APPROVED BY THE STOCKHOLDERS:  MAY 28, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY: APRIL 12, 2018</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: DECEMBER 6, 2018</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Successor to and Continuation of Prior Plans.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan is intended as the successor to and continuation of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2011 Equity Incentive Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;2000 Non-Employee Directors&#8217; Stock Option Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Following the Effective Date, no additional stock awards may be granted under the Prior Plans.  Any unallocated shares remaining available for grant under the Prior Plans as of 12:01 a.m. Pacific time on the Effective Date (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Available Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will cease to be available under the Prior Plans at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In addition, from and after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date, all outstanding stock awards granted under the Prior Plans, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or the Exelixis, Inc. 2010 Inducement Award Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Inducement Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will remain subject to the terms of the Prior Plans, the 2000 Plan or the Inducement Plan, as applicable; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any shares subject to outstanding stock awards granted under the Prior Plans, the 2000 Plan or the Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">required for the vesting of such shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, or (iii)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;other than with respect to outstanding options and stock appreciation rights granted under the Prior Plans, the 2000 Plan or the Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obl</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">igation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with a stock award (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date will be subject to the terms of this Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  However, if required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E)&#160;materially expands the types of Awards available for issuance under the Plan.  Except as provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Section 162(m) and Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Delegation to an Officer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority.  The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Repricing; Cancellation and Re-Grant of Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 13,564,602 shares (which number is the sum of (i) the number of shares (1,564,602) subject to the Prior Plans&#8217; Available Reserve and (ii) an additional 12,000,000 new shares) plus (B) the Prior Plans&#8217; Returning Shares, if any, which become available for grant under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B) 1.55 shares for each share of Common Stock issued pursuant to a Full Value Award.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obl</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">igation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  For each (1) 2014 Plan Returning Share subject to a Full Value Award or (2) Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by 1.55 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by the Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to satisfy the exercise or purchase price of a Stock Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obl</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">igation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Incentive Stock Option Limit.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 66,000,000 shares of Common Stock.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Section 162(m) Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, the following limitations will apply.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.  Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards will not satisfy the requirements to be considered &#8220;qualified performance-based compensation&#8221; under Section 162(m) of the Code unless such additional Stock Award is approved by the Company&#8217;s stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Eligibility for Specific Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ten Percent Stockholders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option.  If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option.  The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent consistent with the Company&#8217;s </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">bylaws, at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dividends.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Conti</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">nuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Performance Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Performance Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Performance Cash Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Committee and Board Discretion.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Section 162(m) Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock).  Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and/or vested under an Award on </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Incentive Stock Option Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that notwithstanding anything to the contrary in the terms of an Award Agreement, no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent that the Board determines that any Award granted hereunder is subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code.  To the extent applicable, the Plan and Award Agreements will be interpreted in accordance with Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Payment for Stock Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reduced Amount was determined pursuant to clause (x) of the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii)) so that </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">becomes reasonably likely to occur</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Board may suspend or terminate the Plan at any time.  No Incentive Stock Option will be granted after</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Impairment of Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;Control Acquisition&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Covered Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; will have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant,  the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2014, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Outside Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Cash Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable): (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder&#8217;s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes; (12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenue or product revenue; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders&#8217; equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Goals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3) to exclude </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; and (5) to exclude the effects of any &#8220;extraordinary items&#8221; as determined under generally accepted accounting principles.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2014 Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ccc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ddd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ten Percent Stockholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>exel20181231exhibit1015.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9E8E7E6B537B84F49F290C8D8C78A992"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.15</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2016 INDUCEMENT AWARD PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  NOVEMBER 18, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY:  APRIL 12, 2018</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  DECEMBER 6, 2018</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Awards under the Plan may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules.  A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards, and (v) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide an inducement material for such persons to enter into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).  However, notwithstanding the foregoing or anything in the Plan to the contrary, the grant of Awards will be approved by the Company&#8217;s independent compensation committee or a majority of the Company&#8217;s independent directors (as defined in Rule 5605(a)(2) of the NASDAQ Listing Rules) in order to comply with the exemption from the stockholder approval requirement for &#8220;inducement grants&#8221; provided under Rule 5635(c)(4) of the NASDAQ Listing Rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  If required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan.  Except as provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code or (B) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Repricing; Cancellation and Re-Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Share Reserve.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and after the Effective Date will not exceed 1,500,000 shares (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to an Award are not issued because such Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obl</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">igation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">such Full Value Award, such shares will again become available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by the Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to satisfy the exercise or purchase price of an Award will no longer be available for issuance under the Plan, including any shares subject to an Award that are not delivered to a Participant because such Award is exercised through a reduction of shares subject to such Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obl</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">igation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in connection with</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;an Option or Stock Appreciation Right, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Eligibility for Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards may only be granted to persons who are Employees described in Section 1(a), where the Award is an inducement material to the individual&#8217;s entering into employment with the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.  For clarity, Awards may not be granted to (1) Consultants or Directors, for service in such capacities, or (2) any individual who was previously an Employee or Director, other than following a bona fide period of non-employment.  Notwithstanding the foregoing, Awards may not be granted to Employees who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Approval Requirements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards must be granted either by a majority of the Company&#8217;s independent directors or by the Company&#8217;s compensation committee comprised of independent directors within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be Nonstatutory Stock Options.  The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PROVISIONS OF AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent consistent with the Company&#8217;s bylaws, at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company or (B) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dividends.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Conti</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">nuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising an Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that notwithstanding anything to the contrary in the terms of an Award Agreement, no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code.  Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent that the Board determines that any Award granted hereunder is subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code.  To the extent applicable, the Plan and Award Agreements will be interpreted in accordance with Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a) and (ii) the class(es) and number of securities and price per share of stock subject to outstanding Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar stock awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar stock award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar stock awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Awards that are held by Current Participants, the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar stock awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Payment for Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of an Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">to the greatest extent possible, the greatest economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reduced Amount was determined pursuant to clause (x) of the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">becomes reasonably likely to occur</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Board may suspend or terminate the Plan at any time.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">No Impairment of Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any right to receive Common Stock granted under the Plan, including a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, or any Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar </font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of two or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.  Consultants are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;Control Acquisition&#8221;);</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.  Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date this Plan is approved by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2016 Inducement Award Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>5
<FILENAME>exel20181231exhibit1032.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFA0DCAD86B925AFFB99C2104241822D7"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.32</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cash Compensation for Non-Employee Directors </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:47%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">12</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Audit Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$15,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$8,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Nominating&#160;&amp; Corporate Governance Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Research&#160;&amp; Development Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  1</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meetings for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  2</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of eight meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  3</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of seven meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  4</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of four meetings.</font></div></td></tr></table><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>6
<FILENAME>exel20181231exhibit1040.htm
<DESCRIPTION>EXHIBIT 10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCB173C190529A67D57080C8F1F45387A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:528px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.40</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment #3</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cooperative Research and Development Agreement #11-1-00006</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Clinical Development of Exelixis Inc.&#8217;s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)/Kinase Insert Domain Receptor (KDR) inhibitor, as an Anti-Cancer Agent&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA).  These changes are reflected below, and except for these changes, all other provisions of the original CRADA remain in full force and effect.  Two originals of this amendment are provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The aforementioned CRADA shall be amended as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Article 2, Definitions, will be amended to add: </font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Quality Technical Agreement or QTA&#8221; means the agreement setting forth in detail the quality assurance arrangements and procedures for the manufacture and supply of the Investigational Agent.&#8221;</font></div><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Regulatory Authority&#8221; means any governmental authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction, including but not limited to the FDA and EMA.&#8221;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The second sentence of Section 3.8.1 is hereby deleted in its entirety and replaced with the following: </font></div></td></tr></table><div style="line-height:138%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Investigational Agent should be suitable for shipment to all countries and sites participating in DCTD-sponsored clinical trials approved under this CRADA. Investigational Agent will be provided in accordance with the Quality Technical Agreement.&#8221;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Section 3.8.2 is hereby deleted in its entirety and replaced with the following:</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;DCTD will provide updated forecasts of amounts of Investigational Agent anticipated for ongoing and anticipated clinical studies under mutually agreed upon Protocol(s) and, in any event, will notify Collaborator of the quantity of Investigational Agent required to maintain adequate supply for each clinical study to be conducted under such Protocol(s) at least [*] before the date on which Collaborator is required to supply such Investigational Agent for use in such studies.  NCI NSC (National Service Center) numbers are required to be on the drug product label provided by Collaborator to DCTD only.  Investigational Agent provided by Collaborator directly to clinical sites outside of the United States are not required to be labeled with the NCI NSC numbers additional  labeling and/or other information may be added by the NCI Pharmaceutical Management Branch (PMB) on the label of Investigational Agent for all DCTD-sponsored clinical trials.  DCTD is responsible for ensuring that appropriate quality standards and regulatory requirements are met for all such, additional labeling and/or other information, as further detailed in the Quality Technical Agreement.&#8221;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaborator contact in Section 3.9 shall be replaced with &#8220;[*].&#8221;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 4.5 is hereby deleted in its entirety and replaced with the following:</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Annual Reports.  DCTD will provide to Collaborator a copy of the Annual Report, or such portion containing Protools using Collaborator&#8217;s Investigational Agent concurrently with the submission of the Annual Report to the FDA.  Such Annual Reports will be CRADA Data, and will be kept confidential by the Parties in accordance with Article 8.&#8221;   </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">All instances of &#8220;FDA&#8221; in Sections 3.9 and 3.11shall be replaced with &#8220;FDA and/or other Regulatory Authority&#8221;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Instances of &#8220;21 CFR 312.33&#8221; shall be replaced with &#8220;21 CFR 312.33, and any applicable local regulatory regulations or guidances&#8221;.</font></div></td></tr></table><div style="line-height:138%;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Signatures begin on next page</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ACCEPTED AND AGREED TO:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">For the National Cancer Institute</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.4017094017094%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:5%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ James H. Doroshow</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/16/2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">James H. Doroshow, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deputy Director, NCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">For Collaborator:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Inc.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.4017094017094%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:5%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Gisela M. Schwab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/29/2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gisela M. Schwab, M.D. <br>President, Product Development and Medical Affairs, CMO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date</font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>exel20181231exhibit211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s71671E29CCF752EC91C38F03764C64AA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:548px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:277px;"></td><td style="width:270px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Name of Subsidiary</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">State or Other Jurisdiction of Incorporation or Organization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis International (Bermuda) Ltd.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Patent Company, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Plant Sciences, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis U.S., LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>exel20181231exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s93C6BA158AD55AD5A7E9F46137B8682F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-226493, 333-223225, </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement&#160; (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>exel20181231exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD1708BED3604566AB5A9884C0D9D2B45"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>exel20181231exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAA5640067591575F8C2AA9EF0AF2FD3B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;22, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>exel20181231exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC312E4D5414A562BBC0B0B4165482FAA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;28, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">22nd</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>exel-20181228.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:67357514e22c4bd8ab75f6410587f472,x:12f7c8e4fa994b9aa7a9f7e3cfca176a-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:exel="http://www.exelixis.com/20181228" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="exel-20181228.xsd" xlink:type="simple" />
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">exel:CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_EquipmentAndFurnitureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:EquipmentAndFurnitureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201618Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Dec30-Dec30_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAFilingAcceptanceHCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2017-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201618Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedfromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CommercialPresenceInMarketsWorldwideMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CommercialPresenceInMarketsWorldwideMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:SecondMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov01-30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-01</xbrli:startDate>
			<xbrli:endDate>2015-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Feb01-Dec28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-01</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb01-29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-01</xbrli:startDate>
			<xbrli:endDate>2016-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:AdditionalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Sep29-Dec28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-29</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug31_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-02</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToBuildingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal_srt_RestatementAxis_srt_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3QTD1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Dec31-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01-Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Dec31-Mar31_srt_ProductOrServiceAxis_exel_CollaborationMember_srt_RestatementAxis_srt_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="clinical_trial">
		<xbrli:measure>exel:clinical_trial</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="option">
		<xbrli:measure>exel:option</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="debt_instrument">
		<xbrli:measure>exel:debt_instrument</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-7A4B7892F233489F84E9BD7E93B56EB0">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-3F0762E8B6117405120EBD7E93BEAC82">--12-28</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-D13BC301639E52CB901195DC60C4914B">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-A027418C0B72593BB3A674DAE3667E9D">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-CC05283C4FA7931B12A1BD7E93BC9D4A">2018-12-28</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5C737FC5969A7148A915BD7E93B11D0F">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-A851BA2FAD0BD7F0FA16BD7E93ADA507">0000939767</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q1Feb12" decimals="INF" id="Fact-59A15FEC4C9B5BC5829F035977A32393" unitRef="shares">300129630</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2AA9F0955806BED95F4ABD7E93C068D9">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-C12A653DBC4061D48F44C32320466396">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-FCA0FAD02DC01759332ABD7E93AE4657">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2018Q2" decimals="-5" id="Fact-8396EF1221C211B57971BD7E93A861C4" unitRef="usd">5531100000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-14CDBA7769BB3ECD7896BD7E93A62A0E">EXELIXIS, INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-E8EC60808C4433A7843FC3239820A0FC">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-E1BDBF51286696064CE7C32358D6727A">false</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-FF2D430C306CCEA7C390BD7E93B22B56">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-6F4C95B6F945CFE91F06BD7E93AD220F">Yes</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5DA771DDE047D1C07FCDBD7E93B53B03">exel</dei:TradingSymbol>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7C5A1D26D1C75713855CEECAF7DCE686" unitRef="usd">18231000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-78ED0BE834A95390B6CBA1C2A0CF5507" unitRef="usd">19849000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-33ACEAB5D1645CAFAE5F7B0FA8BC868C" unitRef="usd">7419000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9746CE6378705C0BB48635510E145F5A" unitRef="usd">8974000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AdditionalUpfrontAndMilestonePayments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-8D44A9FB102744777DA3FF25E917815D" unitRef="usd">1200000</exel:AdditionalUpfrontAndMilestonePayments>
	<exel:AreaOfRealEstatePropertyAvailableToLease contextRef="FI2018Q4_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="0" id="Fact-2076ACC0AB4B5F258C37DA9211AB5B0C" unitRef="sqft">170000</exel:AreaOfRealEstatePropertyAvailableToLease>
	<exel:CapitalandOperatingLeasesNumberofRenewalOptions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember" decimals="INF" id="Fact-60FDBB9E8985AB1F2048BD7E93DBBA76" unitRef="option">2</exel:CapitalandOperatingLeasesNumberofRenewalOptions>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="FI2018Q4" decimals="-3" id="Fact-7E258B9701A472600E0BE3872DBA3E40" unitRef="usd">851621000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-907FE970995557CDE0AFE387F356FB63" unitRef="usd">457176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-3" id="Fact-1480035BB819020A38DFE384BFB70CB8" unitRef="usd">852322000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29" decimals="-3" id="Fact-7175EB337C1DDB16B391E387F0B4E96A" unitRef="usd">457522000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-110446230D1DD54FFD86F871FA1F7B34" unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-B4C6731C3B1158D386792F1FB4D7EB48" unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-E4D2D736B843F8E902ACF8720026B4F9" unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" decimals="-3" id="Fact-22B03472C078A76E0EDEF8F5B14C84E1" unitRef="usd">6883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-77A65D2FA2DC5F61963B505DD7256AA4" unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-14F94BE7C7FB7B677FF0F885B107A8EF" unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-C84DCB2DF685F9C19849F885B5CC7ACE" unitRef="usd">13498000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-E2982102464681BEB97FF885BCAAF299" unitRef="usd">13498000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" decimals="-3" id="Fact-FE5BF8A5EDD219493EA4F8F867C561FE" unitRef="usd">3268000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-527251C71441D854D52BE387F050B73B" unitRef="usd">13498000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-012C0DE878F33B860FE9D3701B276421">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" id="Fact-FB0F1B9A6A0AFCC8004798DBE3892615">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-303FD4B8EED36EE8E11DD37826D83DFC" unitRef="usd">8771000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-50799C99960D451436F9D37826DEF5CD" unitRef="usd">-2140000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-4DA8927BC4474210A7B5D37826D250AB" unitRef="usd">8084000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-2D7A684485E0FCDA9C75FF1B87F7049C" unitRef="usd">240000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="INF" id="Fact-1727FE26FC007F9579FCBD7E93DF53C9" unitRef="usd">110000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-8062E417C03A5F37B85539918F04B611" unitRef="usd">90000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-5" id="Fact-A77C6FDBFCF8B24BBE53FF2999845653" unitRef="usd">20000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale>
	<exel:CollateralProvidedForPurchasingCardProgram contextRef="FI2018Q4" decimals="-5" id="Fact-24832F47739025A7160DBD7E93D7AF98" unitRef="usd">3000000</exel:CollateralProvidedForPurchasingCardProgram>
	<exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-714222623AFD5EDEA49B9A98A0D2A7C6" unitRef="usd">37881000</exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
	<exel:ContractWithCustomerAssetCurrentOtherAdjustments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-54640A8F9F7454A6BF2CE8E908D46CF3" unitRef="usd">-1417000</exel:ContractWithCustomerAssetCurrentOtherAdjustments>
	<exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-DDBD99A94259556387DCD9D733881161" unitRef="usd">4545000</exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
	<exel:ContractWithCustomerAssetNoncurrentOtherAdjustments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-FCCE00AEC6A7556E8F19407BF9EDF1FA" unitRef="usd">-16792000</exel:ContractWithCustomerAssetNoncurrentOtherAdjustments>
	<exel:ContractWithCustomerLiabilityCurrentDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A3D713AB2AFA5E21A2C0053F37A195B8" unitRef="usd">8683000</exel:ContractWithCustomerLiabilityCurrentDeductions>
	<exel:ContractWithCustomerLiabilityCurrentOtherAdjustments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-35A5F87AFA53543BA3EF5B20945AF1A0" unitRef="usd">-1428000</exel:ContractWithCustomerLiabilityCurrentOtherAdjustments>
	<exel:ContractWithCustomerLiabilityNoncurrentDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-BE1F12D5DB2B5B719A89FC2A7EDA9825" unitRef="usd">0</exel:ContractWithCustomerLiabilityNoncurrentDeductions>
	<exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-38870E0DDA09556587E5AA5DD6C7AA3E" unitRef="usd">-16781000</exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments>
	<exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A0986B4F0557534D8CAE51BAE1015943" unitRef="usd">1718000</exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
	<exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-C7BD7230D4AB5AF6AFEEE8316EBC767C" unitRef="usd">7237000</exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
	<exel:CostMethodInvestmentOwnershipPercentage contextRef="I2016Q3Aug31_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="2" id="Fact-C38193D46AE82659C068BD7E93BCBABE" unitRef="number">0.09</exel:CostMethodInvestmentOwnershipPercentage>
	<exel:DebtInstrumentNumberofInstruments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="INF" id="Fact-E7B284ABDFA605AA5AC7BD7E93DD50FA" unitRef="debt_instrument">2</exel:DebtInstrumentNumberofInstruments>
	<exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified contextRef="FI2018Q4" decimals="-3" id="Fact-8BA846C5D157C4A7FDFFBD7E93B1C1CF" unitRef="usd">11366000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
	<exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2DDD4C903C8D35A499D2BD7E93B3CD6B" unitRef="usd">8966000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
	<exel:DefinedContributionPlanNumberofSharesAvailableforGrant contextRef="I2017Q4Dec29" decimals="INF" id="Fact-37836BBB044E1FEF038DBD7E93ED1AF7" unitRef="shares">571674</exel:DefinedContributionPlanNumberofSharesAvailableforGrant>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-681588DFA49CF12029FBBD7E93AFFEE4" unitRef="usd">4726000</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-AF721D087A83D3CDB275BD7E93ACBA6F" unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-D36CA381F6DC9E80F707BD7E93AE1342" unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="FI2018Q4_exel_MilestoneObjectiveAxis_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-7AFA3C21751AEAEC9C63EA8263260216" unitRef="usd">127500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="FI2018Q4_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-1AC33216FF0F50ED8C6E229E720C63C5" unitRef="usd">131500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="FI2018Q4_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-4361800B22C4567C8295338067355727" unitRef="usd">56500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-5E813B172C5A50CA95B0262F665157F3" unitRef="usd">84000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-8F160B8F95445189AA9F374E7F2EB237" unitRef="usd">2300000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-D6BCD3EE0D96523498222264E6FFF796" unitRef="usd">325000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:FinancingObligation contextRef="FI2018Q4" decimals="-3" id="Fact-755F2EFF478610269BA311F270521BDD" unitRef="usd">0</exel:FinancingObligation>
	<exel:FinancingObligation contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5812E134E4576A3133787C48554E6696" unitRef="usd">14530000</exel:FinancingObligation>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B7118A9A51075EFAACD235414CC11DBB" unitRef="usd">-3940000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F735B9ED5D0E5B0594EE2B10F0FBAEB5" unitRef="usd">5718000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-DFDE2B03F0065D00900BE20679D1ADD9" unitRef="usd">-1618000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseInLeaseLiabilityNoncurrent contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-5CB9933A489DFAE2B430829481351F8F" unitRef="usd">0</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
	<exel:IncreaseDecreaseInLeaseLiabilityNoncurrent contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F7FBEE76742B53FF98C483DECD939F53" unitRef="usd">14938000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
	<exel:IncreaseDecreaseInLeaseLiabilityNoncurrent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0D81664C46405EAFB5025C3157528A15" unitRef="usd">-1225000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
	<exel:IncreaseDecreaseInRebatesAndFeesPayable contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-C4233AF1C5BCEDE53CA7828FE84E4596" unitRef="usd">3866000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
	<exel:IncreaseDecreaseInRebatesAndFeesPayable contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-D7DC2955DF35569ABD3D0D33D36F7CE2" unitRef="usd">4145000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
	<exel:IncreaseDecreaseInRebatesAndFeesPayable contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-EF648055EA5B558388E87DED68C81883" unitRef="usd">7389000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-03531883B23D584A97D2D778984B4F01" unitRef="usd">-10938000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-57CC33EC54715FB7899E7E80AB6B80A5" unitRef="usd">6928000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A1B7433FF94759938FE91BD4F0FEBB2D" unitRef="usd">-1555000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:InventoryManufacturedBeforeRegulatoryApproval contextRef="FI2018Q4" decimals="INF" id="Fact-E0CFDBC30DF8F725B44801664F68015A" unitRef="usd">0</exel:InventoryManufacturedBeforeRegulatoryApproval>
	<exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements contextRef="FI2018Q4" decimals="-3" id="Fact-062FC46FB9E3526A86360E94B92A6522" unitRef="usd">8170000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-7DF828DA5F6D5021A0FA3443AFBE931A" unitRef="usd">83000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-8D022ED4AF87567682DD05E03E3A21FD" unitRef="usd">519500000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-5BA193377F65AB22A738FF1C0C3E64F6" unitRef="usd">150000000</exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement>
	<exel:MilestonePaymentsEarned contextRef="D2018Q1Dec30-Dec30_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-C8C1C404ACCC50D7840095D7AFA0B4C6" unitRef="usd">10000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsEarned contextRef="D2018Q4Feb01-Dec28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-C8834B4667CDB6E3AFB198C7A4482014" unitRef="usd">275000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsEarned contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-8E3FE14E93BB29F1B03598D7151DE857" unitRef="usd">140000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsEarned contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-EA72D5460D702478E95E98DF14950F35" unitRef="usd">10000000</exel:MilestonePaymentsEarned>
	<exel:MinimumNumberOfClinicalTrials contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-8D471E542BCD4E583752FF0F34769D9B" unitRef="clinical_trial">50</exel:MinimumNumberOfClinicalTrials>
	<exel:NumberofProductsinCommercialMarket contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-5AA94CC892A35B5F874AB80F8A391877" unitRef="product">4</exel:NumberofProductsinCommercialMarket>
	<exel:NumberofProductsinCommercialMarket contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CommercialPresenceInMarketsWorldwideMember" decimals="INF" id="Fact-E384A3C432BF413EF8580168A9DEBA79" unitRef="product">3</exel:NumberofProductsinCommercialMarket>
	<exel:NumberofProductsinCommercialMarket contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember" decimals="INF" id="Fact-8BDC77EDF9CE5015877DDBC22939E900" unitRef="product">2</exel:NumberofProductsinCommercialMarket>
	<exel:OperatingAndFinanceLeasesLiability contextRef="FI2018Q4" decimals="-3" id="Fact-C5959BFCB67E9C4DD6227C4856E2FC38" unitRef="usd">14965000</exel:OperatingAndFinanceLeasesLiability>
	<exel:OperatingAndFinanceLeasesLiability contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-6173C73E30E85322A2757B60275C395C" unitRef="usd">14938000</exel:OperatingAndFinanceLeasesLiability>
	<exel:OperatingAndFinanceLeasesLiability contextRef="I2018Q1Dec30" decimals="-3" id="Fact-72BB17EF5853966137B6DF98C9C175FC" unitRef="usd">13323000</exel:OperatingAndFinanceLeasesLiability>
	<exel:OperatingAndFinanceLeasesLiability contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-7E97E60EACE8B80CD194DF98C5A1E08E" unitRef="usd">-1615000</exel:OperatingAndFinanceLeasesLiability>
	<exel:OperatingAndFinanceLeasesLiabilityLongTerm contextRef="FI2018Q4" decimals="-3" id="Fact-3E2CC3EC00AD55458683DCD12C33C33A" unitRef="usd">12178000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
	<exel:OperatingAndFinanceLeasesLiabilityLongTerm contextRef="I2017Q4Dec29" decimals="-3" id="Fact-155F7D5B601E53318EAD09DE68822E70" unitRef="usd">14938000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
	<exel:OperatingLeaseAndFinancingObligation contextRef="I2017Q4Dec29" decimals="-3" id="Fact-18EE458E3FCA5F5CA265402B20B62B65" unitRef="usd">15478000</exel:OperatingLeaseAndFinancingObligation>
	<exel:OperatingLeaseObligation contextRef="I2017Q4Dec29" decimals="-3" id="Fact-83439795EA1132A3C3F701347A79447E" unitRef="usd">948000</exel:OperatingLeaseObligation>
	<exel:OperatingLeaseObligationCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-EA3D81EE00542362E096F88431865829" unitRef="usd">540000</exel:OperatingLeaseObligationCurrent>
	<exel:OperatingLeaseObligationNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-4824E8CA27B2FFE80FB5F88432997B57" unitRef="usd">408000</exel:OperatingLeaseObligationNoncurrent>
	<exel:OwnershipInterestByMinorityShareholder contextRef="FI2018Q4" decimals="2" id="Fact-E23A850301275BF0AB4F054884722ACC" unitRef="number">0.10</exel:OwnershipInterestByMinorityShareholder>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-181DD24BCDA7E4EE3B2882A518F5C305" unitRef="usd">7135000</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6C32A43B4E8A04BB000882A518FAAD99" unitRef="usd">0</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F195C937E7364985325782A518F11CCF" unitRef="usd">0</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="2" id="Fact-23F45E666B2C5782A7C7A7C80B4A7893" unitRef="number">0.02</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-A86A3C46363D564A904FE230B276F3A3" unitRef="number">0.12</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-DA03D119464554EF8E1015DBC3663BDA" unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-4AF5433FBBCB53429971B06580BFD36F" unitRef="number">0.3</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-89BB24E16BD15D7AA113EC19EBEBCEAB" unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-2941D751946B56169815E33C40B75208" unitRef="number">0.2</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-4475EBDF0ABB5612A78E9742A708C57F" unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-A28CD12D64985027833D16611AC280C0" unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="2" id="Fact-F6B50924BB7856DAB76071DEF0E63FD0" unitRef="number">0.03</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="INF" id="Fact-6CF345B9B70E0A2D6BC5FF27DEF2B31D" unitRef="number">0.005</exel:PercentOfRoyaltyOnNetSale>
	<exel:PeriodOfSpecificSalesVolumeThreshold contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-1A5C0E73C395C22F1AE1D3727D44E9CB">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
	<exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce contextRef="D2015Q4Nov01-30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="2" id="Fact-B21E453F2985E46FBC71FF0C3E85EB2F" unitRef="number">0.25</exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="2" id="Fact-694C9D5B9BE78FE68F1B19AD4870BA3F" unitRef="number">0.50</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="2" id="Fact-0B4B1BBCB3C0E49ED2A719AD48980595" unitRef="number">0.30</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-FF4FE1D6F65E329A1BFE19AD48ADCF73" unitRef="usd">400000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-42E141141096B4FA741F19AD4805BE11" unitRef="usd">200000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:ProjectInitiationFeePayment contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-55FE71F3A182514482349457D5379D9C" unitRef="usd">2000000</exel:ProjectInitiationFeePayment>
	<exel:PropertyPlantAndEquipmentAdditionsAndTransfers contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" decimals="-5" id="Fact-967C753F61FB57FB9168914A5F0194AC" unitRef="usd">46300000</exel:PropertyPlantAndEquipmentAdditionsAndTransfers>
	<exel:RelatedPartyTransactionsAdvisoryFeesPaid contextRef="D2018Q4Sep29-Dec28" decimals="-5" id="Fact-F318072FD2D7504EBF8824D0C84427EE" unitRef="usd">200000</exel:RelatedPartyTransactionsAdvisoryFeesPaid>
	<exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner contextRef="FI2018Q4" decimals="-5" id="Fact-FE5AE34F6E3B57DB8CE40BAF0742F099" unitRef="usd">298500000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
	<exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner contextRef="I2017Q4Dec29" decimals="-5" id="Fact-B363FC8C51B151AA83967EAAE527DDE5" unitRef="usd">141000000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
	<exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund contextRef="FI2018Q4" decimals="-5" id="Fact-29D5CF85F9235CC9922145B7043F6666" unitRef="usd">3000000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
	<exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund contextRef="I2017Q4Dec29" decimals="-5" id="Fact-79D682EBFC8A5485A5923F129A12B32D" unitRef="usd">1000000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-09EF5F385F9D541F8AA3437F2664A443" unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="2" id="Fact-91749F8F730F548DB295F30FF6772E34" unitRef="number">0.20</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="2" id="Fact-AFE4CADA615F30BFFA2998CA64038DC6" unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:RightOfUseAssetObtainedInExchangeForLeaseLiability contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4BBFA26AAC9007333A2382AE45E14854" unitRef="usd">0</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
	<exel:RightOfUseAssetObtainedInExchangeForLeaseLiability contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FE6A287B78BE528BBE4346AC51AFCEFD" unitRef="usd">0</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
	<exel:RightOfUseAssetObtainedInExchangeForLeaseLiability contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-4D48BAB266F85C77824FCE82B4FC410F" unitRef="usd">17180000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
	<exel:RightofUseAssetAmortization contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-565FE5DF3CF48824612682841D582BA6" unitRef="usd">0</exel:RightofUseAssetAmortization>
	<exel:RightofUseAssetAmortization contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4295690DC6BF509CB6A1A71FA3AA336D" unitRef="usd">0</exel:RightofUseAssetAmortization>
	<exel:RightofUseAssetAmortization contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2D869F30DC5755D38F3D28AE00026E46" unitRef="usd">2854000</exel:RightofUseAssetAmortization>
	<exel:RoyaltyTier contextRef="D2018Q2DEC30-JUN29_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-81F18537421756AD99C5EADC13FDD3F4" unitRef="usd">150000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-F3AF508D47A12A74CA80FF055B4329E4" unitRef="cad">30000000.0</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_RoyaltyTierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-208B4D29DBBB54B0B8F59A34CCC372CF" unitRef="usd">300000000.0</exel:RoyaltyTier>
	<exel:SalesRevenueDiscountExpectedtobeEarnedPercent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-F5033BF1D584560E97E949B18F75DE60" unitRef="number">1.00</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
	<exel:SalesRevenuePercentDiscountForPromptPayment contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-E40D50E418255F38A8CA109711E0D675" unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-7305DB8831225DC6ABBE947A6A581314" unitRef="usd">94427000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-CF2DF66A2E7258D5A4EA2282FA0DF101" unitRef="shares">1081339</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C0570102E95E5432A2A9422B9597BFDF" unitRef="usdPerShare">16.05</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-AD45C23B63F0E5F9237EBD7E93D9EF20" unitRef="usd">13400000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-1682C1865CB1EE4BF868BD7E93D58F73" unitRef="usd">13100000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-768D87345FF01C840E9FBD7E93ECD6B1" unitRef="usd">18900000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-902956120E7820654C8EBD7E93D83C90">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" decimals="2" id="Fact-E97AD99D0ADF5D73902880726724839A" unitRef="number">1.25</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-368487AD1BE6C519FD79BD7E9392BF20" unitRef="usd">-29110000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F5E5CD7272D9A55D10A8BD7E93961556" unitRef="usd">247000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F22311A4815E7C7858FEBD7E9394412B" unitRef="usd">-4254000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-4E7FD60EFB1053D8B92FBA9A6E2803D2" unitRef="usd">2000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-966A7E0469565385A46579A5C977F1C6" unitRef="usd">2000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-D689F3064FE2586EA758E4FE49BA8021" unitRef="usd">3000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontPayments contextRef="D2016Q1Feb01-29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-242380CC0D545698918B3F13B2610259" unitRef="usd">210000000</exel:UpfrontPayments>
	<exel:UpfrontPayments contextRef="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-FBB2EAFD5F2F5FAB85CB69EE421BCCCB" unitRef="usd">50000000</exel:UpfrontPayments>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B27FD9E564D5217475057BD649925AFB" unitRef="usd">55001000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-746F6E4DE7438AEA23497BD648FA58F3" unitRef="usd">7301000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-59257105D57C7C7003A37BD648CC5BF7" unitRef="usd">14390000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-C367EB6BB06BB21C4F397BD648DA9FD4" unitRef="usd">33310000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-59B2AC070DA34D5512AA7BD64938D08D" unitRef="usd">0</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-42B9EB0D9F65381767E47BD66071D18B" unitRef="usd">119600000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-A27C43D2FD6E5E86BB2CB44907E81F7E" unitRef="usd">13015000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-BBEA29856B805195BE60806030758F7C" unitRef="usd">31040000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-216DF9539A07507A852AB152B23B4F78" unitRef="usd">75543000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-D19A9DB507C431B6D0177BD6610B37D9" unitRef="usd">2000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-20E7BB61E42D2E2B701E7BD72D582811" unitRef="usd">-1441000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-EF16A271ABB56CC20F7C7BD72D63FC4C" unitRef="usd">0</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-D35D259B593649C95EA27BD72D46C45A" unitRef="usd">-624000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-C5BDD46B0A498C47222F7BD72D4A55C6" unitRef="usd">-817000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-F3D3D49D7B38365D03217BD72D506725" unitRef="usd">0</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-6AFD95BDEC5719EED5EB7BD77A83C64A" unitRef="usd">-350000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-4F19883B5A68523C93BDDDDF08594AE4" unitRef="usd">206000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-8DC2939673725FFAB2CC8804F163FDFC" unitRef="usd">-153000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-3050D467E9115AE1B87ACBDB20744FF2" unitRef="usd">-403000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-BB18F745F511EF62E2ED7BD779BABC4C" unitRef="usd">0</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-B35150F641D857D2B62104CA796A3DFB" unitRef="usd">10901000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BA87110177A954DE852664496C496C17" unitRef="usd">9575000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C5FC47047F6C5E89A6714D106942A9B6" unitRef="usd">32142000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-CBA9BE10E34954599C9A744AF23B0650" unitRef="usd">21073000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-838A839E493251BA86C86BC53F6662D2" unitRef="usd">17309000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I2017Q4Dec29" decimals="-3" id="Fact-17BB8BCCA45250B5998ED3453C88AF9B" unitRef="usd">22800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-5C9489248AD2517AA22005C028B959C0" unitRef="usd">-701000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-EAAFA21F63F951518C66E96D6EFE9B62" unitRef="usd">-347000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-9BB8692D5E945DA398C9AF65D5C8ACA4" unitRef="usd">2168217000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F86F5073E12A5C7B8F87AB0C66081F82" unitRef="usd">2114184000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7D7AECED34B5BCD6F30DBD7E938C4801" unitRef="usd">22912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6BB25B92387E6C8E86E6BD7E938E38FF" unitRef="usd">22912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0D8263B65CC5DD47346DBD7E93844879" unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-874AA61D6164F9511903BD7E93C59212" unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-56401913889A02C3375A811332C75591" unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5927C9EC1974AB67DA7F81132CB676C4" unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-D5C233BE49A5E637B782BD7E93E4F4AF" unitRef="usd">22912000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-F83564FF4574F253CAE2D3F10425D92C" unitRef="usd">4100000.0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-5DEF7C3CB0F445EC3397BD7E93D7C202" unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-A9BDF12DD101CEAF5AECBD7E93E620D4" unitRef="usd">9366000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-8F10A02A98C084F2BCFFBD7E93E4E29F" unitRef="usd">13546000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C24BCC56A457EA179D36BD7E93E3A204" unitRef="usd">23938000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-DFB3AE5C0988230C1E27BD7E93E50877" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-2331F54A9BC6E3826E7ABD7E93D5B87E" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-411FF6B984915A1F8A50EA3FC5D28AC7" unitRef="usd">7569000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-2B56046C468D5F22B478C6133212B76A" unitRef="usd">16369000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-27FE452D6E292BBC9F67BD7E93E5DE9D" unitRef="usd">40626000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-D76A76F945FA21F41743BD7E93E2EF3C" unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3754063F6BC8558FADF371B7B38CDEF2" unitRef="usd">13115000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-74F289FE37B5504BB8415BF5B75AE8F6" unitRef="usd">27511000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BFEBB972F89259B29D80D1D0894C46BB" unitRef="usd">8432000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A48353EFCAAE5C60812EC3F1FEECDFE2" unitRef="usd">182000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-E617680965405064B2C9F1EAFE60092E" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0D82A85245A565278B9CBD7E93B7BE01" unitRef="shares">62458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-56717B1A0AA83FAB15C819E41AEEA953" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-0E9452099AC65B2180AF40B4D578E228" unitRef="shares">33890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-104024AB04ED507CA7201B08BCF4D216" unitRef="shares">27568000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-547CED0512F351DE9F4C744AD47A3916" unitRef="shares">1645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-76165A8B1FCB109BA2ADBD7E93B825B0" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-88F2E41330675932BEFE2746AC217DF8" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-E13F6C0E8FD3588A82EFCD3199EC88B8" unitRef="shares">1645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0C3D7AC097F45E5BADB089026F361607" unitRef="shares">3968000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-378B7F8DD4DA0047BB62BD7E93B78B66" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-27866BD05B3958DB90DC52D85F4F1B6D" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-D38D637B838254E7AFC1764E6E21DE2E" unitRef="shares">3968000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="FI2018Q4_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="0" id="Fact-8018665D7508592883DB72A987DAB406" unitRef="sqft">134765</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="FI2018Q4_srt_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember" decimals="0" id="Fact-71C4DDD2190755BBBBD2865D51540DD6" unitRef="sqft">116063</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-C8390F6AB2785CCBB196D231B59FBE77" unitRef="usd">1422286000</us-gaap:Assets>
	<us-gaap:Assets contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BC75C75AE3965054A4EC1E94FA1659AB" unitRef="usd">655294000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E84C8514029853138419E5C97BFD434A" unitRef="usd">897016000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-557D731175E1D123D94D82779FAE4EA6" unitRef="usd">484874000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DBE024B47059418F19ACF8721617385A" unitRef="usd">47744000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DD3CD8323D56DF1F95FEF87219FECE94" unitRef="usd">796994000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-044BDF9C4CAF729C2E21F8721DCBA545" unitRef="usd">844738000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1E0A06292582E95A3280F885C03F1D16" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-28A6D5887E2A77F5FDF4F885C54C839D" unitRef="usd">408430000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1C0966FDA0688F09B9EEF885CA2F8627" unitRef="usd">453908000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-ADE0CBE6F8BB96DB3531D39A5612FBEF" unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-9D62016F560B9FB760FDD39BEE999E36" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-ABF97D20F77450BCAB5028265E1977AA" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-25436B1E8816539798AEB3E9752A0717" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-1A570AB93BC552AE99F836F42AC7134B" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-DDDCB17EBCFB6B9F29ECE387F17138E3" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-52D0BF4E0E6650CDAC7E25CB3BC03B34" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-AE403DB3FB0050ACB854F5229F52D544" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-5A876FBD4B0F50C8B757C0179840EC90" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F24F8E77AE2654E2894DEE4EAEB6D43C" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-7CF0A8B19B698A2A711CE387B131B529" unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2FA5648461D356E1876134B81A01A3F2" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-21585F45E07A57B592999708151C90EE" unitRef="usd">857000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-4E251667B25B5466971BB63A26ED77B4" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DC9A30BFF7BD59C2AC131B2E83688DE6" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6AB88F562E054A063B51BD7E93E4088D" unitRef="usd">364000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-973A5C581DA05667922B2958A3E6234C" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-87DB0A3F2CDA5A9EA11FF03F42E9DC64" unitRef="usd">332000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F6C69431372458B4AB4596E048D9FD05" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-AFB40067D61B58078A040BC82490923E" unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-3" id="Fact-C7676A3269A570AECEC2D39A5475F1F4" unitRef="usd">828843000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-EECE3A71075E505197120DCDF185C04C" unitRef="usd">381134000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-D82665C6918652059BBCB0F4B4623C68" unitRef="usd">344741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-58134129E8F65E1FB7BB45FE940449ED" unitRef="usd">47744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-E9DF91335EFA57B9B92882CF2398894D" unitRef="usd">55224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29" decimals="-3" id="Fact-FF33A98E191C2BEA9310BD7E93E54289" unitRef="usd">440756000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-27431B1D88A0586A84563296D7BEA950" unitRef="usd">199647000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-948DAEB1BF545676805B33E72BCBC5E0" unitRef="usd">179336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-A4193EFFBA975349A68998CC2CCAADBE" unitRef="usd">45478000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-34B54BFC9B125E20AC09B90063FACE0C" unitRef="usd">16295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2018Q4" decimals="-3" id="Fact-4B20CCEBADF05915A7E11C9A095FADCD" unitRef="usd">153687000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C317FEAD983550B99DC12C29C208AE7A" unitRef="usd">63255000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2018Q4" decimals="-3" id="Fact-72D3A8E879F0516A9F06EADA1EDF1CA3" unitRef="usd">674455000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5E71FB09C27E52FABF6A61856488F7F0" unitRef="usd">377155000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4" decimals="-3" id="Fact-35D3CA6801426AE71416D39A5AA7A7C6" unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B5F80C42C38D9678036380A87129DEE8" unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2FA842B8F4F25033A73E0225EA658508" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-10C595EE02CE51F19FC49A5479CF74FD" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-4B69F0E45A0453B9BB6752CEDFE0F1EE" unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-9884348539F45BA8B6876DF741C9C6CD" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-772F7E462E8BE042EC0280A8748C399D" unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-239C61C19E3B5A9E9831890CF2EC5BA7" unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-6BE8969558035491A6C1FCFB02B71141" unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-80553B9ACD4D5A4A9DE43F6CF116F1F3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-21C6D6D6D33057C29A8F43F61B01E8D7" unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F225CB9E1AFCCFBB68F680A878A34452" unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-32F3D82BD028CB4D648D80A8622F4AAA" unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-DA4ACBE9A5BDBBCBCCFD80A867B66EE9" unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-AD81B46D02F188662D8F80A85910E67F" unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-AA5754863BBDA835568C80A86D93B955" unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-BE4B6F141C5C5112432549D544846A6C" unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-F5DC178DE6BC407FF6C949D544AE47E6" unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-8312CE797B6CB3C33FFB49D544E0306D" unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-8C110088C66D8C8D6CBE49D5448EA6D9" unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-1798A29B82EB54EC91B8CC37A89F445D" unitRef="usd">440410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5FB5299E0144CA12179FBD7E93AB89DE" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D6527E5459CD59D4839E071402C63DB9" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-7A8E750EBA2A51B5831812ED7F1927FD" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-A2DD07B157AB5A3393067D86CD18C8A7" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-E3CCBF65DFD75C4D91C548048D1659C0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-51F310A3506BBF9644EBBD7E93A42F4D" unitRef="usd">394932000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C6CF35C770A15B6EA2F7C1A4AB8BE1DB" unitRef="usd">199647000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-6B35C17D89F85FDFB847C949B5E04B0A" unitRef="usd">179022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-930221318D9E57288D6AD2939B4A2088" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-AD25F6A51F345BAB8235BE4B65B934C2" unitRef="usd">16263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-15DB4814DAA19A9B56FFBD7E93A98B2E" unitRef="usd">440410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-76BF7C1A1690D3F9D7A9BD7E93A61A1C" unitRef="usd">199647000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-6DA557C62C7EA2014630BD7E93A5CF7E" unitRef="usd">179022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-A9AD7A975139F0E8D6E8BD7E93A998AE" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DCECF2C1EA553947AE22BD7E93AAB879" unitRef="usd">16263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-069E3B74B5FFCDB9FF1ABD7E93E7EE71" unitRef="usd">199647000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-2D9AB770109A38B09569BD7E93E28590" unitRef="usd">179022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-162FD7415E583646E3C4BD7E93E5C13E" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-87EADE1A40A340FA8C2CBD7E93E3D62E" unitRef="usd">16263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-5CF579B1D84A893B5FB482AE567F44C5" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-297E2E318ABC56F29419240A1FBB3BF2" unitRef="usd">524000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-AB0F0CAE1CFF5F029B77015CBA6E8580" unitRef="usd">802000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-AD6D380FF81658A1B5383D2001E68CF0" unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-A8A42B3993DD5947A65E33D53334E147" unitRef="usd">151686000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8E8D3B6248DA52D6BD1A5B88B2A3B51E" unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-605664DEB25A5B5DA0C74BC0CBE1009B" unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" decimals="-3" id="Fact-8D0E08E86431A70F6E98F8F1FDBC4674" unitRef="usd">6883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-49B1D1C2B6075B789BA5BA164D37E4C4" unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-56662E26DC06552087C2AB0DB941925C" unitRef="usd">144284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2016Q4Dec30" decimals="-3" id="Fact-259A6AEDC5D9535EA3D83CB6E8ABB05E" unitRef="usd">155836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2017Q4Dec29" decimals="-3" id="Fact-910DF827134E53659A964EEEE872425C" unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" decimals="-3" id="Fact-C0FB1B9FB941DDAC66B2F8F8638C2976" unitRef="usd">3268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-25AFA551444E01213C2FE3477F66F890" unitRef="usd">13498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-15B6ED99932E5DD196C8B0002A5C2AE5" unitRef="usd">11552000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-923F00C6BE7A5A1CB26FC231BA0C958C" unitRef="usd">32478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-EF33E19109E55D51846A997482439549" unitRef="usd">127561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-B67A5B540E0B5A529F62E4A485CD55D7" unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-087C8CCCAAB45B0C9CF63C55EFE30D0F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="I2017Q4Dec29" id="Fact-0806597F32B35C0DA25A3311E09F1E71" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-EBB431265B4B5E94B2984AF98DAA317E" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-79C43CCB99B655049EF61AF70C923AF8" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-55FF9755FECF5C25BB79D41CB9ADE303" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-731E6DF824B1510A941575DBA40502F2" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-39137A0B4B445A0593F55288E20AE11C" unitRef="shares">299876080</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-3933770F3B0E5D55BC97D973258C85B7" unitRef="shares">296209426</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-DD6B61FD208C590294E9985209615219" unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E9920C54E98F4AB0A0A9198E0157F44E" unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-68E9BD8B973A04392409BD7E93C6CB70" unitRef="shares">227960943</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F66E93018909041F7C73BD7E93BE434E" unitRef="shares">289923798</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29" decimals="INF" id="Fact-366F9CB0A5525945959C9CB0A9B32B9E" unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AFB3C6D49D736BD70ABABD7E93CCD7D8" unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-6617D708494A529C830372CE59E119C1" unitRef="usd">300000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9E74ABC1B036572BA10A7F0E039407EE" unitRef="usd">296000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2E14EC9EBBFD2B943B65BD7E93EA12B0" unitRef="usd">-70406000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9CDF358D4D945CB4B2E73AA10D86FA53" unitRef="usd">154296000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-E34C4297BEAA52C19BC0CBAFFF8B8BB2" unitRef="usd">689716000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-F5C85D78956CC36E037797827F61C1A0" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-D9AA89AA4F53CBFD62FA97827F1E3A77" unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-27FED985A9F2A3B5BD5B97827F38762D" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-20BB196AB85D50E7D1DB97827FC3DA83" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-8D1CD5C906E32D459C8C97827F0DF76C" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-94650E8B14329F8D89BF97827F4A48DE" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="INF" id="Fact-C8EEBE9CB9097788CC6697827FA5033F" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-DF3BAC1A82C956FDB4C75247EECFE4A3" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-0FD00812F1DC5AFEB4BFDE0E1CCB75D0" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-9BBC4CF5AC0952D6A619C1146E1E6591" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-C622572530595BA8983C3C1B9984BC10" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-E9C798873615531196489CD82F8CB606" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-6B4DC0F2F71BA316504E97827F14ECCA" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-5D3DF6800A895191934A817742746CF9" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-223CE71C5E855800A40313D8AF8AD95D" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-8B44A71854FB567E9C02DB362799B6C8" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-0FED3061F97A5F23BC6C88FA59BECE04" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-6ED993DCFFF451C2B74959D82EA7A525" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-4F1F859CABC952EBA2AD03662228FC9C" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-31B4675C3E1114DC68A797827F28F41E" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-5DCBC7F5DEB250C7B8092424E2631A06" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7FCF52CBDF21CDB0E09182AE30C602FA" unitRef="usd">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8240610B14225FBCA241EF2A9FCEF8AD" unitRef="usd">14530000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-BD569A1855D457D4B85A8D79C01ED380" unitRef="usd">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-26DAA8B3D47D542B87739FC1B7AADDFE" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-593FBB5085A75C33A65A545F81C05C75" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-6D2EF2655A6B58979E8A6AF28B2713D8" unitRef="usd">9588000</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-1E28887C6E5BD4B3D422DF988007591E" unitRef="usd">9588000</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0A5A19536F7A53F6A845F32E1AB2ECF4" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-0307BD490D5A5EF0821F9078D070BB3C" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-CDB3B0E1B85F5EE4B79B9B2746E599DD" unitRef="usd">12247000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-0F812DBA3E5C35A3CC4CDF98867AE5EC" unitRef="usd">12247000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetReclassifiedToReceivable contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-94610BEDFA3451E496CAAF2698588C4F" unitRef="usd">46052000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
	<us-gaap:ContractWithCustomerLiability contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-0FD4EE2A5AD56A41A45D98CC4F741C5D" unitRef="usd">13300000</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiability contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-E951A8B9DA1D5C1790F1BD67DB2F3CAA" unitRef="usd">2600000</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D1B1EAE8398A5C198317B42B54038E92" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-762A615C710E59ECB3C3672C8660B554" unitRef="usd">31984000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-8A4A730F65AF54CBBFFFBD347AA6E7D3" unitRef="usd">31984000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-0A2AE99E6D2353C59AFDB7FF2DA357E2" unitRef="usd">8393000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-C8E42BB5468B2915823DDF98A6EDB9A2" unitRef="usd">-23591000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-03CEFC6F76B75195A8ACDC59CC1C7FCF" unitRef="usd">15897000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A99D64982484527F912249511CF578F3" unitRef="usd">238520000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-A291557DF70552E89AAE611C0A6F1F68" unitRef="usd">238520000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-A52B69C23BFA553D9734CD3A5B12BBF3" unitRef="usd">25441000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-CB6B1459846AD35A84F6DF98AF8CB874" unitRef="usd">-213079000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-C1C0E9848E235091B246C9BBFDFB4B21" unitRef="usd">198100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-900E8B0CF99F045B92EB82AED92A2E17" unitRef="usd">286925000</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-52BE996BEB711569D1B382AED92F31B8" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-5B7DE79EA5E69515E75B82AED926E4F5" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:CostMethodInvestmentsRealizedGainLoss contextRef="D2016Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-5" id="Fact-8B5621C06A72339B153A83324B6543F6" unitRef="usd">2500000</us-gaap:CostMethodInvestmentsRealizedGainLoss>
	<us-gaap:CostMethodInvestmentsRealizedGainLoss contextRef="D2017Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-5" id="Fact-FCC1A8DC5145C370B43DBD7E9384DF38" unitRef="usd">3000000</us-gaap:CostMethodInvestmentsRealizedGainLoss>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E36AC9AA68CB9A9099D5BD7E938B3B03" unitRef="usd">6552000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CE6E184131125B17974F0708C67B9425" unitRef="usd">15066000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0933850128E454F3A65907706647D2ED" unitRef="usd">26348000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" decimals="-3" id="Fact-7771FE7D7E994C4138F5BD7E93900F42" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-50961266B225F0A8BE03BD7E93D1C202" unitRef="usd">252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-19E3BF55CD1B8DD61261BD7E93C85B79" unitRef="usd">-252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" decimals="-3" id="Fact-025818CFC4D5E81DDC1E8113D031EE7B" unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D24D656DA1E0B825CAD78113D023066F" unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-D8B0F6B1A3659231B5DBF83DD553DD42" unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9AD5BCC33F5BFBA791FBF83DD2E3FA1C" unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-44ED57C694C0A69328C0BD7E939FC575" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-29E034B43FA70140C2DFBD7E939F523F" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0416158CA1EA70F7E70ABD7E93A4C949" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B478791494323DA199A4BD7E93A15856" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A63DA8BE224748E301E9BD7E93A0110E" unitRef="usd">4350000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-32FCC8AB88D173AE52EBBD7E93A04A95" unitRef="usd">6133000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-60287AB26F8DA2736E29BD7E939F28A8" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FD9B9FDE6E891C697936BD7E939DE46F" unitRef="usd">4350000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-FA8888C2DDBB82A6A0AABD7E93A41CDE" unitRef="usd">6133000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-5290761FBFB554E1B96FB893608B7A0E" unitRef="usd">14954000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D37913072DB55CE3A40F86F5417C2B66" unitRef="usd">7565000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="FI2018Q4" decimals="-3" id="Fact-CBE88ACE9E1C5819A6767A4EAC7D5530" unitRef="usd">48809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-7AFE248FCF2DFA01586C833008D294FA" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-58B7950CE79659519D08410F31DFFFF2" unitRef="usd">39627000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-27722BD19BE6549D88165109CFB8764C" unitRef="usd">9182000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29" decimals="-3" id="Fact-612FA511A883554685EFD4E716DEDFA3" unitRef="usd">22698000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-94FED1CA54FE5A1E88A1CA76529EB743" unitRef="usd">20047000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-723DF66A080055879CC7E2193E0330DA" unitRef="usd">2651000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="FI2018Q4" decimals="-3" id="Fact-3B30F5C668A15B69BDAF5BD9ACA2200B" unitRef="usd">260000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C0BB53635395A8A9A4C983300BAE06EF" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-0F976F13043A5A45B3578F18107EE382" unitRef="usd">251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-678B6227319659BC8E9EB30D98D219AF" unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9F4150A91B0D5D35B9262B8C73DEDAF0" unitRef="usd">45000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E1BBE239877253469DF988D638E9F841" unitRef="usd">36000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-E3BCDBA4C5A452959AE05B7B46528859" unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="FI2018Q4" decimals="-3" id="Fact-B2C4D782C1FA54B898095FE277BB0A5D" unitRef="usd">271358000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C59BB5E53B80D42148F3833000ADAD23" unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-EFC7F7D5A90F579EA5F156C64AD897EE" unitRef="usd">236162000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-0DAE897027405C74A73693DE660AD623" unitRef="usd">28105000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6ED10BBF548058B8BD297CEE23965922" unitRef="usd">154357000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-2FBB8C9CD5FF5AF1BB4DA87E510D627F" unitRef="usd">140746000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-B341E0496281561896A52B91140CE2A1" unitRef="usd">13611000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="FI2018Q4" decimals="-3" id="Fact-8C14020884695A95A8FD443E8451361C" unitRef="usd">623000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D1F342210E236BB494E183300414491C" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-D6299DF39B285F1FB65CF42E2954BBD6" unitRef="usd">606000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-10C4690AC66E59899D78E63E8D79A04D" unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BC5908D88B435CDCA62AE587DE91D53C" unitRef="usd">319000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-B275261B5B23509EA193554D4FB38329" unitRef="usd">296000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-45FACEDEB5F15743A8692AFF9D2FDD23" unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="D2015Q4FY2015" decimals="-3" id="Fact-8E2FCC5154F2B2721D76BD7E93A747A8" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="D2016Q4FYYTD" decimals="0" id="Fact-CC89C46C44A24051A014BD7E93AB7888" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="FI2018Q4" decimals="-3" id="Fact-A91E60AA8E9B5302BB2748D261085ED7" unitRef="usd">320167000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-5B38952510D2BF7B962383300E9B272E" unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-42266F2EE88A5A27A7AF68AC1A939C88" unitRef="usd">275789000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-1C9BB2EDA332538C964DA206EA4DE993" unitRef="usd">37287000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5F8C952D42E957A6980825EDDD306721" unitRef="usd">177055000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-2717BA7354B056278342B26B3E7C86A2" unitRef="usd">160793000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-AF11FD8B4E1B5ADDBF68BA6E95741E25" unitRef="usd">16262000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="FI2018Q4" decimals="-3" id="Fact-59918D5AA8DE5E0F9C2AB6C719C2AE8C" unitRef="usd">883000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B7B57163DC8EE6A60573833010AD9039" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-4C8C6D502CAC5491A0238AEE01C3D1E6" unitRef="usd">857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-C4BC5BFCFDC255BE8D43EAB84B5F1033" unitRef="usd">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-65ADE422323159DC9C9555C829B036BA" unitRef="usd">364000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-23B486ACB86B56B8A45808D6C40775D6" unitRef="usd">332000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-1358E82155FA54ECAA6F888E7C652734" unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="FI2018Q4" decimals="INF" id="Fact-C0C89891267E50C68DEF5FA34DAF63B8" unitRef="investment">199</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="I2017Q4Dec29" decimals="INF" id="Fact-60EAD364A023514485D232B81F91B5AB" unitRef="investment">134</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BC0EB8F7B9E95AD43FABBD7E93A23ACF" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-BD6E902D40B88D5D06CEBD7E93A42E2E" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-21A878D331113FE1D915BD7E93A53CB6" unitRef="usd">-238675000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-CE6B3755A670C673646780C73CB0A969" unitRef="usd">244111000</us-gaap:DeferredIncomeTaxAssetsNet>
	<us-gaap:DeferredIncomeTaxAssetsNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C8683CBB69CD717ADEA382779FBD822B" unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-942A69404F09BEFFFB98BD7E93A31D58" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8D7F6129293F4CD71E05BD7E939EF031" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-7ACC65656FE777E60398BD7E939A4F0F" unitRef="usd">-244111000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-20106DCB029FD6AEF70BBD7E93A1C772" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A4BAD0A22A578B92515EBD7E939C4A46" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-65D7FFDC32439358F1B7BD7E939F05E6" unitRef="usd">-5436000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2018Q4" decimals="-3" id="Fact-FC41C332F7D0C8CDFC5FBD7E93EBC3B2" unitRef="usd">5474000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F7F3A692FA2E493FF4EBBD7E93E94FAA" unitRef="usd">53543000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-44BAB627B7A3E9B859BBBD7E93A7C3E5" unitRef="usd">303502000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-DDD7562285093A29F461BD7E93ECFE84" unitRef="usd">418958000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-BD4EC4107DE9CB700940BD7E93ACD645" unitRef="usd">244111000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2018Q4" decimals="-5" id="Fact-2BFCF4946ADB92512476E39A6035F6D5" unitRef="usd">244100000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-651EF254759771262B27BD7E93E2A0CE" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-09A017014752469CACC7BD7E93AF7410" unitRef="usd">245390000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-12083E7EDBE93B1B2E3FBD7E93AE06E2" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-86B6AAA37E25E1AC60F7BD7E93E4FDF0" unitRef="usd">146701000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E906018D43DC7BE53783BD7E93E6F4B1" unitRef="usd">244205000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2018Q4" decimals="-3" id="Fact-6B4D7639C81DADC65745BD7E93B346EC" unitRef="usd">1140000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="I2017Q4Dec29" decimals="-3" id="Fact-18D8E62AD5FF760524A0BD7E93A6CAB5" unitRef="usd">1088000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-5F9786CC96301759DE70BD7E93A96A40" unitRef="usd">29929000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="I2017Q4Dec29" decimals="-3" id="Fact-15B470A8DC4BA39DF189BD7E93E4AE58" unitRef="usd">39472000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-94540B38C1136E69E669D3EB19CD04D6" unitRef="usd">98467000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="I2017Q4Dec29" decimals="-3" id="Fact-65840661DE8340FDBAE6D3EB19C55345" unitRef="usd">66770000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="FI2018Q4" decimals="-3" id="Fact-387EB98CE20D3F40E465D3E98DF6A2F8" unitRef="usd">10425000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E57C9DD9FE57B85C0956D3E98DDE17D6" unitRef="usd">4914000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-AE69BF71B401578FEFAABD7E93B2CB6F" unitRef="usd">58112000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="I2017Q4Dec29" decimals="-3" id="Fact-23D80DFF01D5038BF485BD7E93B1185C" unitRef="usd">418958000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-55E77E1340292FF511E7BD7E93EACD41" unitRef="usd">1279000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5BE8514CF5842291BEBABD7E93A2E90A" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="FI2018Q4" decimals="-3" id="Fact-33E2A322AE7B2E49D6D3BD7E93A9A15F" unitRef="usd">1279000</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="I2017Q4Dec29" decimals="-3" id="Fact-66B280517CBBF4068CE9BD7E93E70E52" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-89BC1C06ECFEB2DF40A4BD7E93DA112E" unitRef="usd">1100000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-12BE08DFE8B0AE4E55A5BD7E93ED730F" unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-A50A113D55778734278EBD7E93E23A6B" unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-40B2DFA8DD7FE758E26DBD7E93E57CA5" unitRef="number">8500</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-12CDFA1DE05F954BBABBBD7E93E25A69" unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
	<us-gaap:Depreciation contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-71255A260DEA5D173BA297989E290302" unitRef="usd">1000000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-4A4511CE70E25DDD93E62ACC981F10A1" unitRef="usd">1200000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-33496197A8FB53B58531D2CB3512A135" unitRef="usd">4900000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-58ED7B64C7E25AFEBF2AF803C1C08724" unitRef="usd">1002000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6FE9C133F47E5EF0AA0929D957A321A6" unitRef="usd">1187000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-389488E789E1578EA4BAB47483D2C788" unitRef="usd">4915000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q4FYYTD" decimals="2" id="Fact-DBD0A9B56A825D04AC829086DB9A1896" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q1Dec31-Mar31" decimals="2" id="Fact-D41C9A916DF33AD6FA66BD7E93CE8E4F" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q4FYYTD" decimals="2" id="Fact-A782DD1E42A2535793EA872AD9642D35" unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q4Oct01-Dec29" decimals="2" id="Fact-A35ED9F36B7D5006A76A6E29C4336A8F" unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q1Fiscal" decimals="2" id="Fact-ECA81D41AAFF5081FD23BD7E93D2EFF2" unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2Q2QTD" decimals="2" id="Fact-76045EDCE0D609585F1DBD7E93D1F082" unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q3QTD1" decimals="2" id="Fact-2748BB118C1493435B50BD7E93C96190" unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-27B3733439925A0E92141F9C8CAEF7A3" unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="2" id="Fact-A96B76A20C526413A4ECDF9B854E6285" unitRef="usdPerShare">2.60</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-F7DDBCACBCC895B06F01DF9B7ADE4FAA" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="2" id="Fact-4501F86C912C56DE0DADDF9B80AD6F19" unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q4Sep29-Dec28" decimals="2" id="Fact-8C0C07772B8B5FD6AF96F7A9ED2EBC20" unitRef="usdPerShare">1.20</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-5E9CBBB61922565A6D79BD7E93C2EB6E" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-AB53333090A64FAF9F42BD7E93CBB2AE" unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q4FYYTD" decimals="2" id="Fact-C8BABE1AB29A5974A7B65F0B66B49A8D" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q1Dec31-Mar31" decimals="2" id="Fact-4E605AC8B9D0A783FB61BD7E93C294B5" unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q4FYYTD" decimals="2" id="Fact-138585A40D1556A1887BB6ECFD2E885C" unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q4Oct01-Dec29" decimals="2" id="Fact-5A37C752C154518AB3F84C412B9846E5" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q1Fiscal" decimals="2" id="Fact-B7C88C17A8A38CAEC1DBBD7E93CE3AA9" unitRef="usdPerShare">0.37</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2Q2QTD" decimals="2" id="Fact-E1DDE0A6C917A5D15CFFBD7E93CD581C" unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q3QTD1" decimals="2" id="Fact-505969649636E4974D0DBD7E93C22D8A" unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-3381CEFBBFF359EC8A0EC53720387E6D" unitRef="usdPerShare">2.21</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="2" id="Fact-128C7B43A8D8AAE80F01DF9B93941380" unitRef="usdPerShare">2.48</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-029972A2CC164606412FDF9B89EB49A7" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="2" id="Fact-3D4896B0670FBE861857DF9B8FD88AA5" unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q4Sep29-Dec28" decimals="2" id="Fact-C4850492EBAF5CC1B2A3FDE15456D2BE" unitRef="usdPerShare">1.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-99C510BECE63634B6910BD7E93CE231E" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-2DA0DB62F36AD434694CBD7E93CFFF9E" unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-C88A3060DFCA928A371FDF8F809548B4" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-67DC649843C0F999DC68DF8F80B46106" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-B6EA028F8A25DDC1DDA7DF8F808956A2" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-C93BE885ACF752ECA4316365BAEC74C7" unitRef="usd">48000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-BBEA7616B9A15D67B80E43757C0A66EA" unitRef="usd">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-6DEBABA1C8395F5B94CA09D0AD042162" unitRef="usd">81800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-7820D15D97B156ECA29335B904494062">P2Y6M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-52CFD970D2F351219BA34B9B8B7170B3">P3Y0M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-5" id="Fact-84AE087FF1F16DD55C52BD7E93BB1C5D" unitRef="usd">200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
	<us-gaap:FinanceLeaseLiability contextRef="FI2018Q4" decimals="-3" id="Fact-FDE4590EF44C44131B857C48531814BC" unitRef="usd">128000</us-gaap:FinanceLeaseLiability>
	<us-gaap:FinanceLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E91871507DB052E32D7C7C47FC779C80" unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
	<us-gaap:FinanceLeaseLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2FE8B135FD76B92F265A11F22839710D" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
	<us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-97FC3F55DFD38C97705C7C4850081C0C" unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityNoncurrent>
	<us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C3FD1A459CBC8E226CB111F228F1F16C" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-F1EBB1E4AFA456AAA667E24D9F5933DE" unitRef="usd">2494000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8AB5469017D45D48841A9E7341F5CB19" unitRef="usd">2980000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F4B9E6A7AFB15A8F88BE1746A39AB5EB" unitRef="usd">209000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9242461C0A7854339224DE45152F9C5E" unitRef="usd">-13901000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8EE93F3023F753198C091A826EEB6A2F" unitRef="usd">-6239000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-061446F757615842BE844C761473CFD2" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-8C4C0A310956529798A2FC8F90E0AE53" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q4Dec29" decimals="-3" id="Fact-ED45CCB616B852F2A0D0B0105E3E57A6" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-22C1CFBA2274B622A4BFBD7E93C6DFBB" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-8A9D305F5ECF56A4CB19BD7E93C83173" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-040809247BB0D632A649BD7E9386CD30" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GrossProfit contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-8C6F59D4821AE870D75619B0EF8BC03F" unitRef="usd">65674000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2017Q4Oct01-Dec29" decimals="-3" id="Fact-DD0208AF3086E2F82F8BBD7E93C77C64" unitRef="usd">91520000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2018Q1Fiscal" decimals="-3" id="Fact-E7EDB8CC0EC65FA98181D3F7BFC2AB71" unitRef="usd">128633000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-59918F12ABBC9FDF4667D3F7BFB36CEE" unitRef="usd">139839000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2018Q3QTD1" decimals="-3" id="Fact-4DFBB8A537D34F2F2854D3F7BFA49072" unitRef="usd">155586000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2018Q4Sep29-Dec28" decimals="-3" id="Fact-978C1C25C78390AC6071BD7E93CF0EBE" unitRef="usd">168873000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-3B163C0EE15FE8340765BD7E93CA0819" unitRef="usd">84990000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q3QTD" decimals="-3" id="Fact-6F1D0E7B405020B00F57BD7E93D1B4F5" unitRef="usd">91758000</us-gaap:GrossProfit>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-92EC42543C6853BFA1D282036D67A930" unitRef="usd">-70222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-80AE5F1E1E915EA9895266B7CAF54025" unitRef="usd">158577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-8A66540E53E255FB9A8C5D7777728DBB" unitRef="usd">452092000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-115BAA549F30EBD49450DF9B55EB6DA0" unitRef="usd">488547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-CE4FFC2EB5A370742D50DF9B4E490D0B" unitRef="usd">-35882000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-92E02DD66CF780768E5DDF9B52293F61" unitRef="usd">-573000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B577E85A9A0D5A50AA6D8AFCF7D06A27" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0AA7EBFB46B952439EA466CFE0B56577" unitRef="usd">4350000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-D3179D53A90D544E9C2650104499BFA5" unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-319F397A479706FCC7D7DF9B65408B90" unitRef="usd">-286230000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-268A29383046F6648D51DF9B5AE7B4AB" unitRef="usd">48325000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-CE55F1969E9160AD7909DF9B60B35D5D" unitRef="usd">-73000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9AEAAA3980565CE59C3CBD7E93AC08D6" unitRef="usd">6377000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5258FDFAEA6B015ABA84BD7E93B3D43B" unitRef="usd">-34266000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2EBE48FB36288A56BB25BD7E93B2EBD0" unitRef="usd">-315394000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-48C359D3BB7BE6A965B7BD7E93AD7E0A" unitRef="usd">-23876000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8EDB269BB6BA36A6BB76BD7E93B4E4D7" unitRef="usd">53916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0B6028913D7BFD06BE87BD7E93B12EB6" unitRef="usd">94939000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-59AF38B52D0626D170DCD3AAA064A51F" unitRef="usd">2680000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-859E42E2535CE7EE8DDCD3AAA05B8491" unitRef="usd">1367000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-1A01CB7A3E3938354A32D3AAA053C641" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E61D4DFCB9DAA803545FD3AB4780DA6C" unitRef="usd">3155000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1415EECE1752F10F6FDCD3AB47727F35" unitRef="usd">-20548000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-45B419EA5C4D1880EC2AD3AB4769AC3E" unitRef="usd">-5998000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9F2012B1EC6A7FBD977FBD7E93B3D311" unitRef="usd">418000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-664AB5400688058377E3BD7E93B37A2C" unitRef="usd">-4401000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-8BB1E11FC6336E980627BD7E93B130A9" unitRef="usd">2093000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-531637DA57F1A89E0728D3AB02CD7B5F" unitRef="usd">6520000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0EDE63C5144E8529F48FD3AB029E86D1" unitRef="usd">8282000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-E354AD7AA0C564F7B13FD3AB028D5A3C" unitRef="usd">4690000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BFF249D2BFFEB7ECF5DEE393245C5D38" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F9D00274877EA5482107E39324653AAC" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-914EBCF38EB3EC2EF088E393246E821B" unitRef="usd">18308000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxesPaidNet contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FD54F439500FE965F9BE19907212A06D" unitRef="usd">190000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-37875E895A94989A777419907209D9C4" unitRef="usd">538000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-47F474529A504FA87BF91990720D50A6" unitRef="usd">10677000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3829298F088D5DF9B86CFE217F6B9DF1" unitRef="usd">164000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B98B633C7666505AA2557EA7AD4F68B8" unitRef="usd">3010000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-29B621714D685BE4978AC227A9D44140" unitRef="usd">856000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8CA16037B45E569FBB56F977B0481A25" unitRef="usd">38680000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-AE987EA81BAA5380B828E8516E43F125" unitRef="usd">43299000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-94F9D1BE4DA85BCD8A41FF36F4AF9570" unitRef="usd">85471000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-74A4679D68215380B41A5E491B2C8CBB" unitRef="usd">256759000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1A4014C9B316521EAECC877C9638D076" unitRef="usd">13745000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-E00ECFB3D7125F68934687919FF4D8D6" unitRef="usd">271000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-5BDB330B67AFEC74ACFDC3280029F702" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F984AB92711B444D39D4C32800243147" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A8C379BCD27D5F493E66C3280037B52A" unitRef="usd">244111000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-674B642145BA502A9DF86F3FFE602903" unitRef="usd">16705000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4DF878E20A4E5404A1AD34217A5712C7" unitRef="usd">739000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-75C6BF8D86B15AD3BA26E134799B6433" unitRef="usd">11069000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-322001334DAE5F9EBBE98CAB8733E16C" unitRef="usd">722000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C5B7AC3124105854ABCEBC03FF3D3E46" unitRef="usd">3319000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-B0507A5A994E5DC7B523F761C6396729" unitRef="usd">3181000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0ADF27E9202056C48E7777DE53799C16" unitRef="usd">-1077000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-10B942AA377752D8AC6EFCE499978771" unitRef="usd">-430000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0E25BD2AABB4500689BB01D2B144B7CE" unitRef="usd">1086000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-26E4E1D2566C5DC1908395B52112A018" unitRef="usd">1224000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6B3307FFB04451D0A86A81B50A05A916" unitRef="usd">-9173000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-021151859A455842AF7FEBD87BAD4AA8" unitRef="usd">2227000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0E75C99C9440602B9F978123E263AE35" unitRef="usd">-3362000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-730BEE208FFBCB5E2ADE8123E280E02D" unitRef="usd">-2460000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-D8044630DC7A7C7790C68123E277C213" unitRef="usd">4410000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9B3250BE27EDC5DACB2FC327999C6939" unitRef="usd">1610000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9A40D85DA524EE9D737D82839395B1C2" unitRef="usd">3268000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2DD5E5B0689D57B0AEBD42BBBCF429DD" unitRef="usd">3029000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-328B080FD1FE5048B3FCAC2271FCD6F1" unitRef="usd">33060000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-507F2453B38257DB8E4C7863857CD967" unitRef="usd">8679000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-38FF3026F87E582FADAA83F27521FB41" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-3ADAC9E05DDE1D8F04DEDF9B42D4756B" unitRef="usd">-631000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-26D11B026F782C1C9D84DF9B3ECBECDE" unitRef="usd">631000</us-gaap:InterestExpense>
	<us-gaap:InterestIncomeOther contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-D2F569A1E8DB5CAE8D1E4579FC41548C" unitRef="usd">2578000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7315CD8624345328A2FD07D82B39BB35" unitRef="usd">4883000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-24B6C4F6E75A5A38A8D220122F84F32D" unitRef="usd">12840000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestPaidNet contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1D9AE7274AF36C6E549D196E736E4D91" unitRef="usd">21044000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-652EF2904448388609E1196E73619BEE" unitRef="usd">20460000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-945C95B5DB0DFFECB260196E7369AF6E" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoods contextRef="FI2018Q4" decimals="-3" id="Fact-394D8C74383D5B5A94388670D8B27D85" unitRef="usd">3836000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="I2017Q4Dec29" decimals="-3" id="Fact-00E01545856254DAB1E10A82C3A33985" unitRef="usd">2854000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="FI2018Q4" decimals="-3" id="Fact-08F401AA7B26F0494C79BD7E93B4BFD0" unitRef="usd">11928000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-4C8B655C23555895BA91A73C6A801899" unitRef="usd">2090000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-DD8D3BB800BD520EAF678E79B2836724" unitRef="usd">9838000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3EE3FAE528F81906F523BD7E93B12628" unitRef="usd">7349000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-4ABE2F95057553BABABBDB441D1120E3" unitRef="usd">692000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-CE0D08D894365FDDA92EB4E1B026827F" unitRef="usd">6657000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-3" id="Fact-71B64764034A5B368B22CEB7B16E1617" unitRef="usd">9838000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6624448582AB5A649B38D2C58579FD16" unitRef="usd">6657000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterials contextRef="FI2018Q4" decimals="-3" id="Fact-2F46E7A0F1F75F5F907AEFD73E303AC4" unitRef="usd">1922000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials contextRef="I2017Q4Dec29" decimals="-3" id="Fact-86669E49D3505EB59455485B17CC4D3D" unitRef="usd">498000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="FI2018Q4" decimals="-3" id="Fact-C9B8D0CEF30354ACB5CF118F1DE7F48B" unitRef="usd">6170000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8F6EBFF935EA5C148B6F0E377AD2CCD5" unitRef="usd">3997000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWriteDown contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-DD555A528C16E37F46EBBD7E938C8D24" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-238242251CE256F9A9475BDFB7EA341B" unitRef="usd">1200000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-4EE8E2D702B05AA8BFBEAB4E1F9060F2" unitRef="usd">1100000</us-gaap:InventoryWriteDown>
	<us-gaap:LeaseCost contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-58AC0D1483419CBF7E137C4946FCF73A" unitRef="usd">6123000</us-gaap:LeaseCost>
	<us-gaap:LeaseCost contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B5205DB98E415F03B6252F3E12B62997" unitRef="usd">4935000</us-gaap:LeaseCost>
	<us-gaap:LeaseCost contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-4DF13D86B9E457C8B0439AA2FD882521" unitRef="usd">5850000</us-gaap:LeaseCost>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-4EAEC0A1DC995713B81531AB34DDF20C" unitRef="usd">28187000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2018Q4" decimals="-3" id="Fact-A95BFDE7544A55BF9EC8F8D0B5EF421C" unitRef="usd">13584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="FI2018Q4" decimals="-3" id="Fact-9928DBDDF8585A509EC0606A9CAE0A81" unitRef="usd">2794000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2018Q4" decimals="-3" id="Fact-CC65A53E8434563888660A0ABEB8A41E" unitRef="usd">3082000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2018Q4" decimals="-3" id="Fact-A418A7A05FAD58F7A5534FD92180C280" unitRef="usd">3000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2018Q4" decimals="-3" id="Fact-CD531E5ED26E564A8D8870DD9AACABC1" unitRef="usd">2904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2018Q4" decimals="-3" id="Fact-8BD712DAE1E555CAA36838390B931126" unitRef="usd">2823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2018Q4" decimals="-3" id="Fact-204BDCD774565A4F8FF7D1A109AB8402" unitRef="usd">5180000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="INF" id="Fact-479C24E598ECACE0BED3BD7E93E6598C" unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-1864216F8120547EAE792166F77D8020" unitRef="usd">134833000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6CA8A89658125BAC88D10C635BA7E130" unitRef="usd">370333000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-B96D3F8D02FD54FDA1B5462E9ADF7A0E" unitRef="usd">1422286000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2017Q4Dec29" decimals="-3" id="Fact-0C3F1DEEC06C57F9982CC75A209C0838" unitRef="usd">655294000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-92625490D7895CF29CE929910B5504ED" unitRef="usd">105472000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B84457AAD4BA53449BCF5400EE1C49B8" unitRef="usd">115170000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="-5" id="Fact-0C06F6575B34057CC23CBD7E93DC8EFA" unitRef="usd">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" decimals="-5" id="Fact-52B3E28B0E8C24453E99BD7E93EA7306" unitRef="usd">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" decimals="INF" id="Fact-8CE00DB827C15B1E1EACD3F92F75A2D5" unitRef="usd">100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q4Dec29_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="INF" id="Fact-48DC230EB539307FDA1DBD7E93A2C95A" unitRef="usd">1000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" decimals="INF" id="Fact-57603B2CBB58EA06EF21BD7E93E70E00" unitRef="usd">600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-C0CB425654935E3C8CB34A0FE3A6024B" unitRef="usd">157187000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E125BDDE208A55BB8991A0DB8284F46C" unitRef="usd">64255000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A6D435CB9BFA52B6953734228DC35D78" unitRef="usd">15696000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0F93A4A393D357DBB1567EAC2C876C6B" unitRef="usd">-169928000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-243C868718A859A594CDD69AF4AAE6DD" unitRef="usd">9691000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-17BF11A531205C96A633EB0741323CDF" unitRef="usd">-214548000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2016Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member" decimals="-5" id="Fact-191CF6535166A69C441DE32024AD66CF" unitRef="usd">1500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-520E1206D6CE567A915BD89A74FF23AD" unitRef="usd">36795000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2017Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member" decimals="-5" id="Fact-C879077A552750C7994EA1184B492EF5" unitRef="usd">1000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-C3EAB9812C785DC085DCDC6BB75CEDD8" unitRef="usd">-297850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7F36E422FA0357909BD76BEA05C63063" unitRef="usd">210404000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-D8A55954C93158138472D9FB232C7177" unitRef="usd">165611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-7A3FC76B015C53BDA5C211E06BA3EA13" unitRef="usd">415720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-96F05316003C5F86AE27DE25A20E8B79" unitRef="usd">-70222000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AB172E63B4D7842425BDBD7E93C7E645" unitRef="usd">-70222000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-27DA9CB130099429EACEBD7E93CFF13E" unitRef="usd">16700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-608E56327C115214B3ED8D393C25EA5C" unitRef="usd">154227000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9BDF531B90AAB97D9DE0BD7E93CE5D6F" unitRef="usd">154227000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4Oct01-Dec29" decimals="-3" id="Fact-F58C9964BF365B72937BA51C769624F8" unitRef="usd">38489000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q1Fiscal" decimals="-3" id="Fact-952824588245E69E5BE1BD7E93C373A8" unitRef="usd">115857000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-480544E35D9A595B03EFBD7E93CC62E5" unitRef="usd">87494000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q3QTD1" decimals="-3" id="Fact-75094BFF5BE7676098C9BD7E939301ED" unitRef="usd">126630000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-09A0F9AAED7652AB9C80EBBAA8CD300B" unitRef="usd">690070000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-7F6647A15F400457D55CDF9B75FB2700" unitRef="usd">774777000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-4399F7943212FEE3E9CADF9B6A363701" unitRef="usd">-84207000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-A1B254DB2A20E02BFDBADF9B713C4B2C" unitRef="usd">-500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q4Sep29-Dec28" decimals="-3" id="Fact-A9BB7DEDB7E55ADD969F08CD6D13EFB6" unitRef="usd">360089000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-EC1F18CE001CC3AB4BB4BD7E93D0BEA9" unitRef="usd">17656000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-B6BE610D54880F7CFF65BD7E93CEBF14" unitRef="usd">81382000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FC9546A991A075DE8609BD7E93B4913A" unitRef="usd">-70222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B5170FF83F7691176CFABD7E93ACAEA0" unitRef="usd">153860000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-B4BAB48FC3005CD138B6BD7E93B0C827" unitRef="usd">690070000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-5985E1C70B2F10C3C223BD7E93AA8792" unitRef="usd">-70222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-E391E3632D6F8E20AC20BD7E93B37B59" unitRef="usd">153882000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-3287A66CB51C770B0478BD7E93A5C4CF" unitRef="usd">690070000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0F7C5A0692C95A8BB114223A040BA17C" unitRef="usd">-42098000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-306B3F602B2A5805B424955408D6A239" unitRef="usd">-7333000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-1CCCC26A931A5CBF9083DF0A00C1D156" unitRef="usd">13237000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-2B5557818E9D530D3A8EDF9B4B0EEE48" unitRef="usd">12606000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-D597663D51F738CDE812DF9B48A7DB59" unitRef="usd">631000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NumberOfOperatingSegments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="0" id="Fact-8CF9CEB0D3A35059A4E24A696F85E820" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:NumberOfReportableSegments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-65D608C736DD14887027BD7E938B7B2F" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A55251F0151D541C9C431E6175AD35E8" unitRef="usd">219578000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-18A4A594BF2A5BF38AD55854B2C67222" unitRef="usd">286567000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2D84C72D3C7A5B97B703CFCE9BCC6DAE" unitRef="usd">414971000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-620D1409F3B7B8DD503DDF9B38ECE3F1" unitRef="usd">413767000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-0EACE1A926964108FBECDF9B3474EB07" unitRef="usd">1204000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-DD57B1BCD2DC52FEB24843F737417C4E" unitRef="usd">-28124000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-A3B47AB17DD96B59F3B619B0EF92341B" unitRef="usd">20186000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-941B0F3B7D72505CB9ADBB6A2B6A08C0" unitRef="usd">165910000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q4Oct01-Dec29" decimals="-3" id="Fact-4CC7B1142E91FF2305A2D3F7BF90F173" unitRef="usd">37431000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q1Fiscal" decimals="-3" id="Fact-F623A98B60ECE1B7E22DBD7E93D00A01" unitRef="usd">116307000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-FF98D0F21892FCB253AFBD7E93CD8E61" unitRef="usd">85770000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q3QTD1" decimals="-3" id="Fact-944834A423FC6D68B571BD7E93CDF422" unitRef="usd">125176000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-0946536081A05C6E8810E5B9976E5E33" unitRef="usd">438855000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q4Sep29-Dec28" decimals="-3" id="Fact-5D72220FA9135FCD94E7A074EE37C9C2" unitRef="usd">111602000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-AB509DA606927CDB3036BD7E9382F8B4" unitRef="usd">27113000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-144AF39446B2C142C6EFBD7E93CCBEBD" unitRef="usd">81180000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-75585E9E27AA60AFF70E7C492D6F762B" unitRef="usd">8620000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5A21E5B6CF8B5836BB221B4391D14AEF" unitRef="usd">3944000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A3B8C5FF78685B1894B26A71439E587A" unitRef="usd">4189000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseLiability contextRef="FI2018Q4" decimals="-3" id="Fact-69598FC69A2D580FBFA69100C8E9CB04" unitRef="usd">14837000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-AE58AF8D14085267B6157889D4567817" unitRef="usd">2738000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-41EED5E5E90156B3B855EB120EA69401" unitRef="usd">12099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-D7AFEA38A0185E13A4EF57590D98624A" unitRef="usd">3900000</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-CD68CF7B8CF15F55AA974C22D888F98D" unitRef="usd">5867000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D3287600B5A150A99B0AD31E07193C95" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-AB4A5E34EF8650E495A488B5E722C4BA" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2018Q1Dec30" decimals="-3" id="Fact-FC94F7BA883E86711592DF989F8BC389" unitRef="usd">8579000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-5C813015019E8DB697FBDF989C3EDEDA" unitRef="usd">8579000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2018Q4" decimals="4" id="Fact-B72BE5A37CC152669A9ADFB03F500183" unitRef="number">0.0450</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2018Q4" id="Fact-01F03692BA5D5641A9AFCFD1F2CCE39B">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLossCarryforwards contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-6" id="Fact-B763939179CFD829ACDEBD7E939FF5BB" unitRef="usd">614000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-6" id="Fact-B7A2056C29418649C27ABD7E9398F7C5" unitRef="usd">453000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4932620287DB5CB99CE8037DCBA70187" unitRef="usd">21825000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C6DC180F0E0E59088EF41C20F68347F1" unitRef="usd">16150000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-272D505481FF532D8D7B08E14F2EE3D5" unitRef="usd">16150000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-D8CCE0CCBE2DEAE9A321DF98C083D0C6" unitRef="usd">19323000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-39BF93D0C8696A2381D6DF98BC9E6B8F" unitRef="usd">3173000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CD3C397676DA5A29B95B86EAB524D019" unitRef="usd">2424000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-98CEB9BF51FE5D76A6352C52482AB327" unitRef="usd">12092000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3CB35C90514CF70295DBBD7E93E865CA" unitRef="usd">-184000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D7B11DD7F6DC7AA8BB75BD7E93D0BD71" unitRef="usd">-184000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-498EAB2A0D1E594E942FB1AFF11FC8F9" unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-58ECFDE6594A8BA25EB7BD7E93CF7308" unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-1BC451E6BA6D5F5B846EA0C8F6C7019C" unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-25FA28329AB93799B4C30D62A306A047" unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2A45B4B4EED87BF53C8E0D481AB4ABEA" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8509A0B980D72354907D0D47EBB5F007" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-171625B60DA95FE49EC3FAC42D6AACFE" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-72637777025FB9353ECA0D46171991B8" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-347F4FA1BD395F42873B20EA63DA9487" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-E72A6923C5B397EED9B58315BCCF5D9E" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-45B63803A46C5E4A9CB93361C6E0A6DE" unitRef="usd">1286000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2524E1987085577B9F12F2DC2FBD1FE7" unitRef="usd">1705000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0E6B20A1BE0A5789AC5C8CAA0CCB7479" unitRef="usd">-562000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CD83F249F4CC59A4B8A7458F41899665" unitRef="usd">51000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-07C06B2FF52550A780E93E0BFCEE59FB" unitRef="usd">2358000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-161F7EE84E6F539597D55AABF647F5CB" unitRef="usd">-11616000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-01609924F620548F8C0F0AE88CB13850" unitRef="usd">-3537000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-99785C0657C95E00BDD376EE4DF712AB" unitRef="usd">397000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7CAEC27DA6E3DBAC880280BA7C75F471" unitRef="usd">16056000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-319C5C89A0740F4C50BA80BA7C7E076A" unitRef="usd">3892000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="D2015Q4FY2015" decimals="-3" id="Fact-A79C923E0F356F5D2DEABD7E93A5B527" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
	<us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9CD171EA1A7C1639EC46BD7E93AE3F9F" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
	<us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="D2017Q4FYYTD" decimals="0" id="Fact-807BAF4A57F45E929F4F700C77244D51" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
	<us-gaap:PaidInKindInterest contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-62EC4DA62CD95871ADE7BD3125859A3B" unitRef="usd">8008000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-BF80F9E6049D51C29A784B608FC1D865" unitRef="usd">-11825000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-957D8185D8AE516D868314CB29DA7D48" unitRef="usd">0</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-509F62B75C1D57D3BCD99D9A18D1C661" unitRef="usd">4108000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6F3DE387461D5B7D82899206CADC5B0F" unitRef="usd">6563000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-6F2F0EFB8D605573A1336C3E0BEC1FDB" unitRef="usd">7574000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3A10635FEA78586F9C8B3E881EADAC82" unitRef="usd">369187000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-E3D4F99E0E7A5287815F05B43E173533" unitRef="usd">319090000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-690121620AFF5EAA83D0C363DEA3EAD0" unitRef="usd">557832000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4006642814405BEABBB5B6304983185A" unitRef="usd">1703000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4DF4CD0176FA5751BAAEE7C94A01A60B" unitRef="usd">21143000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-DF67C5B24A3F52DFA1ACE8C4DE970A79" unitRef="usd">33297000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-61383A03683B786441E98121B89E23E4" unitRef="usd">1036000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
	<us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-10659328AAC35ED5AFDBCE271BA8B15B" unitRef="usd">1640000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
	<us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-728EA267E6945DEFBEBF91AC0B1887BC" unitRef="usd">3696000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-33C14AC9073D52BEBF077628EC3BBF16" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-34BC4CB25F0C5FC58ED13C3154FAC9A7" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-E1A958F308EB5F5E9A70E71EC4C6311A" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-6D31472636F95189B52AF4D0977CC4AC" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-FE3D76B9E81F5EF182ADF515098F034E" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-8CD0068DF11E5F4A8BA81BAA5122DFAB" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-02236EEDC6A15845A71A85429981E534" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2730C6B4AC09507FB7A5ACEA95772420" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-58B9917ABFAF50659184A5602021441E" unitRef="usd">15017000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-64B8A0981D2F507E91EAECCD8AFB82D8" unitRef="usd">8750000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2551068B5C1753BFB927B21FA2D14C93" unitRef="usd">151485000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-DFE2A4BDB55C50A6939175E9B08680B3" unitRef="usd">336590000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-420DCC0A05875324A6006F8072898085" unitRef="usd">280826000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-261E489A683850D9B42FD5AB69705F8D" unitRef="usd">2494000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-95BD3A1645B95BAEBB4B6F92C0BDDA07" unitRef="usd">2980000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-1AA3394AFB4455DF8A474CB1589DD0A8" unitRef="usd">209000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B87049A990135601A2EAB9CADB5FC33A" unitRef="usd">2266000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A79E707293F55FF78C9795CB35C89E3F" unitRef="usd">37294000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-B4D5F6E0A3B159F98D993C12C2CFEF75" unitRef="usd">11936000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-6245438FAF699E0C11EC8296EC1BFB1F" unitRef="usd">97000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FD95BB882576593298EAE6C393884BF9" unitRef="usd">164000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-5222875A8C7D5C248EA718000B61B7B2" unitRef="usd">308000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7AF1E1196EA853E8BB73964A7EF020AF" unitRef="usd">25327000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-4E57B2CB9D258330B2DBBD7E93D486B6" unitRef="usd">25300000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-E132D841FF5152DFA755D009508AD4ED" unitRef="usd">17555000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-293F48DF91EEFCC7DBDFBD7E93E0B0BE" unitRef="usd">17600000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-7D2891263E6951798AE5E4F32355A5F2" unitRef="usd">12076000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-25ACD1E1EF28A599FB72BD7E93E1BD2B" unitRef="usd">12100000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockPlans contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-880C25D27E2D56378615FA0034336A38" unitRef="usd">2187000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-4C816A44DEDCB8FA1E53BD7E93E15B76" unitRef="usd">2200000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-072B7FC7AAE952168E5623DB3FC655BE" unitRef="usd">4868000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-7555D46EC940484E482CBD7E93D539AC" unitRef="usd">4900000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2D1F7C56C2045B59B7DEA22C97349591" unitRef="usd">5202000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-141072CB591C50C2AF3DBD7E93D27FE7" unitRef="usd">5200000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-3" id="Fact-2EB832D0DCE6898F949A97973574C1C4" unitRef="usd">68206000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-61DAF392A6215251834F67AF348C0337" unitRef="usd">15022000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-8E0180950E33558C8457FECCB3B5E36B" unitRef="usd">5668000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-B6C3733E456C5F70850D3D97560005AD" unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-C1FA99D8FDD95F64AD48A71341B77200" unitRef="usd">12709000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-BEF1C94ED1FA556F9CC067563639DE10" unitRef="usd">33941000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5C27E12574D7568EC0D39797356FC7B8" unitRef="usd">48543000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-8C2BB00884455D99BD056FF2E0BB1A69" unitRef="usd">14146000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-35013F8028E35FC6A7B44EF68DB316A8" unitRef="usd">5959000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-97F6B75BC7335D7FA4BBC7695851AB18" unitRef="usd">22114000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-2A99258232145E8F91C822B61C8F21BC" unitRef="usd">1609000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-0CE017CB205F542A9A280B9BCC2ED8FB" unitRef="usd">4715000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-2CB68F1E683B559B8421135F49BD2BD9" unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D5B786AF9AE15050B07B65BDC2784F1F" unitRef="usd">25743000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-CCCACA4D73B35075A2379551201C7227" unitRef="usd">25743000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2018Q1Dec30" decimals="-3" id="Fact-957302A837D0E2873C59DF989885D550" unitRef="usd">11213000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-FE937DAC585EE61AB787DF989474F3AA" unitRef="usd">-14530000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" id="Fact-0705710E14AD61E5CEB6BD7E93EC77B7">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" id="Fact-8776F2B4B9ABE2E82A40BD7E93E8B8DA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" id="Fact-D16A2B014CC20D6831F6BD7E93CBB015">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_EquipmentAndFurnitureMember" id="Fact-D47CEBA223F4D5B46F2DBD7E93CB3C9E">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" id="Fact-AA0F92D98BBACCC9ECF1BD7E93CA7927">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" id="Fact-05A3662B2C2FA3838159F8575CF5BC44">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D65FEE0A15305C6C83BCC1D1BCAC4BCA" unitRef="usd">162771000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-706EC21B964258FEBBC661CB9545ABAB" unitRef="usd">77300000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-8C2F0ED0F04053D1843BBF8E5C863351" unitRef="usd">3892000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-11AB7921B7139F0ABD38DF9890DF8821" unitRef="usd">11635000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-E579E6E24D1573FE3579DF988D983648" unitRef="usd">7743000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-86F9BFFC0FBEF1C207B58299154F4609" unitRef="usd">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7E3E7C54D0B85034AC16AD4220B9366B" unitRef="usd">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-482D4C4F27CA50059315E6CA387B30D2" unitRef="usd">13000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0190CC27309B5DFD8502E5F9878407B8" unitRef="usd">575000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B88929C1280B5E84B342B6048389777C" unitRef="usd">185788000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F88AFB2B994F5A819E6C1A8161F25ECE" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8D4D3A7E5D515496A9FC77AF513E0B6D" unitRef="usd">95967000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-724162260828569F8F6AD8E8CBE56E6F" unitRef="usd">112171000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-D80ED175AD93509A85824839F9CD812E" unitRef="usd">182257000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FFD1818A8D935D4C8E8B0294ECE404A9" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-41D1080C08CB51498F2CC2812BE07C41" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-1AD309F4A79E54DCB03BB1D791B12925" unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-56B304D260EC53F883F6353C90E1A32F" unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-ACA91740E00B593D994E2469907D27B7" unitRef="usd">4150000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3082BAFE4C3B5B0B9BEFC04504AE6BB6" unitRef="usd">4646000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestructuringCharges contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-C6685F7FAE4A2E000C90BD7E93850F61" unitRef="usd">914000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-ADF73E88ED025820ED9DBD7E938B3BAC" unitRef="usd">-32000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2101646EB2B4183758E6BD7E93977F3D" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-4800906A1DB1518FA9D35EF1ADCC70A2" unitRef="usd">-880363000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B30F4C5BFB195880A3E5EB2A1A20423A" unitRef="usd">-1829172000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-46A083FEB6545CDFB22FBD248E182C58" unitRef="usd">-1829172000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30" decimals="-3" id="Fact-8080620AD7EE5C481711DF98D6514F9E" unitRef="usd">-1570433000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-555A11BDB16388DCB47D978FF5FD94F7" unitRef="usd">234000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-5E12EF02CDBC5D7DAD1770C3099CFDBC" unitRef="usd">200000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-EE49EDF17F35B71FE531978FF611F9DF" unitRef="usd">258505000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-D14F884B1B9F604407D9BD7E9384C50F" unitRef="usd">191454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-1A64689CD08982F00DC697824730A92A" unitRef="usd">16631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-E7422F8A0EDE5DBA886C978246C457F4" unitRef="usd">13143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-3D8BD85EF80FEBCD9BA5978246BE202F" unitRef="usd">17746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-8B7E20AA56995BBD2F77978246CAEBE5" unitRef="usd">63826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-C09989732D4C19554E3E97824700598F" unitRef="usd">33252000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-BFCAB76A56E6D7FF2486978246D34311" unitRef="usd">46856000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-DD09F11CEBC3334266C27BB1C7D75AB4" unitRef="usd">93481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember" decimals="-3" id="Fact-9F028555DE0C53C588AB59E971193904" unitRef="usd">56079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-8E98730F64813197B6CD7BB1C80ABE1F" unitRef="usd">41894000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-1753C56057B0556A7CAED37554C9B3EB" unitRef="usd">2827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" decimals="-3" id="Fact-8CC0AC15990518852C307BBE559E7D4E" unitRef="usd">-207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" decimals="-3" id="Fact-27E79305634F14D2ED857BBE55112FD1" unitRef="usd">151499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" decimals="-3" id="Fact-81B0D51E779AEBF9C46A7BBE546EF44E" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" decimals="-3" id="Fact-5D0D962D3634EB574EB67BBE54AB3AE7" unitRef="usd">16124000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="-3" id="Fact-BDDBD3F6B08A0F4308427BBE544881CA" unitRef="usd">56286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-F3CEF098621799AC4960BD7E939EA472" unitRef="usd">135375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-095EB7E42CF79FA643FD7BBCF6CF3445" unitRef="usd">140709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-A8B1C328CE8A10FF1DB27BBCF6D9CAAE" unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-3" id="Fact-9BED7696C840F1BC89637BBCF6E267BA" unitRef="usd">35745000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-3" id="Fact-266EB2DF0EFEA6923EEBD38BA9BA0301" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-3" id="Fact-6BC08170B3582BD9CD41D3853B7A161E" unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-6B06AA8A059AD067847397B5F82BFBE0" unitRef="usd">33252000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-3" id="Fact-8B73F468513420282261D38948559C6A" unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-18664342788DD7E34B0019B0EF986A2C" unitRef="usd">80887000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q1Dec31-Mar31_srt_ProductOrServiceAxis_exel_CollaborationMember_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="-5" id="Fact-CB12FDFF8420CA4DB308DF87FAEB1585" unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-620B076599655E9D8E2C0D48E580DD32" unitRef="usd">452477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-16B0503E23F659F38EAB329E253A9DC6" unitRef="usd">50716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-7C31242D38D958A9B703926B6BA3AF15" unitRef="usd">48662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-F4A719B5851E563DB2D136A14A289089" unitRef="usd">73921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-43C18E284D2C5F08B27DF6285B150170" unitRef="usd">83059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-E87B84C7200B572A9A6BE8CF9C869691" unitRef="usd">69792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-EACE6EF145FEE738C7F8978246EDFAD9" unitRef="usd">126327000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-8286DF4E6B5D5263970106DDC6761E52" unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CollaborationMember" decimals="-3" id="Fact-8B3232ECC74255F2BC45D18CDE6519E6" unitRef="usd">103469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-D60D8EAA0D45508089C3CBBA10053362" unitRef="usd">25008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-51D06B7D033A50F88687D7275CE7E697" unitRef="usd">6398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" decimals="-3" id="Fact-A40B7FE7355A559FB59ADF3271940FAA" unitRef="usd">-1905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" decimals="-3" id="Fact-B3E86368DD2353B095119EC162BED511" unitRef="usd">402569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" decimals="-3" id="Fact-A32E1B4A2DEC515AB1BACBF96D9AF52B" unitRef="usd">8737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" decimals="-3" id="Fact-05DAFF9DE5565D7AA6216B465C68ADB2" unitRef="usd">53561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="-3" id="Fact-9E2E6082B2FB5D3B99CFDEF7E501C26E" unitRef="usd">96637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-7900D31DE8CF58BEB805F2A10DEAD436" unitRef="usd">349008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-A2DA3A510285584495A29F5EC5BF6468" unitRef="usd">367906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-EFC1256F5B255E8B88C46C3D1C5DCC23" unitRef="usd">14779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-3" id="Fact-14FB10EE82F55828B067AB77B6A4314E" unitRef="usd">69792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-3" id="Fact-8B297E5BF21B1787BADBD38BA735BE7D" unitRef="usd">12500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-3" id="Fact-C3BE946C89BE9787823AD3853B6C9B33" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-E19269EDAF1B5A17BF9BDAC55FCE960B" unitRef="usd">69792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-3" id="Fact-1E52F0849BFBDC2CFFA5D389465DE75C" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-A3681B33F3595AFEAF1C3CBC4A610C5C" unitRef="usd">14779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2017Q4Oct01-Dec29" decimals="-3" id="Fact-CED3F084F0715EF780C8C8F413FA883F" unitRef="usd">120072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q1Fiscal" decimals="-3" id="Fact-458DD4D15C4C8D75708DBD7E93C9DC8C" unitRef="usd">213719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-52B42E22837DE90E700FBD7E93D109BD" unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q3QTD1" decimals="-3" id="Fact-39EDC54A8612516EE0E1BD7E93C1B899" unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-C239AC2E9FA85776A1A01EDC0303BE27" unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-85C68D1058895E52B03F1B83A2099D8E" unitRef="usd">81028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-574BA069F3D050808CF72BFAA50A0D76" unitRef="usd">99916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-C90B2A5B2F6953E9833B897253733050" unitRef="usd">110698000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-ED11BAFDE606501587312835936752EF" unitRef="usd">74244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-B2F11BB05653594997AB6EE444B4F456" unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-9B9829768101AAD42C1D9782471848A6" unitRef="usd">305061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-FD13F5E29EF85840A0CA1EF214F2A8B4" unitRef="usd">599946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember" decimals="-3" id="Fact-F6AFBC75478C51E38482DC7E0EE8D417" unitRef="usd">234547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-706B041B6AB931B754AFDF9AFACA1460" unitRef="usd">-35882000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-DD7D95E3052577EBB6B6DF9B0CEEF265" unitRef="usd">270429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-DC10DAB76FDD5F91AA0033075D717643" unitRef="usd">19333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-36B43395F90B5B588E85BBEAEB274F79" unitRef="usd">5564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" decimals="-3" id="Fact-E79AB346754B559B9C2FD38D232356F7" unitRef="usd">2858000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ProductGrossMember" decimals="-3" id="Fact-B88FF4D5C496518EB9E0BB24AB1C7849" unitRef="usd">738529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" decimals="-3" id="Fact-88EC9774FC1D5B50B8090EFCC3A6B37C" unitRef="usd">39501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" decimals="-3" id="Fact-C48C846E203554EB87F96521C83079E5" unitRef="usd">119250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="-3" id="Fact-55F1477F2E165038B8EF7595D32848A1" unitRef="usd">192188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-6F70EDC6DF2950D6BC999B575E1FD230" unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-EA5B0B6A99A05601BE6B2D1556B92D9D" unitRef="usd">632927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-C7CF436926715D07930289D6684133F9" unitRef="usd">38020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-3" id="Fact-4BA1E306146A57FF9C56207ABE5AAA30" unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-793AABB88598071E1513DF9B1CF745FD" unitRef="usd">889708000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-4971609091450A698913DF9B15038656" unitRef="usd">-35882000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-3" id="Fact-5B4FB9992AFECC173C5919AD48CEF38B" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-3" id="Fact-A0AF66C7F986F21B7D88D3853B72E8A1" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-C87B4E72945E5867A28E0118D4715963" unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-3" id="Fact-FFBDAA28E72DCA262A2FD389446B8AF4" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-7FA5D6DB57F651F2B4B0B6A801A13640" unitRef="usd">18020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q4Sep29-Dec28" decimals="-3" id="Fact-93021DC2B76356F289F22BE57F2B55B8" unitRef="usd">228602000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CD8709FD8AD8B5705B06BD7E93CA7364" unitRef="usd">99008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2C849F8CFFD5F248150DBD7E93D0979C" unitRef="usd">152510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueRemainingPerformanceObligation contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-4BA6B06ADD6052758A57BF3F7AB099A6" unitRef="usd">48000000</us-gaap:RevenueRemainingPerformanceObligation>
	<us-gaap:RevenueRemainingPerformanceObligation contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-76B481DF891853F8B2262ED9D976A60A" unitRef="usd">25600000</us-gaap:RevenueRemainingPerformanceObligation>
	<us-gaap:RoyaltyExpense contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-B28422CF3FCF5E8DBF6FC197CDADA2D0" unitRef="usd">4334000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-71DCC3E13E7E525A8A77AE77ACA7635C" unitRef="usd">12413000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-239F3FA528355106A8BFEC7E3ACE0341" unitRef="usd">23950000</us-gaap:RoyaltyExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2E972D617D4F5011BFAE21C8B5CB42D1" unitRef="usd">116145000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-061CF63F3BD65DA2B8D1D2472443409D" unitRef="usd">159362000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q1Fiscal_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="-5" id="Fact-12196CB74CCE2C72B3ADDF7B1D207FF8" unitRef="usd">-1400000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-BB562DD75C2C5D45B9CFC4D4D4C782E2" unitRef="usd">206366000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" decimals="-3" id="Fact-E0156426F9A0FB83A90FDF9B2AF37395" unitRef="usd">205162000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-E3F16D2E9B6F2C5DFB18DF9B26CF5066" unitRef="usd">1204000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2DB1FC4D05935EEFAF64F9521D345851" unitRef="usd">22912000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-722E28BFAE6954538C9FA96346F37B24" unitRef="usd">23938000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F99DD2E067635D948C0BA6E64D6B886E" unitRef="usd">40626000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2010Q4Jan02-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-D758C7FD4F60272EDCAEBD7E93D494F9">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-909C1EB31E5393639ACCBD7E93D6D8C0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-1B9E0DD84F4708D3BABCBD7E93DFC7E6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-1E0B06E804B86C62BFC8BD7E93E8EF4B" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-E4A418BE0C88D8780165BD7E93D3335F" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-D314C7468AF653A680BA84D47BFC0D09" unitRef="shares">343742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-BA7F9752A8E65B2996AECA77EFD99C42" unitRef="usdPerShare">18.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-A02425D5D81A5E28B922A0B83E67862A" unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-694C84498D60543E916EEB15FB49EFD3" unitRef="shares">2519425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-D69B395A156058C89644536607811021" unitRef="usdPerShare">18.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-7702E16E083E6766A2A5BD7E938F0E94" unitRef="shares">4857334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-090E5DC64EF0582A8FB1997126402B17" unitRef="shares">3762990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-32B95F41339D58D3A4A006A0566A8453" unitRef="usdPerShare">18.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-AEEBE17A05705E2DA7A2BAF9D412DD32" unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-E36A654704735CF886DD49BEDB0C8D12">P2Y1M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-FC8F3255786D5E37B8CC944AF0E07C90" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-AFF14CC37C51558DBDE851AA9B6E8B95" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-C85D9F57FBB0540B9ADFA695E56629D9" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2867148C38B75CD1827CB1778D964125" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-48C5CC12BCEE5709BB11D2409772A533" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-099B3F0C2FC75136AFAE88FB169534B3" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-164B1E91BF285752BCD16FC6D94EA098" unitRef="number">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-C3EB905C454A5AE58C38F70512E30BF6" unitRef="number">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-B90369494979545F8B19869C8B27EC44" unitRef="number">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-9B8EDAF74179541DB08051B4B802B401" unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-7B819260CD6E51B09104E96C815A804B" unitRef="number">0.0193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-A6523385AD715840B291BC25A2FF5060" unitRef="number">0.0281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-6BC4BC54152F5F6A9F66D8F81AA1662A" unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-AEB46BA06144523497B8E1A058F7292B" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-341CE944ADE85A8AB73F54A1C11D21A5" unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-6C19D78233B4547E9A96562A0818B194" unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-823879A0C9AF50C581FAE94D52EB5917" unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-FE36952C76F859E99B42548E78FEFA51" unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="FI2018Q4" decimals="INF" id="Fact-D838EE936D9FA72E3C63BD7E93DC26A1" unitRef="number">0.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2018Q4" decimals="INF" id="Fact-FBDE8A647B2D50B4A71F8E388C433F1F" unitRef="shares">14693867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-E1D68AF805ACC02173E8BD7E93E09286" unitRef="shares">4722008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q4" decimals="INF" id="Fact-47683763AA3957F594F2CD6916F4CB3E" unitRef="shares">16463202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-EAA165DA6FDD523A8F00C36100F80EDC" unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-15A715181CEB51A54A4DBD7E93EC192E" unitRef="usd">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-BF50173FC89A8763C949BD7E93D7E6CD" unitRef="usd">85200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-562CE6ECFF66C214837EBD7E93D773CB" unitRef="usd">39100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-5E978D73015C51ADAB749F7B5F978E46" unitRef="shares">18081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-9EAD2F02BDE8500B9C1A73491CFD07E2" unitRef="shares">288197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-39726F5F84235516AF237666C4B9C453" unitRef="shares">3238473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" decimals="0" id="Fact-EDF1820C4E0D57E18117C2843CAB1388" unitRef="shares">308365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-9AD05BBD335C7B2B6343BD7E93B1E4C8" unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-B81A1A77503EAEE6AE9BBD7E93B2782D" unitRef="usdPerShare">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-884D6DA0E10B5054B7B5029CC1630007" unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E7BBAA2D49B25814913DD673224140BC" unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-A16F07457848597C92ECECC2A797E534" unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A1FE725EA5585838BF708EFA4E1ADA40" unitRef="usdPerShare">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-D88FF0FA52005ED08F2F0F9B62E27C22" unitRef="usd">254201000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-B8E23911AFF9EEEBAED7BD7E938994C8" unitRef="shares">22674062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q4Dec29" decimals="INF" id="Fact-0D76C0567B5F5914972D6AB53287BF0E" unitRef="shares">22208446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-4FC2559E63D0FFC0DD33BD7E93E6BAD9" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-A40BEA01B85259BAAFEE6EE6A44BABC3" unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2017Q4Dec29" decimals="2" id="Fact-553F38444C7F546D9D0735EF76D7854C" unitRef="usdPerShare">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-8E9B2726BD4AFC2B3C77BD7E93DF3732" unitRef="usdPerShare">15.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-50A45D8F51BD02DE8F4ABD7E93DA54D1" unitRef="usdPerShare">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-D97B2DF1B8D6196F7722BD7E93E5BC25" unitRef="usdPerShare">11.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-9439ABFA60079D4437B3BD7E93EC309E" unitRef="shares">559936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-078C6F93BA42F27C004ABD7E93E47943" unitRef="shares">434523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-A02E2C87DCA027F2B5A5BD7E93D27438" unitRef="shares">330492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-3AD33BBED90F54C98F3FDE4EF9664923" unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-5D1E45B9C3FF50B595AC0A94AC7760E6" unitRef="usdPerShare">20.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-FF800955268A51E7811237C3424C6914" unitRef="usdPerShare">15.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="2" id="Fact-86A9745E7B125009A2DECFBF38BA6FD5" unitRef="usdPerShare">19.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9F1F32BE0B12C076D7D8BD7E93DC0BFC">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-6DB45973666F540682ACBB2D67D82236">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-92A903F7B88058AE9A64156561CE6E09">P4Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-D3DC8B155BD55FFE9DE62BA38C82A5FF">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-13FD248BED125E70AABEDD14480ABC36">P4Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-FB635FD27A4C583C97264A1DAD6B9558">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B0070A53A397529CA384BA0ED7B0094A">P4Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2018Q4" decimals="-3" id="Fact-D7DFA8DB2CCB5B29B81C3D8170D816D1" unitRef="usd">229699000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-41E3AEC78B1558EF8C10FF2E72B8DFF0">P2Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-43FC82BC82BE5F21977F55ED81818869">P3Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-B956A7810C55D37E75D4BD7E93E94C6D" unitRef="shares">5870303</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:ShortTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-E36A7B81F19050C9B2131914C70A8ECE" unitRef="usd">378559000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-AD69EC5F0CD950AD93D294C7B1866EAE" unitRef="usd">204607000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-38B75FC1A48EAFE4F4CFBD7E93CB8188" unitRef="shares">54009279</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-88A619C6FF7821F14000BD7E93BF42C2" unitRef="shares">877451</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FE762A0590386F074786BD7E938739E7" unitRef="shares">7953576</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C701D35F471736CD0565BD7E938E447D" unitRef="shares">5408177</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4ADE63E83EBADF7B62CD810F1AFC9D6D" unitRef="shares">3666654</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="INF" id="Fact-618A62C27FE75A0EB92B2EA591FB376A" unitRef="shares">2466579</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E92827B0ADA7DB2AD2C4BD7E9383F964" unitRef="usd">253080000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9B03AFDEE59B00B1ABC7BD7E93837EB0" unitRef="usd">253026000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-163C33295FF8285D9638BD7E938946ED" unitRef="usd">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-61CA7B80745B63D9014CBD7E93C9A6FC" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C534EEE75111229E016ABD7E93CA1FCA" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7F9FF96F6CAB8C271B69BD7E938DE87A" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8EADBFBE0FB87ADD5659BD7E93C0801F" unitRef="usd">24538000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-083057D9032243E6BC25BD7E93856397" unitRef="usd">24530000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-06A1DF1F6CDB52091A1ABD7E93C1962B" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-AADF30F94D2D60DB32DBBD7E93D16522" unitRef="usd">17409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6F9E4EAEEBCCF0D59A2ABD7E93816A9D" unitRef="usd">17404000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5D956BAF38358B10235ABD7E93C6412D" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-A999712C8506CFDED520810F29CB91A4" unitRef="usd">13411000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B9598BC072592CD97ECB810F2321BA52" unitRef="usd">13407000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-02C021D2DC75C62E6AED810F1F293BFB" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-3" id="Fact-18BA16B079E25825BFB57605E1237D66" unitRef="usd">1287453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9B3F5659E26D936899C9198E07D51742" unitRef="usd">-701000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-ECAACD2C222DF7FA8048198E05E53A20" unitRef="usd">2168217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9FEC241957DB25CD08D6198E036816A4" unitRef="usd">300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3233C90B3FA0B2425905198E0A226A4D" unitRef="usd">-880363000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-4BBAD9105789243D428DBD7E9391D7F3" unitRef="usd">-140806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-46D1974B54DC0B9D0D86BD7E9394AE43" unitRef="usd">-232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-254800D71B810C355535BD7E9387FA6B" unitRef="usd">1772123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8285DA4797FB7B0FDCACBD7E9389A5ED" unitRef="usd">228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-11E9F40AC44EF6773284BD7E9394B946" unitRef="usd">-1912925000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30" decimals="-3" id="Fact-CA0D193745ECFBCD5152BD7E93C42893" unitRef="usd">89318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7E94CF366DC37203B954BD7E939385A6" unitRef="usd">-416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1FDA11E083ADC7AAF3C6BD7E93C2A17B" unitRef="usd">2072591000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2E0976ED2D0BDA1A88F2BD7E93887151" unitRef="usd">290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-57D3A1346B3B648F10B9BD7E93D00C9F" unitRef="usd">-1983147000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5A6A487DDCF95ABBAECA41C3E860AC15" unitRef="usd">284961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-8241E840CBD799E34DC0198DAF14B51B" unitRef="usd">-347000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BB32F5E75111F8B18D38BD7E93CD5C7F" unitRef="usd">2114184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-AAD07A4F7B5446243BB7BD7E93D0508D" unitRef="usd">296000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-2F4AABC226F111D7365FBD7E9391E1DB" unitRef="usd">-1829172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:SubleaseIncome contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FC40FFE0B97E3B357DE47C4942618CC4" unitRef="usd">3553000</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-225CAD083C4955FDB7CD2ED9ACB16AF8" unitRef="usd">1225000</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-C1232FB9207C5F068F9ADA6E86FE1FFB" unitRef="usd">0</us-gaap:SubleaseIncome>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-6" id="Fact-D602153285F8219D0540BD7E9397CCAE" unitRef="usd">102000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-6" id="Fact-B1A3BED4344362F8925DBD7E93A176B3" unitRef="usd">34000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CAA4DD7FEFAF5FC99AAC3A6E1628F50B" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8A2824BB74D3537FA471E1E01CD3D2C6" unitRef="usd">367000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-911B56F5D00F54C89B3A567910A395D7" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-D0E56755E66758498672E3ECC457729F" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8B26D779E06F5B1397563CE4DD9DA324" unitRef="usd">-22000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-115867A5F54456EFB4F87B6DE9F392FA" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-C4DD6E258336185CB166BD7E9397D3FD" unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-B7185E70CCCE106B0B7EBD7E9397DCB8" unitRef="usd">88638000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D2B61DE33E19312A5841BD7E9395315D" unitRef="usd">61809000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A5178A13CDEB72F0B3A3BD7E9399961E" unitRef="usd">79342000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-F78C5476FC0D2FCBC9F2BD7E939891D9" unitRef="usd">2304000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-760083731B84F2E02DEFBD7E9395BB19" unitRef="usd">17378000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-2E31955D9185D6756381BD7E93969194" unitRef="usd">1083000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-141AD8799FB8FD02C7D3BD7E9392C698" unitRef="usd">23000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7F37EF62E769287B20CCBD7E9392D740" unitRef="usd">92000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-F884153D885AA0868147BD7E93970A81" unitRef="usd">111000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2018Q4" decimals="-5" id="Fact-75D95F3BC011353D1DF7D3ED7F890EE0" unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-7E239287EF75862E90B3BD7E93A6CE25" unitRef="usd">-210100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-5" id="Fact-CD7E8F6E35AEAB1BD388D3F4ED928C08" unitRef="usd">-360800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4" decimals="-3" id="Fact-F2181091221870E239F97BD5CB75B62A" unitRef="usd">17276000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-2CEB06596791F33B41DC7BD5CB8972DE" unitRef="usd">3038000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-407A282569165DEACDCB7BD5CB7B86A0" unitRef="usd">11916000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-9A935F1FB0595E7E1D177BD5CB937509" unitRef="usd">2322000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-335EA82104D8925423CA7BD5CB81B79C" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2016Q4Dec30" decimals="-3" id="Fact-ECD56F9EDD38415429C97BD52D31E25E" unitRef="usd">5574000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-2AEA3A5ADC107E759DFF7BD52CFD5CAB" unitRef="usd">794000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-68C6AC331AF928C10B167BD52E79E4E6" unitRef="usd">2627000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-D8496C5BD0EC2B247AF37BD52D0C40BC" unitRef="usd">1802000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-26DC5E764CE0CE1F9A237BD52DE2C12F" unitRef="usd">351000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29" decimals="-3" id="Fact-769EA7CE75A9132363BD7BD59CC63017" unitRef="usd">9493000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-0D65153ED15A5EB68E01AD3B75ABB8AC" unitRef="usd">1795000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-8FF6F8F48C995554AA98D96988050078" unitRef="usd">5770000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-6AD490CAFBF05AB6B83B353FAE14F234" unitRef="usd">1928000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-6CAB0505361EF4B607817BD52D793446" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CEC26B62630A37734DA57BD75DACB6B3" unitRef="usd">49641000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-B99DB8A9E329605C68267BD75D79C1DC" unitRef="usd">6300000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-D73D61B7E661494E48A67BD75DF46765" unitRef="usd">10623000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-C436E0BB6E5A669801627BD75D876EAA" unitRef="usd">32367000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-3FA96AC06F60C996AA937BD75E34CA10" unitRef="usd">351000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-1C6027967656B0F0261B7BD79233B536" unitRef="usd">111467000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-9F2200B4C440500EA60AA2C176CA1F15" unitRef="usd">11978000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-469553BF73B55EEAA1E5FE6CDA75617F" unitRef="usd">24741000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" decimals="-3" id="Fact-C23EA7777B845B8D9ABA8CB98FFBBC59" unitRef="usd">74746000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-EFD0C39BC774DDED88F17BD7924817B8" unitRef="usd">2000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:VariableLeaseCost contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1D1493303EF0BC0F64207C4931E214E4" unitRef="usd">1056000</us-gaap:VariableLeaseCost>
	<us-gaap:VariableLeaseCost contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-94759CA1EC9A55418B1FBD6CCD978A26" unitRef="usd">2216000</us-gaap:VariableLeaseCost>
	<us-gaap:VariableLeaseCost contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-E5796A738E075344AC86E14D7AD18037" unitRef="usd">1661000</us-gaap:VariableLeaseCost>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7DFAE0B3E2F05F7296A3616FF66621E1" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-61E4F808C9765868B53897740A287441" unitRef="shares">18415000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-796C0B24B47E5D7CA5C4DC0548AEE208" unitRef="shares">14911000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A92AE6572D8454E887E608CA16D68ECA" unitRef="shares">250531000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-EBE1637752085714B2AF324880F7B946" unitRef="shares">312003000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-651499DE3EE95FEB8EA46A57ED1F53F0" unitRef="shares">312803000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7338FD4F4D4154718384183001F8CF2F" unitRef="shares">250531000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-796886E34D495794A89F9E844999F940" unitRef="shares">293588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" decimals="-3" id="Fact-C343D3B091AB578AAAAEE05D5AF831E7" unitRef="shares">297892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<exel:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-C558419BD8AF99B7AB6CBD7E93BDD0D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
	<exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-6389C13BEDAE050817FC4D81DE5C2164">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing obligation for build-to-suit lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock>
	<exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-17BBA7C03A135871B2297B464874428E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;75,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(74,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(24,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(111,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
	<invest:InvestmentTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2CF757A85878569B74D8BD7E9383FCC3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;CASH AND INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;314,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;183,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;315,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;188,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;852,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;851,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;457,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;457,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nominal&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;236,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;275,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;271,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;320,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;199&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;674,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Cost Method Equity Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized gains of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, related to the August 2016 sale of our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; interest in Akarna Therapeutics, Ltd. (Akarna) to Allergan Holdco UK Limited (Allergan). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other, net in the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;During 2018, BlackRock,&amp;#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that their beneficial ownership increased to more than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, the fair value of cash and investments managed by BlackRock was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$298.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$141.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; invested in the BlackRock Liquidity Money Market Fund. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We incurred &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in fees for BlackRock advisory services performed during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</invest:InvestmentTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-A52B1887620806CEFAD6BD7E93882C50">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&amp;#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, and December 28, 2018 are indicated as being as of and for the years ended (or ending, as applicable) December&amp;#160;31, 2016, 2017 and 2018, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-47DD8EB98F0B67B47F96BD7E93891885">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5775C9C9371DA3D55FEEBD7E939B348D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COLLABORATION AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, Daiichi Sankyo, Merck &amp;amp; Co., Inc. (Merck) and Bristol-Myers Squibb Company (BMS) for other compounds and programs in our portfolio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 2. Revenues&amp;#8221; for information on collaboration revenues recognized during the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Commercial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Description of the Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&amp;#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Consideration under the Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of December 31, 2018, we have also achieved aggregate milestones of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to development, regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, including &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$140.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones recognized during 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$84.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$519.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with sales-based milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We were initially entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on the initial $&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;150.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales; this amount was reached in the second quarter of 2018. As of December 31, 2018 and going forward, we are entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales (with separate tiers for Canada); these &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on the first CAD&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of annual net sales and a tiered royalty thereafter to&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales; these &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty tiers for Canada will also reset each calendar year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Consistent with our historical agreement with GSK, we are required to pay a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such costs, provided Ipsen chooses to opt into such trials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied at our cost, as defined in the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Revenues from the Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$48.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Ipsen was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets. See &amp;#8220;&amp;#8212;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8221;, below, for additional information related to the revenue recognition for this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Description of the Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&amp;#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&amp;#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&amp;#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Consideration under the Collaboration&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upfront nonrefundable payment from Takeda. During the year ended December 31, 2018, we also achieved a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; development related milestone.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of December&amp;#160;31, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestone payments, without limit, for additional potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$83.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with sales volume milestones and receive &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;on the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, and following this initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, we are then entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;on annual net sales thereafter; these &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty tiers will reset each calendar year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Consistent with our historical agreement with GSK, we are required to pay a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Takeda is responsible for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs associated with the global cabozantinib development plan&amp;#8217;s current and future trials, provided Takeda opts into such trials, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Revenues from the Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:504px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$25.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of December&amp;#160;31, 2018, the net contract liability for the collaboration agreement with Takeda was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have allocated the transaction price for each of these collaborations, which are described below, to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The portion of the transaction price allocated to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union (EU) for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Based on our evaluation of the collaboration agreements as of January 1, 2018, the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone we expected to achieve during the three months ended March 31, 2018. Other than that &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the year ended December&amp;#160;31, 2018, the transaction price increased as a result of the achievement of various milestones described above. We further updated the transaction price based upon the impact of research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December 31, 2018, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib Development Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;BMS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&amp;#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC and HCC in the CheckMate 9ER and CheckMate 040 trials, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the terms of the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&amp;#8217;s compounds in the conduct of each clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Each party will be responsible for supplying finished drug product for the applicable clinical trial and unless otherwise agreed between the parties, costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear two-thirds of the costs for such study treatment arms and we will bear one-third of the costs. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;The Roche Group (Roche) Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib in combination with Roche&amp;#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b trial evaluating the safety and tolerability of the combination in patients with locally advanced or metastatic tumors, and in December 2018, we initiated COSMIC-312, a phase 3 pivotal trial evaluating the combination versus sorafenib in previously untreated advanced HCC, with an exploratory arm also evaluating cabozantinib monotherapy in previously untreated advanced HCC. We are the trial sponsor, and Roche is providing atezolizumab free of charge.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;GSK&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, GSK continues to be entitled to a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay on all net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;StemSynergy&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Therapeutics, Inc. (StemSynergy) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we entered into an exclusive collaboration and license agreement with&amp;#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#945;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;), a component of the Wnt&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; signaling pathway implicated in key oncogenic processes. Under the terms of the a&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;greement,&amp;#160;we&amp;#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#945;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we paid&amp;#160;StemSynergy an upfront payment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;in initial research and development funding and provided &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in additional research and development funding. StemSynergy is eligible for up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in additional such funding on an as needed basis. The research and development funding costs incurred to date were included in Research and development expenses in the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;StemSynergy will also be eligible for up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$56.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Invenra&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, Inc. (Invenra) C&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ollaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2018, we entered into a collaboration and license agreement with Invenra, which is focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and a project initiation fee of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The payments were included in Research and development expenses in the accompanying Consolidated Statements of Operations. As of December 31, 2018, we also have the right to initiate five additional discovery projects for development subject to an upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts. Invenra is eligible to receive payments based on the achievement of specific development and regulatory milestones of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$131.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for a product containing the lead preclinical asset in the first indication and up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$127.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for a product developed from each addition project we initiate. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$325.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per product if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project, basis at any time prior to commercialization, for any or no reason, upon thirty days&amp;#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Genentech&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits on the U.S. commercialization of COTELLIC for the year ended December 31, 2018 were included Collaboration revenues and profits and losses on for the years ended December&amp;#160;31, 2017 and 2016 were included in Selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &amp;#8220;&amp;#8212;Performance Obligations and Transaction Prices for our Other Collaborations&amp;#8221;, below, for additional information related to revenue recognition for this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&amp;#160;November&amp;#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&amp;#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&amp;#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allows for us to provide up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the total sales force for approved cobimetinib indications in the U.S. Between November 2015 and December 2017, we fielded &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a review of the commercial landscape, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Cobimetinib Profit Sharing and Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&amp;#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of U.S. actual sales, decreasing to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from U.S. actual sales in excess of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. These tiers will reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Cobimetinib Clinical Development Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cobimetinib is being evaluated by Genentech in a development program consisting of more than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;50&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; clinical trials. These trials are being sponsored by Genentech or through Genentech&amp;#8217;s investigator sponsored trial program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Daiichi Sankyo&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;&amp;#8212;Performance Obligations and Transaction Prices for our Other Collaborations&amp;#8221;, below, for additional information related to revenue recognition for this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. In January 2019, subsequent to our year-end, Daiichi Sankyo received approval from the Japanese Ministry of Health, Labour and Welfare for MINNEBRO as a treatment for patients with hypertension. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible to receive additional development, regulatory and sales-based milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$110.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; under this collaboration agreement, including a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone payment upon the first arm&amp;#8217;s-length sale of MINNEBRO in Japan. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8217; written notice, in which case Daiichi Sankyo&amp;#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;0.5%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Ligand on net sales of MINNEBRO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Merck&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Merck collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;&amp;#8212;Performance Obligations and Transaction Price for our Other Collaborations&amp;#8221;, below, for additional information related to revenue recognition for this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December&amp;#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (PI3K-&amp;#948;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-&amp;#948; program. Subsequent to December 31, 2018, we have been notified by Merck that they will be terminating their PI3K-&amp;#948; program, including their development activities under this collaboration agreement. Upon the termination of the collaboration agreement by Merck, the license granted to Merck will terminate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;BMS - ROR Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;BMS collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;&amp;#8212;Performance Obligations and Transaction Prices for our Other Collaborations&amp;#8221;, below, for additional information related to revenue recognition for this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Since July 2013, BMS has been solely responsible for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible for additional development and regulatory milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$240.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate and sales-based milestones of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&amp;#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&amp;#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Performance Obligations and Transaction Prices for our Other Collaborations &amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have evaluated our collaborations agreements with Genentech, Daiichi Sankyo, Merck and BMS and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-EB4DE64CB4A50A7F0B2FBD7E93E26418">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMITMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As described further in &amp;#8220;Note 1. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Organization and Summary of Significant Accounting Policies&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we adopted Topic 842 as of January 1, 2018. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into the Lease with Ascentris for office and research facilities located at the Premises in Alameda, California. The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134,765&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$8.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. The Lease&amp;#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, following the conclusion of a partial twelve-month rent abatement period&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term; none of these optional periods have been considered in the determination of the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;right-of-use asset or the lease liability for the Lease as we did not consider it &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay to Ascentris certain variable costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;170,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space, as that additional space becomes available at 1601, 1701 and 1751 Harbor Bay Parkway, Alameda, California over the remainder of the initial term of the Lease at a market rate determined pursuant to the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We had an additional operating lease which expired in July 2018 for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; buildings in South San Francisco, California with a total area of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;116,063&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have performed an evaluation of our other contracts with customers and suppliers in accordance with Topic 842 and have determined that, except for the leases described above, a nominal operating lease for space at a data center to house our data servers and a nominal financing lease for office equipment, none of our contracts contain a lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing obligation for build-to-suit lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs, which were included in Operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.40476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in Net cash provided by operating activities in our Consolidated Statements of Cash Flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Operating leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average remaining lease term is &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;9.0 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the weighted average discount rate used to determine the operating lease liability was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;4.50%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Letters of Credit and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have obtained &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; standby letters of credit related to the Lease with Ascentris with a combined credit limit of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We have also obtained standby letters of credit related to a workers compensation insurance policy with credit limits of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. We had also previously obtained a standby letter of credit related to our South San Francisco lease with a credit limit of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which was released during 2018. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit. The certificate of deposits used to collateralize the standby letters of credit were included in short-term and long-term restricted cash and investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We were previously required to provide collateral as part of an employee purchasing card program. The collateral requirement for the purchase card program at &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we were notified that we had been released from this collateral requirement. The collateral was invested in certificates of deposit which were included in long-term restricted cash and investments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2AE167C16EC6CE7CF1AABD7E93859D24">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-0C1FFDA5DB9D8D28C93D7B4341880E1F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(46,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-7B6D30BF148D7AC1FBB1BD7E93BC500C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;236,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;275,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;271,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;320,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-443B1E933AEF6EFE4F617B444E874A59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;738,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;402,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(119,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;619,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;192,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;96,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;56,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development service revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;103,469&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;56,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development service revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only development cost reimbursements earned on our collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Duri&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ng the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenue, were recorded in accordance with Topic 808 for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;599,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;324,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;619,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;110,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;73,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;74,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;305,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;126,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;46,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;632,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;367,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-6DC1EE941493C983314ABD7E93D49EAD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,511&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we granted stock options and RSUs to employees and directors. At &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;14,693,867&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year vesting term, an exercise price equal to the fair market value on the date of grant, and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year life from the date of grant. Stock options issued prior to May 2011 have a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year life from the date of grant. RSUs granted to our employees generally vest annually over a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&amp;#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;its outstanding &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;stock options accelerated with the exercise period being extended to no more than one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the beginning of the offering period or&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the end of each&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;month purchase period. Compensation expense related to our ESPP was&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;for the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively. As of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, we had&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;4,722,008&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares available for issuance under our ESPP. Pursuant to the ESPP, we issued&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;330,492&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;434,523&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares, and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;559,936&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares of common stock at an average price per share of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$15.74&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$11.20&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$3.91&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;during the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;Cash received&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;from purchases under the ESPP in the years ended December 31, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&amp;#8217; current expectations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,238,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,466,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(288,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(18,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,674,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;254,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,463,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;229,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, in connection with our long-term incentive compensation program, we granted &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;308,365&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; stock options to our President and Chief Executive Officer that have a market vesting condition (PSOs). In addition to the standard service conditions included in our other stock options, these PSOs &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equal to or greater than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;125%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized over the service period of the award, which commenced on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5,870,303&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; performance-based stock options vested during &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and we recognized&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;in stock-based compensation for those&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock option grants&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;. We did&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;t have any&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock options outstanding during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and therefore, did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;stock-based compensation for&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;options during that year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$48.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested stock options, including the PSOs described above. The compensation expense for the unvested stock options will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.5 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the stock option holders had all stock option holders exercised their stock options on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The total intrinsic value of stock options exercised &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on the dates of exercise &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$39.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$85.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. Cash received from option exercises during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$12.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$17.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$25.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$18.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Activity for RSUs during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,519,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,081,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(343,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,857,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, in connection with our long-term incentive compensation program, we awarded &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;693,131&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). These PSUs are included in the RSU activity table presented above. The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Expense recognition for PSUs commences when the attainment of the performance goal is determined &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;by management &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to be probable. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the year ended December 31, 2018, we did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;not recognize any compensation expense related to these PSUs. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the total unrecognized compensation expense related to the unvested PSUs was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. There were no &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based RSUs&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; issued prior to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$81.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3.1 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;401(k) Retirement Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sponsor the Exelixis, Inc. 401(k) Plan (the 401(k) Plan) whereby eligible employees may elect to contribute up to the lesser of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. During 2018, we made matching contributions in the form of our common stock of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$8,500&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of each participant&amp;#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$3.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;As of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;571,674&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares were available for issuance under the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;401(k) Plan&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-9EB5671E7E6D80B6F557BD7E93D4E0FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;297,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potential shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2014 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Deerfield Notes were repaid in June 2017. Warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock issued in January 2014 (2014 Warrants) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-7BBE2BDB1D95F19B07DABD7E93DFD823">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;780,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;796,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;844,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;408,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;453,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-416E29D74ED6D71589FDBD7E93DE153C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;780,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;796,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;844,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;408,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;453,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 11. Commitments&amp;#8221; regarding the determination of the amount of our operating lease liabilities as of December 31, 2018. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-89A444B29FCAB153022EBD7E93BA1C35">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-C7B9100AC44781F68C1EE3BB1F1F1043">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-7ADAC2C4BFD61DAAA846BD7E93BDC77B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&amp;#8217;s goodwill exceeds its implied fair value. We continue to operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-E780864F16BD507E4091BD7E938641DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-22EE57F92677BA4EBD72BD7E93A6157C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income (loss) before income taxes is derived solely from within the U.S. The Income tax benefit (provision) was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. Our historical net operating losses are sufficient to fully offset any federal taxable income. The Income tax provision for the year ended December 31, 2017, related to state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of the U.S. federal income tax (provision) benefit at the statutory federal income tax rates of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2018, 2017 and 2016, respectively, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to our Income tax benefit (provision) was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax (provision) benefit at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(94,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;315,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt extinguishment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;146,701&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;98,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;66,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Book over tax depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;29,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of deferred stock compensation &amp;#8211; non-qualified&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;303,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(58,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;245,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We applied the guidance in the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Securities and Exchange Commission&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Staff Accounting Bulletin No. 118&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; when accounting for the enactment-date effects of the Tax Cuts and Jobs Act in 2017 and throughout 2018. At December 31, 2017, we had not completed our accounting for all the enactment-date income tax effects of the Tax Cuts and Jobs Act for Section 162(m) related to the deduction limitation for the remuneration of certain employees. As of December 31, 2018, we have now completed our accounting for all of the enactment-date income tax effects of the Tax Cuts and Jobs Act and the impact was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &amp;#8220;more likely than not.&amp;#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2018, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; December 31, 2018 and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;forecasts of future operating results, as well as considering the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;utilization of net operating losses and tax credits prior to their expiration&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$244.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are realizable and the valuation allowance was reduced accordingly. As of December 31, 2018, we continue to carry a valuation allowance of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$58.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance decreased by &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$360.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during 2018 and 2017, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had federal net operating loss carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$614 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2031&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and federal business tax credits of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$102 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2021&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2038&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We also had state net operating loss carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$453 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2028&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and California research and development tax credits of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$34 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which do not expire.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 study through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and concluded that an ownership change, as defined under Section 382, had not occurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(29,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We do not anticipate that the amount of unrecognized tax benefits existing as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; will significantly change over the next 12 months. As of December 31, 2018, we had &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$76.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in unrecognized tax benefits, of which &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Operations as a component of income taxes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2018 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5B6AB268C21072415972BD7E93BA72B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &amp;#8220;Note 8. Income Taxes&amp;#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the technical merits of the position&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-F90926CC6026F91A7BF3BD7E938C0B8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory included in Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,090&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets in the accompanying Consolidated Balance Sheets. As of both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the non-current portion of inventory consisted of a portion of our finished goods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2F9D5D685C19D9D60AF2BD7E938811B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory-related costs are recognized as Cost of goods sold in the accompanying Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-8B10487E06F06460A398BD7E93B8EE6D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;674,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LeaseCostTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-09259F1F5C0B213CB1414D812B82C5A4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs, which were included in Operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.40476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-23ACAA10687074E6F0A4E3BA31616BEE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determine if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in our Consolidated Balance Sheet at December 31, 2018. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;not to apply the recognition requirements of Topic 842 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for short-term leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For lease agreements entered into after the adoption of Topic 842 that include lease and non-lease components, such components are generally accounted for separately. For our building leases, as a result of us having elected to adopt the package of practical expedients permitted under the Topic 842 transition guidance, we account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-E03E4A0CAE98F150882397BBC0A96334">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Operating leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-1944F075DCE411B5D349BD7E9384F913">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net in the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments in the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-B6D9D9B15C7BC2DCB35D018252353DC5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we adopted ASU No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2016-18)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash are included with cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;etrospective transition method in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-18, we no longer include purchases &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of restricted cash and proceeds from maturities of restricted cash &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; increase in Net cash provided by investing activities for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 4. Cash and Investments&amp;#8212;Cash, Cash Equivalents and Restricted Cash&amp;#8221; for a reconciliation of cash and cash equivalents presented in our previously published Consolidated Statement of Cash Flows for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and 2016 and Cash, cash equivalents and restricted cash reported in the accompanying Consolidated Statement of Cash Flows for the same periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2018, we adopted &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification (ASC) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 605)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On July 1, 2018 we early adopted Topic 842. We adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2018 in accordance with ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under previous lease guidance, ASC Topic 840: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 840). We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2018.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Impact of Adoption of Topic 606 and Topic 842&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded a net reduction of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$258.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We also recorded a net reduction of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 842, with the impact relating to a change in the classification of certain of our buildings in our Lease Agreement (the Lease) with Ascentris 105, LLC (Ascentris) from a build to suit lease to an operating lease. For a description of the Lease, see &amp;#8220;Note 11. Commitments.&amp;#8221; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract assets: unbilled collaboration revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract liabilities: deferred revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,829,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;258,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,570,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Includes deferred rent and current portion of operating lease liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen&amp;#8217;s filing with the European Medicines Agency (EMA) for cabozantinib as a treatment for patients with previously treated HCC, that was deemed probable under Topic 606 prior to January 1, 2018. Deferred revenue as of January 1, 2018 was related to the up-front, nonrefundable, fees and milestones earned that were allocated to our research and development services performance obligation which had not been satisfied as of that date. Contract assets and liabilities are netted by collaboration agreement in our Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 842 primarily related to the recognition of an operating lease right-of-use asset and operating lease liability for the Lease. In addition, the adoption of Topic 842 resulted in a change in classification of the build-to-suit component of the Lease under Topic 840 to an operating lease under Topic 842 and as a result we derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December 31, 2017, as we had been deemed to own these buildings under Topic 840. For a description of the Lease, see &amp;#8220;Note 11. Commitments&amp;#8221; in these Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 606 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 842 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balances Without the Adoption of Topic 606 or 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;270,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;889,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;205,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;414,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;413,767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;488,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(48,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;286,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(84,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;774,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If we had not adopted Topic 606, we would also have recognized a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone in the first quarter of 2018 upon the validation of Ipsen&amp;#8217;s filing with the EMA for cabozantinib as a treatment for patients with previously treated HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously reported deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&amp;#160;2018-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Topic 808 to the unit of account guidance in ASC 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-15,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Consolidated Financial Statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&amp;#160;2017-04,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2670E302E198426CD568BD7E9383A7FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;products resulting from our discovery efforts have progressed through clinical development an&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;d received regulatory approval; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; have a growing commercial presence in markets worldwide, and we expect that the fourth will soon enter the marketplace in Japan.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&amp;#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC) and COMETRIQ&amp;#174;&amp;#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other commercially available products resulting from our discovery efforts include COTELLIC&amp;#174; (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech), and MINNEBRO&amp;#8482; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&amp;#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, and December 28, 2018 are indicated as being as of and for the years ended (or ending, as applicable) December&amp;#160;31, 2016, 2017 and 2018, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &amp;#8220;Note 2. Revenues&amp;#8221; for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we adopted ASU No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2016-18)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash are included with cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;etrospective transition method in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-18, we no longer include purchases &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of restricted cash and proceeds from maturities of restricted cash &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; increase in Net cash provided by investing activities for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 4. Cash and Investments&amp;#8212;Cash, Cash Equivalents and Restricted Cash&amp;#8221; for a reconciliation of cash and cash equivalents presented in our previously published Consolidated Statement of Cash Flows for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and 2016 and Cash, cash equivalents and restricted cash reported in the accompanying Consolidated Statement of Cash Flows for the same periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2018, we adopted &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification (ASC) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 605)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On July 1, 2018 we early adopted Topic 842. We adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2018 in accordance with ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under previous lease guidance, ASC Topic 840: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 840). We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2018.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Impact of Adoption of Topic 606 and Topic 842&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded a net reduction of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$258.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We also recorded a net reduction of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 842, with the impact relating to a change in the classification of certain of our buildings in our Lease Agreement (the Lease) with Ascentris 105, LLC (Ascentris) from a build to suit lease to an operating lease. For a description of the Lease, see &amp;#8220;Note 11. Commitments.&amp;#8221; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract assets: unbilled collaboration revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract liabilities: deferred revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,829,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;258,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,570,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Includes deferred rent and current portion of operating lease liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen&amp;#8217;s filing with the European Medicines Agency (EMA) for cabozantinib as a treatment for patients with previously treated HCC, that was deemed probable under Topic 606 prior to January 1, 2018. Deferred revenue as of January 1, 2018 was related to the up-front, nonrefundable, fees and milestones earned that were allocated to our research and development services performance obligation which had not been satisfied as of that date. Contract assets and liabilities are netted by collaboration agreement in our Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 842 primarily related to the recognition of an operating lease right-of-use asset and operating lease liability for the Lease. In addition, the adoption of Topic 842 resulted in a change in classification of the build-to-suit component of the Lease under Topic 840 to an operating lease under Topic 842 and as a result we derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December 31, 2017, as we had been deemed to own these buildings under Topic 840. For a description of the Lease, see &amp;#8220;Note 11. Commitments&amp;#8221; in these Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 606 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 842 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balances Without the Adoption of Topic 606 or 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;270,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;889,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;205,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;414,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;413,767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;488,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(48,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;286,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(84,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;774,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If we had not adopted Topic 606, we would also have recognized a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone in the first quarter of 2018 upon the validation of Ipsen&amp;#8217;s filing with the EMA for cabozantinib as a treatment for patients with previously treated HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously reported deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net in the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments in the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were nominal. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory-related costs are recognized as Cost of goods sold in the accompanying Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&amp;#8217;s goodwill exceeds its implied fair value. We continue to operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any impairment charges in any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&amp;#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&amp;#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&amp;#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&amp;#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&amp;#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarters&amp;#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&amp;#160;D Coverage Gap Discount Program. In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to customer, plus an accrual balance for known prior quarters&amp;#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&amp;#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. See &amp;#8220; &amp;#8212; Recently Adopted Accounting Pronouncements &amp;#8212; Impact of Adoption of Topic 606 and Topic 842&amp;#8221; above, for more information about the impact of the adoption on Topic 606.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Topic 808: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808). &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Sales-based Milestone Payments and Royalties:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; amounts remaining related to previously expensed materials in our inventory balances as of December&amp;#160;31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determine if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in our Consolidated Balance Sheet at December 31, 2018. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;not to apply the recognition requirements of Topic 842 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for short-term leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For lease agreements entered into after the adoption of Topic 842 that include lease and non-lease components, such components are generally accounted for separately. For our building leases, as a result of us having elected to adopt the package of practical expedients permitted under the Topic 842 transition guidance, we account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 840&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. See &amp;#8220; &amp;#8212; Recently Adopted Accounting Pronouncements &amp;#8212; Impact of Adoption of Topic 606 and Topic 842&amp;#8221; above, for more information about the impact of the adoption on Topic 842.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) is estimated as the value of the underlying shares of our common stock. The grant date fair value of stock-options is estimated using a Monte Carlo simulation pricing model for stock options that include market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on an accelerated basis over the requisite service period for awards with a market or performance condition and on a straight-line basis over the requisite service period for all other awards. Compensation expense relating to awards subject to performance conditions is recognized when management determines that it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis. We have made an election to record forfeitures when they occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &amp;#8220;Note 8. Income Taxes&amp;#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;based on the technical merits of the position&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&amp;#160;2018-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Topic 808 to the unit of account guidance in ASC 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-15,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Consolidated Financial Statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&amp;#160;2017-04,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-6194B54F3D35AF494723BD7E93AB26A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;68,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(17,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into the Lease for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134,765&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. For a description of the Lease, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;see &amp;#8220;Note 11. Commitments.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$46.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in related Leasehold improvements, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-C3E0CA21618A913CB3FBBD7E9384F874">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-451575031FAD37875260BD7E93ABEEE1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;866&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;68,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(17,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-BA4F69E588776602A137BD7E939186FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2018:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;228,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;225,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;213,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;168,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;139,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;128,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;111,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;125,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;85,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;116,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;360,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;126,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;115,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;120,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;84,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See &amp;#8220;Note 3. Collaboration Agreements&amp;#8221; for more information on our collaboration agreement with Genentech.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as Net product revenues less Cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-CD2131726D342A0A26D4BD7E938654F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-9DBB95C76D97AD8CDF74BD7E93BDFF5E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&amp;#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&amp;#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&amp;#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&amp;#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&amp;#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarters&amp;#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&amp;#160;D Coverage Gap Discount Program. In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to customer, plus an accrual balance for known prior quarters&amp;#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&amp;#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. See &amp;#8220; &amp;#8212; Recently Adopted Accounting Pronouncements &amp;#8212; Impact of Adoption of Topic 606 and Topic 842&amp;#8221; above, for more information about the impact of the adoption on Topic 606.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Topic 808: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808). &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Sales-based Milestone Payments and Royalties:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-0516BF85CAF6857B644B7B41ED5ED2EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;REVENUES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;738,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;402,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(119,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;619,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;192,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;96,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;56,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development service revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;103,469&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;56,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development service revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only development cost reimbursements earned on our collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Duri&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ng the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included royalties we paid to GSK on Ipsen&amp;#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenue, were recorded in accordance with Topic 808 for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;599,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;324,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;619,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;110,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;73,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;74,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;305,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;126,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;46,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;632,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;367,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;191,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&amp;#8217; headquarters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;75,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(403&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(74,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(24,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(111,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of Trade receivables, net and the remaining reserve balances are classified as Other current liabilities in the accompanying Consolidated Balance Sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(46,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$198.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Daiichi Sankyo&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-CCAC10DBA361638BB9DBBD7E93D511B6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potential shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2014 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-6E19B2D7CFAC7A3C37D18320E8D87D41">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;314,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;183,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;315,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;188,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-EBFB1B2F13AB50554F21E336B2558C62">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Merck collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;BMS collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:504px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Such royalties were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:416px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-BB44A94A43825A2C7996BD7E93A0D2B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Income tax benefit (provision) was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-85631F5D4FA5ECF07BAABD7E93A82B00">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;146,701&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;98,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;66,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Book over tax depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;29,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of deferred stock compensation &amp;#8211; non-qualified&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;303,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(58,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;245,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-E494BA6293DDFA04B11EBD7E93D67981">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;297,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-AE650B1EB3A8C65682AABD7E93AD1A0E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of the U.S. federal income tax (provision) benefit at the statutory federal income tax rates of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2018, 2017 and 2016, respectively, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to our Income tax benefit (provision) was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax (provision) benefit at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(94,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;315,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt extinguishment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-FA3BA1C9CFF66D06DA2EBD7E93EBF3CD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,511&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-D4D40AF04509D6DD79D9BD7E938922F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory included in Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,090&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-9917898AD3F1E86D05BCDF9A08A1D462">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract assets: unbilled collaboration revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract liabilities: deferred revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,829,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;258,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,570,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Includes deferred rent and current portion of operating lease liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 606 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Effect of Adoption of Topic 842 Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balances Without the Adoption of Topic 606 or 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;234,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;270,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;853,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;889,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;205,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;414,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;413,767&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;452,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(35,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;488,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income tax benefit (provision)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;237,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(48,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;286,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;690,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(84,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;774,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5DBFE1EC5D8088531FD3BD7E93EC61D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for RSUs during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,519,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,081,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(343,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,857,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.1 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-D2FE4851A2FE07FE5F06BD7E93935217">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2018:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;228,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;225,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;213,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;168,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;139,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;128,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;111,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;125,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;85,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;116,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;360,089&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;126,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;115,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;120,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;84,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See &amp;#8220;Note 3. Collaboration Agreements&amp;#8221; for more information on our collaboration agreement with Genentech.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as Net product revenues less Cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-7955FBE6F54F901FF96C832281D26A9C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;314,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;183,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;315,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;188,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-3C4E628C0EF8DAEBDF08BD7E93E2FB8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,238,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,466,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(288,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(18,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options outstanding at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,674,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;254,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,463,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;229,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5D423DE0312D592DFA73BD7E93EB39F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-673451F7E8478BA1D452BD7E93DCDC4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-A12D728E5AFF8B7991C3BD7E93AD5F2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(29,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-5CA4692018E29DB8B1E801809741D577">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-F47EAE48BFD7BCD88224BD7E93D45DFF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The weighted average grant-date fair value per share of stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-1761980EA68EA9B9A683BD7E938B02AE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) is estimated as the value of the underlying shares of our common stock. The grant date fair value of stock-options is estimated using a Monte Carlo simulation pricing model for stock options that include market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on an accelerated basis over the requisite service period for awards with a market or performance condition and on a straight-line basis over the requisite service period for all other awards. Compensation expense relating to awards subject to performance conditions is recognized when management determines that it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis. We have made an election to record forfeitures when they occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-2A2EEEEF064E4D335938BD7E938D799B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were nominal. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-94D52647D139EA455A43BD7E93B77DB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;381,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;344,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;828,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;852,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;851,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;457,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;457,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="D2018Q4Q4YTD-DEC3017-DEC2818" id="Fact-ADB82477B792145DC7BABD7E938E283B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-1BC451E6BA6D5F5B846EA0C8F6C7019C" xlink:label="Fact-1BC451E6BA6D5F5B846EA0C8F6C7019C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3CB35C90514CF70295DBBD7E93E865CA" xlink:label="Fact-3CB35C90514CF70295DBBD7E93E865CA_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-498EAB2A0D1E594E942FB1AFF11FC8F9" xlink:label="Fact-498EAB2A0D1E594E942FB1AFF11FC8F9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4BBFA26AAC9007333A2382AE45E14854" xlink:label="Fact-4BBFA26AAC9007333A2382AE45E14854_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4D48BAB266F85C77824FCE82B4FC410F" xlink:label="Fact-4D48BAB266F85C77824FCE82B4FC410F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FE6A287B78BE528BBE4346AC51AFCEFD" xlink:label="Fact-FE6A287B78BE528BBE4346AC51AFCEFD_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1BC451E6BA6D5F5B846EA0C8F6C7019C_lbl" xlink:to="Footnote-9EF2308A74FC3FE51C51BD7E93FB85CC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3CB35C90514CF70295DBBD7E93E865CA_lbl" xlink:to="Footnote-9EF2308A74FC3FE51C51BD7E93FB85CC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-498EAB2A0D1E594E942FB1AFF11FC8F9_lbl" xlink:to="Footnote-9EF2308A74FC3FE51C51BD7E93FB85CC_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4BBFA26AAC9007333A2382AE45E14854_lbl" xlink:to="Footnote-6D0201EB71ECF377A19D196D7E3AACFF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4D48BAB266F85C77824FCE82B4FC410F_lbl" xlink:to="Footnote-6D0201EB71ECF377A19D196D7E3AACFF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FE6A287B78BE528BBE4346AC51AFCEFD_lbl" xlink:to="Footnote-6D0201EB71ECF377A19D196D7E3AACFF_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-6D0201EB71ECF377A19D196D7E3AACFF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for the year ended December&#160;31, 2018 include the transition adjustment for the adoption of Topic 842.</link:footnote>
		<link:footnote xlink:label="Footnote-9EF2308A74FC3FE51C51BD7E93FB85CC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities. During the year ended December&#160;31, 2018, there was a tax benefit of $0.2 million related to other comprehensive income as a result of the release of our valuation allowance for our deferred tax assets; there was no income tax benefit or provision related to other comprehensive income (loss) during the remaining periods presented.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>exel-20181228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20181228" xmlns:exel="http://www.exelixis.com/20181228" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20181228_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20181228_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20181228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20181228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2105100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsGrossUnrealizedLossesDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails">
        <link:definition>2405405 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2405404 - Disclosure - Cash and Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2405402 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails">
        <link:definition>2405406 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails">
        <link:definition>2405403 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2305301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails">
        <link:definition>2403414 - Disclosure - Collaboration Agreements Collaboration Agreements (Merck, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenueTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesBmsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails">
        <link:definition>2403415 - Disclosure - Collaboration Agreements (Collaboration Revenues - BMS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails">
        <link:definition>2403411 - Disclosure - Collaboration Agreements (Collaboration Revenues - Daiichi Sankyo) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesMerckDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails">
        <link:definition>2403413 - Disclosure - Collaboration Agreements (Collaboration Revenues - Merck) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDaiichiSankyoNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails">
        <link:definition>2403412 - Disclosure - Collaboration Agreements (Daiichi Sankyo, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInvenraCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails">
        <link:definition>2403410 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.exelixis.com/role/Commitments">
        <link:definition>2114100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails">
        <link:definition>2414403 - Disclosure - Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsComponentsOfLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails">
        <link:definition>2414404 - Disclosure - Commitments (Components of Lease Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsLeasesNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails">
        <link:definition>2414402 - Disclosure - Commitments (Leases Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails">
        <link:definition>2414406 - Disclosure - Commitments (Letters of Credit and Restricted Cash Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>2414405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.exelixis.com/role/CommitmentsTables">
        <link:definition>2314301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2113100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>2413402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2313301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2111100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>2411402 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2411405 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails">
        <link:definition>2411404 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails">
        <link:definition>2411403 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>2411406 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exelixis.com/role/IncomeTaxesTables">
        <link:definition>2311301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2106100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetails" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails">
        <link:definition>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetailsCalc2" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2">
        <link:definition>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2306301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2112100 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>2412402 - Disclosure - Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareNarrativeDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails">
        <link:definition>2412404 - Disclosure - Net Income (Loss) Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails">
        <link:definition>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
        <link:definition>2401406 - Disclosure - Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails">
        <link:definition>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Condensed Consolidated Balance Sheet) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails">
        <link:definition>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Consolidated Statements of Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2107100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2307301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2119100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails">
        <link:definition>2419402 - Disclosure - Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2319301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details">
        <link:definition>2402407 - Disclosure - Revenues (Changes in Contract Assets and Liabilities under Topic 606) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2110100 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2410402 - Disclosure - Stock-based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2410403 - Disclosure - Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails">
        <link:definition>2410405 - Disclosure - Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails">
        <link:definition>2410407 - Disclosure - Stock-based Compensation (Summary of All RSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails">
        <link:definition>2410406 - Disclosure - Stock-based Compensation (Summary of All Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2310301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails">
        <link:definition>2410404 - Disclosure - Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" name="AdditionalDevelopmentAndRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AdditionalUpfrontAndMilestonePayments" name="AdditionalUpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AkarnaTherapeuticsLtd.Member" name="AkarnaTherapeuticsLtd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AlamedaCaliforniaMember" name="AlamedaCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AreaOfRealEstatePropertyAvailableToLease" name="AreaOfRealEstatePropertyAvailableToLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" name="CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalandOperatingLeasesNumberofRenewalOptions" name="CapitalandOperatingLeasesNumberofRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CashAndRestrictedCashMember" name="CashAndRestrictedCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ChangeInContractWithCustomerAssetCurrentRollForward" name="ChangeInContractWithCustomerAssetCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" name="ChangeinContractwithCustomerAssetNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" name="ChangeinContractwithCustomerLiabilityCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" name="ChangeinContractwithCustomerLiabilityNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChargebacksAndDiscountsForPromptPaymentMember" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossfromAgreement" name="CollaborativeArrangementIncomeLossfromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale" name="CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithInvenraMember" name="CollaborativeArrangementWithInvenraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithStemSynergyMember" name="CollaborativeArrangementWithStemSynergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithBMSMember" name="CollaborativeArrangementwithBMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithDaiichiSankyoMember" name="CollaborativeArrangementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithMerckMember" name="CollaborativeArrangementwithMerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollateralProvidedForPurchasingCardProgram" name="CollateralProvidedForPurchasingCardProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CommercialPresenceInMarketsWorldwideMember" name="CommercialPresenceInMarketsWorldwideMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentOtherAdjustments" name="ContractWithCustomerAssetCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" name="ContractWithCustomerAssetNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityCurrentDeductions" name="ContractWithCustomerLiabilityCurrentDeductions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" name="ContractWithCustomerLiabilityCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityNoncurrentDeductions" name="ContractWithCustomerLiabilityNoncurrentDeductions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" name="ContractWithCustomerLiabilityNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CostMethodInvestmentOwnershipPercentage" name="CostMethodInvestmentOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtInstrumentNumberofInstruments" name="DebtInstrumentNumberofInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" name="DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DefinedContributionPlanNumberofSharesAvailableforGrant" name="DefinedContributionPlanNumberofSharesAvailableforGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_DevelopmentAndRegulatoryMilestoneMember" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiscoveryProjectMember" name="DiscoveryProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAFilingAcceptanceHCCMember" name="EMAFilingAcceptanceHCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" name="EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_EquipmentAndFurnitureMember" name="EquipmentAndFurnitureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinalTierMember" name="FinalTierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinancingLeaseLiabilitiesAbstract" name="FinancingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_FinancingObligation" name="FinancingObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_FirstProductToReachMarketMember" name="FirstProductToReachMarketMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlobalMember" name="GlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseAccruedClinicalLiabilities" name="IncreaseDecreaseAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" name="IncreaseDecreaseInLeaseLiabilityNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInRebatesAndFeesPayable" name="IncreaseDecreaseInRebatesAndFeesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseinAccruedCollaborationLiability" name="IncreaseDecreaseinAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InitialMember" name="InitialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_InventoryManufacturedBeforeRegulatoryApproval" name="InventoryManufacturedBeforeRegulatoryApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" name="LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" name="LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" name="MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveAxis" name="MilestoneObjectiveAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveDomain" name="MilestoneObjectiveDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsEarned" name="MilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_MinimumNumberOfClinicalTrials" name="MinimumNumberOfClinicalTrials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiability" name="OperatingAndFinanceLeasesLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityLongTerm" name="OperatingAndFinanceLeasesLiabilityLongTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingLeaseAndFinancingObligation" name="OperatingLeaseAndFinancingObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesAbstract" name="OperatingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" name="OperatingLeaseLiabilitiesDurationOfMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingLeaseObligation" name="OperatingLeaseObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingLeaseObligationCurrent" name="OperatingLeaseObligationCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingLeaseObligationNoncurrent" name="OperatingLeaseObligationNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCollaborationMember" name="OtherCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCustomersMember" name="OtherCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherGeographicalAreasMember" name="OtherGeographicalAreasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OwnershipInterestByMinorityShareholder" name="OwnershipInterestByMinorityShareholder" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_PaymentsforConversionofConvertibleDebt" name="PaymentsforConversionofConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentOfRoyaltyOnNetSale" name="PercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceShareOptionsPSOMember" name="PerformanceShareOptionsPSOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceStockOptionsMember" name="PerformanceStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PeriodOfSpecificSalesVolumeThreshold" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductCommercializationMember" name="ProductCommercializationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductGrossMember" name="ProductGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedfromCabozantinibMember" name="ProductsDerivedfromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" name="ProfitSharingAgreementOptionalPercentOfTotalSalesForce" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementPercentOfProfits" name="ProfitSharingAgreementPercentOfProfits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementProfitThreshold" name="ProfitSharingAgreementProfitThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierOneMember" name="ProfitSharingTierOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierThreeMember" name="ProfitSharingTierThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierTwoMember" name="ProfitSharingTierTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersAxis" name="ProfitSharingTiersAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersDomain" name="ProfitSharingTiersDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProjectInitiationFeePayment" name="ProjectInitiationFeePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PropertyPlantAndEquipmentAdditionsAndTransfers" name="PropertyPlantAndEquipmentAdditionsAndTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsAdvisoryFeesPaid" name="RelatedPartyTransactionsAdvisoryFeesPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ResearchandDevelopmentMember" name="ResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_RightofUseAssetAmortization" name="RightofUseAssetAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_RoyaltyTier" name="RoyaltyTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltyTierAxis" name="RoyaltyTierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierDomain" name="RoyaltytierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SalesDiscountsAndAllowancesMember" name="SalesDiscountsAndAllowancesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenuePercentDiscountForPromptPayment" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SecondMember" name="SecondMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SecuredConvertibleNotesDueJune2018Member" name="SecuredConvertibleNotesDueJune2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SouthSanFranciscoCaliforniaMember" name="SouthSanFranciscoCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" name="StandbyLetterOfCreditRelatedToBuildingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" name="StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontPayments" name="UpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" name="WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>exel-20181228_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20181228.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20181228.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20181228.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20181228.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20181228.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20181228.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20181228.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20181228.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20181228.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20181228.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20181228.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20181228.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20181228.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20181228.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20181228.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20181228.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20181228.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:href="exel-20181228.xsd#InventoryScheduleOfInventoryDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20181228.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20181228.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20181228.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20181228.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20181228.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20181228.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20181228.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20181228.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20181228.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20181228.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20181228.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5ad2bd9a-8a3d-b589-f487-66423fdb193d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_97b62833-0a42-058f-3886-4b4d65c49079" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5ad2bd9a-8a3d-b589-f487-66423fdb193d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_97b62833-0a42-058f-3886-4b4d65c49079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_db9e5922-2e70-406b-1ac3-0318ebdc102f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5ad2bd9a-8a3d-b589-f487-66423fdb193d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_db9e5922-2e70-406b-1ac3-0318ebdc102f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5fba5b8c-f33f-c8fe-316d-96157b5eaddf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9dc7d38b-d1f1-ee4c-83ca-bf0de39ac02c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5fba5b8c-f33f-c8fe-316d-96157b5eaddf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9dc7d38b-d1f1-ee4c-83ca-bf0de39ac02c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_540feb58-a104-9e2c-e527-965521238e74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5fba5b8c-f33f-c8fe-316d-96157b5eaddf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_540feb58-a104-9e2c-e527-965521238e74" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_EDD8732A3320174BB059E384B5B57AA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_EDD8732A3320174BB059E384B5B57AA6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_EDD8732A3320174BB059E384B5B57AA6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_50FA706CCFFB071CBF38E38724A2E506" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_50FA706CCFFB071CBF38E38724A2E506" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_37D093EB511C24BE8B62E37F6C22B9B1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_50FA706CCFFB071CBF38E38724A2E506" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_37D093EB511C24BE8B62E37F6C22B9B1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_819AE53938EED0E40ED35F3FBECA86F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiability_819AE53938EED0E40ED35F3FBECA86F7" xlink:to="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_f8462fb4-d805-7572-eefc-3247d0b39ea6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiability_819AE53938EED0E40ED35F3FBECA86F7" xlink:to="loc_us-gaap_FinanceLeaseLiability_f8462fb4-d805-7572-eefc-3247d0b39ea6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1396153e-4fa1-90ea-08ee-fec369a9d7aa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f8462fb4-d805-7572-eefc-3247d0b39ea6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1396153e-4fa1-90ea-08ee-fec369a9d7aa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a2966f09-089c-308f-404f-2425a9943c5c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f8462fb4-d805-7572-eefc-3247d0b39ea6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a2966f09-089c-308f-404f-2425a9943c5c" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseAndFinancingObligation" xlink:label="loc_exel_OperatingLeaseAndFinancingObligation_63A01019F3627CF6527F01369DDF697F" xlink:type="locator" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligation" xlink:label="loc_exel_OperatingLeaseObligation_387303143B7DCA15AA3D013473C3AF82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingLeaseAndFinancingObligation_63A01019F3627CF6527F01369DDF697F" xlink:to="loc_exel_OperatingLeaseObligation_387303143B7DCA15AA3D013473C3AF82" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationCurrent" xlink:label="loc_exel_OperatingLeaseObligationCurrent_821A3D0F47DEFC41280201323FC7CE74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingLeaseObligation_387303143B7DCA15AA3D013473C3AF82" xlink:to="loc_exel_OperatingLeaseObligationCurrent_821A3D0F47DEFC41280201323FC7CE74" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationNoncurrent" xlink:label="loc_exel_OperatingLeaseObligationNoncurrent_8846FFB0A6E59393067C0133E2526020" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingLeaseObligation_387303143B7DCA15AA3D013473C3AF82" xlink:to="loc_exel_OperatingLeaseObligationNoncurrent_8846FFB0A6E59393067C0133E2526020" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinancingObligation" xlink:label="loc_exel_FinancingObligation_53B82A8944C0332729A4873F5324B4B9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingLeaseAndFinancingObligation_63A01019F3627CF6527F01369DDF697F" xlink:to="loc_exel_FinancingObligation_53B82A8944C0332729A4873F5324B4B9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_f08a7953-47bc-6d58-e55f-aa8ab4131b72" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:to="loc_us-gaap_OperatingLeaseCost_f08a7953-47bc-6d58-e55f-aa8ab4131b72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_2317d2f1-d2dd-7935-e8f7-d1cdeade960b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:to="loc_us-gaap_VariableLeaseCost_2317d2f1-d2dd-7935-e8f7-d1cdeade960b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_72a2a52d-40f7-d0f1-973c-653a09af02ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:to="loc_us-gaap_SubleaseIncome_72a2a52d-40f7-d0f1-973c-653a09af02ec" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3a0c6ffb-47c2-45d0-2849-d495af322c78" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3a0c6ffb-47c2-45d0-2849-d495af322c78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_de07b845-be4f-d00e-5843-e6abacc85b7f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_de07b845-be4f-d00e-5843-e6abacc85b7f" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_c7cc5ac7-440a-da11-55a9-d495af540045" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_c7cc5ac7-440a-da11-55a9-d495af540045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B8671B784F17471C6D57C64EFA41947C" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B8671B784F17471C6D57C64EFA41947C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5212eab8-bedb-997a-101c-3c3b65fbee4f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5212eab8-bedb-997a-101c-3c3b65fbee4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_82393af8-00cf-c878-caac-887e4fcb1248" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_LongTermInvestments_82393af8-00cf-c878-caac-887e4fcb1248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6544a746-9524-1b61-e235-04d48d39f116" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6544a746-9524-1b61-e235-04d48d39f116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_99289045-641b-e134-789c-dbf0b6bfb577" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_99289045-641b-e134-789c-dbf0b6bfb577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_6a9d7275-5213-3bff-10b0-bd7eaf4e6f67" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_exel_PaymentsforConversionofConvertibleDebt_6a9d7275-5213-3bff-10b0-bd7eaf4e6f67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_9d96fe52-eed0-e442-4c00-33d2270f0962" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_9d96fe52-eed0-e442-4c00-33d2270f0962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2d1473c-d06a-7053-5039-5cb1510f932e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2d1473c-d06a-7053-5039-5cb1510f932e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_384520b7-32ac-fc30-c0af-ad6e58ee8c3e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_384520b7-32ac-fc30-c0af-ad6e58ee8c3e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_37008172-d4a9-0abe-2f55-538227757e8a" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_37008172-d4a9-0abe-2f55-538227757e8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_852a0148-80e8-01e7-45e2-04986579e466" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_852a0148-80e8-01e7-45e2-04986579e466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_366aa09e-f759-b63b-77e0-83ad3a947a55" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_366aa09e-f759-b63b-77e0-83ad3a947a55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_9ed0673e-74ec-09d4-e879-d495afb657f3" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_9ed0673e-74ec-09d4-e879-d495afb657f3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_98E327BAAF0BA68645CBAD5222652B77" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_98E327BAAF0BA68645CBAD5222652B77" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_054deb55-d794-f036-6d0f-d495afd08d32" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_054deb55-d794-f036-6d0f-d495afd08d32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_629DFD90D245106E3E63AD488876CDA5" xlink:type="locator" />
    <link:calculationArc order="22" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_629DFD90D245106E3E63AD488876CDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="23" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RightofUseAssetAmortization" xlink:label="loc_exel_RightofUseAssetAmortization_6D61A814ABCFC0DABD7E0815996C5B14" xlink:type="locator" />
    <link:calculationArc order="24" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_exel_RightofUseAssetAmortization_6D61A814ABCFC0DABD7E0815996C5B14" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_927f3a49-3cce-f44d-2750-b82061b05961" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestIncomeOther_927f3a49-3cce-f44d-2750-b82061b05961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b4dece9a-8c95-7770-52f2-bc14b57aa839" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b4dece9a-8c95-7770-52f2-bc14b57aa839" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_298e3cc3-7605-e96f-85bd-bd7eaf594695" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_298e3cc3-7605-e96f-85bd-bd7eaf594695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_e7fc24f5-9cf4-0219-5e82-84d266913d5f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_e7fc24f5-9cf4-0219-5e82-84d266913d5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0e2dc226-85ed-d782-cf37-e83741c371ce" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0e2dc226-85ed-d782-cf37-e83741c371ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3e7fd080-3ec6-50fa-98f3-b61bc68dbdcf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3e7fd080-3ec6-50fa-98f3-b61bc68dbdcf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_403b8245-2a5c-b405-4865-11cfdebd2992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_46fd3e47-b379-3d5b-dad7-1fdc5e88b67f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2fc8d554-3ed0-9aae-a23b-3842180d9904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_7c88fa1f-0edb-d24c-9b87-0646da5010cf" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_7c88fa1f-0edb-d24c-9b87-0646da5010cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_dccbbcdf-3af2-54ab-0e51-b4372916415d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_dccbbcdf-3af2-54ab-0e51-b4372916415d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_147896db-b2dd-402f-9f5b-8c57c745a45a" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_2b6b2464-f484-e738-fa9e-bd7eaf3e4255" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_2b6b2464-f484-e738-fa9e-bd7eaf3e4255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1c8f4a72-9556-38d6-3d32-089e2d1a35fe" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_aec9630a-9e19-cd8f-8217-90be7ac55d44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryRawMaterials_aec9630a-9e19-cd8f-8217-90be7ac55d44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_9a39fd9b-6ecf-21de-0dc6-98f2a03e9440" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryWorkInProcess_9a39fd9b-6ecf-21de-0dc6-98f2a03e9440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4e166bbb-377c-800b-7f59-05671dfec1ab" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c874fd7d-1c88-8feb-a9e1-2ace184ce14d" xlink:to="loc_us-gaap_InventoryFinishedGoods_4e166bbb-377c-800b-7f59-05671dfec1ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>exel-20181228_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20181228.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20181228.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20181228.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20181228.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20181228.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20181228.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20181228.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20181228.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20181228.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20181228.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20181228.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20181228.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20181228.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20181228.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20181228.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20181228.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20181228.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20181228.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20181228.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20181228.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20181228.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20181228.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20181228.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20181228.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20181228.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20181228.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20181228.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20181228.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_33BE4E73481E4BFA0C6D8313C47C0E73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_33BE4E73481E4BFA0C6D8313C47C0E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_FFE97DF54D5CA9E0EDDC8313C48260F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_FFE97DF54D5CA9E0EDDC8313C48260F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0BC57EC249E367BBBDD583303CB539CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_CommercialPaperMember_0BC57EC249E367BBBDD583303CB539CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:to="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:to="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:to="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:to="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsAdvisoryFeesPaid" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:to="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B08F7AD95DA8788572D0F8F1D31D54E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B08F7AD95DA8788572D0F8F1D31D54E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6659A740787E27D9F5D7F8F1D320D3A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CommercialPaperMember_6659A740787E27D9F5D7F8F1D320D3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_B4059983343AEA3CE014F8F1D3209CEE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_B4059983343AEA3CE014F8F1D3209CEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_5F6F71C36F676C4E177AF8F1D32082EE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_5F6F71C36F676C4E177AF8F1D32082EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_D07F7FBDE73524E48C89F8F1D320475D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CertificatesOfDepositMember_D07F7FBDE73524E48C89F8F1D320475D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_9D5E6ED6C0AAC1F93137015E9C97B314" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_9D5E6ED6C0AAC1F93137015E9C97B314" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:to="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D7BA20355B836CFAB3C7DF7017068C83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D7BA20355B836CFAB3C7DF7017068C83" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2547F72297BEDEA369DDFED765CEF8D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2547F72297BEDEA369DDFED765CEF8D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E3A96F22B96DBF2F2C2CFED765EA81F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E3A96F22B96DBF2F2C2CFED765EA81F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:to="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:to="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:to="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:to="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_071EFAF14C703FF37BF3015E9D249049" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_071EFAF14C703FF37BF3015E9D249049" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_330F460043F725D853CEDF70171FB35F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_330F460043F725D853CEDF70171FB35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73765E484F5E29E7B774DF701720A097" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73765E484F5E29E7B774DF701720A097" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_EA88AB8640AF37D70C59FED765E3E39F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_EA88AB8640AF37D70C59FED765E3E39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:to="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:to="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:to="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9646C9365FFA4B98AFE2FF2904E7EC01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:to="loc_srt_MaximumMember_9646C9365FFA4B98AFE2FF2904E7EC01" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_26EC87BF407381D08347FED765E4CACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_26EC87BF407381D08347FED765E4CACC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_E8A78E3F4BAEDF6CC954FF27DEE2A5A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_E8A78E3F4BAEDF6CC954FF27DEE2A5A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:to="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:to="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:to="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_187DCAF1714721266F28015E9D3B5013" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_UpfrontAndMilestonePayments_187DCAF1714721266F28015E9D3B5013" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3890B2A29489B6BA2C4D015E9D3C30ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3890B2A29489B6BA2C4D015E9D3C30ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:to="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:to="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_C544F46E7C473796D502FF357FF7DA7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_C544F46E7C473796D502FF357FF7DA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_3FA29D8EC428F141B06AFF357F4EB658" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_3FA29D8EC428F141B06AFF357F4EB658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_FEC54D7FD33FB8E132C9FF357FA3AC72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_FEC54D7FD33FB8E132C9FF357FA3AC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_163C123494108990514CFED7664D71E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:to="loc_srt_RangeMember_163C123494108990514CFED7664D71E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:to="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:to="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:to="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:to="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:to="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:to="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:to="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_E8B344D3B7E4A0F25B0BFED76650CCEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:to="loc_exel_GlaxoSmithKlineMember_E8B344D3B7E4A0F25B0BFED76650CCEA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_4FBF9451F5D6A1996E30FED76651C1B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_MilestonePaymentsEarned_4FBF9451F5D6A1996E30FED76651C1B6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_C0A5E49ECEE31B187BA6FED76651A14A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_C0A5E49ECEE31B187BA6FED76651A14A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_7FA01BAA13A5BA186CB2FED766517DBF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_7FA01BAA13A5BA186CB2FED766517DBF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:to="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:to="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_756603CBA958539336F806388395CF71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_756603CBA958539336F806388395CF71" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_2FBEA1096BE9DD528DC506388395DA85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_2FBEA1096BE9DD528DC506388395DA85" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_8E25ED8EE065033E6C14063883953D5D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_8E25ED8EE065033E6C14063883953D5D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_3F784CF8B6C95DDA5ECC06388395B27D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_3F784CF8B6C95DDA5ECC06388395B27D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_43C7195397B56501E51306388395D128" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_GlaxoSmithKlineMember_43C7195397B56501E51306388395D128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:to="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:to="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_822A091CE9ACD772F24406388396030A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:to="loc_exel_GlaxoSmithKlineMember_822A091CE9ACD772F24406388396030A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:to="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:to="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E8E24A3767070F329AB90638839791E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:to="loc_srt_MaximumMember_E8E24A3767070F329AB90638839791E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2CE28762B69462B2ED8C06388397D06B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:to="loc_srt_MinimumMember_2CE28762B69462B2ED8C06388397D06B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_A7DF19910345BBAC6DF506388398E71E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_A7DF19910345BBAC6DF506388398E71E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_469FC2E6E1274C53EDAC06388398087E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_469FC2E6E1274C53EDAC06388398087E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_892362776D5D121E6ED406388398227D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_892362776D5D121E6ED406388398227D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_38E0D7D41E113DFAA6C6063883992674" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_us-gaap_RoyaltyExpense_38E0D7D41E113DFAA6C6063883992674" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MinimumNumberOfClinicalTrials" xlink:label="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:to="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:to="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:to="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:to="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:to="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:to="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:to="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:to="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:to="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_6F6A3A4C451CA0F530AB015E9DAED033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_6F6A3A4C451CA0F530AB015E9DAED033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:to="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:to="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_39B46E587588E8553BCD015E9DAFC1AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:to="loc_srt_MinimumMember_39B46E587588E8553BCD015E9DAFC1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FEB7FED6222A63CE9ED6015E9DB04FAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:to="loc_srt_MaximumMember_FEB7FED6222A63CE9ED6015E9DB04FAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:to="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:to="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_D07C06DE0AB31F49F09F015E9DB1D3F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:to="loc_exel_InitialMember_D07C06DE0AB31F49F09F015E9DB1D3F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_4B624815C4F080DEE2CA015E9DB138E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:to="loc_exel_FinalTierMember_4B624815C4F080DEE2CA015E9DB138E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:to="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:to="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:to="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:to="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_5374952B4F3699C9E861015E9DB3AAE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_UpfrontPayments_5374952B4F3699C9E861015E9DB3AAE7" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_1BD5BB201B662D9BBCB8015E9DB31DA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_MilestonePaymentsEarned_1BD5BB201B662D9BBCB8015E9DB31DA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_CCFC68BD4EDA30831925015E9DB4C431" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_CCFC68BD4EDA30831925015E9DB4C431" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_69973759010603009EEE015E9DB48C5B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_69973759010603009EEE015E9DB48C5B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_F1D583B60A0DB7650071015E9DB4A0C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_F1D583B60A0DB7650071015E9DB4A0C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_8C8912AD1965A4324B7D015E9DB4870C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_RoyaltyTier_8C8912AD1965A4324B7D015E9DB4870C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_B014366FCF04118A7B92015E9DB56BCC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_B014366FCF04118A7B92015E9DB56BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4B0128AE5575CCE27406015E9DB5CF00" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4B0128AE5575CCE27406015E9DB5CF00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_EF50DBBA7E32E525E127015E9DB5A446" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_us-gaap_ContractWithCustomerLiability_EF50DBBA7E32E525E127015E9DB5A446" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3E60559DCAAD9691D583015E9DB53237" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3E60559DCAAD9691D583015E9DB53237" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:to="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:to="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:to="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:to="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:to="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:to="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:to="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:to="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:to="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:to="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:to="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_B6E8469177ED9364AFDF0137631C9AE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:to="loc_exel_CollaborationMember_B6E8469177ED9364AFDF0137631C9AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E477B14A62765A4212FB0137631D9D9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E477B14A62765A4212FB0137631D9D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B5C4FDF236306986BA290137631EEE9B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B5C4FDF236306986BA290137631EEE9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_963F027B77C63D3DAC1C0137631F3D4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_InterestExpense_963F027B77C63D3DAC1C0137631F3D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07A56AF8104F47D2B9B801376320F055" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_07A56AF8104F47D2B9B801376320F055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0218FF9C2E9931E4D0640137632008EE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_NetIncomeLoss_0218FF9C2E9931E4D0640137632008EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_4D6F087100CBC6A74A1A013763206140" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_EarningsPerShareBasic_4D6F087100CBC6A74A1A013763206140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_99FE78058FB1B4E9E76D01376320AE0F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_EarningsPerShareDiluted_99FE78058FB1B4E9E76D01376320AE0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:to="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_FC2A29AF74837D7148511656286A040B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_FC2A29AF74837D7148511656286A040B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_97654719B948B81A77F41656286A7969" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_97654719B948B81A77F41656286A7969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:to="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:to="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_855DE420A1858EDAB4D11656286DB17E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_855DE420A1858EDAB4D11656286DB17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:to="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:to="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:to="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_306AA1A4868FE46C448680A8FD47D690" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_306AA1A4868FE46C448680A8FD47D690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_E10619628EBFD6C24BA6F83D4784C4F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_LaboratoryEquipmentMember_E10619628EBFD6C24BA6F83D4784C4F1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_146014E84C96E24996A1F83D4785867B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_146014E84C96E24996A1F83D4785867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1C290570021B062560F9F83D47851900" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1C290570021B062560F9F83D47851900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:to="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:to="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:to="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5730F6E946A536D1CC25F83D47862EA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:to="loc_srt_MinimumMember_5730F6E946A536D1CC25F83D47862EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16CFF4BED69DCCAA27E5F83D478663D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:to="loc_srt_MaximumMember_16CFF4BED69DCCAA27E5F83D478663D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:to="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:to="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:to="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_007ABE10059CCBC609530638852922A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_007ABE10059CCBC609530638852922A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_226B536D55011E04322B0638852977D5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_226B536D55011E04322B0638852977D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9324C3C7D3BFCE397D550638852A0826" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9324C3C7D3BFCE397D550638852A0826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84B56FD093D7DC8286310638852A5F26" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84B56FD093D7DC8286310638852A5F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_616B3C7358B521D71D5C0638852AB5A6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_616B3C7358B521D71D5C0638852AB5A6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FAAA687F529AC72290F10638852A59D0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FAAA687F529AC72290F10638852A59D0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_EA6C15957239F3AB37C6128DAA954C01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_EA6C15957239F3AB37C6128DAA954C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A5DDE2657F785771438E128DAA95F4EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A5DDE2657F785771438E128DAA95F4EC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" xlink:label="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_85C020BCE02E25682079128DAA9C6769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_85C020BCE02E25682079128DAA9C6769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_98C639B391F3EF9F2084128DAA9DBFA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_98C639B391F3EF9F2084128DAA9DBFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:to="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:to="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:to="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858D05874B0DED528AB7128DAA9E0D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858D05874B0DED528AB7128DAA9E0D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:type="locator" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:to="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:to="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CommercialPresenceInMarketsWorldwideMember" xlink:label="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:to="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_E45954767A26B3D7E86F163C48ABCD8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_E45954767A26B3D7E86F163C48ABCD8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0CC653AF36A572AC2E94163C48ABD22E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0CC653AF36A572AC2E94163C48ABD22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_B403A7B200AE9B56B062163C48ACF4AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_B403A7B200AE9B56B062163C48ACF4AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:to="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:to="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_CD37481D95F4CB2694E2163C48AD5D8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:to="loc_srt_RestatementAdjustmentMember_CD37481D95F4CB2694E2163C48AD5D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_F9F5E4235B177B3880A2163C48B32010" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_F9F5E4235B177B3880A2163C48B32010" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:to="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:to="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_40475FF8C3D8C5125729163C48B4F40C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:to="loc_exel_GlaxoSmithKlineMember_40475FF8C3D8C5125729163C48B4F40C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_AE464C756A3306DF7484163C48B6B180" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_AE464C756A3306DF7484163C48B6B180" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:to="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:to="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:to="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_C7E193AB6CACD944D554063882B7F872" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:to="loc_exel_AlamedaCaliforniaMember_C7E193AB6CACD944D554063882B7F872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:to="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_EA15B9F52E5784C9A638063882B9070C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_EA15B9F52E5784C9A638063882B9070C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:to="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:to="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:to="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:to="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:to="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:to="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:to="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2358780A5D8144F2B6D6DF97B3A91BDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:to="loc_srt_RestatementAdjustmentMember_2358780A5D8144F2B6D6DF97B3A91BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5143A8C455C01418CA3ADF97B3A9A27C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5143A8C455C01418CA3ADF97B3A9A27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8E2382D0402870D2D0BE0CFAC1DBED0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8E2382D0402870D2D0BE0CFAC1DBED0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_19C5D98DF27ABB3FCE770CFAC1DB9B63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_19C5D98DF27ABB3FCE770CFAC1DB9B63" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:to="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:to="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:to="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:to="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:to="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:to="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:to="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:to="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:to="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:to="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:to="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:to="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EBAD0728881B4E98FABA165627780473" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EBAD0728881B4E98FABA165627780473" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:to="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:to="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:to="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908F84C4E6C5F0AECAD7DF70175C73D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908F84C4E6C5F0AECAD7DF70175C73D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FC9DA44D6DC999218106DF701768BAF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FC9DA44D6DC999218106DF701768BAF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:to="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:to="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A5886E73FC13E580BA45BD7EDDBDF6B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A5886E73FC13E580BA45BD7EDDBDF6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_C86DE2B5E21BC599C9E8BD7EDDBD7AD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:to="loc_us-gaap_EmployeeStockMember_C86DE2B5E21BC599C9E8BD7EDDBD7AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:to="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A80C7BDF194CFAA3113606388221D352" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A80C7BDF194CFAA3113606388221D352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:to="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3428EF8EDDDA40EB2E07BD7EDFB87132" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3428EF8EDDDA40EB2E07BD7EDFB87132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_A034C7525BE8160C2774BD7EDFB8416E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:to="loc_us-gaap_EmployeeStockMember_A034C7525BE8160C2774BD7EDFB8416E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>exel-20181228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C_terseLabel_en-US" xlink:label="lab_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C_label_en-US" xlink:label="lab_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTextBlock" xlink:label="loc_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:to="lab_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:to="lab_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:to="lab_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:to="lab_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:to="lab_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:to="lab_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:to="lab_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:to="lab_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17_terseLabel_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17_label_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17_documentation_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:to="lab_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2_terseLabel_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Options [Member]</link:label>
    <link:label id="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2_label_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Options [Member]</link:label>
    <link:label id="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2_documentation_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Stock Options [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:to="lab_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life of stock options granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:to="lab_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise threshold, percentage of per share exercise price of the PSO</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF_verboseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of employee options vested and expensed</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expensed, Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, vested and expensed, fair value.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options in vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan, employee contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contributions for first 3% of participant contributions (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of participant contributions into the 401(k) Retirement Plan (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="arc" />
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9_terseLabel_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance under 401(k) Retirement Plan (in shares)</link:label>
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9_label_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Number of Shares Available for Grant</link:label>
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9_documentation_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:to="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:to="lab_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:to="lab_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:to="lab_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:to="lab_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44_verboseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:to="lab_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:to="lab_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) matching contributions made in common stock</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:type="arc" />
    <link:label id="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94_terseLabel_en-US" xlink:label="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94_label_en-US" xlink:label="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94_documentation_en-US" xlink:label="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RightofUseAssetAmortization" xlink:label="loc_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:to="lab_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid in kind</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:to="lab_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E_label_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:to="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due customers</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:to="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E_label_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:to="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:to="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on financing lease obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:type="arc" />
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79_negatedTerseLabel_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on conversion of convertible notes</link:label>
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79_label_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Conversion of Convertible Debt</link:label>
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79_documentation_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Conversion of Convertible Debt</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:to="lab_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:to="lab_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activity:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment deemed to have been acquired in build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:to="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred to acquire Property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:to="lab_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:to="lab_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B_label_en-US" xlink:label="lab_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:to="lab_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175_label_en-US" xlink:label="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175_documentation_en-US" xlink:label="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:to="lab_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E_label_en-US" xlink:label="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E_documentation_en-US" xlink:label="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:to="lab_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="lab_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="lab_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:to="lab_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:to="lab_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:to="lab_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723_label_en-US" xlink:label="lab_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:to="lab_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:to="lab_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:to="lab_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C_label_en-US" xlink:label="lab_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:to="lab_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76_label_en-US" xlink:label="lab_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:to="lab_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:to="lab_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:to="lab_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9_terseLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8_label_en-US" xlink:label="lab_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:to="lab_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:to="lab_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="lab_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:to="lab_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:to="lab_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:to="lab_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:to="lab_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAxis_98CA423C3DA7885680850638852024D9_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_98CA423C3DA7885680850638852024D9_label_en-US" xlink:label="lab_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:to="lab_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="arc" />
    <link:label id="lab_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90_label_en-US" xlink:label="lab_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:to="lab_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:to="lab_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:to="lab_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847_verboseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets: unbilled collaboration revenue, gross: Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets: unbilled collaboration revenue, gross: Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:to="lab_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7_terseLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:to="lab_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D_label_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:to="lab_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3_label_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:to="lab_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="arc" />
    <link:label id="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09_terseLabel_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Product To Reach Market</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09_label_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09_documentation_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:to="lab_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:to="lab_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:to="lab_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="arc" />
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3_terseLabel_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional upfront and milestone payments</link:label>
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3_label_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Upfront And Milestone Payments</link:label>
    <link:label id="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3_documentation_en-US" xlink:label="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Upfront And Milestone Payments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:to="lab_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:to="lab_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:to="lab_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="arc" />
    <link:label id="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955_terseLabel_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alameda, California</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955_label_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955_documentation_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:to="lab_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="arc" />
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F_terseLabel_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F_label_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F_documentation_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:to="lab_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="arc" />
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E_terseLabel_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of property available for lease (in squire feet)</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E_label_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E_documentation_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:to="lab_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="arc" />
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC_terseLabel_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC_label_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Renewal Options</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC_documentation_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Renewal Options</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:to="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:to="lab_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:to="lab_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:to="lab_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:to="lab_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:to="lab_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="arc" />
    <link:label id="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D_terseLabel_en-US" xlink:label="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Calculated Under Guidance In Effect Before Topic 606 And Topic 842 [Member]</link:label>
    <link:label id="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D_label_en-US" xlink:label="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated Under Guidance In Effect Before Topic 606 And Topic 842 [Member]</link:label>
    <link:label id="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D_documentation_en-US" xlink:label="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Calculated Under Guidance In Effect Before Topic 606 And Topic 842 [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" xlink:label="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:to="lab_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC_terseLabel_en-US" xlink:label="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC_label_en-US" xlink:label="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC_documentation_en-US" xlink:label="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:to="lab_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:to="lab_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E_label_en-US" xlink:label="lab_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:to="lab_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:to="lab_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:to="lab_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:to="lab_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37_label_en-US" xlink:label="lab_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:to="lab_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:to="lab_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book over tax depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:type="arc" />
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred stock compensation &#8211; non-qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets amortization of deferred stock compensation - non-qualified.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:to="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:to="lab_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="arc" />
    <link:label id="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0_terseLabel_en-US" xlink:label="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Presence in Markets Worldwide</link:label>
    <link:label id="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0_label_en-US" xlink:label="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Presence In Markets Worldwide [Member]</link:label>
    <link:label id="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0_documentation_en-US" xlink:label="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Presence In Markets Worldwide [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CommercialPresenceInMarketsWorldwideMember" xlink:label="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:to="lab_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C_label_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C_documentation_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:to="lab_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-18</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-18 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:to="lab_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="arc" />
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74_terseLabel_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74_label_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC [Member]</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74_documentation_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:to="lab_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:to="lab_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:to="lab_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in net cash provided by investing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:to="lab_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:to="lab_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="arc" />
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01_terseLabel_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory expensed as research and development, not capitalized as inventory</link:label>
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01_label_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Manufactured Before Regulatory Approval</link:label>
    <link:label id="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01_documentation_en-US" xlink:label="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Manufactured Before Regulatory Approval</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:to="lab_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Adoption of Topic 606 and Topic 842</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:type="arc" />
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200_verboseLabel_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200_label_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</link:label>
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200_documentation_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:to="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (provision)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Ipsen</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7_label_en-US" xlink:label="lab_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:to="lab_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_163C123494108990514CFED7664D71E1_terseLabel_en-US" xlink:label="lab_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_163C123494108990514CFED7664D71E1_label_en-US" xlink:label="lab_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:to="lab_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8_label_en-US" xlink:label="lab_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:to="lab_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA_label_en-US" xlink:label="lab_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:to="lab_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57_label_en-US" xlink:label="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57_documentation_en-US" xlink:label="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:to="lab_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90_label_en-US" xlink:label="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="lab_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final tier</link:label>
    <link:label id="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49_label_en-US" xlink:label="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49_documentation_en-US" xlink:label="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:to="lab_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="arc" />
    <link:label id="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E_terseLabel_en-US" xlink:label="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E_label_en-US" xlink:label="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E_documentation_en-US" xlink:label="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:to="lab_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="arc" />
    <link:label id="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD_terseLabel_en-US" xlink:label="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second</link:label>
    <link:label id="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD_label_en-US" xlink:label="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD_documentation_en-US" xlink:label="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:to="lab_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1_label_en-US" xlink:label="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1_documentation_en-US" xlink:label="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:to="lab_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB_label_en-US" xlink:label="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB_documentation_en-US" xlink:label="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:to="lab_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:to="lab_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="arc" />
    <link:label id="lab_country_US_52C10224C57E8CBA3BD1DF70175C557F_terseLabel_en-US" xlink:label="lab_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_52C10224C57E8CBA3BD1DF70175C557F_label_en-US" xlink:label="lab_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:to="lab_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA_label_en-US" xlink:label="lab_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:to="lab_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="arc" />
    <link:label id="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5_terseLabel_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
    <link:label id="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5_label_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Geographical Areas [Member]</link:label>
    <link:label id="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5_documentation_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Geographical Areas [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:to="lab_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:to="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="arc" />
    <link:label id="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152_terseLabel_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and restricted cash</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152_label_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152_documentation_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:to="lab_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D7FA20182BCA2E45393FF8FF0B251340" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_B31F926A7365348518A3F8FF0B262334" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:to="lab_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="arc" />
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4_terseLabel_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Warrants [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4_label_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4_documentation_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:to="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:type="arc" />
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472_label_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472_documentation_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="lab_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19_terseLabel_en-US" xlink:label="lab_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19_label_en-US" xlink:label="lab_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:to="lab_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906_label_en-US" xlink:label="lab_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:to="lab_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:to="lab_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:to="lab_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:to="lab_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A_label_en-US" xlink:label="lab_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:to="lab_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:to="lab_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:to="lab_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB_label_en-US" xlink:label="lab_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:to="lab_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:to="lab_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:to="lab_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C_label_en-US" xlink:label="lab_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:to="lab_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:to="lab_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10_label_en-US" xlink:label="lab_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:to="lab_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:to="lab_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:to="lab_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:to="lab_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:to="lab_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letters of credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:to="lab_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="arc" />
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7_terseLabel_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workers Compensation Insurance Policy</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7_label_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7_documentation_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:to="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="arc" />
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49_terseLabel_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building lease</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49_label_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Building Lease [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49_documentation_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Building Lease [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:to="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of letters of credit entered into (in debt instruments)</link:label>
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242_label_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Instruments</link:label>
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242_documentation_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Instruments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:to="lab_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="arc" />
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6_terseLabel_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral provided for purchasing card program</link:label>
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6_label_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Provided For Purchasing Card Program</link:label>
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6_documentation_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collateral Provided For Purchasing Card Program</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:to="lab_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:type="arc" />
    <link:label id="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76_terseLabel_en-US" xlink:label="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery Project</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76_label_en-US" xlink:label="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76_documentation_en-US" xlink:label="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:to="lab_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="arc" />
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A_terseLabel_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A_label_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A_documentation_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:to="lab_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="arc" />
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD_terseLabel_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD_label_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD_documentation_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:to="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="arc" />
    <link:label id="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D_terseLabel_en-US" xlink:label="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Commercialization</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D_label_en-US" xlink:label="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D_documentation_en-US" xlink:label="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:to="lab_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Invenra</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Invenra [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement With Invenra [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:to="lab_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="arc" />
    <link:label id="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6_terseLabel_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project initiation fee</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6_label_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6_documentation_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:to="lab_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B_label_en-US" xlink:label="lab_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="lab_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="lab_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:to="lab_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:to="lab_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:to="lab_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update (ASU) No. 2016-09, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:to="lab_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on warrant exercise (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:type="arc" />
    <link:label id="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8_terseLabel_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8_label_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:label id="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8_documentation_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment And Furniture [Member].</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:to="lab_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:to="lab_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="arc" />
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A_verboseLabel_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deerfield Notes [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A_label_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A_documentation_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:to="lab_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:to="lab_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potentially dilutive shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:type="arc" />
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580_terseLabel_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture and Fixtures, Computer Equipment and Software</link:label>
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580_label_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture And Fixtures, Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580_documentation_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture And Fixtures, Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:to="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9_label_en-US" xlink:label="lab_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:to="lab_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="arc" />
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C_terseLabel_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress capitalized</link:label>
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C_label_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Additions And Transfers</link:label>
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C_documentation_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Additions And Transfers</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:to="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets and Liabilities under Topic 606</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:type="arc" />
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D_terseLabel_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D_label_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D_documentation_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:to="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for royalties on sales under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:to="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:to="lab_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2018 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2018 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options outstanding at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) allocable to common stock for basic net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment to net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) allocable to common stock for diluted net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:to="lab_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:to="lab_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF_label_en-US" xlink:label="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation, Current</link:label>
    <link:label id="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF_documentation_en-US" xlink:label="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation, Current</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationCurrent" xlink:label="loc_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:to="lab_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1_label_en-US" xlink:label="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation, Noncurrent</link:label>
    <link:label id="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1_documentation_en-US" xlink:label="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation, Noncurrent</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationNoncurrent" xlink:label="loc_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:to="lab_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:to="lab_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4_totalLabel_en-US" xlink:label="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4_label_en-US" xlink:label="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation</link:label>
    <link:label id="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4_documentation_en-US" xlink:label="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Obligation</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligation" xlink:label="loc_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:to="lab_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:type="arc" />
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51_terseLabel_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities:</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51_label_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51_documentation_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:to="lab_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:type="arc" />
    <link:label id="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4_terseLabel_en-US" xlink:label="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing obligation for build-to-suit lease</link:label>
    <link:label id="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4_label_en-US" xlink:label="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Obligation</link:label>
    <link:label id="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4_documentation_en-US" xlink:label="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Obligation</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_FinancingObligation" xlink:label="loc_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:to="lab_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:to="lab_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1_totalLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:to="lab_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24_totalLabel_en-US" xlink:label="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24_label_en-US" xlink:label="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease And Financing Obligation</link:label>
    <link:label id="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease And Financing Obligation</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseAndFinancingObligation" xlink:label="loc_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:to="lab_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:to="lab_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:to="lab_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:to="lab_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="lab_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring (recovery) charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:to="lab_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:to="lab_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:to="lab_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:to="lab_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:to="lab_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:to="lab_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory included in Other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:to="lab_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="lab_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:to="lab_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:to="lab_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:to="lab_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2_label_en-US" xlink:label="lab_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:to="lab_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:to="lab_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274_label_en-US" xlink:label="lab_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:to="lab_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359_terseLabel_en-US" xlink:label="lab_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359_label_en-US" xlink:label="lab_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:to="lab_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64_terseLabel_en-US" xlink:label="lab_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64_label_en-US" xlink:label="lab_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:to="lab_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="arc" />
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC_terseLabel_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd.</link:label>
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC_label_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd. [Member]</link:label>
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC_documentation_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd. [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:to="lab_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263_label_en-US" xlink:label="lab_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="lab_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on sale of cost method investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530_terseLabel_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on sale of cost method investment</link:label>
    <link:label id="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530_label_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost-method Investments, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:to="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="arc" />
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0_terseLabel_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost method investment ownership percentage</link:label>
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0_label_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0_documentation_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:to="lab_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="arc" />
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45_terseLabel_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership interest by BlackRock (more than)</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45_label_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Interest By Minority Shareholder</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45_documentation_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minority Ownership, Ownership Interest</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:to="lab_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees for advisory services paid to BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Paid</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Paid</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsAdvisoryFeesPaid" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:to="lab_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal income tax (provision) benefit at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">State tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-deductible interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:type="arc" />
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD_negatedTerseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341" xlink:to="lab_us-gaap_OperatingLeaseCost_204EA2238378095AFA627C403DFD6341" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A" xlink:to="lab_us-gaap_VariableLeaseCost_F5ED9AC9D3977C128DB67C403DFEFE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904" xlink:to="lab_us-gaap_SubleaseIncome_41B8AC9E18A6A799EA287C403DFE9904" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9_label_en-US" xlink:label="lab_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9" xlink:to="lab_us-gaap_LeaseCost_1BC5D63A2DD43A01A1667C403DFEDDF9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA_label_en-US" xlink:label="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA_documentation_en-US" xlink:label="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:to="lab_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:to="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB_verboseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balances Without the Adoption of Topic 606</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="arc" />
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90_terseLabel_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Current Portion</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90_label_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90_documentation_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:to="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfer to receivables from contract assets recognized at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Reclassified to Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:to="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:to="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Current Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:to="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85_negatedTerseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Deductions</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Deductions</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:to="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:to="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:to="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8_negatedTerseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Deductions</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Deductions</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:to="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:to="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C_label_en-US" xlink:label="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C_documentation_en-US" xlink:label="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:to="lab_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C.</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:to="lab_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:to="lab_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="arc" />
    <link:label id="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E_terseLabel_en-US" xlink:label="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others, individually less than 10% of Total revenues for all periods presented</link:label>
    <link:label id="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E_label_en-US" xlink:label="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:label id="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E_documentation_en-US" xlink:label="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:to="lab_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA_label_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA_documentation_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:to="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:type="arc" />
    <link:label id="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E_terseLabel_en-US" xlink:label="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global</link:label>
    <link:label id="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E_label_en-US" xlink:label="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E_documentation_en-US" xlink:label="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:to="lab_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="arc" />
    <link:label id="lab_country_JP_C9221E3946618CA04F23015E9DB205CC_terseLabel_en-US" xlink:label="lab_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_C9221E3946618CA04F23015E9DB205CC_label_en-US" xlink:label="lab_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:to="lab_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="arc" />
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales volume period</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:to="lab_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:type="arc" />
    <link:label id="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45_label_en-US" xlink:label="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45_documentation_en-US" xlink:label="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:to="lab_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="arc" />
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A_terseLabel_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A_label_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A_documentation_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:to="lab_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_24729069CEB186755D731656277759B2_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="lab_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A_label_en-US" xlink:label="lab_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:to="lab_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services revenues</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:to="lab_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="arc" />
    <link:label id="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E_terseLabel_en-US" xlink:label="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration revenues</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E_label_en-US" xlink:label="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E_documentation_en-US" xlink:label="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:to="lab_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0_negatedTerseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Awards outstanding at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Awards outstanding at December 31, 2018</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:to="lab_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:to="lab_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5_label_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:to="lab_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF_label_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="lab_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD_label_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:to="lab_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357_label_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:to="lab_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF_label_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:to="lab_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share of the Company in promotions</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:to="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:to="lab_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:to="lab_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56_verboseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sales</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="arc" />
    <link:label id="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF_terseLabel_en-US" xlink:label="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of clinical trials (more than)</link:label>
    <link:label id="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF_label_en-US" xlink:label="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Number Of Clinical Trials</link:label>
    <link:label id="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF_documentation_en-US" xlink:label="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum Number Of Clinical Trials</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_MinimumNumberOfClinicalTrials" xlink:label="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:to="lab_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones upon first arm's-length sale</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones Upon First Sale</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones Upon First Sale</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net loss resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit) related to other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126_label_en-US" xlink:label="lab_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:to="lab_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:to="lab_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250_netLabel_en-US" xlink:label="lab_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:to="lab_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Years ending December 31,</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE_negatedTerseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:to="lab_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>exel-20181228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20181228.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20181228.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20181228.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20181228.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20181228.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20181228.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20181228.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:href="exel-20181228.xsd#CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:href="exel-20181228.xsd#CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20181228.xsd#CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20181228.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20181228.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20181228.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20181228.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20181228.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20181228.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20181228.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20181228.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20181228.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20181228.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20181228.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20181228.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20181228.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20181228.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20181228.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20181228.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20181228.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20181228.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20181228.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20181228.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20181228.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20181228.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20181228.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20181228.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20181228.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20181228.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20181228.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20181228.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20181228.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20181228.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20181228.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTextBlock" xlink:label="loc_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EAADEDE73D751B65370EBD8390546FDB" xlink:to="loc_invest_InvestmentTextBlock_F9A939D7E98DF2C3178DBD8390546F1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0C7AD78B1C2D826094058313C47B1EC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0C7AD78B1C2D826094058313C47B1EC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C3EBCBCD9A9580E6A2B38313C47CA09E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_33BE4E73481E4BFA0C6D8313C47C0E73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_33BE4E73481E4BFA0C6D8313C47C0E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_FFE97DF54D5CA9E0EDDC8313C48260F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_FFE97DF54D5CA9E0EDDC8313C48260F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0BC57EC249E367BBBDD583303CB539CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27F566410CDFED2CDA6E8313C47C122A" xlink:to="loc_us-gaap_CommercialPaperMember_0BC57EC249E367BBBDD583303CB539CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_A7CE2D1CD6E23E49EBBC8313C47C5093" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_B720686D420C57E73D4F8313C4839340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8CCC1FF844550A8C9D458313C4831487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8898C8DB8CD37B6472618313C4821AC7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A41259CB62F334D887158313C483B6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7758FC7CEEFE67366EF78313C482740A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_55456CB9C915CB7571AB8313C484B26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_AE9367DB1CA3A9D9C1108313C48403B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_B3437D7B044071ED79B78313C4834475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_22B87C80976752728F888313C484F8E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E87287CC5B8BE69A2105063882FAC2CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E87287CC5B8BE69A2105063882FAC2CC" xlink:to="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:to="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentAxis_CDDA656E2115F37F7FA7063882FBE359" xlink:to="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentDomain_F3B881D01B4801ABB566063882FB2F64" xlink:to="loc_exel_AkarnaTherapeuticsLtd.Member_CBDEF638693D25C8E3E6063882FC4EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_B095EA3535E718C992EE063882FAC274" xlink:to="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_9D87276F194EC178CB20063882FD5F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_88F65EFAAEDA5EDE0C9C063882FD9E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_D2CAC0A12BFBE48818B7063882FD195B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_BE129766FB707AD94B0F068FBD6AA9BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_70169B340D8914AF07AF063882FD1530" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_CostMethodInvestmentOwnershipPercentage_B842382D99B15F8233F5063882FECFA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_OwnershipInterestByMinorityShareholder_C431007F3C66DB8BFD59063882FE9D45" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_FFD42A8DC732D6289DA7063882FEEC26" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_4B2804AF16D10A70B50A063882FE9481" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RelatedPartyTransactionsAdvisoryFeesPaid" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_8515C57E6D0C73959469063882FC7263" xlink:to="loc_exel_RelatedPartyTransactionsAdvisoryFeesPaid_DE43C322BB87B59280FB063882FF0C3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5E1C0DDC4EC2EAD956C8163C47639A37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2C09065D9B2613F1964D163C47638291" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5E1C0DDC4EC2EAD956C8163C47639A37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2C09065D9B2613F1964D163C47638291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_C84CBBD883FCEDC6DC06164D9D299908" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5E1C0DDC4EC2EAD956C8163C47639A37" xlink:to="loc_us-gaap_RestrictedCashCurrent_C84CBBD883FCEDC6DC06164D9D299908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_A8CC737BFB5CF4C3C53C164DD984FED7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5E1C0DDC4EC2EAD956C8163C47639A37" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_A8CC737BFB5CF4C3C53C164DD984FED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5E1C0DDC4EC2EAD956C8163C47639A37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75EB7BFEAFDF3529D984163C47646FA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6F76E64F8208427BA8F5D37A0723A4D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6F76E64F8208427BA8F5D37A0723A4D6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED76C2EA13FC3E656E35D37A072376DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6F76E64F8208427BA8F5D37A0723A4D6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_362301AB3864A444CDF3D37A07231A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6F76E64F8208427BA8F5D37A0723A4D6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49A61F35F640C0B0990DD37A0723767A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8F314070002C3FB42873F8F1D3186114" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8F314070002C3FB42873F8F1D3186114" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:to="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_169F1DD77753D225A374F8F1D31CC43C" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B08F7AD95DA8788572D0F8F1D31D54E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B08F7AD95DA8788572D0F8F1D31D54E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6659A740787E27D9F5D7F8F1D320D3A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CommercialPaperMember_6659A740787E27D9F5D7F8F1D320D3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_B4059983343AEA3CE014F8F1D3209CEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_B4059983343AEA3CE014F8F1D3209CEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_5F6F71C36F676C4E177AF8F1D32082EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_5F6F71C36F676C4E177AF8F1D32082EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_exel_CashAndRestrictedCashMember_A90245DD5F503204CBA3F8F748A0E152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_D07F7FBDE73524E48C89F8F1D320475D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34BB5444F5F15E4B31F0F8F1D31DF474" xlink:to="loc_us-gaap_CertificatesOfDepositMember_D07F7FBDE73524E48C89F8F1D320475D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59E51050130A9B074F0DF8F1D31B2947" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4BAF1F4E4ABF2CF681F0F8F1D3215CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_DAB61B8D86D39EDC981CF8F1D3213ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1C160588321C04419482F8F1D32169CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_666EBBAA89E552F68DDDF8F1D32158C3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6B9878452DDB89D0355CF8F1D3229275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56B00E1AA8D107F07016F8F1FD7A5FDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56B00E1AA8D107F07016F8F1FD7A5FDB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_76BE309DAC9A9366193BF8F1D32276E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_431F1325E011DC5F083CF8FF0B1EB100" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_76BE309DAC9A9366193BF8F1D32276E2" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_AD8DD9E546091F857E53F8F1D323703F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_C1952B4FC0D14872176EF8F1D3219C80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_80492C6B56188EEC8332F8F1D32348F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_F4DC960952AC08972DFE832193A14E12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EC85D7738FD9E389B5D7832281C8293B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_34D708EFC0E5960D53828313C4BFE9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_A40C1B1383EBB4CEAC968313C4BFB705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7267503A9359AD4DF9428313C4BFD655" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B875D457CCA20FD1F5388313C4BF7B82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_507699821AD6131E9A8C976F0465F3BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_507699821AD6131E9A8C976F0465F3BA" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8BA59B3985BE74A03E4C976F04666249" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationAgreementsMerckNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0407BF02BC9A98740588015E9C9592C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0407BF02BC9A98740588015E9C9592C3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1B01898C564BEE3468A9015E9C96BA0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_9D5E6ED6C0AAC1F93137015E9C97B314" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A18C67871C636477AA73015E9C966C59" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_9D5E6ED6C0AAC1F93137015E9C97B314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44C84C82146BF98FE526015E9C95D84F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_B44A1BF5BCEE6EC4359A015E9C983C07" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0723B336E5519F6A484F015E9C97B1BD" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_E94C78DE3128BE4FD8CC015E9C981F32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD98226830EDC887015EDF70170484F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD98226830EDC887015EDF70170484F9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:to="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45548F12B122F7DA09ADDF7017059AFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1267AB926B4DE68235C8DF7017054ADB" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_95A288C2301717B5E913DF7017059DA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_219FB17E2525E00D20BFDF701704E516" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D7BA20355B836CFAB3C7DF7017068C83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CF1655A983450912DBF8DF701706FA5C" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D7BA20355B836CFAB3C7DF7017068C83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8FF535F4C6AB7643D145FED765CD4F45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8FF535F4C6AB7643D145FED765CD4F45" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EAA0DD9C58BBF66BA22FED765CD8317" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B9EDD2991C082627FEECFED765CDF9B4" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_B7C8408A7CE1D5B5BCE9FED765CE0936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A438C477AC17686E773BFED765CD9F8B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2547F72297BEDEA369DDFED765CEF8D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D9768289C95D5BD9D35FED765CEF138" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2547F72297BEDEA369DDFED765CEF8D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_467567914DD3E636F9C1FED765E884D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_467567914DD3E636F9C1FED765E884D4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20CB8CD3FAF6A615D639FED765E94AFA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BFCB066D036775B08B45FED765E921BC" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_79442875711227536544FED765EAADE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3FDA214C563F9097D38AFED765E85441" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E3A96F22B96DBF2F2C2CFED765EA81F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_927C281C3276F3907DF9FED765EA5E28" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E3A96F22B96DBF2F2C2CFED765EA81F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47F7F803B6BA66D860BB015E9D185644" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47F7F803B6BA66D860BB015E9D185644" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5C6179CC4FFB45F37187015E9D1917E4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7F853E21C91A8F57E488015E9D1A38AA" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_7376A981AF5798F8AAC1015E9D1AE860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:to="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B3280F9EEC3894FD9C38015E9D1B71DE" xlink:to="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B5269337BDCEAF10263D015E9D1B3F32" xlink:to="loc_exel_CotellicMember_03C0EAD32F5B772FD517015E9D2229FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B436C174CE0461219B7D015E9D192003" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_B5FF833D22BC3F6C7EBD015E9D24ADD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_071EFAF14C703FF37BF3015E9D249049" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BFA0F51BF56BEE72209F015E9D23FCB1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_071EFAF14C703FF37BF3015E9D249049" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C8CA8FC13D7A28FFCFD3DF70171EF22C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C8CA8FC13D7A28FFCFD3DF70171EF22C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21CA61F9815CC9D9297DDF70171F440E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_330F460043F725D853CEDF70171FB35F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DF1D046A7A671CBD6CADF70171F68FC" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_330F460043F725D853CEDF70171FB35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FBDF4A4B07FD6B34E751DF70171EDDFE" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73765E484F5E29E7B774DF701720A097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_027AA9E0ADE14EAB5728DF7017203C0F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73765E484F5E29E7B774DF701720A097" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98963D23CB95F7238DA0FED765DB51F2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76ED933146DC767FDC5FFED765DCE52D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BD4B9515CE5A650457BFFED765DC2870" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_F8FB97FD5E12C7474A78FED765DC2CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6B02990ACEA06C669A4FFED765DBFAB0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D0C2BC60AE1B6FCEC623FED765DD5D9B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3EE6540E971452ED4438FED765DDC779" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_850925B7D07CFDCE0205FED765E2189A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_850925B7D07CFDCE0205FED765E2189A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43284734F3B404BDF959FED765E29D64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_EA88AB8640AF37D70C59FED765E3E39F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D311A53AB54EB4FF529EFED765E24E62" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_EA88AB8640AF37D70C59FED765E3E39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:to="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76341017B12CE8652EC2FF28DF090C44" xlink:to="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9646C9365FFA4B98AFE2FF2904E7EC01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_EC2FB86F56C620663699FF28DF0EC424" xlink:to="loc_srt_MaximumMember_9646C9365FFA4B98AFE2FF2904E7EC01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BA6A0F1C018D009291F4FED765E276BE" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_26EC87BF407381D08347FED765E4CACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_26EC87BF407381D08347FED765E4CACC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale_906FA7BB1E35C52F8B45FF2A708C8651" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_E8A78E3F4BAEDF6CC954FF27DEE2A5A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B8BDB2778EB07D1CDF51FED765E4F63D" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_E8A78E3F4BAEDF6CC954FF27DEE2A5A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00C449292ADE8D783F05015E9D352506" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00C449292ADE8D783F05015E9D352506" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:to="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_90EEC9FB5950B023A4AF015E9D372660" xlink:to="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_DiscoveryProjectMember_A60350BA8825A1ABC538015E9D37CC76" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_0626BAC3D26F62368BC7015E9D380F1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_C3C85339EA2C12CAE788015E9D38F9AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_92CBA8F6D5508802871D015E9D373FF1" xlink:to="loc_exel_ProductCommercializationMember_5368CB98DF4601B37C9F015E9D39F79D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0573D5A041196BC5AEAF015E9D394C0D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_247C1BFE92001AE20619015E9D391BF4" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_A6FDAFB82A37A03B30C6015E9D3AF7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8AA3B5AD7D5FF00B2996015E9D36A4A5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_187DCAF1714721266F28015E9D3B5013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_UpfrontAndMilestonePayments_187DCAF1714721266F28015E9D3B5013" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3890B2A29489B6BA2C4D015E9D3C30ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_3890B2A29489B6BA2C4D015E9D3C30ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67D7CBA7279EA4860A1C015E9D3A1E2E" xlink:to="loc_exel_ProjectInitiationFeePayment_6AD77B67970CA772F8FC015E9D43A0D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6D1E899C52B893D9B67AFED7664C6CE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6D1E899C52B893D9B67AFED7664C6CE7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_AAFD5D3D24C03BC6590BFF357EB74E0A" xlink:to="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_C544F46E7C473796D502FF357FF7DA7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_0D5F21EC46BB9BDD03AEFF357EB99E6A" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_C544F46E7C473796D502FF357FF7DA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_57D6C361948A66A859C7FF357E6AFD3C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_3FA29D8EC428F141B06AFF357F4EB658" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_6763FB5F92CC181FB684FF357E6C6B4B" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_3FA29D8EC428F141B06AFF357F4EB658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44E274F94502EA08FC15FF357E42A062" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_FEC54D7FD33FB8E132C9FF357FA3AC72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F808B55BF3C0816844EBFF357E4537C7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_FEC54D7FD33FB8E132C9FF357FA3AC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AA91B2EB34814CCBDE3DFED7664C693A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D3DD177330D7A13E0119FED7664C2429" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_C656741E6BDE7314CC5EFED7664DD47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ABBCE82E16ACD00D412FFED7664D71D7" xlink:to="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:to="loc_srt_MinimumMember_83E1B6E11E30CAA0AA0CFED7664E0FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_163C123494108990514CFED7664D71E1" xlink:to="loc_srt_MaximumMember_90D98E61F4BC58C8F1A1FED7664EF9FA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_6646223A0E78F0F68EEFFED7664E2F57" xlink:to="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_FinalTierMember_89629F7543A34AFEE154FED7664F1C49" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_InitialMember_0FE487E1D1BEC0593C75FED7664FF92E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4DA9F5A8CE578DADE62EFED7664EAD90" xlink:to="loc_exel_SecondMember_FC32CE54FE6A1DF50F46FED7664FD1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_D5E2B2EB873BD0A8AF4DFED7664FC945" xlink:to="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_E8B344D3B7E4A0F25B0BFED76650CCEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85C617F37B5542528FA8FED7664F8594" xlink:to="loc_exel_GlaxoSmithKlineMember_E8B344D3B7E4A0F25B0BFED76650CCEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E68706A1A54EB48B5DEDFED7664CBEB5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_7BEA6C6C0BE5B843A406FED76650B7D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_UpfrontPayments_60B249009304643646A9FED766516DD1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_4FBF9451F5D6A1996E30FED76651C1B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_MilestonePaymentsEarned_4FBF9451F5D6A1996E30FED76651C1B6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_C0A5E49ECEE31B187BA6FED76651A14A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_C0A5E49ECEE31B187BA6FED76651A14A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C748155D63EFAC479BCFED76651B41A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_7FA01BAA13A5BA186CB2FED766517DBF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_7FA01BAA13A5BA186CB2FED766517DBF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_RoyaltyTier_DC2E82C9405F8E650835FED7665186AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_E6043EE7B01316B74DB3FED76651FD72" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_FCEC2737A57422C0006FFED76652291D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC92DE363FD660C4A6D0FED76650DF10" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4A7BFE329E54128C6BB5FED76652A6A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A1D6A6B468CCA6F6240C063883915311" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A1D6A6B468CCA6F6240C063883915311" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersAxis_5CDAC079466F74C2CC3D0638839261D5" xlink:to="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierOneMember_BCAD87D36C54E76D46A006388393F0CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierTwoMember_906CCC7EE38F7417B60F06388393D357" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_16B366D81CC594C69303063883932CAF" xlink:to="loc_exel_ProfitSharingTierThreeMember_5AD9D72DF93F6995C58306388393D5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C1E8F0EC75D7D7A752D706388394C17C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_756603CBA958539336F806388395CF71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_756603CBA958539336F806388395CF71" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_2FBEA1096BE9DD528DC506388395DA85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_2FBEA1096BE9DD528DC506388395DA85" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_8E25ED8EE065033E6C14063883953D5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_8E25ED8EE065033E6C14063883953D5D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_3F784CF8B6C95DDA5ECC06388395B27D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_3F784CF8B6C95DDA5ECC06388395B27D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_43C7195397B56501E51306388395D128" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E8C2D24117E5D61FBB8063883944DAD" xlink:to="loc_exel_GlaxoSmithKlineMember_43C7195397B56501E51306388395D128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_FC01D6D94CB028BA0D6606388396D6E3" xlink:to="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FE22F09998807C763F1406388396EB94" xlink:to="loc_exel_GlaxoSmithKlineMember_43C7195397B56501E51306388395D128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_FE4153456746E770754A06388396C9F0" xlink:to="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E8E24A3767070F329AB90638839791E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:to="loc_srt_MaximumMember_E8E24A3767070F329AB90638839791E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2CE28762B69462B2ED8C06388397D06B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5A793D8389A8B095FFA06388397089A" xlink:to="loc_srt_MinimumMember_2CE28762B69462B2ED8C06388397D06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A7299FFEBC84752912FA063883928699" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5DAAEF31F580DBAEFEB0638839752F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_18D9408EB9D35FC18AFC06388398510B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_49D6D880E7D42FD3E7D706388398479C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_A7DF19910345BBAC6DF506388398E71E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_A7DF19910345BBAC6DF506388398E71E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_469FC2E6E1274C53EDAC06388398087E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_469FC2E6E1274C53EDAC06388398087E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_892362776D5D121E6ED406388398227D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_892362776D5D121E6ED406388398227D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_D18DB4B25940B3B9E7C406388399AF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_38E0D7D41E113DFAA6C6063883992674" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_us-gaap_RoyaltyExpense_38E0D7D41E113DFAA6C6063883992674" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MinimumNumberOfClinicalTrials" xlink:label="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A20353DB6B53C9F53D8306388397F0DA" xlink:to="loc_exel_MinimumNumberOfClinicalTrials_FA8799E96791C88EC54506388399AFEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E577E2598947F82E2FF015E9D7146DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E577E2598947F82E2FF015E9D7146DC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:to="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_C9F60D3842A8280C475A015E9D727C59" xlink:to="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8DA2645CEF120DED0E35015E9D727051" xlink:to="loc_exel_GlaxoSmithKlineMember_79103E5F569883CF6E74015E9D736DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6999FDD1B8E8B9740708015E9D73C47B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_E86BAF076D3348F142FF015E9D748232" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32BE7C18C137C597F93F015E9D742727" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_342F403A964219981986015E9D7594A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F5A59348D897027E8553015E9D71444B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_FD0F234FFA314C119C8E015E9D753020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42A8981836D101198EF1015E9D75370E" xlink:to="loc_us-gaap_RoyaltyExpense_37A5D47719950F940E7E015E9D762460" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FA611B9834BE25084F39015E9D544FB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FA611B9834BE25084F39015E9D544FB0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:to="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_FC76B9D2184120B2DE7E015E9D55E76D" xlink:to="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_823E3DE8F89DACFB5D77015E9D56C4B3" xlink:to="loc_exel_FirstProductToReachMarketMember_56EDA4232695D9CD25C3015E9D576E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D7E63159FB3FF3B3A00015E9D5C3759" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AC50B602C8C23EE67E4E015E9D5CE881" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_6194518A50507798632C015E9D5DC277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_17CF8CEEB4AC61ABADD2015E9D5571D8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_UpfrontAndMilestonePayments_AD0574345A359EC885DF015E9D5DDB14" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AdditionalUpfrontAndMilestonePayments" xlink:label="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_AdditionalUpfrontAndMilestonePayments_DBE8E0BE1241CF03918F015E9D5EECF3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FBDEE2C64E6119A4EAC6015E9D5DEECD" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2913C67BE7188146BC7E015E9D5E8772" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7BEF0C7417B9C1CC4950D0DFF0AD9A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7BEF0C7417B9C1CC4950D0DFF0AD9A9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3DB42E377B53F2828D5F0D0DFF0AD655" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E2E0E21CA2C27E02E241015E9DAC5B44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E2E0E21CA2C27E02E241015E9DAC5B44" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19245920864A87836FE6015E9DAD65EA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_6F6A3A4C451CA0F530AB015E9DAED033" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84BF642B039EF71633F1015E9DAD619D" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_6F6A3A4C451CA0F530AB015E9DAED033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_07AE0C08AEAB906C98CA015E9DAF6605" xlink:to="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_39B46E587588E8553BCD015E9DAFC1AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:to="loc_srt_MinimumMember_39B46E587588E8553BCD015E9DAFC1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FEB7FED6222A63CE9ED6015E9DB04FAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8C02466B75C6729701B3015E9DAFC1D1" xlink:to="loc_srt_MaximumMember_FEB7FED6222A63CE9ED6015E9DB04FAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTierAxis" xlink:label="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_215F498F7DC03322A2D1015E9DB0F795" xlink:to="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_D07C06DE0AB31F49F09F015E9DB1D3F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:to="loc_exel_InitialMember_D07C06DE0AB31F49F09F015E9DB1D3F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_4B624815C4F080DEE2CA015E9DB138E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_1935F8E2A08AD1AF5C20015E9DB0E67A" xlink:to="loc_exel_FinalTierMember_4B624815C4F080DEE2CA015E9DB138E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ED47D3F72859E936E16A015E9DB1464F" xlink:to="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:to="loc_exel_GlobalMember_86417CDE9BA54FA679F3015E9DB2485E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AA2BEE7D272485B0C618015E9DB2F34E" xlink:to="loc_country_JP_C9221E3946618CA04F23015E9DB205CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4D5E7194C071092D0C0F015E9DADE8AE" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_5374952B4F3699C9E861015E9DB3AAE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_UpfrontPayments_5374952B4F3699C9E861015E9DB3AAE7" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_1BD5BB201B662D9BBCB8015E9DB31DA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_MilestonePaymentsEarned_1BD5BB201B662D9BBCB8015E9DB31DA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_CCFC68BD4EDA30831925015E9DB4C431" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_CCFC68BD4EDA30831925015E9DB4C431" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_69973759010603009EEE015E9DB48C5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_69973759010603009EEE015E9DB48C5B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_F1D583B60A0DB7650071015E9DB4A0C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_F1D583B60A0DB7650071015E9DB4A0C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_8C8912AD1965A4324B7D015E9DB4870C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_RoyaltyTier_8C8912AD1965A4324B7D015E9DB4870C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_B014366FCF04118A7B92015E9DB56BCC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_B014366FCF04118A7B92015E9DB56BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4B0128AE5575CCE27406015E9DB5CF00" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4B0128AE5575CCE27406015E9DB5CF00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_EF50DBBA7E32E525E127015E9DB5A446" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_us-gaap_ContractWithCustomerLiability_EF50DBBA7E32E525E127015E9DB5A446" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3E60559DCAAD9691D583015E9DB53237" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3E60559DCAAD9691D583015E9DB53237" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_563F47793D11F1AC4316015E9DB38738" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF72E4F0C840654A7434015E9DB66FB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AA9BE1494B2357DE845ABD7EDD59B606" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AA9BE1494B2357DE845ABD7EDD59B606" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_E49119BD57B13BFDF247BD7EDD599B8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CE0539D33EA6D3A8CA211F22C98A091" xlink:type="locator" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CE0539D33EA6D3A8CA211F22C98A091" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_17DCF997D9BFA468CCCF11F22C983B23" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationCurrent" xlink:label="loc_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_exel_OperatingLeaseObligationCurrent_13DEEE9AEAA38206B9B111F22C990AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_D0EA04D8A406B74657D711F22C990E06" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligationNoncurrent" xlink:label="loc_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_exel_OperatingLeaseObligationNoncurrent_988EA729CAD6EF73DC4311F22C9A3AD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_us-gaap_OperatingLeaseLiability_1E1A0D9E18252793E77E11F22C9A7373" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseObligation" xlink:label="loc_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_946D4D8C59F31846FF2711F22C98678E" xlink:to="loc_exel_OperatingLeaseObligation_1222490E3A73B3B7C61711F22C9A51F4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CE0539D33EA6D3A8CA211F22C98A091" xlink:to="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_FinancingObligation" xlink:label="loc_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:to="loc_exel_FinancingObligation_C3C11AA8D72CB0972D4411F22C9A5DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_388C6D2AC32D7A36990011F22C9BBE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_068A1AB3064247EEB37211F22C9B9DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_C2411B38AAA42FD6A4E811F22C9ADF51" xlink:to="loc_us-gaap_FinanceLeaseLiability_1BA96E46233A710DBB0411F22C9B2273" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CE0539D33EA6D3A8CA211F22C98A091" xlink:to="loc_exel_OperatingAndFinanceLeasesLiability_C37D6B12AB2D82D5FD5611F22C9B9DF1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseAndFinancingObligation" xlink:label="loc_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CE0539D33EA6D3A8CA211F22C98A091" xlink:to="loc_exel_OperatingLeaseAndFinancingObligation_7F7ED96D6BFD2D44380311F22CA1ED24" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_073E9CAD10715F930D827C403DFA28DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_921C843BDFB651C27B477C3968488D22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_073E9CAD10715F930D827C403DFA28DA" xlink:to="loc_us-gaap_OperatingLeaseCost_921C843BDFB651C27B477C3968488D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_ADDBD34E2D3C380CC4B77C396848D723" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_073E9CAD10715F930D827C403DFA28DA" xlink:to="loc_us-gaap_VariableLeaseCost_ADDBD34E2D3C380CC4B77C396848D723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_6A0BC4B511D3C57595707C396848956E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_073E9CAD10715F930D827C403DFA28DA" xlink:to="loc_us-gaap_SubleaseIncome_6A0BC4B511D3C57595707C396848956E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_5BFFBF38B5030AF6FA557C39684889F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_073E9CAD10715F930D827C403DFA28DA" xlink:to="loc_us-gaap_LeaseCost_5BFFBF38B5030AF6FA557C39684889F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22EE9A701BF5BB2D00D706388197D6DD" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:to="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_D81B401ABA82CCCA657A0638819712F3" xlink:to="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:to="loc_exel_AlamedaCaliforniaMember_D941304E9636B7A70DFB06388198E955" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_18E069AB8C163959F33306388198DA64" xlink:to="loc_exel_SouthSanFranciscoCaliforniaMember_E2036F05F8E39C8B8C6B063881985C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5737261CC75253EFF21C06388197357A" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1ED7929EC8F7F51B2B010638819A9456" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_7FF0B51A6B5919E1F87A0638819A173A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AreaOfRealEstatePropertyAvailableToLease" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_5E2BA28E88585F5B16BF0638819A196E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_63A61C591616809F71A60638819A92AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeasePayments_D5186737A7432C9B8BBF0638819AF04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8E2844D8EF3B4050FD250638819A19B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DF5C7A63BD0DC253CF8306388199B011" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2298875B431B311FDD500638819B97F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CF28EB75A4BD27C36B0D37A05B6A831" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7CF28EB75A4BD27C36B0D37A05B6A831" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_CE8E7CF4D6E115ED1AA5D37A05B6AE66" xlink:to="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_445C6D42AE9AB80C0486D37A05B6A8D1" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_3D28C749BCB0B20A0876D37A05B73CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_E5695A760B6EF94D8E71D37A05B7E44C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_EEBD6B8034578A859F40D37A05B846E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC2E9672853DB6AB954CD37A05B7738E" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_885FCFBFDE29833DA88FD37A05B8EA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C0B1FF422348909A31F6D37A05B67615" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_exel_DebtInstrumentNumberofInstruments_0FB5FA9BBE34F25A1B1AD37A05B8B242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E30487D112B4F24D9919D37A05B9E1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_931044FBCA12061295A8D37A05B9F9FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3A1E87394BEBA1908511D37A05B8F2AA" xlink:to="loc_exel_CollateralProvidedForPurchasingCardProgram_F9FA0420A96587058920D37A05B989B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_666F83FB3CE9D4C8046EFED763C3F177" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_666F83FB3CE9D4C8046EFED763C3F177" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:to="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6345D33AE01881220674FED763C43246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_DC875AE557BC39E7F2C3FED763C58F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D6EC3D65E40210F4F8D3FED763C53000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_E44C5C85EC5D2B35263BFED763C5DC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_941ACE18B6F4A02E111CFED763C5739E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F0777DE1889A233E0EDAFED763C6B285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F16001E49574FAEE157BFED763C4CA0D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3F45A95D8997175279BDFED763C6E40C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_728AFBCDCD708C2D7446FED763C6441D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_F0CE97AECC38AADA2CBAFED763C6F5B6" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_3F9BA826052153AEAFE6FED763C7F7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92D63868A0AECAF359D7FED763C41FCD" xlink:to="loc_us-gaap_OperatingLeaseLiability_ED0763F294CFC0BF657AFED763C71A37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A0AA96E382D7563FE706976F0229ECCB" xlink:type="locator" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A0AA96E382D7563FE706976F0229ECCB" xlink:to="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_B473F26D16B696ADB5D7976F022904FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A0AA96E382D7563FE706976F0229ECCB" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_B874B3688BCC238EA0BA976F022ACCF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A0AA96E382D7563FE706976F0229ECCB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D91917DFF5A73EC65665976F022ABA33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:to="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4430698AB33AF0E07D18165628D4F982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_ShortTermInvestments_E8308B12FC67A9D9352B165628D4B7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_RestrictedCashCurrent_3FBA5567B58B01DDF8D5165628D47BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_ReceivablesNetCurrent_FE5AA43101A7D6A7F460165628D4B156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_11BFA5FF30685B2EE939165628D589E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_InventoryNet_878FCA01FC411DDEE97E165628D50723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_775CDA2E69573F368AF6165628D5CB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_EEA6438472A6D3089856165628D3A61D" xlink:to="loc_us-gaap_AssetsCurrent_4BD776CEA0DEADBFDBE9165628D5CDF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_LongTermInvestments_CDC5AAD147AC51CAD4B1165628D5F167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_A12B5EB5056985E08597165628D5F134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4FC76BC37B641FE745FD165628D616C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2A66AE38EDA8BF38CB93165628D6E326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_587B3D620F272E9B581D165628D68EC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_Goodwill_1DFBEAA1355A19D64D29165628D6868C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_04AE6F17EBC40DBB22FD165628D61C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_81697C9680B027A8301E165628D3D30C" xlink:to="loc_us-gaap_Assets_BFBC1E49B72238C72BA8165628D78C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_AccountsPayableCurrent_A737E998D3071D297472165628D7F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_2BD89F48D1969C614C70165628D73075" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_A87C29A5D8DEFDCF9B57165628D8FF86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_E68BACEC5946212A5634165628D89617" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_BB92EDAF337DE2A57269165628D80C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4D55D24D14464E685437165628D82217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8FF7F998A3FCA61B9FF0165628D8A99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_86647E3908382D2EC381165628D79DE5" xlink:to="loc_us-gaap_LiabilitiesCurrent_30BF3D04095E4F327FB2165628D8EEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8EF9225D4480C1C98EAD165628D9310A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_B473DE007033C01617F3165628D9EDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_598DFD0BFB90D610CD59165628D9B5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_us-gaap_Liabilities_F9DB1FAA12ED19D4DDE2165628D9A1F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9CEC53F6F75B7E109F0F165628D78D16" xlink:to="loc_us-gaap_CommitmentsAndContingencies_469DB8DA8E1495ACF937165628D9D3D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:to="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_PreferredStockValue_06425BF19421B57E6DDF165628DAE599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_CommonStockValue_6267E1510D9B3633F3D9165628DAB33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_AdditionalPaidInCapital_36DC6FA7F999D0565995165628DA16B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78393E4183ADAFF73ACD165628DA2DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DFAA2CB61C971D5CF16D165628DA6912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_01AD100874E18E4528C8165628D9D7BB" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3D93F0E81860DC77845D165628DBF25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_08D73B9C536904160502165628D3C719" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_B301E3CA386BF3A1366F165628DBD642" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A25EB581934A0454768ABD7EDDF4BFED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4905DE72AD168488CE69BD7EDDF4D9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7E2077DAF5A541921B30BD7EDDF47BA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_D717CA53542DC9DC018FBD7EDDF447E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A1E45E4E099614A8306DBD7EDDF5B744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_CommonStockSharesIssued_F2C77800E650BD71CF05BD7EDDF57DAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_EE8631294EC68F8809C4BD7EDDF35BEC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_163D25A862C9F0EFCFF3BD7EDDF51ECE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:to="loc_us-gaap_NetIncomeLoss_763642176FF7C4777E7C163B654608AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_18311A521D163B37EBE4163B65468B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_ShareBasedCompensation_B232B4629E3D6C76B531163B654787B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_D144B6D2523C72BDCC10163B6547FA27" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RightofUseAssetAmortization" xlink:label="loc_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_exel_RightofUseAssetAmortization_02CAE4EFBAB1138900FB163B6547DA94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_533F3C726C5904693B7F163B65477E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A8120DA7A64287FD97F6163B6547D2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0E28495A170AA5B2AF8B163B6548DF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_PaidInKindInterest_DA3D1C7802310D0CBA83163B6548F45C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6BF7D9D7484D4CF1DFDC163B654862E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_F628D622A5601BBC6C6F163B65487EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D13C0D73BB6F84A6E1BF163B65463E95" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46F939FA73757AC86E5B163B65480CEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_EFB0E8E2A4FF440E8ABB163B65492E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2CBFDF841E4E645B5F44163B6549A8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4A92C978C25688D9BD2E163B654990CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_331BC78E110D65DAD380163B65494E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D50EEDE18C1E43C4A593163B654904F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_856EFD224A28ADFE9E4B163B654AF4B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_78333037EF4A5DBB3F68163B654ABF4E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_64103265D0D356D7FE1C163B654A4766" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_14BC9BB739FDFF9AB4D7163B654A208E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_081DCDCC240444A151C3163B654A4F85" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_830BBA93FA6E7DE2EE04163B654AE17D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_71CB9598F1ABECE5D4AB163B65485796" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7FEFFF903FE35887811B163B654BDB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_FE7829F9B68819D2A8A8163B65430C4F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C2CB7B49972DC3D19CF4163B654B6291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_490DFDF491FEA98AB954163B654B5FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4261671888A017BEF016163B654BFF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24DC763E99A06AE76612163B654C6DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_14EF8D98D2E56966D824163B655125FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_42C95D744FDD46C8C0B3163B65519387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_203E41A37317CC63DC0C163B655155CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_E18A3BA14F32F3523728163B654BA363" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_AA4ECCD122AD74E6943D163B65511586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E005F86D5E4AA23460B2163B655254F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_E6183AFB6F531A556641163B6552BD50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_ProceedsFromStockPlans_E6183AFB6F531A556641163B6552BD50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_202AD78F3C0845EE3940163B6552C3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_B3558721F4A1A5B1A9B6163B65525BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_417C85726F5C5F71902E163B6553B049" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_exel_PaymentsforConversionofConvertibleDebt_841F82A46F345C5F7737163B65536D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D03D514B1CF9AFC7701D163B6552251E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66906092C8EAB7B8CB0D163B6553F033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C689FB4A26D38A75C54B163B65538576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E3BCF9067789C5F5F9A5163B655324B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72C37966CDE7E1948B87163B6553AF1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:to="loc_us-gaap_InterestPaidNet_AD69E040B12BF2B5057F163B6554AC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280B8B6CE8C5F26CD54F163B65545300" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_2819DFD0DC5F74161E04163B6554F344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D1307B5F6F70CC754D77163B65407CAF" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_BF471B852221421C0C32163B655459BA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_81E1F205888E6E0800A7163B6555E754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_29DB0281BD5F3B85D056163B6555D744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_956750E1F12E770B1581163B6554995B" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_01387BA5595714EA64A5163B655511C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_999CABBEDD3B0B617DCB80A8FFD999AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:to="loc_us-gaap_NetIncomeLoss_999CABBEDD3B0B617DCB80A8FFD999AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_E961391620C56777B9BE80A8FFD92A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21CCD8AEBB7B904E815280A8FFD9A7A6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F111792F5B41159DA8F480A8FFDAA1D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E39A44D32AB4AD3067770D426C56C5E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E39A44D32AB4AD3067770D426C56C5E8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_D6F29FE5C67D14C399EE0D426C568F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E39A44D32AB4AD3067770D426C56C5E8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_11781F68CC2B96815D780D426C56DBCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_695DEE0D33B2E8172ACC0137631B4265" xlink:to="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:to="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80E3BD2DEE920883DF630137631BE485" xlink:to="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:to="loc_us-gaap_ProductMember_166736C425482A8C28C50137631C3EB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_B6E8469177ED9364AFDF0137631C9AE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ACB4774F41635DED9B340137631BFAC6" xlink:to="loc_exel_CollaborationMember_B6E8469177ED9364AFDF0137631C9AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DEBE415BA032BAC4085F0137631BC660" xlink:to="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E477B14A62765A4212FB0137631D9D9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_D0F5B04A2DA70C3FDEF90137631D7432" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E477B14A62765A4212FB0137631D9D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4B29D288FE03EC99A3D20137631E39DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25FC31745F8F888A46A30137631EFBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B5C4FDF236306986BA290137631EEE9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B5C4FDF236306986BA290137631EEE9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_RestructuringCharges_B330BEDEDB5B568AFC910137631E05B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FDC9686D3FF9358724490137631D5C54" xlink:to="loc_us-gaap_OperatingExpenses_A270F3761C6F4F079F540137631EA81A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_OperatingIncomeLoss_3DE40CEA8806BDC149300137631E21EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_InterestIncomeOther_D6ED0C6F25FF71BC60A30137631FDBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_963F027B77C63D3DAC1C0137631F3D4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_InterestExpense_963F027B77C63D3DAC1C0137631F3D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_AACF2C0CF6AABC91F50E0137632074C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2989F9F6233D4F0B2F050137631FF354" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61F2DB5B478D3300F97001376320A479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_903585FE7A96F479F0C50137632008B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07A56AF8104F47D2B9B801376320F055" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_07A56AF8104F47D2B9B801376320F055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0218FF9C2E9931E4D0640137632008EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_NetIncomeLoss_0218FF9C2E9931E4D0640137632008EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_4D6F087100CBC6A74A1A013763206140" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_EarningsPerShareBasic_4D6F087100CBC6A74A1A013763206140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_99FE78058FB1B4E9E76D01376320AE0F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_EarningsPerShareDiluted_99FE78058FB1B4E9E76D01376320AE0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F19FC3BB0E39DFB834D00137632146E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6528423EE1A3E26E293E0137631CF31B" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C716393AFC3DDF53905F0137632102C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_406486949E420ADAFB8D16562869C483" xlink:to="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ADB7DB17C0194F779045165628694450" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_A5E8D1288D342E9DC8BD1656286AC55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_FC2A29AF74837D7148511656286A040B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_FC2A29AF74837D7148511656286A040B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_97654719B948B81A77F41656286A7969" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86465BA7EA6560BFDC211656286AAEE7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_97654719B948B81A77F41656286A7969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658F6C77A983FE3832C91656286AC281" xlink:to="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_CommonStockMember_869C90CB85F69561D10E1656286B4407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7BD4D267540BC15A39731656286B660D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F98E477D5B7C171C13B71656286BF539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8E68223DFF3C45769FC91656286B62BB" xlink:to="loc_us-gaap_RetainedEarningsMember_FDEC6C145F5EDBA19F2A1656286CB0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3CCEBC04F109D20720AE16562869598B" xlink:to="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86CC75711361DDBDDCF21656286CA5B2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7E8BC322BD4774E9FDC71656286C1217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E25A1752A8E7CEFA509D1656286CAC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_F83034BCA310F7DF0FC11656286D8EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_NetIncomeLoss_F8A04399C9597F3A02DF1656286D8948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_855DE420A1858EDAB4D11656286DB17E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_855DE420A1858EDAB4D11656286DB17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1405FBB80F3C4C0BF14C1656286DB1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_522843AEE67FA8C650E61656286D24E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_AFDDC02463399910A1F01656286D327A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_E7F5D028F5EDF12B46B51656286E1451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_9B38FD663363FB9B5B651656286E5CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_5D3384963BBD57C159691656286E9C6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_27CF8B22E0BEBF69E0441656286E333E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_DB1240BA073FEBCDB0451656286E493C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4146C4FBC35DE4B6AB651656286CEE64" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0188D1E380CDE11665271656286E579E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="exel-20181228.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_DocumentType_C723FF4B5E58FB8EBECEC31F7A571F19" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_AmendmentFlag_D7AA0B2678A260559585C31F7A574906" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_DocumentPeriodEndDate_EC8B308255420FE7FEC5C31F7A580688" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_DocumentFiscalYearFocus_1218D97D5E4C37E44EC9C31F7A5819AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5EE585732CA1130EB428C31F7A582B25" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_TradingSymbol_F90B5B9EC66F71561314C31F7A581C5A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityRegistrantName_3A73FED61648FF5A4D49C31F7A583DB9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityCentralIndexKey_3FF5AC8CA8BA22BF8DF4C31F7A59520E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityFilerCategory_201E6E4E289E5DEF30E2C31F7A5983DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityEmergingGrowthCompany_83614BFD4222E911EE5CC323221DB411" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntitySmallBusiness_0D3929B50979DB9FDA3BC32358BFD531" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityShellCompany_0D170384195EBE0F8C6BC32398112C1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_CurrentFiscalYearEndDate_CF4266001785F8BCD095C31F7A59F2D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_50C75C0C0433F08B6330C31F7A5A8BEE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_CC58F6A42A86B9D3D3E7C31F7A5ADD40" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityPublicFloat_02C06A6F834193210C63C31F7A5A8D10" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityCurrentReportingStatus_1F2A327F1E1E95364CE6C31F7A5A35E2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_187DE7D0C6B85FD88197C31F7A56E472" xlink:to="loc_dei_EntityVoluntaryFilers_EA6712932CC1DA1DD732C31F7A5A3294" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_533D0A8618C157F7945ABD7EDDB239FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_533D0A8618C157F7945ABD7EDDB239FC" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1606B753F73D09C5195DBD7EDDB2F0DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_689FA7E8C3C00323956AFED730D139A5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_B997BF065F2A7FA71D61FED730D4B83B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3B6A1B85D7E42195A032FED730D5B4AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CommercialPaperMember_5A98631D3AC3C79E28F0FED730D5B9DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_309A062F3E369F088B53FED730D6E88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_19C5AA588BB331978F92FED730D61D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E721E90D77F9CD9292AAFED730D55263" xlink:to="loc_us-gaap_CertificatesOfDepositMember_999C8162C6CD1FEDC520FED731012AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_312B8E3CE373555422BEFED730D64301" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A1043BE094553ACFA9DEFED730D63F10" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_727C76FE8AC3B639C763FED730D70EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50FD39FD09641018EC7AFED730D7F3AA" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3C8E9829E313173632F0FED730D7CE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D75D8083D67A34F4883CFED730D73334" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_156C1853CEEAA32BDEF2FED730DA5FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FD1588083F0D0417A7C3FED730D31B40" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1D4DBC0AF89CC43357A5FF1367DAFC79" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_66BC5E78DBF2AD8CB886FF14F8E9DC44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5CB79CC568C4075C5CFFFED730DF98ED" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7017C4DE3F4F405873A0FED730DF49EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6F2FE9405E758C25CB1880A6793EA4A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6F2FE9405E758C25CB1880A6793EA4A5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_017AC041C98300FFA34280A6793FB1AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A38A0CF22AD034335871BD7EDC7F1689" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A38A0CF22AD034335871BD7EDC7F1689" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1F620B24485A90A427D0BD7EDC7FE0FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_70837903D4EAE337050A0137604746BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70837903D4EAE337050A0137604746BB" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_01E4E0A84194972CFB950137604751FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_BA272B1D4E408DC246EA01376048F8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7C8DB67074472FF3B0B601376047746D" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6DC68D1D2FF2724E8F20013760480AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70837903D4EAE337050A0137604746BB" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_D14F1FA2200BA797BC63013760484F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_A9652495EE0C675B974D01376048DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_02B395296032566659EF013760483610" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_D7EF51D0954838FCC7C7013760494BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70837903D4EAE337050A0137604746BB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5E2923E16489C94763C501376049BF0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_45DE31307DC3B99AE649E39A95D1B8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5DD030DEC78E274D8FE9E397EE859D63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_D4818F7302CD278FB8B6E394BD2441F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A1C3F2AFF1EECA26A4BCE394BD21DD96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_C27EE4D40DA2F7D769C3E394BD226947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_940A4EF6A6FF4497AD5CE394BD213623" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_A8049F31BC571B0F200FE394BD221B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_84B7017BE758B6C06009E394BD2225F0" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_568264C14C90998A9593E394BD23630E" xlink:to="loc_us-gaap_ResearchMember_C1443FA14AAA74422FD9E394BD234E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_193802C7AB545392FE55E394BD200000" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2698ED24196637832A03E394BD2484A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_AFCB499D763708EE74E1E394BD236597" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0C6D7CD4E39F444C8ED9E394BD24319B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_089FEFAF5F64602F3CF9E394BD24BB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2FFAA69457A7F59B53D8E394BD201AD6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_B3C8CB3E8DA234504BD0E394BD25D1B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A275B21B9C91A7E047DAFED7648F314E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A275B21B9C91A7E047DAFED7648F314E" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_723C09649579F0F33341FED76490A36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_C64EF6DD6E6989860BB6FED76490C1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_2353DE30595B7F486546FED764901127" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_E75FFD33284261DD7392FED764918E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_F4128EAA48495718529FFED76491348A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7A108D10FCF4EE32DB4CFED76491ECC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0650AD57B4BFDC353294FED7649101CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_29BBA300E8804013BD0CFED764924DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7310CF0120C49415F65FFED764925FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_99A6289D062A08CF573CFED764908875" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_35928CCA8C08B087CEA8FED764923508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A275B21B9C91A7E047DAFED7648F314E" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_D7BC455F91EC9BFB9AF0FED7649367D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_F2F8ECE4A5C44A82C38CFED764921E1B" xlink:to="loc_us-gaap_DeferredTaxLiabilities_705CE9CC642BC91AF5A6FED76493DE6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A275B21B9C91A7E047DAFED7648F314E" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_697D2ADAB10A5D09E4CAFED764930C32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9F784EB4869F9A1D8A690137603599EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_052542B043FC4F8D6BE10137603B3C41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_EF707D96EA248AEB617C0137603B7C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_AB2977F0D646841C56990137603B1B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6916B53F34542CC54EC80137603BC03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_01B463F68DDABF694D4B0137603CF4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_35975DA09177F3FBA5F40137603C539C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_4669E2F9A502551827A80137603C40FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_AA525C2D68009C2966EC0137603CDED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_EB51857962104B018C860137603C589B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CB4C828CCCB6EB89833701376035D7B7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_EB51857962104B018C860137603C589B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3EB7DECBE0FFB05B6F65BD7EDDD2288C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3EB7DECBE0FFB05B6F65BD7EDDD2288C" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0089882BE1372F0B3ED5BD7EDDD33236" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_7A9FEFD2583F6E5F99BFBD7EDDD3B08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_CF8FBC9EF8BDC3A109E6BD7EDDD30213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_B828E24E9180BCC34D08BD7EDDD4EF19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_97ECE3A966FEC05DF0C5BD7EDDD3D455" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2926ADB08010A9018727BD7EDDD4C79D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04C1B8790AAA263B82B9976F02F41048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_BEEC61EDA6147FD92C5E976F02F4D0F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0F74AEABC76AA72FBF49976F02F4408B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B3072C3AF2599961DE57976F02F35E8A" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80C2C8239A213C7E2471976F02F4F40E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D0A3E8675F288C59D7F6BD7EDCF151E9" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1AAF9194D526C0311A41BD7EDCF298B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_47A6593F05235E014A22F83D452F0258" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_47A6593F05235E014A22F83D452F0258" xlink:to="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D544EF5D56BF034CDD35F83D4530BE2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:to="loc_us-gaap_InventoriesMember_E462308876FE553EF1F0F83D45302B8E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BF64DD9F8EFE6E7DD4ADF83D4530846C" xlink:to="loc_exel_OtherLongtermAssetsMember_376A819F784285287BBAF83D4531858F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_636D7357BBB825DC830FF83D45302CE1" xlink:to="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryRawMaterials_DED45C3A3057AA7A0D6AF83D45313793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryWorkInProcess_5BF10ADA51705B3BF6A6F83D45318462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryFinishedGoods_E22B87C7DAA3722D0C41F83D4532E186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryGross_365C13DF066F00404D65F83D4532C5F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C5EB2F3F369F99BBB982F83D4531C82F" xlink:to="loc_us-gaap_InventoryWriteDown_13D16E7C4FB4CD376E68F83D453264AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_51F4EE1726F7E00DCF63BD7EDDD69477" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_51F4EE1726F7E00DCF63BD7EDDD69477" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A6ED23CC4FFED785A3B2BD7EDDD618BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6109673E484B59F11800BD7EDDD82669" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6109673E484B59F11800BD7EDDD82669" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_08D831A4FBCD20BD47BCBD7EDDD8F95C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E255FCF4B22B38E693248313C28B7E0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E255FCF4B22B38E693248313C28B7E0D" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2BD50462DFEBB54C5E658313C28CB869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="loc_us-gaap_NetIncomeLoss_2BD50462DFEBB54C5E658313C28CB869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_728B8335DF96514247808313C28C85ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_DA5E1615A23928A7F17C8313C28CD15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_1B992A65159A96CDBB7C8313C28D5BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_F6B7B6637F30D12B90038313C28CC2E2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_C19EB86369DA91C6370C8313C28D2D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E255FCF4B22B38E693248313C28B7E0D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9278FE563534F5383BDF8313C28D6313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6B09FFD2B767D3FE8E3D8313C28D4212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4F37182C403366945E288313C28ED438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="loc_us-gaap_EarningsPerShareBasic_A0B13DFCC819490478718313C28EE16E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_DBA52BE47F2EEF76AD828313C28DEBE4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_BFAD7C8E12CF403CDF358313C28E396B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92A16142CDC8A8D1829880AF7E51BB77" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9A374F96570172A1E1F280AF81482410" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_979A0532666537F918B680AF814A56E6" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_52D74D8363B4F1EF6DC980AF815C67A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E6576B374892A9760F7B80AF8132C5C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_B09831F39F8EAFC4B35C80AF81338C80" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6E9AD692B0E04AAA739A80AF813D5149" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6A946313911F4818C40E80A8FD44E3D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6A946313911F4818C40E80A8FD44E3D6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_68B834916E9C6A658B4480A8FD4562AF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AC965090C3CADA3874A980A8FD45A53B" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_DFE9174957B7A8E5D9E480A8FD46C70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FAEF770F479FBD99B1D080A8FD463666" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_us-gaap_StockCompensationPlanMember_BB5C14454DF2CCFA668880A8FD47E3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_81EB0808EBD9C950798180A8FD47DC18" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_306AA1A4868FE46C448680A8FD47D690" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_442C1A901050CB353A9080A8FD4696C8" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_306AA1A4868FE46C448680A8FD47D690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A3F0BDD984C74DE521EE80A8FD45AC20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_573706C9F82433F2D2BD80A8FD472368" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F95E22EBC2930635020980A8FD479748" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ECC34BB63F6518D2EF36BD7EDDFFC31D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ECC34BB63F6518D2EF36BD7EDDFFC31D" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79E06B64B9CCC3D98C8BBD7EDDFF69AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ECC34BB63F6518D2EF36BD7EDDFFC31D" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AAEC2412F974F74978E3BD7EDDFF6FFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD5DA65ABB9D26DD02D9BD7EDF59BA54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD5DA65ABB9D26DD02D9BD7EDF59BA54" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_DC62643F25D6921B2549BD7EDF59A676" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5DE0A0623B190F59FDA0F83D4783212D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5DE0A0623B190F59FDA0F83D4783212D" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0A30E53CC4A1F3BD48A9F83D47847797" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_E10619628EBFD6C24BA6F83D4784C4F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_LaboratoryEquipmentMember_E10619628EBFD6C24BA6F83D4784C4F1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_EquipmentAndFurnitureMember_D8B924511059AD75F4E7F83D478525F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_us-gaap_OfficeEquipmentMember_CD9DF5846B6A324A8B9DF857DC3518C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_146014E84C96E24996A1F83D4785867B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_146014E84C96E24996A1F83D4785867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1C290570021B062560F9F83D47851900" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_EBE89AD8133CED1B6227F83D47849168" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1C290570021B062560F9F83D47851900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:to="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6D91EA88155D1AF120A4F83D4785FC5F" xlink:to="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5730F6E946A536D1CC25F83D47862EA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:to="loc_srt_MinimumMember_5730F6E946A536D1CC25F83D47862EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16CFF4BED69DCCAA27E5F83D478663D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6CC2C73A8E90A299A4EAF83D47851AFE" xlink:to="loc_srt_MaximumMember_16CFF4BED69DCCAA27E5F83D478663D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_894E2B0907DB6E7B132DF83D478321D7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AC32700C8AD5FDC4E38BF83D4786630E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_847624B5FF6852A963EFF83D4786CEEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C39B478CB4C5DA7CED80638851F727C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C39B478CB4C5DA7CED80638851F727C" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_98CA423C3DA7885680850638852024D9" xlink:to="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2EEA370D82FCAB038309063885269C90" xlink:to="loc_srt_RestatementAdjustmentMember_312BCC2ED2559B4A895B063885264624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_AF60D0E169D4B2E511FC063885267D8A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_ADEC9DBAF3045BA5B80D063885279C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_80F326907F4FA3E0BA260638852792F0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_4DE4C29C49575B0B426E063885275B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_33CE074932F456E234610638852744E4" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_5C6092A474DEFE2A42A906388528B595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3EFE6FFEAFA3C09DB79506388528E5E5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_C884C842E7F62024D4D206388528A847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_590230D57CFC7F73AAFC06388520EE9B" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_70BB59308AF00C646A86064E16E85F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_127F4F8DB8C7B655CA61064E62777382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ReceivablesNetCurrent_7A008339577A4E931B9806388529EC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_007ABE10059CCBC609530638852922A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_007ABE10059CCBC609530638852922A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_226B536D55011E04322B0638852977D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_226B536D55011E04322B0638852977D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9324C3C7D3BFCE397D550638852A0826" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9324C3C7D3BFCE397D550638852A0826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84B56FD093D7DC8286310638852A5F26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84B56FD093D7DC8286310638852A5F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_616B3C7358B521D71D5C0638852AB5A6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_616B3C7358B521D71D5C0638852AB5A6" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OperatingAndFinanceLeasesLiability" xlink:label="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_exel_OperatingAndFinanceLeasesLiability_69D90D255D99633974410638852AD0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FAAA687F529AC72290F10638852A59D0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_B2D6BB9DC627C1B747EB06388528EDEC" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FAAA687F529AC72290F10638852A59D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7A912005FD77B8320468128DAA936E8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7A912005FD77B8320468128DAA936E8D" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_400AF449C2B6E0141610128DAA94239F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_EA6C15957239F3AB37C6128DAA954C01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_EA6C15957239F3AB37C6128DAA954C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A5DDE2657F785771438E128DAA95F4EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A5DDE2657F785771438E128DAA95F4EC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member" xlink:label="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D38D238E65588D8D03A8128DAA94AA2E" xlink:to="loc_exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member_C7B509E1D979ECF896D5128DAA95396D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DCF575A7B67382CD5B10128DAA9CCD59" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_85C020BCE02E25682079128DAA9C6769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_85C020BCE02E25682079128DAA9C6769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_98C639B391F3EF9F2084128DAA9DBFA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_1566EDA19A789F27FAB7128DAA9CEDF8" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_98C639B391F3EF9F2084128DAA9DBFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_707C1279E27ECDD89908128DAA9DE75C" xlink:to="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_BCBED0B624DA427ACB39128DAA9D054A" xlink:to="loc_exel_CollaborationMember_3372570F1215B4B8220E128DAA9DB1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_A470CBE30E4B27E1BC59128DAA946184" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858D05874B0DED528AB7128DAA9E0D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858D05874B0DED528AB7128DAA9E0D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21749C80186401ADB137128DAA9EBB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_OperatingExpenses_314C82D6A62982E653D8128DAA9E63F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_InterestExpense_F9737A9D1528086E5711128DAA9F1E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_C6E5EBF3EA9F5809BE7E128DAA9FF75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15238D84E5973F105940128DAA9F21B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_88FF0A16B00F04417880128DAA9F17FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_NetIncomeLoss_25C0B48AEE3FE0AE3F43128DAA9FB7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_EarningsPerShareBasic_F8527FE2CA3D092A0500128DAA9FBF91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D72457E1A76CE2BC4395128DAA9E07D0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5288D5F6E4380DDC3F14128DAAA0ADC6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0683254C3960BEE42DAC163C48A905DB" xlink:type="locator" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0683254C3960BEE42DAC163C48A905DB" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_88FDC4BFD6BB69E95C63163C48AA0EA5" xlink:to="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CommercialPresenceInMarketsWorldwideMember" xlink:label="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:to="loc_exel_CommercialPresenceInMarketsWorldwideMember_BA72020000F3DE9C2307163C48AA38C0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F4923A767B0CEEA240DE163C48AAD803" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_4F527200D2B4AD35CA38163C48AB189C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_532EE0497D0911813166163C48AB7E1A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_E89775EB170CEB530D70163C48AB496E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_E45954767A26B3D7E86F163C48ABCD8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_E45954767A26B3D7E86F163C48ABCD8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0CC653AF36A572AC2E94163C48ABD22E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_970DDDFC4D2D284B5DF8163C48ABD4D4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0CC653AF36A572AC2E94163C48ABD22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4C381B61F28181868208163C48AC1B62" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_B403A7B200AE9B56B062163C48ACF4AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_3C70382113BE962FA48E163C48ACEBB4" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_B403A7B200AE9B56B062163C48ACF4AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_7D21F7C9F52500C6DE70163C48ACC0BD" xlink:to="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_CD37481D95F4CB2694E2163C48AD5D8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_E7057E6F65A40B627A23163C48AD3EB0" xlink:to="loc_srt_RestatementAdjustmentMember_CD37481D95F4CB2694E2163C48AD5D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8392329418EC9C4F63CC163C48B23417" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_F9F5E4235B177B3880A2163C48B32010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9F72A1CF3B4DE5BFFDDD163C48B2F78A" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_F9F5E4235B177B3880A2163C48B32010" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_CADC1F8B1550B299B382163C48B33491" xlink:to="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_D9EFB8326B6FFA98733A163C48B3C635" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_60D963FCB89CF226D343163C48B3FD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0F852895F46F1263FB70163C48B46F4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_40475FF8C3D8C5125729163C48B4F40C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3D3455E4AEA1F3B52D4F163C48B4855E" xlink:to="loc_exel_GlaxoSmithKlineMember_40475FF8C3D8C5125729163C48B4F40C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_262BF2721539E2163396163C48A95BA8" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_NumberofProductsinCommercialMarket_FABB54CD4DD93E364F73163C48B5D929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2AC81C1A09545A06D282163C48B53E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_A09A65696181D00EB90B163C48B5E308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74B891E57C79A8C81A83163C48B522A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_MilestonePaymentsEarned_F61313E4B0457B1A8EF3163C48B5155A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_NumberOfReportableSegments_1CD3017986A03F8E3F7F163C48B6ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_693634E1C1452F262E3A163C48B64694" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_F70377ED4C20C041B9C6163C48B6B560" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_C2F201D0DC1D6FD7EF60163C48B618A3" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_AE464C756A3306DF7484163C48B6B180" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_AE464C756A3306DF7484163C48B6B180" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_InventoryManufacturedBeforeRegulatoryApproval" xlink:label="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_35AF641B5D5251358348163C48B4BE66" xlink:to="loc_exel_InventoryManufacturedBeforeRegulatoryApproval_CA57E66682F68D53A3F5163C48B6DB01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_74A7E683865BBD9FD890015E9F1EFB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9283EB092CF0247C7BAE015E9F1E1791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EDFF39998E6F6EBC69740180971D289D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_UseOfEstimates_CBA64B963FBE775A1715015E9F1E1F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C4A88A4B66AD2D0CA86F015E9F212319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9141298EE84565412F99015E9F1F363D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_C2FB79103C982F96B910015E9F1F7694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8207FC6939B3917573EB015E9F1FCEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7A34C3EA6C5001333FAC015E9F1F7DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ECBF15754F6D8E63803015E9F1FBCBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_D6AAEB214F2BC15E4C47015E9F1F2693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_01EA19AAC363EF3A6658015E9F201D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_AA97CA6C2E8339EA9D84015E9F20EB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_45F81818E0DAB4FEE550015E9F206AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_44A70D635EEF5C4AE31F015E9F207942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_E34BBB9678AFD680F809015E9F207216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_418A1095FF304E7629FA015E9F2098CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_FA44EFA874455B90E64A015E9F217BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BE697E2C6AC18FAB17C015E9F1EF4DB" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_FB7F1C38969F48AB38E3015E9F2139EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F58B18777E2BED9A639DF97B7C6D6EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F58B18777E2BED9A639DF97B7C6D6EC" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_BC73F2BD1AA78926C737DF9A35E9203D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F58B18777E2BED9A639DF97B7C6D6EC" xlink:to="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_7BC9923C127B621BF773DF97B7C6C200" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_98D246738E23CAA341B0BD7EDD51AC53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_98D246738E23CAA341B0BD7EDD51AC53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_CE6C08E0F628356FBEADBD7EDD52DE6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5A72B2D30F9A7C3C11A5063882B4B5C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5A72B2D30F9A7C3C11A5063882B4B5C8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:to="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_A3DDFDFC8E9901FA34FC063882B7380E" xlink:to="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_C7E193AB6CACD944D554063882B7F872" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_D0C1C3B8EE32B3D30C64063882B70A72" xlink:to="loc_exel_AlamedaCaliforniaMember_C7E193AB6CACD944D554063882B7F872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022E586CFBEEB76599B4063882B7C7EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_77C277DF030DBF71D581063882B80625" xlink:to="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_28C430D40ED3BF029BE7063882B85580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_760C4E030B05B5BFBAC7063882B418FE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_us-gaap_Depreciation_6EE5B2494316DCA5CF75063882B973A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_EA15B9F52E5784C9A638063882B9070C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_EA15B9F52E5784C9A638063882B9070C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77523584AB0A5A0D01E2063882B90CED" xlink:to="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_6B6D09B3B30B5D028ACC063882BAB59C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_611F691EAD2049D5C12D976F03A8BEBA" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DD16BFA3F49D22CE1B96976F03A9BE69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2CA1C53015E5BBC07122976F03AAD948" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_12219D66F7E312719856976F03A992F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_CA5DE7378D726B0F9FA5976F03AAD06C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_exel_LaboratoryEquipmentMember_58BAF8FE6D05AF42BA68976F03A92CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_FB5F5CAADB47606E6E6E976F03A939A4" xlink:to="loc_us-gaap_ConstructionInProgressMember_8794A19BA2E7EFE721BF976F03AA5020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61BCB51E837719CECF7D976F03A8636A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_CC620ABDA7F7CF3FF6C9976F03ABE0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8CCD439E23011F09A1C8976F03AB6BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_63D4DBDD2E676604E09D976F03AAD7DD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D770F56868B14097D278976F03AB0068" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3A5F3BD6998AB10E8D2EBD7EDDDB1928" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3A5F3BD6998AB10E8D2EBD7EDDDB1928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97B7A3C276156DC204F3BD7EDDDB88FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_51C8D03E98E76524DA4DBD7EDB27A3DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_51C8D03E98E76524DA4DBD7EDB27A3DA" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4A44D4E05224C02195E0BD7EDB2773C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84A1B0532C4CB358BD5DDF97B3A0861C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84A1B0532C4CB358BD5DDF97B3A0861C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_GrossProfit_67EE26C247790E2E6E4FDF97B3A0C126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_OperatingIncomeLoss_175BFBFE2409C6F80C07DF97B3A1CE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA57CB0212EF85A43EFFDF97B3A11120" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_NetIncomeLoss_DA57CB0212EF85A43EFFDF97B3A11120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_56E5E1A64089C8535BEDDF97B3A1EDF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_EarningsPerShareBasic_56E5E1A64089C8535BEDDF97B3A1EDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9B2325F62B3984E437A9DF97B3A17015" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9B2325F62B3984E437A9DF97B3A17015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_952E36342A69A707B158DF97B3A0F0AC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:to="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_74B39B14F9D6CEA67786DF97B3A14CDC" xlink:to="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CD1CAD74FF8C7553849DF97B3A291C2" xlink:to="loc_exel_CollaborationMember_3DDEE39C9A581A596A41DF97B3A28250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:to="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_81AA5278CEA7B49D2843DF97B3A22CBF" xlink:to="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2358780A5D8144F2B6D6DF97B3A91BDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_86EDAB34C3C5E6D44541DF97B3A3F59A" xlink:to="loc_srt_RestatementAdjustmentMember_2358780A5D8144F2B6D6DF97B3A91BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BD9120476495BEA9C8EADF97B3A16198" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5143A8C455C01418CA3ADF97B3A9A27C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5143A8C455C01418CA3ADF97B3A9A27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2D5FB242F40311A2773ADF97B3A95362" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5FC4C235DE462BB4CFB8DF97B3A93580" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29AAE7D4E9CB80468722BD7EDFAEEF4D" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_74DE98E6378E5B8B9490BD7EDFAFB7E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D837B6920EF378D7EB75976F04F0599F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D837B6920EF378D7EB75976F04F0599F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9114873A5E1D52A04D53976F04F1B4A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97ED9C67526DD80C81310638848236FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97ED9C67526DD80C81310638848236FA" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_43BA73FCE142DADA44790638848305EE" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6294DD8390D0FC52A68106388483B9D0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_61CA0950E2192B64381506388484CCB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_exel_AllowanceForProductRebatesMember_FDF1A482C367ED37EB5206388484D923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_78F0DC285F36BBFEDD7206388483F64D" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_9FB609DDFAE51A43C65106388484F682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_383AA0DDE25AB19C80D106388482561B" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_09CD379C981B2D6820BA063884846849" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8E7B23553B9193D36FF906388485CF71" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_BAD3C1F6587E7BF58D8E06388486F05C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_19A65483CC8BA9D3242606388485A47A" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_E1CED662F7C08A9B9AED06388486849D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_8C380F211F55A4B3EFBC063884865622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_40177ECD00C5D65DDE5C063884852BC0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A7E2CAE15EC3D2B7E3B40638848625FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_73EDA4F1C7A9F2618EDF0CFAC1D9BA41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_73EDA4F1C7A9F2618EDF0CFAC1D9BA41" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_4A0AC68FB8ED31D5DB060CFAC1DAC33A" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_85717B5BAB6AB27DF7400CFAC1DA1FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8E2382D0402870D2D0BE0CFAC1DBED0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8E5E7DA40597C6A4156E0CFAC1DA6EE5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_8E2382D0402870D2D0BE0CFAC1DBED0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_726FE02F80E6AD33DA370CFAC1DB6BF1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_19C5D98DF27ABB3FCE770CFAC1DB9B63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_09112F139EE86EEEF0B30CFAC1DBD36B" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_19C5D98DF27ABB3FCE770CFAC1DB9B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_637AD2336EB28CEF9DF20CFAC1D933D0" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_F76BE35E2266A41E866E0CFAC1DC1A80" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_692D805A201DDD3E3D240CFAC1DCB240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_F0C6D6F932A2EDBABA5B0CFAC1DC86B1" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_1C0D986A8BD71C4BDCE30CFAC1DD7584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_DD9FE487D3DF48B993110CFAC1DC0D90" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_8045E8F19A462C1E730A0CFAC1DDE230" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4985B9F1CBC275A93F800CFAC1E2F90D" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_5FE1717F45B85FA32FB20CFAC1E31D8B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_F2F5E8C536929C65DF900CFAC1E37F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_DC9D0125A4957446D29A0CFAC1DD1152" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_C32190F7A713AEC68A3F0CFAC1E3BCA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5A3FE2171E07EE7B52B50CFAC1E3507E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_157ACBB5AFC813F94B270CFAC1E450B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_23CAA7FC63C09E10FF250CFAC1E4BA85" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_6943C5745D7DB98B56B10CFAC1E45B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_423D42F3A2C4BDD59ADA0CFAC1E3CA7F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A6F4C7D4A1D94C6484830CFAC1E4DCDF" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_C2EA669A1BABE3797AF00CFAC1DB67FB" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69041B48AA702DA1907F0CFAC1E5609E" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_17D02BEB46F8A004FD110CFAC1E56853" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_7881BBFE9EFF4DD112460CFAC1E5A6B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_013ACC9F1D11F1AAAC840CFAC1E5DE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_7AD741FDF092B49823F30CFAC1E57000" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_D139E5D3CA940F1533A80CFAC1E60A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_73EDA4F1C7A9F2618EDF0CFAC1D9BA41" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_272C5958D0B07889922D0CFAC1E610A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ED17481DB06DB33253307BAF918A2501" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:to="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6926019AD1549B2C35D87BAF918A02B2" xlink:to="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12527566C51FEB0EE17E7BAF918BE5E8" xlink:to="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:to="loc_exel_CabometyxMember_E8D76A575C0473E696737BAF918E5175" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_DD6FF359F9F63150DB287BAF918D1A1B" xlink:to="loc_exel_CometriqMember_F4E5892A8D4FCF3B77067BAF918E612E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_819D197CC21E6934DB577BAF918A3EF7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6B46BED2AC8BA6AA45137BAF918E9DB6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5AD2E083F11A9B7065707BAF918FD8A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2C6BBBF5AE9F24028FE1165627759E1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2C6BBBF5AE9F24028FE1165627759E1E" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:to="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_146A3C49CF5F96DC14A116562776531F" xlink:to="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:to="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:to="loc_exel_ProductGrossMember_FE9F6D1F2276DA86944A165627764B45" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2D71FFF928B142230F461656277634DD" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_3538AC9D30374F43E24D16562777756A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_30F1D275DC13222FC582165627768075" xlink:to="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_us-gaap_LicenseMember_8874201E6ACEE94F12EF16562777FA1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_exel_ResearchandDevelopmentMember_FCFCC33044903865B8DC16562777061C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_24729069CEB186755D731656277759B2" xlink:to="loc_exel_OtherCollaborationMember_8CBE9BCCA52B0C65AF3416562777928E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CF1D8E6652E9B2C9686B16562775431A" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EBAD0728881B4E98FABA165627780473" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_F117AC2F6D2840F37AB11656277854BF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EBAD0728881B4E98FABA165627780473" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B9CE6A08975D83A17911DF70175AFEA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B9CE6A08975D83A17911DF70175AFEA0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:to="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6AA1A6D80FA49D53A736DF70175BEC91" xlink:to="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_country_US_52C10224C57E8CBA3BD1DF70175C557F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_srt_EuropeMember_238477714000AD2040E0DF70175C8FFA" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_184A5C83DE09501F4074DF70175B8663" xlink:to="loc_exel_OtherGeographicalAreasMember_95CF8D1D40107E0FCFD6DF70175C2CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F8A7D7968CCCDE71B25DDF70175BBDCF" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908F84C4E6C5F0AECAD7DF70175C73D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_362F88F275FC028C8AEDDF70175CCAC9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908F84C4E6C5F0AECAD7DF70175C73D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D35E309D6E08534DCD34DF701764B979" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_D35E309D6E08534DCD34DF701764B979" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_FE7873E74D73055C8799DF701764ED6A" xlink:to="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_IpsenMember_CB1D2D4C51D4572ABAABDF701765EF7C" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_CaremarkL.L.C.Member_50981BC54491317C60ECDF7017650703" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_A11E076270FE1CC94368DF701765B871" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_AccredoHealthIncorporatedMember_6610D381A8933EBBF558DF701766597F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_68C93A864537A8491A8DDF701766112F" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FB3BC36FA98BFE6F9BD4DF70176589CB" xlink:to="loc_exel_OtherCustomersMember_27059C1A9A394F5A13C9DF701766EC1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_EEFF506F713D086112CEDF701766EA23" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D6FA996E095C568A3CA6DF70176743CA" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_3C6ADE971B21A5530BAADF70176706A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_86377D75ECC7CCB797A4DF70176725CD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ABF402A398276F8A3D61DF701767B601" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1EA0AB53ECEA5D78EA9BDF701768FCE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_248EE89A6769F5CEE13ADF701764EC6F" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FC9DA44D6DC999218106DF701768BAF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FC9DA44D6DC999218106DF701768BAF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D210A979308B1278EDD9DF70176884BB" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_B910FADB553F39552683DF70176950E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2BB2011F2B13DE712B80D426BA7D45B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2BB2011F2B13DE712B80D426BA7D45B" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A45CE1A5BA7EA892EB440D426BA70BFC" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2BB2011F2B13DE712B80D426BA7D45B" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_C116A3D0D515585E92E30D426BA870A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_881033830921E3A48E9D0D426BA87273" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2BB2011F2B13DE712B80D426BA7D45B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_881033830921E3A48E9D0D426BA87273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2BB2011F2B13DE712B80D426BA7D45B" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_F56F6A9C07ADED8EA7AF0D426BA88E3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F55021434C63992C584ABD7EDDFA1284" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F55021434C63992C584ABD7EDDFA1284" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_244A9E042F066C8B1F24BD7EDDFA95D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D55517D713DA6C000D2C128DA807A96D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:to="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8D66F5ACA1605464CA16128DA807D384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0E6D20EF2207C24D6F1F128DA808907D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_PerformanceSharesMember_0C087D6E75B86F26B755128DA8083ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41AFE7BD99C218A035E0128DA808C74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_us-gaap_EmployeeStockMember_B1489B8D07DF651A4252128DA809AE98" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_235D6AE1C9DDD0A321C4128DA8098E17" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_818358414AC8E37EA103128DA8084ABA" xlink:to="loc_exel_PerformanceStockOptionsMember_B0DBA49125FDADE68B4B128DA809ABD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1EAE2DB0D03404360A51128DA807B174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3382AE2EB56D1C7C4640128DA80A1632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF96D651AA4C1EBCDB70128DA80A5A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18BB90BE471B6B253167128DA80AC74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8BEA1E81D92EEFDC64B7128DA80B02BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1D5802BA9D65B4E0FA86128DA80BED7B" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_EF0A274FD0DBC13BD6FC128DA80BE08E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_CE17DEDA8D56EDB06A3C128DA80BAB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6C61F22679128C4039C5128DA80C2177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_61E05E59EB7F99368957128DA80C9B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ProceedsFromStockPlans_D790D8BE2A02DD1A42AD128DA80C7BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80FB2E6953B733996867128DA8095E99" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_E2FC5D8093685CF5DD60128DA80A65BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6FF70E1F706606144BA2128DA80C3ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0813041414CAAC42DAE3128DA80C5A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_007B517C120FF48E7173128DA80C28B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_C9E5EC40BF1C6881B37B128DA80DBCBB" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_C74390E09BDB0EE34CC6128DA80D1FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_E096D565D9877C24D333128DA80A8359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_BD0A55452BBFA7FCACA2128DA80DFBD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4C67BCCDF432A5490348128DA80D064C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8756F162D09DB6EEE67C128DA80DCB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_A138CD2EA88348C7DB02128DA80DB759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_AE916BB768B7264A612A128DA80E31CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1ABC3C4527C384488F42128DA80E4CD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18FE887340832B872B36128DA809A737" xlink:to="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_C85939F32C89E9DF83D2128DA80E44C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_790C787DAE2BDAFE3C9DBD7EDF272319" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_790C787DAE2BDAFE3C9DBD7EDF272319" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8A071FA281DA815D4598BD7EDF28AF14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36A8EEA5D68562811014BD7EDF287FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_96542ABEB706FECEFD82BD7EDF285305" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_989A2739E9854911B30EBD7EDF29CEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EA03DBE8608E7EF73D9CBD7EDF27ABBA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F2367479C55CF6372060BD7EDF297A1C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_21AE4224106B0A59920CBD7EDF29F395" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F8F144A66F04B6A524F2BD7EDDBC30D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F8F144A66F04B6A524F2BD7EDDBC30D6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:to="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_DDBE9372D7CEB2299973BD7EDDBC6940" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A5886E73FC13E580BA45BD7EDDBDF6B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A5886E73FC13E580BA45BD7EDDBDF6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_C86DE2B5E21BC599C9E8BD7EDDBD7AD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D237E7DFDF10AC47064DBD7EDDBDB4AD" xlink:to="loc_us-gaap_EmployeeStockMember_C86DE2B5E21BC599C9E8BD7EDDBD7AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E436E5FB9B0A2AE1C614BD7EDDBC4991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1D6D7A5DB9832D45A298BD7EDDBEF9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_BA5179AEEB5AC52793D2BD7EDDBEC81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_249330F69654DEEA23C1BD7EDDBE2EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5FD36372F9318019D6CEBD7EDDBEFD38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1AB2E8CE53EA8F99F20FBD7EDDBF33BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B061493754D52AF4DA50638821F7649" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B061493754D52AF4DA50638821F7649" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:to="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E99535EE660A1D91C12506388220AB81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A80C7BDF194CFAA3113606388221D352" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83DE64BE4F1EAEB52BE706388220429D" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A80C7BDF194CFAA3113606388221D352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_791713D97D2B8A5F29980638822005B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C97B639BE85FBC5F993806388221A2E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18EF5F804854D60CB44806388222C667" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_45CBF018D43DFBA5B1CD063882228ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37F97996CF1415BE5441063882229BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0B0939F35059144EEBC80638822102F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02B8CDDC7A28C3C176EC06388222FD00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595EEB6E449FF6EFF7C7063882233567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9E9C0BB78DB568C8648E06388223ECC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_7878DC9FA2EF5A6E805B063882232A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5D4C729EB4251E1BFE71063882237D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0025D52B7B6A9611D83D063882226A41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48997E511A7C0C15FDEE063882232276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_98B33669A21C82320B6F06388224EC88" xlink:type="arc" />
    <link:loc xlink:href="exel-20181228.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66C072CA268AE0839B2E063882218F79" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_EC1B4D550558D9C4D39A06388224770B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C39DBF9C9F487EAD0E39F83D445C9A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5A2B009D85D789A9BFBAF83D445C8F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_364E2B621551E2572196F83D445C377E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F100490F95E633707A1EF83D445C5C0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D96A67B65106C6B7538DF83D445CD1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08D2A760FE566724DA94F83D445BE223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4405DBF82502053FD521F83D445D9383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A8793C1A32477A2F3616F83D445DB4E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C5A9B7E72EEDA9480C77F83D445DB322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5D8544AC12D12C5F7C6BF83D445DC8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5960F2DF362BE735A919F83D445DD90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53C5BD5C100BA4CA6137F83D445E3748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_88500F6AAC1B6D8667CEF83D445E85AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16BC64359ABF04739E05F83D445D3F5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2D4E219C31BA07C37C8CF83D445E9CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DBF10781B0A5F4A9CDCFF83D445EBC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_360AC1C221347331C551F83D445ED012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0217CA45B8F073AB0646F83D445FA610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_147CA0C335AF88718919F83D445FE44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0993F4590A776070795DF83D445BA919" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_37640751FF8B69FFB90BF83D445F6AE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A6050F5A25DB4D876132BD7EDD11E3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_328FC234F470CE26EAD3BD7EDD11FD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0B4A5F7A77554B685112BD7EDD11D09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_03E993F4C2AB3D43F05FBD7EDD11D29A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_A481A7AADC21DE52F287BD7EDD113BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09BF4D37A5D1BB4BD91FBD7EDD10FCB6" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_10CA6C68BFDE9135148EBD7EDD122D63" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97DAD86AB7C1C7D4E4F6BD7EDFB75EA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97DAD86AB7C1C7D4E4F6BD7EDFB75EA6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:to="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2C3AEEA9B0E50A25D726BD7EDFB7F515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3428EF8EDDDA40EB2E07BD7EDFB87132" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3428EF8EDDDA40EB2E07BD7EDFB87132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_A034C7525BE8160C2774BD7EDFB8416E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66096BB2FC104E4C42E5BD7EDFB7FD5B" xlink:to="loc_us-gaap_EmployeeStockMember_A034C7525BE8160C2774BD7EDFB8416E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C3FF1177C98EB0941E2BD7EDFB79358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F32EF0BFD055E4379BBABD7EDFB83C21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6F20CF56CFE5BC96AFB7BD7EDFB82703" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exellogo2017aa04.jpg
<TEXT>
begin 644 exellogo2017aa04.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
MA4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;6^,G_16O
MB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KX
MF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;6^,G
M_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_
MT5KXF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;
M6^,G_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&U
MOC)_T5KXF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =
MH_X;6^,G_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':
M/^&UOC)_T5KXF?\ A4WW_P =KS+YO:CYO:BR"[/?_P!G/]L'XMZY^T)X#LKW
MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
MV2,2JRLH96&"".M?CA_P4I_9%;]EOXZS3:7:F/P?XG+WNDE1\EJ<_O;7/_3-
MB-H_N,G)(-?LC7E?[8O[--A^U9\"]5\+W7DPZAM^U:5=.,_9+M =C9[*V2C8
M_A=N^*^#\0N$XY[E;ITU^^IWE!^?6/I):>MGT/U3PAX^EPMGD:M9_P"SU;0J
MKLKZ3]8/7ORN26Y^&]%:'BKPOJ'@GQ+J&CZK:RV6I:7<26MU;R##0R(Q5E/T
M(-9]?QC.,H2<9*S6Y_I%3J1G%3@[IZIK9I]4%%%%24%%%% !1110!Z=^R)^T
MEJ'[*OQRTGQ59^;-9QM]GU.T1L?;;1R/,3ZC 9<]&1?>OV\\(^+-/\=>%M/U
MK2;J.^TO5K>.[M+B/[LL3J&5O7D'H>17\^M?H1_P1F_:^^SW$WPEUZZ_=R&2
M\\/22-]UN6FM1]?FD7W$@[J*_;/!_C#ZGB_['Q,OW=5^XWTGV]);>J7=G\T_
M2(\/?[1P"XBP4?WU!6FEO*GW]8/7_"W?9(_12BBBOZ@/X="BBB@ HHHH ***
M* "BBB@ HHHH ***^>_^"@W[;=C^R'\,=EC)#<^--<1H])M2 P@'1KF0?W$[
M _?; Y <KY^:YIALNPD\;BY<L(*[?Z+NV]$NK/6R'(\;G&/I9;E\.:K4=DOS
M;?1):M]$FSR?_@JQ^WW_ ,*IT*X^''@^^V^)]4AVZM=PM\VE6[C_ %:MVFD4
M]1RBG/!92/R_J[XA\07WBS7;S5-2NI[[4-0F:XN;B9]TDTC'+,Q[DG-4J_BW
MB_BK$Y]CWBZVD5I"/2,?\WNWU?DDE_I1X>\"8/A3*8Y?AO>F]:D[:SEW]%M%
M=%YMME%%%?*GW04444 365E-J5Y#;V\4DUQ<.(XXT7<TC$X"@=R20,5^UW[!
MO[,,/[*O[/>EZ)+%'_;^H8U#6I5Y+W+@93/]V-=J#'!VEL L:^%?^"/7[*O_
M  M;XOR^/=7M?,T'P9(#9AURMUJ!&4Z]?*4^9V(8Q=>17ZI5_2?@OPK[*A+.
M\0O>G>,/*/VI?-JR\D^C/XQ^DEQY]8Q,.&,)+W:=IU;=9->['_MU/F:[M=8A
M1117[R?RJ%%%% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?
M\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 '
MS>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]
MAFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** .7^-/Q6TWX&_";Q%XPU=O^)?
MX=L);Z50<-+L4E8U_P!IVPH]V%?SQ_%GXG:M\:?B;KOBS7)O/U;Q!>R7MRPS
MM5G;.U1V51A5'90!VK]0/^"_7Q[;PM\&?"_P]LYMMQXKO&U&_"M_RZVV-B,/
M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
M3G:5]-5\R_\ !8K_ )1Q_$;_ +AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^
M;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O\ R6/PE_V&;/\ ]'I7
M,?-[5T_P5_Y+'X2_[#-G_P"CTI ?T?4445RG0%%%% !1110 4444 %?F3_P7
M(_89D%Q_PNCPS:;D<1VOB>"-?ND82&\QZ8VQOZ8C..6(_3:JFN:)9^)M%N]-
MU"UAO;"_A>WN;>9 \<\;@JR,#P002"#ZU496=Q-7/YI?F]J/F]J^JO\ @II_
MP3BU/]C?QW+K>AV]Q??#C69S]@NLF1M,D;G[+,>V.=C'[RCJ6#5\J_-[5T)W
MV,-@^;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4
M?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U !\WM7HGP-_:T^)'[-M\LW@OQAK&BQJVYK1)?-L
MY#U^:!]T3'W*YYKSOYO:CYO:EN!^E_[-7_!?UU:WT[XK>%U9>$.LZ$,$=!F2
MV<_B61Q[)VK[^^!_[2'@;]I#PTNJ^"?$VF:_:[09$@DVW%MGM+"V)(S[.HK^
M=+YO:M?P)X_USX8>*+76_#NK:AHFK63;H+NRG:&:/U^92#@]".A'!S6<J:Z%
MJ;/Z3J*_,']C/_@NW=64EKH/QEL_M4/$:>)-.@"R)SUN;=1AA_M1 $ ?<8DD
M?I1X&\>:+\3?"EGKGA[5+'6='U"/S+>[M)A+%*OL1W'0@\@@@@$5G*+6YHI)
MFM1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y^?^"@?_ ">Y\5?^
MQFOO_1K5Y!\WM7K_ /P4#_Y/<^*O_8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4
M?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO
M:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^
M;VK]I_\ @A["T?[!FFLRLJR:Q?,I(^\-X&1Z\@C\*_%CYO:OWT_X)M_"6;X*
M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
M\$^H?V0_AC_PD'B*UC;XA>)X%:\+ ,=)MSAEM%/][HTA'!8 <A 3\^?\$6/^
M"> N9;/XS>-+',<9W^%K&=/O,,@WS*?3I%[Y?LC5^G-85)=#2,>H4445F:!1
M110 4444 %%%% !1110!RGQM^#&@?M!_"[6/"'B:S6\T?6H##*O&^)NJ2H?X
M9$8!E/8@=>E?@I^UY^ROK_['WQLU+PAKBM)''_I&G7P7;'J5JQ(29?R(8?PL
MK#G&3_0M7@__  4%_8ETK]MKX)S:1)Y-IXHTG?<Z#J+C_CWF(&Z-CU\J0 *P
M[$*V"4 JHRL3*-S\$OF]J/F]JT_&_@K5?AQXOU+0=<L;C3=7TBX>UN[:9=KP
MR*<$'_$<$8(R"#69\WM708A\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@#] ?\ @C-_P41_X5;XAM_A-XTOMOAO6)B-!O9W^73+IS_Q
M[L3TBE;[O99#Z.2OZR5_,TK;3D<$<@CM7[$?\$@O^"B/_#1W@I/A_P"+[X-X
MZ\.V_P#HEQ,WS:W9H -V3]Z:,8#CJRX?GYR,:D>J-(RZ'V[11161H%%%% !1
M110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\ Z!;U
M4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!W7[+W
M_)ROP[_[&;3?_2J*OZ*Z_G4_9>_Y.5^'?_8S:;_Z515_176%0TIA11169H%%
M%% !1110!PO[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK^BO]J#_DVGXB?]BSJ7_I
M++7\ZGS>U;4C.H'S>U'S>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !
M\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1
M\WM1\WM0 ?-[4?-[4?-[4?-[4 ?J+_P;O?\ (F?%+_K\T[_T"XK](*_.7_@W
MBL)(_AY\3KH[?+FU&QB7GG*13$_^AC]:_1JN:I\1M'8****DH*^9?^"Q7_*.
M/XC?]PW_ -.=I7TU7S+_ ,%BO^4<?Q&_[AO_ *<[2JCN@/PT^;VH^;VH^;VH
M^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K_R6/PE_P!A
MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\N_;"_:-L_V6?@)K7BNX:-[Z-/
MLNEV[G_CZO) 1&N.X&"[8YV(QKU&OR1_X*S?M5_\+V^/+>&=+N/,\->"&>T0
MHV4NKP\3R^X4@1KU'R,0</7P_B!Q0LCRF=>#_>S]V'^)]?\ MU:^MEU/T[PE
MX'EQ/Q!3PM1?N*?OU7_=3^'UF[1[VNUL?+NO:[>>)]<O-2U"XEO+_4)WN;F>
M0Y>:1V+,Q/J22?QJG117\6RDY/FEJS_2B,8QBHQ5DMD@K[:_X)2_L#?\+:UV
MW^)'B^RW>%]+GSI-G,ORZK<(?]8P/WH8V'3H[C!R%93Y+_P3]_8GOOVO?BA_
MIBSVO@W0W235[M?E\W/*VT9_YZ/W/\"Y/4J#^Q_A[P]8^$]"L]+TRU@L=/T^
M%;>VMX4VQPQJ %51V  Q7[5X4\ _7ZJSC'Q_<Q?N)_;DNK_NQ?WO39-/^:?'
MCQ7_ +*H2X=RF?\ M%1?O)+>G%K9/I.2^<8Z[M-7:***_J _A\**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CFF6WA:
M21E1$4L[,<*H'4DT >"?\%&_VIQ^RY^SO?7%C<>5XG\1;M-T<*<-$[#]Y./^
MN2'(/]\Q@]:_&1W:1RS$LS'))/)->[?\%$/VI6_:E_:(U"^LYVD\,Z'G3=&7
M/RO$K?//CIF5\MGKMV _=KP>OXU\2N*O[:S:7LG>C2O&'9]Y?]O/;R2/]&_!
M?@3_ %:X?A[>-L17M.IW5U[L/^W4]?[SD%=]^S7^SMKW[4/Q8T_PKX?C_>W!
M\R[NF7,6GVX(WS/[#(P,@LQ51R:Y7P5X+U3XB^+=/T+1+*;4=6U6=;:UMX1E
MI78X ] .Y)P  22 ":_9O]AG]CK2_P!C_P"%$>GKY-WXEU0)/K6H ?ZZ4 XB
M0]?+CR0OJ<L<%L"?#_@FKG^-_>75"&LWW_NKS?X+7>R=^+7B91X3RW]RU+%5
M4U3CV[SDOY8]%]IZ;7:[SX$_!'0?V=OA?I?A/PY;^1I^FQX:1L&:[E/WYI#_
M !.QY/8<  * !V-%%?V-A\/3H4HT:,5&,4DDMDELD?YTXS%UL57GB<3)RG-M
MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>fiveyearchart2018.jpg
<TEXT>
begin 644 fiveyearchart2018.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (<! ,# 2(  A$! Q$!_\0
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MS320%Y)9'9F9V)9F8DDDDU[9_P .G?V6?^C:?V?_ /PWFD?_ "/1_P $G?\
ME%E^S3_V2KPO_P"FBUKZ H ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^
MRS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT
M[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_
M (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y
M'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_
M )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#A
MO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[
M/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_
ML_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_
M $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+
M/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT
M[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\
MAT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G
M_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@**
M/G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH
M"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>
MOH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_
M )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\
MTC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L_
M_P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_
ML_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\
M1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+
M/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O
M[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\
MAT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>
MC_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\
MD>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\
MTC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;
MS2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L_
M_P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\
M1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_
M]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O
M[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'
M3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_
M /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^
M?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@*
M* /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^
M@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\
MD>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2
M/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;
MS2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__
M .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&
MT_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_
M]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._L
ML_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'
M3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/
M^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1
MZ/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2
M/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-
M(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__
M .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_
M /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&
MT_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T
M;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._L
ML_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=.
M_LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\
M^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y_
M_P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH
M ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ
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M_B7Q]HL)\'_'#3?AIXDUT^'=)^+%_P"#'@\!ZC=;Y(D\N_,F\J\T;1!C"-K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _D"_P"#H[_E.O\ '/\ [@'_ *C^F44?\'1W_*=?XY_]P#_U'],HH _I
M]_X)._\ *++]FG_LE7A?_P!-%K7T!7S_ /\ !)W_ )19?LT_]DJ\+_\ IHM:
M^@* "OC']J[_ ((?_#G]J'X[>(_B'8_$3XZ?"+7/'5I#9^,(?AUXP.B67C%(
M8S%$;^$Q2"4K"S1_+M!5FR"22?LZBI<8MIM?T]T^Z?9Z%*32:77]-5]W<^9?
MCM_P22^#?QN_90\$_!^VT[7/ .@?#&XMKWP5J?A'5)--UKPE=0 A+FTNCO;S
MB&?<THDWLY=LR!7%C]B?_@EQ\/\ ]B:3QAJ4&N>/_BCXQ\?1QVNO^+?B)KAU
M_7-3LXTV16;S,B+]G12V$"#.?F+;5V_25%5+5SE+5SO>^M[Z._FTDF^JT>A"
MBE&,5M&UO*VJ7HGJELGJM3X-^&7_  ;P_!?X9?$30;Q?&7QP\0?#WPGK']NZ
M!\+=;\:27O@;1;I9'EA:&P:/>1%([.HDE?))W[P6!^\J**KF?*H]/UTU?=Z+
M5ZZ+L@LG)SZO^K>FK=MKMOJPHHHJ1GS_ /L;_P#)Q7[6/_95;'_U"/"E?0%?
M/_[&_P#R<5^UC_V56Q_]0CPI7T!0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?R!?\ !T=_RG7^.?\ W /_
M %'],HH_X.CO^4Z_QS_[@'_J/Z910!_3[_P2=_Y19?LT_P#9*O"__IHM:^@*
M^?\ _@D[_P HLOV:?^R5>%__ $T6M?0% !1110 4444 %%%% !1110!\_P#[
M&_\ R<5^UC_V56Q_]0CPI7T!7S_^QO\ \G%?M8_]E5L?_4(\*5] 4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '\@7_  ='?\IU_CG_ -P#_P!1_3**/^#H[_E.O\<_^X!_ZC^F44 ?T^_\
M$G?^467[-/\ V2KPO_Z:+6OH"OG_ /X)._\ *++]FG_LE7A?_P!-%K7T!0 4
M444 %%%% !1110 4444 ?/\ ^QO_ ,G%?M8_]E5L?_4(\*5] 5\__L;_ /)Q
M7[6/_95;'_U"/"E?0% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117EO[77[8/@
MG]BKX27GB[QIJ4=O$BLMC81LIO-6G XA@0G+,<C)^ZH.YB ,UE6K4Z--U:K2
MBM6WLCNRO*\7F.+IX' 4W4JU&HQC%7;;V21Z)?\ B;3=*UBPTZZU"QMM0U4R
M"RM99U2:\,:[I/+0G+[5Y.T' Y/%7J_FQ_:=_P""D7Q,_:6_:;L_B=+K5WX?
MU+P_/O\ #=K83$1:!&#D)'_>9L#S&8?O.A&W"#]AO^"6O_!6CPW^W-X/L_#_
M (BNM-\/_%2S3RKC3&E$2:WM1G:XLU8Y;Y4=GC&6CVL>5PU?*9/QG@\?BI89
M>Z[^ZW]I?H^R[>9_0'B1]&GB3A+(J&>3:K1Y;UXP5_8RNW_V]!*RE-:*2?V6
MF?9%%%%?8'\XA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /BZZRB@#D_^%^>!?^AT\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH
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MZRB@#D_^%^>!?^AT\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH Y/\
MX7YX%_Z'3PG_ .#>W_\ BZ/^%^>!?^AT\)_^#>W_ /BZZRB@#D_^%^>!?^AT
M\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH Y/\ X7YX%_Z'3PG_ .#>
MW_\ BZ/^%^>!?^AT\)_^#>W_ /BZZRB@#D_^%^>!?^AT\)_^#>W_ /BZ/^%^
M>!?^AT\)_P#@WM__ (NNLHH Y/\ X7YX%_Z'3PG_ .#>W_\ BZ/^%^>!?^AT
M\)_^#>W_ /BZZRB@#D_^%^>!?^AT\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__
M (NNLHH Y/\ X7YX%_Z'3PG_ .#>W_\ BZ/^%^>!?^AT\)_^#>W_ /BZZRB@
M#D_^%^>!?^AT\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH Y/\ X7YX
M%_Z'3PG_ .#>W_\ BZ/^%^>!?^AT\)_^#>W_ /BZZRB@#D_^%^>!?^AT\)_^
M#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH Y/\ X7YX%_Z'3PG_ .#>W_\
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M /BZZRB@#D_^%^>!?^AT\)_^#>W_ /BZ/^%^>!?^AT\)_P#@WM__ (NNLHH
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M\VX=>'H_7\%/VV&;LII6<6_LU(ZN$_)MQEJX2DDV/_X7YX%_Z'3PG_X-[?\
M^+H_X7YX%_Z'3PG_ .#>W_\ BZZRBO:/FCD_^%^>!?\ H=/"?_@WM_\ XNC_
M (7YX%_Z'3PG_P"#>W_^+KK** .3_P"%^>!?^AT\)_\ @WM__BZ/^%^>!?\
MH=/"?_@WM_\ XNNLHH Y/_A?G@7_ *'3PG_X-[?_ .+H_P"%^>!?^AT\)_\
M@WM__BZZRB@#D_\ A?G@7_H=/"?_ (-[?_XNC_A?G@7_ *'3PG_X-[?_ .+K
MK** .3_X7YX%_P"AT\)_^#>W_P#BZ/\ A?G@7_H=/"?_ (-[?_XNNLHH Y/_
M (7YX%_Z'3PG_P"#>W_^+H_X7YX%_P"AT\)_^#>W_P#BZZRB@#D_^%^>!?\
MH=/"?_@WM_\ XNC_ (7YX%_Z'3PG_P"#>W_^+KK** .3_P"%^>!?^AT\)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KG?BM\5="^"G@'4?$WB2^CT[2-+C\R:5N2QZ*BKU9V.
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MHH **** /Y O^#H[_E.O\<_^X!_ZC^F44?\ !T=_RG7^.?\ W /_ %'],HH
M_I]_X)._\HLOV:?^R5>%_P#TT6M?0%?/_P#P2=_Y19?LT_\ 9*O"_P#Z:+6O
MH"@ HHHH **** "BBB@ HHHH ^?_ -C?_DXK]K'_ +*K8_\ J$>%*^@*^?\
M]C?_ ).*_:Q_[*K8_P#J$>%*^@* "BBB@ HHHH **** "BBB@ HHHH ****
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MX#TJ^CAN-3NY[87$@DNI%VPVT$9)EN60J@VEE4$E>;_8X_X*QZE\6/B[X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M217*LX+$,P-']BS_ ()W_!?_ ()W^"-2\/?!OP%IG@O3=:N1=:@8YY[RZOG
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M^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\
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M#D_['\=?]#'X3_\ "<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\
M0Q^$_P#PG+C_ .3J/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?]#'X3_\
M"<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J
M/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?]#'X3_\ "<N/_DZC^Q_'7_0Q
M^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\ 0Q^$_P#P
MG+C_ .3JZRB@#D_['\=?]#'X3_\ "<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK**
M .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_[
M'\=?]#'X3_\ "<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$
M_P#PG+C_ .3J/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?]#'X3_\ "<N/
M_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\
M=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?]#'X3_\ "<N/_DZC^Q_'7_0Q^$__
M  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\ 0Q^$_P#PG+C_
M .3JZRB@#D_['\=?]#'X3_\ "<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_
M +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?
M]#'X3_\ "<N/_DZC^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#P
MG+C_ .3J/['\=?\ 0Q^$_P#PG+C_ .3JZRB@#D_['\=?]#'X3_\ "<N/_DZC
M^Q_'7_0Q^$__  G+C_Y.KK** .3_ +'\=?\ 0Q^$_P#PG+C_ .3J/['\=?\
M0Q^$_P#PG+C_ .3JZROFGXX_%37OVHOB+J'PC^&E])I^GV)\KQIXK@Y72XSD
M&RMST:X< @D'Y!D=0Q7S<TS2&"I*33E.3M&*WE+LOS;>D4FWHCVLCR2KF59P
M4E"G!<TYR^&$5O)]^T8K64FHQ3;.7\=^+O'W[:WC?7/AGX3\3Z5;^"-+/V?Q
M3XKTW2I;</)SG3[<M<OYN[@2,I4 9&<$!_>O 7PJ\1?"_P ':?X?T#5/!>EZ
M/I<0AMK:'PW<!8U'/_/]DDDDECDDDDDDDUT7PI^%6A?!3P#IWAGPW81Z=I&E
MQ^7#$O)8]6=FZL[')+'DDUT5<V597.E*6,QC4J\UJUM%=(0[17?>3]Y]$NS/
ML[I5X1R_+HN&%IN\4_BG+9U*EM'.71;0C[L>KER?]C^.O^AC\)_^$Y<?_)U'
M]C^.O^AC\)_^$Y<?_)U=917MGS)R?]C^.O\ H8_"?_A.7'_R=1_8_CK_ *&/
MPG_X3EQ_\G5UE% ')_V/XZ_Z&/PG_P"$Y<?_ "=1_8_CK_H8_"?_ (3EQ_\
M)U=910!R?]C^.O\ H8_"?_A.7'_R=1_8_CK_ *&/PG_X3EQ_\G5UE% ')_V/
MXZ_Z&/PG_P"$Y<?_ "=1_8_CK_H8_"?_ (3EQ_\ )U=910!R?]C^.O\ H8_"
M?_A.7'_R=1_8_CK_ *&/PG_X3EQ_\G5UE% ')_V/XZ_Z&/PG_P"$Y<?_ "=1
M_8_CK_H8_"?_ (3EQ_\ )U=910!R?]C^.O\ H8_"?_A.7'_R=1_8_CK_ *&/
MPG_X3EQ_\G5UE% ')_V/XZ_Z&/PG_P"$Y<?_ "=7C7Q/_8R\777Q%?XA>"/%
MOAWPKX\1#Y[66BS6UEK_ '$5ZAN9%8'^^$+C.>2%Q](T5PYAEN'QM/V6(5[.
MZ:T<7T<6M4UW3_ ]3*<XQ>6UO;X25KJTDTG&47O&<7=2B^J::Z[I,^;?@=^U
M3XN\?^-;CP3XPN_#/@'XB6>2VBWVA3R1WZ<XEM)_MH6=#@GY>1@\$ FO9O['
M\=?]#'X3_P#"<N/_ ).K/^/W[-_A;]I'PJFF^(K-_/M6\W3]2M7\F^TN7@B2
M"4<JP(!QRIP,@XKR'0OCYXR_8[U>U\._&.5]>\'SR"WTKQ];PG:F3A(M1C&3
M&_;S!D-W+'<P\6.88C+'[/,WS4NE6UK>55+2+_OKW'U4':_TDLGP>=1=;)(\
ME?>6'NW?NZ#>LE_T[;=1?9=17:]N_L?QU_T,?A/_ ,)RX_\ DZC^Q_'7_0Q^
M$_\ PG+C_P"3JZ;3M2M]8T^&[L[B&ZM;J-989H7$D<J,,AE8<$$<@C@U-7TZ
M::NCXB46G9[G)_V/XZ_Z&/PG_P"$Y<?_ "=1_8_CK_H8_"?_ (3EQ_\ )U=9
M13$<G_8_CK_H8_"?_A.7'_R=1_8_CK_H8_"?_A.7'_R=7644 <G_ &/XZ_Z&
M/PG_ .$Y<?\ R=1_8_CK_H8_"?\ X3EQ_P#)U=910!R?]C^.O^AC\)_^$Y<?
M_)U']C^.O^AC\)_^$Y<?_)U=910!R?\ 8_CK_H8_"?\ X3EQ_P#)U']C^.O^
MAC\)_P#A.7'_ ,G5UE% ')_V/XZ_Z&/PG_X3EQ_\G4?V/XZ_Z&/PG_X3EQ_\
MG5UE% !1110 4444 %%%% !1110!_(%_P='?\IU_CG_W /\ U'],HH_X.CO^
M4Z_QS_[@'_J/Z910!_3[_P $G?\ E%E^S3_V2KPO_P"FBUKZ KY__P""3O\
MRBR_9I_[)5X7_P#31:U] 4 %%%% !1110 4444 %%%% 'S_^QO\ \G%?M8_]
ME5L?_4(\*5] 5\__ +&__)Q7[6/_ &56Q_\ 4(\*5] 4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]G+PK^TCX372_$MDSR6S^=8W]L_DWNF3<$2P2CE&! ..5.!D&O'=$^//C/\
M8UU>V\/_ !AEE\0^"YY%M]*\?6\)/E9.$BU&,9*/T'FC(/&2QW,OTY7#_M)_
M$'3OA7\!_%/B#5_#>J>+]+TNP>6ZT;3[$7UQJ$?"E!$>&7G+$\*H9CP#7@YG
ME2<WC\+/V59+65KQDETG'[2[/24?LM:I_8</9Q5J\F2XJE]8HU))1A>THRDT
MKTIOX)-VNG>$OMQ=DUB_M-?ME> /V3/@POCSQ9K,?]AW#Q1V7V%DN)M3:0C:
M+=0P$GRDN2#@(I/05WW@OQKI/Q&\):=KV@ZC::MHVK0)=6=Y:R"2&YB895E8
M=0:_F#^/_P >=0^.OC.XNFCFTGP[;W,\FBZ EY+<6>A0RON,4/F,<9X+,,;B
M,X P!]/?\$AO^"H?B[]D'QY;^![C1_$7CSP/X@G(BT'28#=ZG:73<A[&/(W%
MS]Z+(#?>!#9W?'Y;XAJKC%2Q4%&#25TV[2ZO9-I]-$U]Y_5_%'T.\7@>%OK^
M6XAU,=3<ISA+EC%T[*T(N[2J02;;YG&3;2>D6_WRHHHK]./X@"BBB@ HHHH
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M_"Z='_Y\_%G_ (2VI_\ R/0!UE%<G_PNG1_^?/Q9_P"$MJ?_ ,CT?\+IT?\
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MV=917)_\+IT?_GS\6?\ A+:G_P#(]'_"Z='_ .?/Q9_X2VI__(] '645R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_*++]FG_ +)5X7_]-%K7T!7S_P#\$G?^467[-/\ V2KPO_Z:+6OH"@ HHHH
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MJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\
MDB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K*
M*Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2
MVC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\
MS^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *
MG4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\
M^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%
M+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^
M>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_P
MJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\
MDB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K*
M*Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2
MVC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\
MS^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *
MG4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\
M^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%
M+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^
M>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_P
MJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\
MDB@#K**Y/_A2VC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K*
M*Y/_ (4MH_\ S^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2
MVC_\_GBS_P *G4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\
MS^>+/_"IU/\ ^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y/_A2VC_\_GBS_P *
MG4__ )(H_P"%+:/_ ,_GBS_PJ=3_ /DB@#K**Y/_ (4MH_\ S^>+/_"IU/\
M^2*/^%+:/_S^>+/_  J=3_\ DB@#K**Y"?X.Z);0O))?^*HXXU+,S>*M3"J!
MR23]HZ5\[>,?C*OQ9\2W7A/X&6?B;Q?JMN_DW_B6Z\5:JGA_1B>YE%QF=QU"
MQY!ZC=@BO-S'-L/@HIUG[TM(Q2O*3[1BM7Y]%NVEJ>SD^0XS,Y26&BN6&LYR
M:C""[RD]%Y+=O2*;T/H;XV_'_P )?L[^$FUKQ=K%OI=JV5@C/S7%XX&?+BC'
MS.WL!QG)('->)G3_ (K?MN\WAU3X/_"^XZ6R$+XDUV(_WSR+6-A_#RW4'>IR
M-GX2?\$\_#_AW4+7Q%XZUSQ%\0?'L05AK=[JES"UB1GY+8)(#&HSU+$]2",X
MKUG_ (4MH_\ S^>+/_"IU/\ ^2*\KZCC<R]['MTJ7_/N+]Y_]?)K\80=NCE)
M:'O_ -J9;DWNY2E7KK_E]./NQ?\ TZIR6ZZ5*BYNL80:N.^#WP1\*_ /PA'H
M?A+1K31]/C^9Q$N9+A^F^1SEI&_VF)/;IQ755R?_  I;1_\ G\\6?^%3J?\
M\D4?\*6T?_G\\6?^%3J?_P D5]#0H4Z%-4J,5&,=$DK)+LDMCX_%8JMB:TL1
MB)N<Y.[E)MMONV]6SK**Y/\ X4MH_P#S^>+/_"IU/_Y(H_X4MH__ #^>+/\
MPJ=3_P#DBMCG.LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/
M_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2*
M.LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_
M^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC
M_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_
M  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4
M_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_
M (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH_
M_/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+
M/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/
M_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2*
M.LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_
M^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC
M_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_
M  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4
M_P#Y(H_X4MH__/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_
M (4MH_\ S^>+/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH_
M_/YXL_\ "IU/_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+
M/_"IU/\ ^2* .LHKD_\ A2VC_P#/YXL_\*G4_P#Y(H_X4MH__/YXL_\ "IU/
M_P"2* .LHKD_^%+:/_S^>+/_  J=3_\ DBC_ (4MH_\ S^>+/_"IU/\ ^2*
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MIOK)A1117K'@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGI7 ?\/C?A/>_P#(*TGXG:ZK<1M8>#[QQ,_]Q=RK\V>.<#)ZTG_#V#3;P_\
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M_!FIP7VE_#*Z\+V%K=306LWG6=E>:Q&WGW-O'(%W1F-59455$>U"OZ1*H10
M, < #M7H8BLJE2K66U27,H_R^;Z<TKI.S:M".O1<%&E*G"E1>OLXM.7\U[;=
M;*S>J3O)Z=65YG\;?%7QCT'7[2/X<> _AGXKTM[?=<W'B3QW?>'[B&;<1L2*
M#2+Y73;M.\R(<DC9@;CZ917,=!\B?L%>(?B=>?%[]J";7?"'@/3==D^*-H;^
MSL/%]W>VELX\&^& @BG?387E!B$;$M#&5=W0!@@D?Z/_ +9\=?\ 0N>$_P#P
MH[C_ .0:\K_8W_Y.*_:Q_P"RJV/_ *A'A2OH"@#D_P"V?'7_ $+GA/\ \*.X
M_P#D&C^V?'7_ $+GA/\ \*.X_P#D&NLHH Y/^V?'7_0N>$__  H[C_Y!H_MG
MQU_T+GA/_P *.X_^0:ZRB@#D_P"V?'7_ $+GA/\ \*.X_P#D&C^V?'7_ $+G
MA/\ \*.X_P#D&NLHH _)O_@O9\3OBI\0=<\$_"_5/ =KH7A&ZU)-3L]=M[YM
M0AU6[6%X]JOY<9A$233;D==S?>'R@$_-OC_X,Z5XA^%]MHC>=#!HZ*]O)!&'
ME&P<X'<L,\=R<U^RW[8W[*DG[6GA/1=';Q!'H-KH]^=2R=.%VTLWE/$A!\Q"
MNU)91WSO]J^2_!?_  2=\<:Q\6?%&E:WJ6GZ+X3TI83HVO1!;N372XRP^RAU
M:#R\$-O<Y)&W>,L/F<]S+/XU<+2R_FY:,Y3C).*]^7X*,8KE3DM;R3O?7YOB
M+AE9SB:N+P^&IPC&C"$_?BN?E=G)*<U*4Y2DG*,+M)<T8QA'W?+_ /@G1^V!
M\1K;]G31_AS\*T\&QZ;X;>XBLKCQ%J%K8W^HM-<RW#[$><EPKRLN1$!C RQ!
M(]Y\0_"W]M_QZNS_ (27P#H7F+N#-K3QK%_LD6UD&SSC(8].IXKW'X7?\$Z_
MAOX/^ FC^!=?\.Z#XJ326NF&H2:>+>X8SW,MPVUPS21@&4C"R8X&,# &7_PP
M%>?#=A)\*_BCXX\!K'_JM-N)QK&DIZ 6\_3TR6/%=6+Q6/6*J8FKA?;QG*4E
M^]FJB3;:4H<\:4I);M22;O9)'U&5<)Y)B,NP^'GCZV&JQIPC*,HJ5+F44I<L
MZ:=2,;IV3IR:5DY-J[^;[W_@GI^UEXL@9?$7CKX4ZP9,AFN]7UZY*CV!"@\8
MX(QQ3]&_X)@_M#Z1M-MXJ^!%EY:[0K>&6U -_M$W44AS^E?1O_"P?VCO@[G^
MW?!?A+XH:9'_ ,O7AV^.FWX3^\\,PVNW^S'5[PY_P4D^';ZK'I?BZ/Q'\-M:
MDX^Q^*-+EL\GN1* T>W_ &F9<BJH\6912DE7P].A+_I[1BODIS3B_E)FTO!W
M$R7M<&Y8J*ZT:SF[=W&#52/_ &]")XGH'[#?[6&BKL3X_P#A.QB4?(ND>%;#
M32,]<F.S^8>U:7_#!?[0FJ?\A;]H'QE,LGS2_8-?6P)?KE2NGG8N?X1QCBOL
MCPOXPTGQQI27VBZIINL6,GW;BRN4N(F^C(2/UK2KZZEGU=Q3H\B73EITTOE:
M*/FI\+X2G)TZBJ76ZE5JO[TYGQ+_ ,.RO'^I_-JWQH^-U^TAQ-%'\6)[>WF7
M^Z8UTO@$<'!YY-'_  Z;BO/FU+5O'FL2+PDEY\5]19HQZ#;8CCO7VU16G^L&
M8=*K7I9?DD3_ *LY9]JBGZMO\VSXE_X<U?#"\.-1^%NEZQ&OW$O/B5K;+&?4
M;85YK8T?_@DK\)]#,9A^ _P[D\I=J_:/%^IW&1TY\RW;<?<Y-?85%3+/\SDK
M/$3_ / Y?YE1X:RB+NL+3O\ X(_Y'S'I'_!.SX=Z(L8A_9]^"K^4^]?M%Z]Q
MDYSSYE@VX>QR*Z73/V2/"^BHRV?P$^!%HLARPACBC#'WQIM>[T5S3S+%S^.K
M)^LG_F==/*<##X*,%Z12_0\OTOX;WFB2L]E\,_A?9NR[2T&HM&2/3(T_I706
MM_XVL;=(8?"_@^&&,;41/$,ZJH] !8\5V%%<DJDI?$[G;"G"'PI+T.3_ +9\
M=?\ 0N>$_P#PH[C_ .0:/[9\=?\ 0N>$_P#PH[C_ .0:ZRBI+/-?BGX3\5_%
M_P"&'B3PEJWA[PVFE^*-+N=(O&M_$TZ3+#<1-$Y1C8$!MKG!((!QP:^&?^(=
M3P1_SW\5?^%M;_\ RDK],**]3+\ZQV!BXX2JX)[V/'S/A_+LQE&>-HJ;CHK]
M$?*7["O_  3X/_!/F/Q0O@O3UU(^+C:F\;6O%AF*?9_.\L1^5I<0'^O?.<YX
MZ8Y^@?[9\=?]"YX3_P#"CN/_ )!KK**Y,9C*V*JNOB).4GNWN[*R_!'=@<#A
M\'0CAL+%1A&]DME=W?XMLY/^V?'7_0N>$_\ PH[C_P"0:/[9\=?]"YX3_P#"
MCN/_ )!KK**YCJ.3_MGQU_T+GA/_ ,*.X_\ D&C^V?'7_0N>$_\ PH[C_P"0
M:ZRB@#D_[9\=?]"YX3_\*.X_^0:/[9\=?]"YX3_\*.X_^0:ZRB@#D_[9\=?]
M"YX3_P#"CN/_ )!H_MGQU_T+GA/_ ,*.X_\ D&NLHH Y/^V?'7_0N>$__"CN
M/_D&C^V?'7_0N>$__"CN/_D&NLHH Y/^V?'7_0N>$_\ PH[C_P"0:/[9\=?]
M"YX3_P#"CN/_ )!KK** .3_MGQU_T+GA/_PH[C_Y!H_MGQU_T+GA/_PH[C_Y
M!KF_BG^VE\*_@RTD?B#QQH5O=19#6EO-]KN@?0Q0AG'X@5P3?MQ>*?B0?+^&
M?P;\;>(XWX34M:V:'I[#^^CRY,BCKC"D]*\/$\29;1G[)U5*?\L+SE_X#!2E
M^!]-@^#<YQ-)8B-!PIO[=1JG#_P.HXQ_$]2\4^/_ !9X*\,ZEK.J:+X/L],T
MFUEO;NX?Q%<E8(8T+NY L2<!5)X&>*_#[_@JA_P5P\0?MSZI_P (KH*MH'PX
MTR;/V6"=W;794;Y;B9F2-O+& 4C9!C[S#=@)^N!^&7[1?Q;YU_Q_X3^&^GR?
M>L_#.FF^NRO]UI[@C8W^U'D5\ ?\%3/^"&LGPI^'UY\2OAC?ZSXC_L]);WQ1
M87[1O<NO+R7D&Q%!5>2\>"0!N!."*^1XJQ6:X["-82A.%)*\N;E4I+R2DY6Z
MM.*?J?TI]&W_ %)R/B:$N(L13J8N34:#3E*G3F[_ !-P4.=Z*$E.23?1V9\U
M?\$_?^"JOQ$_8JT:^\(Z;J=C)X3UN0>7_:<,ES'X>F=@'NH$7G&"2T>&#$!@
MI.0WZ]?LE? .XM-'TGXGK:>'_B1XF\6:?!JD'BS6->NA-+;SQ"2,V\+V&;9"
MCC"8#J&VDX&!\8_\$8/^"-\?B&WT?XQ?%C34DT^14OO#/A^Y3<MT#AH[RY4]
M8SPT<9^]PS?+@-^NE7P;D5=TH8K,?>4?X<97?+_>2;LF^CMS);-+1S])[C;A
MVMGM7 \*KEK-M8JI3Y5&K)67(VH\TG&WOM24&]XRDN9<G_;/CK_H7/"?_A1W
M'_R#1_;/CK_H7/"?_A1W'_R#7645^CG\CG)_VSXZ_P"A<\)_^%'<?_(-']L^
M.O\ H7/"?_A1W'_R#7644 <G_;/CK_H7/"?_ (4=Q_\ (-']L^.O^A<\)_\
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M_P *.X_^0:/[9\=?]"YX3_\ "CN/_D&NLHH Y/\ MGQU_P!"YX3_ /"CN/\
MY!H_MGQU_P!"YX3_ /"CN/\ Y!KK** .3_MGQU_T+GA/_P *.X_^0:/[9\=?
M]"YX3_\ "CN/_D&NLHH Y/\ MGQU_P!"YX3_ /"CN/\ Y!H_MGQU_P!"YX3_
M /"CN/\ Y!KK** .3_MGQU_T+GA/_P *.X_^0:/[9\=?]"YX3_\ "CN/_D&N
MLHH Y/\ MGQU_P!"YX3_ /"CN/\ Y!H_MGQU_P!"YX3_ /"CN/\ Y!KK** .
M3_MGQU_T+GA/_P *.X_^0:/[9\=?]"YX3_\ "CN/_D&NLHH Y/\ MGQU_P!"
MYX3_ /"CN/\ Y!H_MGQU_P!"YX3_ /"CN/\ Y!KK** .3_MGQU_T+GA/_P *
M.X_^0:/[9\=?]"YX3_\ "CN/_D&NLHH Y/\ MGQU_P!"YX3_ /"CN/\ Y!H_
MMGQU_P!"YX3_ /"CN/\ Y!KK** .3_MGQU_T+GA/_P *.X_^0:/[9\=?]"YX
M3_\ "CN/_D&NLHH Y/\ MGQU_P!"YX3_ /"CN/\ Y!H_MGQU_P!"YX3_ /"C
MN/\ Y!KK** .3_MGQU_T+GA/_P *.X_^0:/[9\=?]"YX3_\ "CN/_D&NLHH
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M$S1%7)'N2*GZKG.'_@UHUEVJ+DE_X'!<O_E,T^O<.8S_ 'C#SP\N]*7M(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?[CBI)?RU/WL?O;53_RH>M_K+@,5IFF!A)_S4G[&?W14J7_E(Y?X:_'#P?\
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MP3\MO#'@O0=-N(<;+K[,)KH?]MI-TG_CU:?6LYQ'\&C&BN]27-+_ , A[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '\@7_!T=_RG7^.?_< _]1_3**/^#H[_ )3K_'/_
M +@'_J/Z910!_3[_ ,$G?^467[-/_9*O"_\ Z:+6OH"OG_\ X)._\HLOV:?^
MR5>%_P#TT6M?0% !1110 4444 %%%% !1110!\__ +&__)Q7[6/_ &56Q_\
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M%% !1110!_(%_P '1W_*=?XY_P#< _\ 4?TRBC_@Z._Y3K_'/_N ?^H_IE%
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M** /G_\ X=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\
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MI'_R/7T!10!\_P#_  Z=_99_Z-I_9_\ _#>:1_\ (]'_  Z=_99_Z-I_9_\
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M /\ AO-(_P#D>C_AT[^RS_T;3^S_ /\ AO-(_P#D>OH"B@#Y_P#^'3O[+/\
MT;3^S_\ ^&\TC_Y'H_X=._LL_P#1M/[/_P#X;S2/_D>OH"B@#Y__ .'3O[+/
M_1M/[/\ _P"&\TC_ .1Z/^'3O[+/_1M/[/\ _P"&\TC_ .1Z^@** /G_ /X=
M._LL_P#1M/[/_P#X;S2/_D>C_AT[^RS_ -&T_L__ /AO-(_^1Z^@** /G_\
MX=._LL_]&T_L_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\ Y'KZ HH
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MJO*MG3YE?^:]2*NUT;BMEHG;6UWTG[#G[>/_  V]9>(IO^%,_'KX0_\ ".O
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M<M6]69PA&$5".B6B"BBBI*"BBB@ HHHH **** "BBB@ KY'_ &_?^"/'@_\
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M%% !1110!_(%_P '1W_*=?XY_P#< _\ 4?TRBC_@Z._Y3K_'/_N ?^H_IE%
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M<W1VZL2G1IN#>MVD^[565-M]%[L7):WYG;M?]=J***DH**** "BBB@ HHHH
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M )4T?\/+/AU_T+G[0'_AB?&__P J:^@** /G_P#X>6?#K_H7/V@/_#$^-_\
MY4T?\/+/AU_T+G[0'_AB?&__ ,J:^@** /G_ /X>6?#K_H7/V@/_  Q/C?\
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M3XW_ /E31_P\L^'7_0N?M ?^&)\;_P#RIKZ HH ^?_\ AY9\.O\ H7/V@/\
MPQ/C?_Y4T?\ #RSX=?\ 0N?M ?\ AB?&_P#\J:^@** /G_\ X>6?#K_H7/V@
M/_#$^-__ )4T?\/+/AU_T+G[0'_AB?&__P J:^@** /G_P#X>6?#K_H7/V@/
M_#$^-_\ Y4T?\/+/AU_T+G[0'_AB?&__ ,J:^@** /G_ /X>6?#K_H7/V@/_
M  Q/C?\ ^5-'_#RSX=?]"Y^T!_X8GQO_ /*FOH"B@#Y__P"'EGPZ_P"A<_:
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MS]H#_P ,3XW_ /E31_P\L^'7_0N?M ?^&)\;_P#RIKZ HH ^?_\ AY9\.O\
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M .'EGPZ_Z%S]H#_PQ/C?_P"5-'_#RSX=?]"Y^T!_X8GQO_\ *FOH"B@#Y_\
M^'EGPZ_Z%S]H#_PQ/C?_ .5-'_#RSX=?]"Y^T!_X8GQO_P#*FOH"B@#Y_P#^
M'EGPZ_Z%S]H#_P ,3XW_ /E31_P\L^'7_0N?M ?^&)\;_P#RIKZ HH ^?_\
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M>J?'_P"/_A7]F/X5:IXR\9:I%I>B:6F68\R7#G.V*)>KR,1@*/<G !(^,/V
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M<SABD:01Q-,A4(_F&1%$.QO-,>TX]HK\2?V%=/B_9@_;R\ _M%>.?"5SX=^
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MTB7J+#("%&[SR5!4J3\>^-/VX?$G[3?@'X-Z8/VEH?%#:'\0/"-YJOP4\-?
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M^S/_ ,$^?'MEX6^+GQ6TKPQXDOH#=+ID&GWNJW4$7RX::.SAF: ,&!3S0F\
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MQ#IL^F:9_P *)M_V7HAX@T2_M[F.3R4O%:/$L3JUPUU]H21D#R-\[,A^[O\
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MO_\ ,Q0!] 45\_\ _"Q_VIO^B-_L_P#_ (>35_\ YF*/^%C_ +4W_1&_V?\
M_P /)J__ ,S% 'T!17S_ /\ "Q_VIO\ HC?[/_\ X>35_P#YF*/^%C_M3?\
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M /X6/^U-_P!$;_9__P##R:O_ /,Q1_PL?]J;_HC?[/\ _P"'DU?_ .9B@#Z
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M /\ AY-7_P#F8H ^@**^?_\ A8_[4W_1&_V?_P#P\FK_ /S,4?\ "Q_VIO\
MHC?[/_\ X>35_P#YF* /H"BOG_\ X6/^U-_T1O\ 9_\ _#R:O_\ ,Q1_PL?]
MJ;_HC?[/_P#X>35__F8H ^@**^?_ /A8_P"U-_T1O]G_ /\ #R:O_P#,Q1_P
ML?\ :F_Z(W^S_P#^'DU?_P"9B@#Z HKY_P#^%C_M3?\ 1&_V?_\ P\FK_P#S
M,4?\+'_:F_Z(W^S_ /\ AY-7_P#F8H ^@**^?_\ A8_[4W_1&_V?_P#P\FK_
M /S,4?\ "Q_VIO\ HC?[/_\ X>35_P#YF* /H"BOG_\ X6/^U-_T1O\ 9_\
M_#R:O_\ ,Q1_PL?]J;_HC?[/_P#X>35__F8H ^@**^?_ /A8_P"U-_T1O]G_
M /\ #R:O_P#,Q1_PL?\ :F_Z(W^S_P#^'DU?_P"9B@#Z HKY_P#^%C_M3?\
M1&_V?_\ P\FK_P#S,4?\+'_:F_Z(W^S_ /\ AY-7_P#F8H ]H^(GA/\ X3[X
M?Z[H7VC[)_;6GW%AY_E^9Y/FQLF_;D;L;LXR,XZBN!_8:_9C_P"&+_V0/AU\
M*?[<_P"$D_X0'0[?1O[4^Q_8_M_E+CS/)WR>7G^[O;'J:Y7_ (6/^U-_T1O]
MG_\ \/)J_P#\S%'_  L?]J;_ *(W^S__ .'DU?\ ^9BB/N\UOM6O_P!N\UON
MYG]^NR"6MK]+V^=K_?RK[O4^@**^?_\ A8_[4W_1&_V?_P#P\FK_ /S,4?\
M"Q_VIO\ HC?[/_\ X>35_P#YF* /H"BOG_\ X6/^U-_T1O\ 9_\ _#R:O_\
M,Q1_PL?]J;_HC?[/_P#X>35__F8H ^@**^?_ /A8_P"U-_T1O]G_ /\ #R:O
M_P#,Q1_PL?\ :F_Z(W^S_P#^'DU?_P"9B@#Z HKY_P#^%C_M3?\ 1&_V?_\
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MT!17S_\ \+'_ &IO^B-_L_\ _AY-7_\ F8H_X6/^U-_T1O\ 9_\ _#R:O_\
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M0!_3]17\P/\ Q&K?M3?]"#^S_P#^"/5__EG1_P 1JW[4W_0@_L__ /@CU?\
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M?M3?]"#^S_\ ^"/5_P#Y9T ?T_45_,#_ ,1JW[4W_0@_L_\ _@CU?_Y9T?\
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MW[4W_0@_L_\ _@CU?_Y9T?\ $:M^U-_T(/[/_P#X(]7_ /EG0!_3]17\P/\
MQ&K?M3?]"#^S_P#^"/5__EG1_P 1JW[4W_0@_L__ /@CU?\ ^6= ']/U%?S
M_P#$:M^U-_T(/[/_ /X(]7_^6='_ !&K?M3?]"#^S_\ ^"/5_P#Y9T ?T_45
M_,#_ ,1JW[4W_0@_L_\ _@CU?_Y9T?\ $:M^U-_T(/[/_P#X(]7_ /EG0!_3
M]17\P/\ Q&K?M3?]"#^S_P#^"/5__EG1_P 1JW[4W_0@_L__ /@CU?\ ^6=
M']/U%?S _P#$:M^U-_T(/[/_ /X(]7_^6='_ !&K?M3?]"#^S_\ ^"/5_P#Y
M9T ?T_45_,#_ ,1JW[4W_0@_L_\ _@CU?_Y9T?\ $:M^U-_T(/[/_P#X(]7_
M /EG0!_3]17\P/\ Q&K?M3?]"#^S_P#^"/5__EG1_P 1JW[4W_0@_L__ /@C
MU?\ ^6= ']/U%?S _P#$:M^U-_T(/[/_ /X(]7_^6='_ !&K?M3?]"#^S_\
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M]7_^6='_ !&K?M3?]"#^S_\ ^"/5_P#Y9T ?T_45_,#_ ,1JW[4W_0@_L_\
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M0!_3]17\P/\ Q&K?M3?]"#^S_P#^"/5__EG1_P 1JW[4W_0@_L__ /@CU?\
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M?M3?]"#^S_\ ^"/5_P#Y9T ?T_45_,#_ ,1JW[4W_0@_L_\ _@CU?_Y9T?\
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;I\7V6TALX_+2:2609CMT+;I&RQ8C ( * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789024352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Feb. 12, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 28,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">exel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,129,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,531.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789490048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 314,775<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">378,559<span></span>
</td>
<td class="nump">204,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash and investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">162,771<span></span>
</td>
<td class="nump">77,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">16,056<span></span>
</td>
<td class="nump">3,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">9,838<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,017<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">897,016<span></span>
</td>
<td class="nump">484,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">157,187<span></span>
</td>
<td class="nump">64,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50,897<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,867<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">244,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">12,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,422,286<span></span>
</td>
<td class="nump">655,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,901<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">21,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">18,231<span></span>
</td>
<td class="nump">19,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">14,954<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">7,419<span></span>
</td>
<td class="nump">8,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">21,825<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,472<span></span>
</td>
<td class="nump">115,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">15,897<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">12,178<span></span>
</td>
<td class="nump">14,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">134,833<span></span>
</td>
<td class="nump">370,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,168,217<span></span>
</td>
<td class="nump">2,114,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(701)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(880,363)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,287,453<span></span>
</td>
<td class="nump">284,961<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,422,286<span></span>
</td>
<td class="nump">$ 655,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Long Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796421664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="nump">296,209,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="nump">296,209,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788809248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">26,348<span></span>
</td>
<td class="nump">15,066<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">182,257<span></span>
</td>
<td class="nump">112,171<span></span>
</td>
<td class="nump">95,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">206,366<span></span>
</td>
<td class="nump">159,362<span></span>
</td>
<td class="nump">116,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (recovery) charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">414,971<span></span>
</td>
<td class="nump">286,567<span></span>
</td>
<td class="nump">219,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">438,855<span></span>
</td>
<td class="nump">165,910<span></span>
</td>
<td class="num">(28,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">12,840<span></span>
</td>
<td class="nump">4,883<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
<td class="num">(33,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">397<span></span>
</td>
<td class="num">(3,537)<span></span>
</td>
<td class="num">(11,616)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net:</a></td>
<td class="nump">13,237<span></span>
</td>
<td class="num">(7,333)<span></span>
</td>
<td class="num">(42,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">452,092<span></span>
</td>
<td class="nump">158,577<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">237,978<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income (loss) per share, basic (in shares)</a></td>
<td class="nump">297,892<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">312,803<span></span>
</td>
<td class="nump">312,003<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 619,279<span></span>
</td>
<td class="nump">$ 349,008<span></span>
</td>
<td class="nump">$ 135,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 234,547<span></span>
</td>
<td class="nump">$ 103,469<span></span>
</td>
<td class="nump">$ 56,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780974784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(354)<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 689,716<span></span>
</td>
<td class="nump">$ 154,296<span></span>
</td>
<td class="num">$ (70,406)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities. During the year ended December&#160;31, 2018, there was a tax benefit of $0.2 million related to other comprehensive income as a result of the release of our valuation allowance for our deferred tax assets; there was no income tax benefit or provision related to other comprehensive income (loss) during the remaining periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6665965488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net loss resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Income tax expense (benefit) related to other comprehensive income</a></td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792739504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Jan. 01, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">227,960,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jan. 01, 2016</a></td>
<td class="num">$ (140,806)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 1,772,123<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
<td class="num">$ (1,912,925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(70,222)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(184)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,009,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="nump">253,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">253,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,953,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">24,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">289,923,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 30, 2016</a></td>
<td class="nump">89,318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">2,072,591<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,983,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154,227<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">69<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,408,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,409<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">17,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">877,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock on exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 23,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 29, 2017</a></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 29, 2017</a></td>
<td class="nump">$ 284,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">2,114,184<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">690,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income | ASU 2016-02</a></td>
<td class="num">(500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(354)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,666,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">13,411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">13,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 40,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 28, 2018</a></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,168,217<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (880,363)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities. During the year ended December&#160;31, 2018, there was a tax benefit of $0.2 million related to other comprehensive income as a result of the release of our valuation allowance for our deferred tax assets; there was no income tax benefit or provision related to other comprehensive income (loss) during the remaining periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789410448">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,915<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,626<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
<td class="nump">22,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash', window );">401(k) matching contributions made in common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightofUseAssetAmortization', window );">Right-of-Use Asset, Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,854<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(244,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">13,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">8,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,825)<span></span>
</td>
<td class="nump">8,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
<td class="num">(2,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,358)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(85,471)<span></span>
</td>
<td class="num">(43,299)<span></span>
</td>
<td class="num">(38,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,410)<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,181)<span></span>
</td>
<td class="num">(3,319)<span></span>
</td>
<td class="num">(722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,029)<span></span>
</td>
<td class="num">(3,268)<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,086)<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">856<span></span>
</td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,069<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">16,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,618)<span></span>
</td>
<td class="nump">5,718<span></span>
</td>
<td class="num">(3,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInRebatesAndFeesPayable', window );">Rebates and fees due customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,389<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">3,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseinAccruedCollaborationLiability', window );">Accrued collaboration liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,555)<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
<td class="num">(10,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">271<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
<td class="nump">256,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,225)<span></span>
</td>
<td class="nump">14,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,227<span></span>
</td>
<td class="num">(9,173)<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">415,720<span></span>
</td>
<td class="nump">165,611<span></span>
</td>
<td class="nump">210,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33,297)<span></span>
</td>
<td class="num">(21,143)<span></span>
</td>
<td class="num">(1,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">308<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(557,832)<span></span>
</td>
<td class="num">(319,090)<span></span>
</td>
<td class="num">(369,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">280,826<span></span>
</td>
<td class="nump">336,590<span></span>
</td>
<td class="nump">151,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,936<span></span>
</td>
<td class="nump">37,294<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(297,850)<span></span>
</td>
<td class="nump">36,795<span></span>
</td>
<td class="num">(214,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,076<span></span>
</td>
<td class="nump">17,555<span></span>
</td>
<td class="nump">25,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,202<span></span>
</td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,574)<span></span>
</td>
<td class="num">(6,563)<span></span>
</td>
<td class="num">(4,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on financing lease obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(185,788)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentsforConversionofConvertibleDebt', window );">Payments on conversion of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,691<span></span>
</td>
<td class="num">(169,928)<span></span>
</td>
<td class="nump">15,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127,561<span></span>
</td>
<td class="nump">32,478<span></span>
</td>
<td class="nump">11,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,314<span></span>
</td>
<td class="nump">155,836<span></span>
</td>
<td class="nump">144,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
<td class="nump">155,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,460<span></span>
</td>
<td class="nump">21,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,677<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Property and equipment deemed to have been acquired in build-to-suit lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred to acquire Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 286,925<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for the year ended December&#160;31, 2018 include the transition adjustment for the adoption of Topic 842.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInRebatesAndFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Rebates And Fees Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInRebatesAndFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseinAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseinAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentsforConversionofConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Conversion of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentsforConversionofConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785644640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">products resulting from our discovery efforts have progressed through clinical development an</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">d received regulatory approval; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have a growing commercial presence in markets worldwide, and we expect that the fourth will soon enter the marketplace in Japan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other commercially available products resulting from our discovery efforts include COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech), and MINNEBRO&#8482; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, and December 28, 2018 are indicated as being as of and for the years ended (or ending, as applicable) December&#160;31, 2016, 2017 and 2018, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2016-18)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash are included with cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in Net cash provided by investing activities for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 4. Cash and Investments&#8212;Cash, Cash Equivalents and Restricted Cash&#8221; for a reconciliation of cash and cash equivalents presented in our previously published Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2016 and Cash, cash equivalents and restricted cash reported in the accompanying Consolidated Statement of Cash Flows for the same periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification (ASC) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 605)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2018 we early adopted Topic 842. We adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2018 in accordance with ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under previous lease guidance, ASC Topic 840: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 840). We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2018.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Impact of Adoption of Topic 606 and Topic 842</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 842, with the impact relating to a change in the classification of certain of our buildings in our Lease Agreement (the Lease) with Ascentris 105, LLC (Ascentris) from a build to suit lease to an operating lease. For a description of the Lease, see &#8220;Note 11. Commitments.&#8221; </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Includes deferred rent and current portion of operating lease liabilities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen&#8217;s filing with the European Medicines Agency (EMA) for cabozantinib as a treatment for patients with previously treated HCC, that was deemed probable under Topic 606 prior to January 1, 2018. Deferred revenue as of January 1, 2018 was related to the up-front, nonrefundable, fees and milestones earned that were allocated to our research and development services performance obligation which had not been satisfied as of that date. Contract assets and liabilities are netted by collaboration agreement in our Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 842 primarily related to the recognition of an operating lease right-of-use asset and operating lease liability for the Lease. In addition, the adoption of Topic 842 resulted in a change in classification of the build-to-suit component of the Lease under Topic 840 to an operating lease under Topic 842 and as a result we derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December 31, 2017, as we had been deemed to own these buildings under Topic 840. For a description of the Lease, see &#8220;Note 11. Commitments&#8221; in these Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 606 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 842 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balances Without the Adoption of Topic 606 or 842</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">889,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">205,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">413,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">488,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(48,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(84,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">774,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we had not adopted Topic 606, we would also have recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2018 upon the validation of Ipsen&#8217;s filing with the EMA for cabozantinib as a treatment for patients with previously treated HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously reported deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were nominal. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory-related costs are recognized as Cost of goods sold in the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Office equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 606.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Topic 808: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> amounts remaining related to previously expensed materials in our inventory balances as of December&#160;31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in our Consolidated Balance Sheet at December 31, 2018. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For lease agreements entered into after the adoption of Topic 842 that include lease and non-lease components, such components are generally accounted for separately. For our building leases, as a result of us having elected to adopt the package of practical expedients permitted under the Topic 842 transition guidance, we account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 840</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 842.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) is estimated as the value of the underlying shares of our common stock. The grant date fair value of stock-options is estimated using a Monte Carlo simulation pricing model for stock options that include market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on an accelerated basis over the requisite service period for awards with a market or performance condition and on a straight-line basis over the requisite service period for all other awards. Compensation expense relating to awards subject to performance conditions is recognized when management determines that it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis. We have made an election to record forfeitures when they occur. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 8. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Topic 808 to the unit of account guidance in ASC 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778686800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">REVENUES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">402,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(119,250</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,561</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,124</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">192,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,286</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenue, were recorded in accordance with Topic 808 for all periods presented.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">599,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">110,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">305,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">46,856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">632,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&#8217; headquarters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(74,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,978</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of Trade receivables, net and the remaining reserve balances are classified as Other current liabilities in the accompanying Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(46,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,417</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,428</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$198.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786312560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, Daiichi Sankyo, Merck &amp; Co., Inc. (Merck) and Bristol-Myers Squibb Company (BMS) for other compounds and programs in our portfolio.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit sharing payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of December 31, 2018, we have also achieved aggregate milestones of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$275.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to development, regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$140.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones recognized during 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$84.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$519.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with sales-based milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were initially entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales; this amount was reached in the second quarter of 2018. As of December 31, 2018 and going forward, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales (with separate tiers for Canada); these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of annual net sales and a tiered royalty thereafter to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers for Canada will also reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Consistent with our historical agreement with GSK, we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such costs, provided Ipsen chooses to opt into such trials.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied at our cost, as defined in the agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$48.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets. See &#8220;&#8212;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Description of the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Consideration under the Collaboration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upfront nonrefundable payment from Takeda. During the year ended December 31, 2018, we also achieved a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development related milestone.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestone payments, without limit, for additional potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with sales volume milestones and receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and following this initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales thereafter; these </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers will reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Consistent with our historical agreement with GSK, we are required to pay a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenues from the Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:504px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of December&#160;31, 2018, the net contract liability for the collaboration agreement with Takeda was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term portion of deferred revenue in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified two performance obligations for both the Ipsen and Takeda collaboration agreements: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have allocated the transaction price for each of these collaborations, which are described below, to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The portion of the transaction price allocated to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union (EU) for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on our evaluation of the collaboration agreements as of January 1, 2018, the date adoption of Topic 606, we determined that for both agreements, the up-front, nonrefundable payments, the milestones and royalties achieved as of December 31, 2017, and our estimate for the reimbursements of our research and development services performance obligation over the term of each agreement constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. In addition, the transaction price for the Ipsen collaboration agreement included a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expected to achieve during the three months ended March 31, 2018. Other than that </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone, variable consideration for both agreements related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the year ended December&#160;31, 2018, the transaction price increased as a result of the achievement of various milestones described above. We further updated the transaction price based upon the impact of research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December 31, 2018, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">BMS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC and HCC in the CheckMate 9ER and CheckMate 040 trials, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Each party will be responsible for supplying finished drug product for the applicable clinical trial and unless otherwise agreed between the parties, costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear two-thirds of the costs for such study treatment arms and we will bear one-third of the costs. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The Roche Group (Roche) Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b trial evaluating the safety and tolerability of the combination in patients with locally advanced or metastatic tumors, and in December 2018, we initiated COSMIC-312, a phase 3 pivotal trial evaluating the combination versus sorafenib in previously untreated advanced HCC, with an exploratory arm also evaluating cabozantinib monotherapy in previously untreated advanced HCC. We are the trial sponsor, and Roche is providing atezolizumab free of charge.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, GSK continues to be entitled to a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay on all net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">StemSynergy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Therapeutics, Inc. (StemSynergy) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">), a component of the Wnt</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> signaling pathway implicated in key oncogenic processes. Under the terms of the a</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">greement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#945;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we paid&#160;StemSynergy an upfront payment of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in initial research and development funding and provided </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional research and development funding. StemSynergy is eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in additional such funding on an as needed basis. The research and development funding costs incurred to date were included in Research and development expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy will also be eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Invenra</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, Inc. (Invenra) C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ollaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with Invenra, which is focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a project initiation fee of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The payments were included in Research and development expenses in the accompanying Consolidated Statements of Operations. As of December 31, 2018, we also have the right to initiate five additional discovery projects for development subject to an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts. Invenra is eligible to receive payments based on the achievement of specific development and regulatory milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a product containing the lead preclinical asset in the first indication and up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$127.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a product developed from each addition project we initiate. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$325.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per product if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project, basis at any time prior to commercialization, for any or no reason, upon thirty days&#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC for the year ended December 31, 2018 were included Collaboration revenues and profits and losses on for the years ended December&#160;31, 2017 and 2016 were included in Selling, general and administrative expenses. The royalty revenues on ex-U.S. sales were included in Collaboration revenues for all periods presented. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allows for us to provide up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the total sales force for approved cobimetinib indications in the U.S. Between November 2015 and December 2017, we fielded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a review of the commercial landscape, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Profit Sharing and Royalty Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of U.S. actual sales, decreasing to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. These tiers will reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cobimetinib Clinical Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cobimetinib is being evaluated by Genentech in a development program consisting of more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> clinical trials. These trials are being sponsored by Genentech or through Genentech&#8217;s investigator sponsored trial program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. In January 2019, subsequent to our year-end, Daiichi Sankyo received approval from the Japanese Ministry of Health, Labour and Welfare for MINNEBRO as a treatment for patients with hypertension. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional development, regulatory and sales-based milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$110.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> under this collaboration agreement, including a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone payment upon the first arm&#8217;s-length sale of MINNEBRO in Japan. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">90 days</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">0.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Merck</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Merck collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Price for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (PI3K-&#948;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-&#948; program. Subsequent to December 31, 2018, we have been notified by Merck that they will be terminating their PI3K-&#948; program, including their development activities under this collaboration agreement. Upon the termination of the collaboration agreement by Merck, the license granted to Merck will terminate. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">BMS - ROR Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">BMS collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Since July 2013, BMS has been solely responsible for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible for additional development and regulatory milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$240.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate and sales-based milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Performance Obligations and Transaction Prices for our Other Collaborations &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have evaluated our collaborations agreements with Genentech, Daiichi Sankyo, Merck and BMS and have determined that those collaboration agreements each have one performance obligation: the delivery of intellectual property licenses to the collaboration partner. We have further determined that the licenses we provided represent functional intellectual property that was transferred at a point in time, when the agreements were executed</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> prior to the adoption of Topic 606. Potential variable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones and therefore, any additional consideration earned and received from these collaborations will be fully recognized when the milestone is no longer constrained. Any variable consideration related to royalties and other sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778686800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentTextBlock', window );">Cash and Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CASH AND INVESTMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">314,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">852,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">851,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">zero</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">236,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">275,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">320,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">199</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">674,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Cost Method Equity Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, related to the August 2016 sale of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> interest in Akarna Therapeutics, Ltd. (Akarna) to Allergan Holdco UK Limited (Allergan). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other, net in the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;During 2018, BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that their beneficial ownership increased to more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and investments managed by BlackRock was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$298.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$141.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> invested in the BlackRock Liquidity Money Market Fund. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We incurred </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in fees for BlackRock advisory services performed during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments, including all tables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 6<br> -Section 10<br> -Paragraph (c)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778638192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory included in Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets in the accompanying Consolidated Balance Sheets. As of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of a portion of our finished goods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778532608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">68,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into the Lease for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. For a description of the Lease, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">see &#8220;Note 11. Commitments.&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in related Leasehold improvements, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778677696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,511</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we granted stock options and RSUs to employees and directors. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">14,693,867</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term, an exercise price equal to the fair market value on the date of grant, and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year life from the date of grant. Stock options issued prior to May 2011 have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year life from the date of grant. RSUs granted to our employees generally vest annually over a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">its outstanding </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">stock options accelerated with the exercise period being extended to no more than one year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">4,722,008</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">330,492</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">434,523</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">559,936</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$15.74</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$11.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$3.91</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Cash received</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP in the years ended December 31, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,238,473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,466,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(288,197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(18,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,674,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">254,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,463,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">229,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, in connection with our long-term incentive compensation program, we granted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">308,365</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> stock options to our President and Chief Executive Officer that have a market vesting condition (PSOs). In addition to the standard service conditions included in our other stock options, these PSOs </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equal to or greater than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">125%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the per share exercise price of the PSO over a period of at least 30 consecutive calendar days. The stock-based compensation expense for the PSO is being recognized over the service period of the award, which commenced on the date of grant.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5,870,303</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based stock options vested during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and we recognized</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">in stock-based compensation for those</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock option grants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">. We did</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">t have any</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock options outstanding during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and therefore, did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">stock-based compensation for</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">options during that year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$48.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options, including the PSOs described above. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.5 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the stock option holders had all stock option holders exercised their stock options on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of stock options exercised </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the dates of exercise </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$39.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$85.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from option exercises during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of stock options vested and recorded as expense during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Activity for RSUs during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,519,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,081,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(343,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,857,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, in connection with our long-term incentive compensation program, we awarded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">693,131</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). These PSUs are included in the RSU activity table presented above. The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when the attainment of the performance goal is determined </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">by management </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to be probable. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the year ended December 31, 2018, we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not recognize any compensation expense related to these PSUs. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the total unrecognized compensation expense related to the unvested PSUs was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based RSUs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> issued prior to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$81.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">401(k) Retirement Plan</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the Exelixis, Inc. 401(k) Plan (the 401(k) Plan) whereby eligible employees may elect to contribute up to the lesser of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. During 2018, we made matching contributions in the form of our common stock of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$8,500</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of each participant&#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$3.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">571,674</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares were available for issuance under the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">401(k) Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778491488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income (loss) before income taxes is derived solely from within the U.S. The Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The income tax benefit for the year ended December 31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. Our historical net operating losses are sufficient to fully offset any federal taxable income. The Income tax provision for the year ended December 31, 2017, related to state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax (provision) benefit at the statutory federal income tax rates of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended December 31, 2018, 2017 and 2016, respectively, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax (provision) benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(94,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">303,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(58,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">245,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We applied the guidance in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Securities and Exchange Commission&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Staff Accounting Bulletin No. 118</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> when accounting for the enactment-date effects of the Tax Cuts and Jobs Act in 2017 and throughout 2018. At December 31, 2017, we had not completed our accounting for all the enactment-date income tax effects of the Tax Cuts and Jobs Act for Section 162(m) related to the deduction limitation for the remuneration of certain employees. As of December 31, 2018, we have now completed our accounting for all of the enactment-date income tax effects of the Tax Cuts and Jobs Act and the impact was not material.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2018, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> December 31, 2018 and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecasts of future operating results, as well as considering the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">utilization of net operating losses and tax credits prior to their expiration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$244.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are realizable and the valuation allowance was reduced accordingly. As of December 31, 2018, we continue to carry a valuation allowance of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$58.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> against our California state deferred tax assets. Prior to December 31, 2018, because of our history of operating losses, management believed that recognition of the deferred tax assets was not more likely than not (as defined in Topic 740) to be realized and, accordingly, had provided a full valuation allowance. The valuation allowance decreased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$360.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during 2018 and 2017, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had federal net operating loss carryforwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$614 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2031</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$102 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2021</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2038</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carryforwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$453 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2028</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$34 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which do not expire.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 study through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and concluded that an ownership change, as defined under Section 382, had not occurred. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> will significantly change over the next 12 months. As of December 31, 2018, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$76.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in unrecognized tax benefits, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would reduce our income tax provision and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Operations as a component of income taxes. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2018 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778687664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,911</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potential shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. Warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock issued in January 2014 (2014 Warrants) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785642976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">780,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">796,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">844,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">453,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Commitments&#8221; regarding the determination of the amount of our operating lease liabilities as of December 31, 2018. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778687664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As described further in &#8220;Note 1. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Organization and Summary of Significant Accounting Policies&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we adopted Topic 842 as of January 1, 2018. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into the Lease with Ascentris for office and research facilities located at the Premises in Alameda, California. The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, following the conclusion of a partial twelve-month rent abatement period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term; none of these optional periods have been considered in the determination of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">right-of-use asset or the lease liability for the Lease as we did not consider it </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay to Ascentris certain variable costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space, as that additional space becomes available at 1601, 1701 and 1751 Harbor Bay Parkway, Alameda, California over the remainder of the initial term of the Lease at a market rate determined pursuant to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We had an additional operating lease which expired in July 2018 for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> buildings in South San Francisco, California with a total area of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116,063</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have performed an evaluation of our other contracts with customers and suppliers in accordance with Topic 842 and have determined that, except for the leases described above, a nominal operating lease for space at a data center to house our data servers and a nominal financing lease for office equipment, none of our contracts contain a lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing obligation for build-to-suit lease</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,216</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,794</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,904</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,187</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9.0 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the weighted average discount rate used to determine the operating lease liability was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> standby letters of credit related to the Lease with Ascentris with a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have also obtained standby letters of credit related to a workers compensation insurance policy with credit limits of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We had also previously obtained a standby letter of credit related to our South San Francisco lease with a credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was released during 2018. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">none</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit. The certificate of deposits used to collateralize the standby letters of credit were included in short-term and long-term restricted cash and investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were previously required to provide collateral as part of an employee purchasing card program. The collateral requirement for the purchase card program at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we were notified that we had been released from this collateral requirement. The collateral was invested in certificates of deposit which were included in long-term restricted cash and investments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785572752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31, </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">225,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">213,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">168,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">111,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">125,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">360,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See &#8220;Note 3. Collaboration Agreements&#8221; for more information on our collaboration agreement with Genentech.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796066784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended (or ending, as applicable) December 30, 2016, December 29, 2017, and December 28, 2018 are indicated as being as of and for the years ended (or ending, as applicable) December&#160;31, 2016, 2017 and 2018, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; operating lease assets and liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2016-18)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash are included with cash when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in Net cash provided by investing activities for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 4. Cash and Investments&#8212;Cash, Cash Equivalents and Restricted Cash&#8221; for a reconciliation of cash and cash equivalents presented in our previously published Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2016 and Cash, cash equivalents and restricted cash reported in the accompanying Consolidated Statement of Cash Flows for the same periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification (ASC) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 605)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2018 we early adopted Topic 842. We adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment as of January 1, 2018 in accordance with ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 842. Prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under previous lease guidance, ASC Topic 840: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 840). We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2018.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Impact of Adoption of Topic 606 and Topic 842</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to opening accumulated deficit as of January 1, 2018, due to the cumulative impact of adopting Topic 842, with the impact relating to a change in the classification of certain of our buildings in our Lease Agreement (the Lease) with Ascentris 105, LLC (Ascentris) from a build to suit lease to an operating lease. For a description of the Lease, see &#8220;Note 11. Commitments.&#8221; </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Includes deferred rent and current portion of operating lease liabilities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen&#8217;s filing with the European Medicines Agency (EMA) for cabozantinib as a treatment for patients with previously treated HCC, that was deemed probable under Topic 606 prior to January 1, 2018. Deferred revenue as of January 1, 2018 was related to the up-front, nonrefundable, fees and milestones earned that were allocated to our research and development services performance obligation which had not been satisfied as of that date. Contract assets and liabilities are netted by collaboration agreement in our Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 842 primarily related to the recognition of an operating lease right-of-use asset and operating lease liability for the Lease. In addition, the adoption of Topic 842 resulted in a change in classification of the build-to-suit component of the Lease under Topic 840 to an operating lease under Topic 842 and as a result we derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of December 31, 2017, as we had been deemed to own these buildings under Topic 840. For a description of the Lease, see &#8220;Note 11. Commitments&#8221; in these Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 606 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 842 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balances Without the Adoption of Topic 606 or 842</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">889,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">205,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">413,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">488,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(48,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(84,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">774,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we had not adopted Topic 606, we would also have recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2018 upon the validation of Ipsen&#8217;s filing with the EMA for cabozantinib as a treatment for patients with previously treated HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously reported deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Topic 808 to the unit of account guidance in ASC 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments in the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were nominal. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 606.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Topic 808: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory-related costs are recognized as Cost of goods sold in the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the accompanying Consolidated Balance Sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Office equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determine if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in our Consolidated Balance Sheet at December 31, 2018. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">not to apply the recognition requirements of Topic 842 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for short-term leases.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For lease agreements entered into after the adoption of Topic 842 that include lease and non-lease components, such components are generally accounted for separately. For our building leases, as a result of us having elected to adopt the package of practical expedients permitted under the Topic 842 transition guidance, we account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of restricted stock units (RSUs) is estimated as the value of the underlying shares of our common stock. The grant date fair value of stock-options is estimated using a Monte Carlo simulation pricing model for stock options that include market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on an accelerated basis over the requisite service period for awards with a market or performance condition and on a straight-line basis over the requisite service period for all other awards. Compensation expense relating to awards subject to performance conditions is recognized when management determines that it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis. We have made an election to record forfeitures when they occur. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Remeasurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 28, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 8. Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on the technical merits of the position</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785693808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Adoption of Topic 606 and Topic 842</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2018 was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Adjustments Due to the Adoption of Topic 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Includes deferred rent and current portion of operating lease liabilities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) Long-term portion of operating lease liabilities and Financing obligation for build-to-suit lease.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 and Topic 842 on the accompanying Consolidated Statements of Operations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 606 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Effect of Adoption of Topic 842 Higher / (Lower)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balances Without the Adoption of Topic 606 or 842</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">889,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">205,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">414,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">413,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(35,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">488,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(48,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(84,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">774,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Office equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778732368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">402,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(119,250</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,561</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,124</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">192,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,286</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development service revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Upon the adoption of Topic 606 as of January 1, 2018, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition have changed. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, prior to the adoption of Topic 606, we did not allocate any of our upfront payments or milestones to research and development services; therefore, Research and development service revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenues. Other collaboration revenues for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib and product supply revenues, as the profits and losses on the U.S. commercialization of COTELLIC for the period were included in Selling, general and administrative expenses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included royalties we paid to GSK on Ipsen&#8217;s sales of products containing cabozantinib, the profit on the U.S. commercialization of COTELLIC from Genentech and product supply revenue, were recorded in accordance with Topic 808 for all periods presented.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">599,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">619,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">110,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">305,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">46,856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">632,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(74,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,978</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50%, and increasing to 70% in 2019, of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply services, each of these payment types were within the scope of Topic 606 during the year ended December 31, 2018. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Prior period amounts continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220; &#8212; Recently Adopted Accounting Pronouncements &#8212; Impact of Adoption of Topic 606 and Topic 842&#8221; above, for more information about the impact of the adoption on Topic 606.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with ASC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Topic 808: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We recognized an annual profit under the agreement for the year ending December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues in the accompanying Consolidated Statements of Operations. Prior to 2018, the commercialization of cobimetinib in the U.S. had not been profitable for any annual period and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. Portions of the manufacturing costs for inventory sold during the years ended December 31, 2018, 2017 and 2016 were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract Assets and Liabilities under Topic 606</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(46,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,417</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,428</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778530928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Merck collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">BMS collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:504px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:416px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656650224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">314,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">314,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">852,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">851,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">236,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">275,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,358</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">320,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">674,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778669728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory included in Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785559344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">68,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780545024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,511</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,626</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The weighted average grant-date fair value per share of stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of All Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,238,473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,466,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(288,197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(18,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,674,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">254,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,463,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">229,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of All RSU Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,519,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,081,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(343,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,857,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778462944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of the U.S. federal income tax (provision) benefit at the statutory federal income tax rates of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended December 31, 2018, 2017 and 2016, respectively, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to our Income tax benefit (provision) was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax (provision) benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(94,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit (provision)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">303,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(58,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">245,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778677696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,911</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potential shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. (Deerfield Notes)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701786288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">381,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">344,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">780,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">828,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">796,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">844,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">453,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785585808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock', window );">Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing obligation for build-to-suit lease</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,216</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,794</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,904</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,187</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Financing Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778530496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31, </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">225,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">213,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">168,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">111,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">125,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,307</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">360,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See &#8220;Note 3. Collaboration Agreements&#8221; for more information on our collaboration agreement with Genentech.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796155280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297,850,000)<span></span>
</td>
<td class="nump">$ 36,795,000<span></span>
</td>
<td class="num">$ (214,548,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,570,433,000<span></span>
</td>
<td class="nump">$ 880,363,000<span></span>
</td>
<td class="nump">1,829,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 880,363,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InventoryManufacturedBeforeRegulatoryApproval', window );">Inventory expensed as research and development, not capitalized as inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member', window );">ASU 2016-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(258,505,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606 | Collaborative Arrangement with Ipsen | EMA Filing Acceptance - HCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Restatement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (234,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CommercialPresenceInMarketsWorldwideMember', window );">Commercial Presence in Markets Worldwide</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InventoryManufacturedBeforeRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Manufactured Before Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InventoryManufacturedBeforeRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CommercialPresenceInMarketsWorldwideMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CommercialPresenceInMarketsWorldwideMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781137248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Condensed Consolidated Balance Sheet) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 30, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets: unbilled collaboration revenue, gross: Current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract assets: unbilled collaboration revenue, gross: Long-term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">162,771<span></span>
</td>
<td class="nump">11,635<span></span>
</td>
<td class="nump">$ 77,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50,897<span></span>
</td>
<td class="nump">11,213<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,867<span></span>
</td>
<td class="nump">8,579<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">15,897<span></span>
</td>
<td class="nump">25,441<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">21,825<span></span>
</td>
<td class="nump">19,323<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiability', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">14,965<span></span>
</td>
<td class="nump">13,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (880,363)<span></span>
</td>
<td class="num">(1,570,433)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets: unbilled collaboration revenue, gross: Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract assets: unbilled collaboration revenue, gross: Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiability', window );">Long-term portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets: unbilled collaboration revenue, gross: Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract assets: unbilled collaboration revenue, gross: Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiability', window );">Long-term portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798228176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Consolidated Statements of Operations) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,366<span></span>
</td>
<td class="nump">159,362<span></span>
</td>
<td class="nump">116,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,971<span></span>
</td>
<td class="nump">286,567<span></span>
</td>
<td class="nump">219,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
<td class="num">(33,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,237<span></span>
</td>
<td class="num">(7,333)<span></span>
</td>
<td class="num">(42,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452,092<span></span>
</td>
<td class="nump">158,577<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,978<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 360,089<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 115,857<span></span>
</td>
<td class="nump">$ 38,489<span></span>
</td>
<td class="nump">$ 81,382<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,547<span></span>
</td>
<td class="nump">$ 103,469<span></span>
</td>
<td class="nump">$ 56,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (84,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606 | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member', window );">Calculated Under Guidance In Effect Before Topic 606 And Topic 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 889,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_CalculatedUnderGuidanceInEffectBeforeTopic606AndTopic842Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782327840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 28, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781398848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues by Disaggregated Category) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,279<span></span>
</td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">135,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,529<span></span>
</td>
<td class="nump">402,569<span></span>
</td>
<td class="nump">151,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,250<span></span>
</td>
<td class="nump">53,561<span></span>
</td>
<td class="nump">16,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,547<span></span>
</td>
<td class="nump">103,469<span></span>
</td>
<td class="nump">56,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,188<span></span>
</td>
<td class="nump">96,637<span></span>
</td>
<td class="nump">56,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember', window );">Research and development services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,501<span></span>
</td>
<td class="nump">8,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember', window );">Other collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="num">$ (1,905)<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_OtherCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781255168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Net Product Revenues Disaggregated by Product) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,279<span></span>
</td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">135,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,946<span></span>
</td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">93,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,333<span></span>
</td>
<td class="nump">$ 25,008<span></span>
</td>
<td class="nump">$ 41,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796599360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Significant Customer) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,879<span></span>
</td>
<td class="nump">$ 69,792<span></span>
</td>
<td class="nump">$ 33,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,698<span></span>
</td>
<td class="nump">$ 73,921<span></span>
</td>
<td class="nump">$ 17,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C. | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,916<span></span>
</td>
<td class="nump">$ 48,662<span></span>
</td>
<td class="nump">$ 13,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,028<span></span>
</td>
<td class="nump">$ 50,716<span></span>
</td>
<td class="nump">$ 16,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,244<span></span>
</td>
<td class="nump">$ 83,059<span></span>
</td>
<td class="nump">$ 63,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,061<span></span>
</td>
<td class="nump">$ 126,327<span></span>
</td>
<td class="nump">$ 46,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented | Sales revenue, net | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781972320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Geographic Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,927<span></span>
</td>
<td class="nump">367,906<span></span>
</td>
<td class="nump">140,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,879<span></span>
</td>
<td class="nump">69,792<span></span>
</td>
<td class="nump">35,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_OtherGeographicalAreasMember', window );">Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,020<span></span>
</td>
<td class="nump">$ 14,779<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_OtherGeographicalAreasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_OtherGeographicalAreasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789316096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 9,493<span></span>
</td>
<td class="nump">$ 5,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">119,600<span></span>
</td>
<td class="nump">55,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(1,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(111,467)<span></span>
</td>
<td class="num">(49,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">17,276<span></span>
</td>
<td class="nump">9,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">75,543<span></span>
</td>
<td class="nump">33,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(403)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(74,746)<span></span>
</td>
<td class="num">(32,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">13,015<span></span>
</td>
<td class="nump">7,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(11,978)<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">3,038<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">5,770<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">31,040<span></span>
</td>
<td class="nump">14,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(24,741)<span></span>
</td>
<td class="num">(10,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">11,916<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780615744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Changes in Contract Assets and Liabilities under Topic 606) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="nump">$ 37,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Transfer to receivables from contract assets recognized at the beginning of the period</a></td>
<td class="num">(46,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments', window );">Other</a></td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="nump">4,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="num">(16,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityCurrentDeductions', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="num">(8,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments', window );">Other</a></td>
<td class="num">(1,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="nump">238,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="nump">7,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityNoncurrentDeductions', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="num">(16,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="nump">15,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">198,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="nump">$ 238,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeInContractWithCustomerAssetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerAssetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityCurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityCurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityNoncurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityNoncurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796693072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details) - Collaborative arrangement with Ipsen<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payment(s)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Second</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember', window );">EMA Filing Acceptance - HCC | Adjustments Due to the Adoption of Topic 606 | ASU 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_SecondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_SecondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798290240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,879<span></span>
</td>
<td class="nump">$ 69,792<span></span>
</td>
<td class="nump">$ 33,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780661952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Takeda Collaboration, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Sales volume period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payment(s)</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780387744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenue - Takeda) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,020<span></span>
</td>
<td class="nump">$ 14,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6668067152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 23,950<span></span>
</td>
<td class="nump">$ 12,413<span></span>
</td>
<td class="nump">$ 4,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780494000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details) - Collaborative Arrangement With StemSynergy - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AdditionalUpfrontAndMilestonePayments', window );">Additional upfront and milestone payments</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember', window );">First Product To Reach Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AdditionalUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Upfront And Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AdditionalUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780395376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Invenra Collaboration, Narrative) (Details) - Collaborative Arrangement With Invenra - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProjectInitiationFeePayment', window );">Project initiation fee</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember', window );">Discovery Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember', window );">Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">131.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember', window );">Additional Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">$ 127.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember', window );">Product Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProjectInitiationFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project Initiation Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProjectInitiationFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796132160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Genentech) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossfromAgreement', window );">Collaborative Arrangement, Income (Loss) from Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,084<span></span>
</td>
<td class="num">(2,140)<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,564<span></span>
</td>
<td class="nump">$ 6,398<span></span>
</td>
<td class="nump">$ 2,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossfromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossfromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780735952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Other Collaborations, Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>clinical_trial</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MinimumNumberOfClinicalTrials', window );">Number of clinical trials (more than) | clinical_trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Collaborative Arrangement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Collaborative Arrangement with Daiichi Sankyo | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember', window );">Collaborative Arrangement with BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement', window );">Maximum amount eligible for royalties on sales under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember', window );">Profit Sharing Tier One | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember', window );">Profit Sharing Tier Two | Collaborative Arrangement with Genentech | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MinimumNumberOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Number Of Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MinimumNumberOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Optional Percent of Total Sales Force</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementPercentOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Percent of Profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementPercentOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementProfitThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Profit Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementProfitThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780410544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Daiichi Sankyo) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Collaborative Arrangement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656650224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Daiichi Sankyo, Narrative) (Details) - Collaborative Arrangement with Daiichi Sankyo<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">$ 110,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale', window );">Maximum amount eligible for development and regulatory milestones upon first arm's-length sale</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones Upon First Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestonesUponFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780409440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Merck) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember', window );">Collaborative Arrangement with Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798298816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - BMS) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember', window );">Collaborative Arrangement with BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6699070800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 314,775<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
<td class="nump">$ 151,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash and investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 315,875<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
<td class="nump">$ 155,836<span></span>
</td>
<td class="nump">$ 144,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781081648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Security Type) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investments available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 828,843<span></span>
</td>
<td class="nump">$ 440,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(883)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">828,142<span></span>
</td>
<td class="nump">440,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
<td class="nump">$ 155,836<span></span>
</td>
<td class="nump">$ 144,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">852,322<span></span>
</td>
<td class="nump">457,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Total, Fair Value</a></td>
<td class="nump">851,621<span></span>
</td>
<td class="nump">457,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investments available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investments available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">381,134<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">381,133<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investments available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">344,741<span></span>
</td>
<td class="nump">179,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">344,064<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Investments available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">55,224<span></span>
</td>
<td class="nump">16,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">55,201<span></span>
</td>
<td class="nump">16,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">6,883<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">6,883<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">16,596<span></span>
</td>
<td class="nump">13,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 16,596<span></span>
</td>
<td class="nump">$ 13,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783593600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain (loss) on sales of investments available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OwnershipInterestByMinorityShareholder', window );">Beneficial ownership interest by BlackRock (more than)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner', window );">Fair value of cash and investments managed by BlackRock</a></td>
<td class="nump">$ 298,500,000<span></span>
</td>
<td class="nump">$ 298,500,000<span></span>
</td>
<td class="nump">141,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund', window );">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsAdvisoryFeesPaid', window );">Fees for advisory services paid to BlackRock</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member', window );">Akarna Therapeutics, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gain on sale of cost method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMethodInvestmentsRealizedGainLoss', window );">Realized gain on sale of cost method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CostMethodInvestmentOwnershipPercentage', window );">Cost method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CostMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CostMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OwnershipInterestByMinorityShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Ownership, Ownership Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OwnershipInterestByMinorityShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsAdvisoryFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Advisory Fees Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsAdvisoryFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 12<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMethodInvestmentsRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gain (loss) realized during the period from the sale of investments accounted for under the cost method of accounting and any losses recognized thereon for impairments of other than a temporary nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMethodInvestmentsRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84241550&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789388896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Gross Unrealized Losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">$ 271,358<span></span>
</td>
<td class="nump">$ 154,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">48,809<span></span>
</td>
<td class="nump">22,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">320,167<span></span>
</td>
<td class="nump">177,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(883)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">236,162<span></span>
</td>
<td class="nump">140,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">39,627<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">275,789<span></span>
</td>
<td class="nump">160,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">28,105<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">9,182<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">37,287<span></span>
</td>
<td class="nump">16,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">7,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">7,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795710432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 674,455<span></span>
</td>
<td class="nump">$ 377,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">153,687<span></span>
</td>
<td class="nump">63,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 828,142<span></span>
</td>
<td class="nump">$ 440,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780252144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">6,170<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">11,928<span></span>
</td>
<td class="nump">7,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">9,838<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Inventory included in Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789355136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 30, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 68,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(17,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50,897<span></span>
</td>
<td class="nump">$ 11,213<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">15,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">12,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780279392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember', window );">Leasehold Improvements, Buildings, Furniture and Fixtures, Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PropertyPlantAndEquipmentAdditionsAndTransfers', window );">Construction in progress capitalized</a></td>
<td class="nump">$ 46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">134,765<span></span>
</td>
<td class="nump">134,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PropertyPlantAndEquipmentAdditionsAndTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Additions And Transfers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PropertyPlantAndEquipmentAdditionsAndTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796734512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">14,693,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 40,626,000<span></span>
</td>
<td class="nump">$ 23,938,000<span></span>
</td>
<td class="nump">$ 22,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">$ 5,202,000<span></span>
</td>
<td class="nump">4,868,000<span></span>
</td>
<td class="nump">2,187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">3,238,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="nump">$ 12,076,000<span></span>
</td>
<td class="nump">$ 17,555,000<span></span>
</td>
<td class="nump">25,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">22,674,062<span></span>
</td>
<td class="nump">22,208,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Retirement Plan, employee contribution (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contributions for first 3% of participant contributions (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of participant contributions into the 401(k) Retirement Plan (as a percent)</a></td>
<td class="nump">850000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DefinedContributionPlanNumberofSharesAvailableforGrant', window );">Number of shares available for issuance under 401(k) Retirement Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Life of stock options granted</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">2 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 39,100,000<span></span>
</td>
<td class="nump">$ 85,200,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="nump">12,100,000<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="nump">25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue', window );">Fair value of employee options vested and expensed</a></td>
<td class="nump">18,900,000<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="nump">693,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 81,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="nump">2,519,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">4,722,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="nump">330,492<span></span>
</td>
<td class="nump">434,523<span></span>
</td>
<td class="nump">559,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 15.74<span></span>
</td>
<td class="nump">$ 11.20<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember', window );">Performance Share Options (PSO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">308,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises', window );">Exercise threshold, percentage of per share exercise price of the PSO</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember', window );">Performance Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options in vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DefinedContributionPlanNumberofSharesAvailableforGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Number of Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DefinedContributionPlanNumberofSharesAvailableforGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and expensed, fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778479104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 40,626<span></span>
</td>
<td class="nump">$ 23,938<span></span>
</td>
<td class="nump">$ 22,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">13,115<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 27,511<span></span>
</td>
<td class="nump">$ 16,369<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789475968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781902672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.81%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 4 months 20 days<span></span>
</td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.93%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784142832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Summary of All Stock Option Activity) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">22,208,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,238,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(2,466,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(288,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(18,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">22,674,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2018 (in shares) | shares</a></td>
<td class="nump">16,463,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">15.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">20.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">8.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2018 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding at December 31, 2018</a></td>
<td class="text">3 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2018</a></td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding at December 31, 2018 | $</a></td>
<td class="nump">$ 254,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2018 | $</a></td>
<td class="nump">$ 229,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784206352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Summary of All RSU Activity) (Details) - RSUs [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">3,762,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">2,519,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(1,081,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(343,742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4,857,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">18.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">16.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">18.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term, Awards outstanding at December 31, 2018</a></td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Awards outstanding at December 31, 2018 | $</a></td>
<td class="nump">$ 94,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6698358448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Income Tax Expense (Benefit)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(6,133)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="num">(6,133)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">238,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">244,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">$ 237,978<span></span>
</td>
<td class="num">$ (4,350)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778747776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax (provision) benefit at statutory rate</a></td>
<td class="num">$ (94,939)<span></span>
</td>
<td class="num">$ (53,916)<span></span>
</td>
<td class="nump">$ 23,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax expense</a></td>
<td class="num">(4,690)<span></span>
</td>
<td class="num">(8,282)<span></span>
</td>
<td class="num">(6,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">315,394<span></span>
</td>
<td class="nump">34,266<span></span>
</td>
<td class="num">(6,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="nump">18,308<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5,998<span></span>
</td>
<td class="nump">20,548<span></span>
</td>
<td class="num">(3,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,367)<span></span>
</td>
<td class="num">(2,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount', window );">Debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(2,093)<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">$ 237,978<span></span>
</td>
<td class="num">$ (4,350)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784364080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 146,701<span></span>
</td>
<td class="nump">$ 244,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">98,467<span></span>
</td>
<td class="nump">66,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Book over tax depreciation and amortization</a></td>
<td class="nump">29,929<span></span>
</td>
<td class="nump">39,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified', window );">Amortization of deferred stock compensation &#8211; non-qualified</a></td>
<td class="nump">11,366<span></span>
</td>
<td class="nump">8,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">10,425<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">5,474<span></span>
</td>
<td class="nump">53,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">303,502<span></span>
</td>
<td class="nump">418,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(58,112)<span></span>
</td>
<td class="num">(418,958)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">245,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,279)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,279)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 244,111<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization of deferred stock compensation - non-qualified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782359136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 244,111<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">58,112<span></span>
</td>
<td class="nump">418,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(360,800)<span></span>
</td>
<td class="num">(210,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">76,060<span></span>
</td>
<td class="nump">79,342<span></span>
</td>
<td class="nump">$ 61,809<span></span>
</td>
<td class="nump">$ 88,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701101392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 79,342<span></span>
</td>
<td class="nump">$ 61,809<span></span>
</td>
<td class="nump">$ 88,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="num">(4,254)<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="num">(29,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">17,378<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 76,060<span></span>
</td>
<td class="nump">$ 79,342<span></span>
</td>
<td class="nump">$ 61,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798725088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 360,089<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 115,857<span></span>
</td>
<td class="nump">$ 38,489<span></span>
</td>
<td class="nump">$ 81,382<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) allocable to common stock for basic net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,070<span></span>
</td>
<td class="nump">153,860<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Adjustment to net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) allocable to common stock for diluted net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 153,882<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,892<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,911<span></span>
</td>
<td class="nump">18,415<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
<td class="nump">312,003<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778572992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">3,968<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">62,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">3,968<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">27,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember', window );">2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member', window );">Deerfield Notes [Member] | Convertible debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6698887184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember', window );">2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784330032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">$ 828,142<span></span>
</td>
<td class="nump">$ 440,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">828,142<span></span>
</td>
<td class="nump">440,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">844,738<span></span>
</td>
<td class="nump">453,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">780,398<span></span>
</td>
<td class="nump">394,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">796,994<span></span>
</td>
<td class="nump">408,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">47,744<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">381,133<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">381,133<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">381,133<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">344,064<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">344,064<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">344,064<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">55,201<span></span>
</td>
<td class="nump">16,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">55,201<span></span>
</td>
<td class="nump">16,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale</a></td>
<td class="nump">55,201<span></span>
</td>
<td class="nump">16,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">16,596<span></span>
</td>
<td class="nump">13,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">16,596<span></span>
</td>
<td class="nump">13,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">$ 16,596<span></span>
</td>
<td class="nump">$ 13,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789145328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Leases Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Tenant improvement reimbursements | $</a></td>
<td class="nump">$ 8,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities | $</a></td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft)</a></td>
<td class="nump">134,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AreaOfRealEstatePropertyAvailableToLease', window );">Area of property available for lease (in squire feet)</a></td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft)</a></td>
<td class="nump">116,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalandOperatingLeasesNumberofRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AreaOfRealEstatePropertyAvailableToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Real Estate Property, Available To Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AreaOfRealEstatePropertyAvailableToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalandOperatingLeasesNumberofRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital and Operating Leases, Number of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalandOperatingLeasesNumberofRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778811280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Balance Sheet Classification of Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 30, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseObligationCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">12,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseObligationNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">14,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseObligation', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_FinancingLeaseLiabilitiesAbstract', window );"><strong>Financing lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_FinancingObligation', window );">Financing obligation for build-to-suit lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 14,965<span></span>
</td>
<td class="nump">$ 13,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAndFinancingObligation', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_FinancingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_FinancingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_FinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_FinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAndFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease And Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAndFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781666816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Components of Lease Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,189<span></span>
</td>
<td class="nump">$ 3,944<span></span>
</td>
<td class="nump">$ 8,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(3,553)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 5,850<span></span>
</td>
<td class="nump">$ 4,935<span></span>
</td>
<td class="nump">$ 6,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6664827808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Maturities of Operating Lease Liabilities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract', window );"><strong>Years ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 2,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">2,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">3,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">13,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Thereafter</a></td>
<td class="nump">28,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(5,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Tenant improvement reimbursements</a></td>
<td class="num">(8,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 14,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities, Duration Of Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784726432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Letters of Credit and Restricted Cash Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>debt_instrument</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollateralProvidedForPurchasingCardProgram', window );">Collateral provided for purchasing card program</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember', window );">Workers Compensation Insurance Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember', window );">Building lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentNumberofInstruments', window );">Number of letters of credit entered into (in debt instruments) | debt_instrument</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollateralProvidedForPurchasingCardProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collateral Provided For Purchasing Card Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollateralProvidedForPurchasingCardProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentNumberofInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentNumberofInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796252912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">168,873<span></span>
</td>
<td class="nump">155,586<span></span>
</td>
<td class="nump">139,839<span></span>
</td>
<td class="nump">128,633<span></span>
</td>
<td class="nump">91,520<span></span>
</td>
<td class="nump">91,758<span></span>
</td>
<td class="nump">84,990<span></span>
</td>
<td class="nump">65,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">111,602<span></span>
</td>
<td class="nump">125,176<span></span>
</td>
<td class="nump">85,770<span></span>
</td>
<td class="nump">116,307<span></span>
</td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">81,180<span></span>
</td>
<td class="nump">27,113<span></span>
</td>
<td class="nump">20,186<span></span>
</td>
<td class="nump">438,855<span></span>
</td>
<td class="nump">165,910<span></span>
</td>
<td class="num">(28,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 360,089<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 115,857<span></span>
</td>
<td class="nump">$ 38,489<span></span>
</td>
<td class="nump">$ 81,382<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,366<span></span>
</td>
<td class="nump">$ 159,362<span></span>
</td>
<td class="nump">$ 116,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 228,602<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,719<span></span>
</td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">853,826<span></span>
</td>
<td class="nump">452,477<span></span>
</td>
<td class="nump">191,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,547<span></span>
</td>
<td class="nump">103,469<span></span>
</td>
<td class="nump">56,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,547<span></span>
</td>
<td class="nump">$ 103,469<span></span>
</td>
<td class="nump">$ 56,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue | Restatement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782426048">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(252,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">258,505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 258,505,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #"@59.(60(=NX    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!2L0P$(9?17)OI\GJ@J&;B^))07!!\1:2V=U@DX9DI-VW-ZV[
M740?P&-F_GSS#4QKHC1]PN?41TSD,%^-O@M9FKAA!Z(H ;(YH->Y+HE0FKL^
M>4WEF?80M?G0>P31-&OP2-IJTC !J[@0F6JMD2:AICZ=\-8L^/B9NAEF#6"'
M'@-EX#4'IJ:)\3AV+5P $XPP^?Q=0+L0Y^J?V+D#[)0<LUM2PS#4PVK.E1TX
MO#T]OLSK5BYDTL%@^96=I&/$#3M/?EW=W6\?F!(-OZT:40FQY6O)A;RY?I]<
M?_A=A'UOW<[]8^.SH&KAUUVH+U!+ P04    " #"@59.F5R<(Q &  "<)P
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MW;IEH><.K"SH39"ZA0-S^*UI,/NW T+[K>N[;Q//];42:@*518>O\!/$K^[
MY A-4<YU RVO:>LPN&S=3_YFGRN]%ORNH>>SOJ,J.5+ZH@;?SEO74T! X"14
M!"R;.^R!$!5(8OP=8[I32F6<]]^B?]&URUJ.F,.>DC_U651;-W.=,USPC8AG
MVG^%L9[8=<;BO\,=B)0K$IGC1 G7_\[IQ@5MQB@2I<&O0UNWNNV'E3@=;79#
M,!J"R>!'[QK"T1 :!C20Z5(_8X'+@M'>8<-A=5A]$_XFE)MY4I-Z[_2:K);+
MV7N9)@6ZJSBC9#=(@IDD6"KV:T483Q(D\T\0@14BT/YP#I':_:'5'VI_-/=G
M1A&#)-.25DN\)\_SC4(^4BU8(BM+M&;)#99!$L^R^-[P,W >$"Z(8BM1O"+*
MC$2[>)7(1'E/L6!(K S)FL'8^UWRT E]I%JPI%:6=,UB?-"[=%5MY-F/Z!'E
M@BFS,F5KIM!@RE:9@CS/TL0S3W-O4R:!ET=!8F?*K4SYFBDRF/*'F6Q*.Q.:
M75WJ*?F!V;5NN7.D0MZ"^JZZ4"I 1O6>9,!*OE[3@,!%J&XJ^VRXPX>!H-WX
M/*'IC2S_ U!+ P04    " #"@59.0WA-[&<$  #]$P  &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;(V886^C1A"&_PKBN\/.["ZPD6,IP:I:J95.5UW[
MF=B;V#HP+I#X^N^[8.)S9@:K7V(@SRSO#+OSPBY/3?N]VWG?1S_JZM ]Q+N^
M/]XG2;?9^;KL[IJC/X3_O#1M7?;AM'U-NF/KR^T85%<)*I4F=;D_Q*OE>.U+
MNUHV;WVU/_@O;=2]U779_OODJ^;T$$/\<>'K_G77#Q>2U?)8OOH_??_M^*4-
M9\EEE.V^]H=NWQRBUK\\Q(]POT8W!(S$7WM_ZJZ.HR&5YZ;Y/IS\MGV(U:#(
M5W[3#T.4X>?=%[ZJAI&"CG^F0>/+/8? Z^./T7\9DP_)/)>=+YKJ[_VVWSW$
M>1QM_4OY5O5?F].O?DK(QM&4_>_^W5<!'Y2$>VR:JAO_1INWKF_J:90@I2Y_
MG'_WA_'W-(W_$28'X!2 EP!(;P;H*4#_## W \P48$A <DYEK,VZ[,O5LFU.
M47M^O,=RF$5P;T+U-\/%L=CC_T)YNG#U?97;9?(^C#,A3V<$KQ"X$$D8_'('
ME.[PA"P</]^@X(0F&M8<R5-9A!;3U&.\OH[/Y'@CQILQWES'YZ1,9R0;D<-4
M29UC2I+EF+%HLHPDS#%P8*R115M1M.5).SD^%>-3EK13).DS8J]D8JH-*4W!
M*; J)959<RJU%F7!F2@XXX*!",ZXE!S1DO(7 @8(&1EMS3%G73HSLW)1<\XU
MD_7QE/,BJU33^A4< ^MT2D9;"QBD86K)HITHVG'1FHAV[#9D[A2<6&@JEC-A
M%<A*0<D-3G&MAG8XQ6YCP#CZN N!PSRU*5V\$@?.9OF,\IG6#%PYZ\W E>L\
MMY8JYQRDUH&BRCFWP!QPKN9BRW\$9)W'S;1KD/LU:)Y[1G/7/"?,#9UF F;R
M7-/$.87S#TPV"> NX:A+3,RM=2$@BSS-'%4L8%JK5,UHECT"+-?LJ&;+[J3I
MTR@$:*&M9DM#P(;^,S<]9&<";DV@J#>!8#L:J:)"P!:9UFR"")A!Y>:FB.Q0
MP"T*%/4HX+82WA$4]85"X,#FEKU+"-PB4X@SW@JR40%W*E#4JD#P*IVYC+X1
M"-S":,O:$<?FIK=L5,"="A2UJ@FZ?ME*G5(96YB< VL06;TY=ZO>*!L7<N,"
M19UK@MQUO>^HBQ8"I>XL]5J!6J@[G)G@*)L6<M,"15UK@CZK1NJV J7N#&V#
M G5+M6Q8B(+JE*I&/K?#S&;+4N2TI1\,:XFSRNJYKRO9*9$[)2AJE<C=30>O
MI"NAD#E%N;7 W90N^R5ROP0U]^!D^T+A&V?F]1ME*T%N)>S3;F(^-0AP2"VY
M$#AM0B=A3YYS,'CES#LXREZ"DI?,?."AW-,Q___EDQLL\@;+R\?[(>KP+4N=
M6.!"LS8I6_*<LZG*:.K)U1Y([=O7<7^IBS;-VZ$?]A*NKE[VL!YQV$,AUY_@
M?GW>B?HYS'EC[(^R?=T?NNBYZ?NF'O=17IJF]T%E:+!QM//E]G)2^9=^.,S"
M<7O>D#J?],UQVFQ++CM^J_\ 4$L#!!0    ( ,*!5DY+'1G780(  $X'   8
M    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC55=;]L@%/TKEM]7;/R9R(G4
M.)DV:9.B5MN>B4-BJ]AX0.+NWP^PXSJ8=GL)<'W.O>< N60=92^\Q%@XKS5I
M^,HMA6B7 /"BQ#7B#[3%C?QRHJQ&0B[9&?"68734I)H Z'DQJ%'5N.M,Q_9L
MG=&+(%6#]\SAE[I&[,\&$]JM7-^]!9ZJ<RE4 *RS%IWQ,Q8_VCV3*S!F.58U
M;GA%&X?AT\I]])>[5.$UX&>%.SZ9.\K)@=(7M?AZ7+F>$H0)+H3*@.1PQ3DF
M1"62,GX/.=VQI").Y[?LG[5WZ>6 .,XI^54=1;ER4]<YXA.Z$/%$NR]X\!.Y
MSF#^&[YB(N%*B:Q14,+UKU-<N*#UD$5*J=%K/U:-'KLA_XUF)\"! /^7$ R$
M8"3X\8>$<""$;X3P0T(T$"*# 'KO>C.W2*!UQFCGL/XZM$C=.G\9R>,J5%"?
MCOXF]Y/+Z'7M^UX&KBK1@,E[#)QB1@20V<<2T%8BAS,ZO"^PG2."Z!ZRFT/2
MV"XBL/H,-#^X\_F.B]":(-0)PFD"+S VJL<D&M-H3+SPO,38S^T<YD<AA(EA
M>0[[E'@00KOJR*HZFJOVC=W?V#"FLQX33;4$46CXFH/BA>')DL=/0[NCV.HH
MMJ@UA.3Q_!S21>+'AMXY3)W#PH#MYC!Y#J'WSO5+#-5W'U.KI?3?!["Q82)#
M 9C\Z6O,SKH#<Z>@ET8H[B0Z-OD-5$W#B.>R^?N6^&.RW":6^"9=;O5C =[*
M]B_-=\3.5<.= Q6RA>E&<Z)48&G)>Y#7H)2/V[@@^"34-)%SUK?X?B%H.[Q>
M8'Q"UW\!4$L#!!0    ( ,*!5DZPMSMH P(  ($%   8    >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&ULA53;CMHP$/V5*.]=YPH(A4@+J&JE5D);=?MLPN2B
MM>/4=LCV[SMV0A9"2GG GLDY9\XXSB2=D&^J!-#..V>UVKBEULV:$)65P*EZ
M$@W4^"07DE.-H2R(:B30DR5Q1@+/6Q!.J]I-$YL[R#01K695#0?IJ)9S*O]L
M@8ENX_KN)?%2%:4V"9(F#2W@!^B?S4%B1$:54\6A5I6H'0GYQGWVU_O8X"W@
MM8).7>T=T\E1B#<3?#UM7,\8 @:9-@H4ES/L@#$CA#9^#YKN6-(0K_<7]<^V
M=^SE2!7L!/M5G72Y<5>N<X*<MDR_B.X+#/W$KC,T_PW.P!!NG&"-3#!E_YVL
M55KP006M</K>KU5MUV[0O]#F"<% "$:"OWA(" ="^$&('A*B@1!-"*1OQ9[-
MGFJ:)E)TCNS?;D/-)?+7$9Y^9I+VL.TS/!Z%V7/J^XN$G(W0@-GVF. :,R((
MJH\E@KD2V^".'MP6V-TCPO@6LK^'K!;S)L+9/D/+#V_Z_$<7T:Q 9 6B&X'E
MY*!ZS-)B:HOQ)IW^%[%_A+BQ&<_:C&=LKB8VX[L2GW!.X&]B]AXW-?L(T9LE
M5Q>1@RSL1ZZ<3+2U-N_S*CO.D>? 7.1)?HOSI1\''S+]</I.95'5RCD*C9^)
MO<RY$!K0H/>$#DN<AV/ (-=FN\2][*="'VC1# ./C%,W_0M02P,$%     @
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M%5TSKKGR<^9)CAS)@[$:\E<F[F\P%D]@Y @<U"<DL-O"09"2":8/W?_SGL3
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M74"7,W"OO6M=+O1=*N0(C,'%8$LQR"2!T79AQ<JYEG&D2LT6+2,J\98QN!B
M*\@D@0%L5/V-1+K\1JIB]<V86@RV%F5-4#/ 5@XF2>XZ38"00ZPD<&%_.0=R
MA42!,;ZX M&T &V'6>( 2^1F?.T (\A$.=.0+*I4:@IDY)D*B]MAD#BP!RC3
MG]KIJLB3D7$)J%Q292%043$B.8PN!] 5);H<0$WT46X,(UGFM@07DCE;VEAS
M&%P.@$MF-K5#.WTL75_<,9R>E9RZ+3R% M22EZ]VFC'J$10JPE(FFYH:B("Q
M$/$=AI4#L(H25D[#19F^*)D"R2A:+OG%A'* 4#(@U$XSI<H<EY91T10J75T!
MH?7'CWA.C6-&.<"H*!GE0-U$T0=E7>N87%3&07>YQBSLA#D,*@= )<]4.U X
MI<1610^@\S[)Y&&*=,Y1*CT6QIQRH,R*LLQRNC+B7/;*13 !.C3$*=*=#O'T
MV3#FHS<:L:7=8H]1Y0&JY)9J[2\_K@(2,GJO&,ERH5:X8QZ3R@-2R>=,M0<[
M>";(Q30!,J]*>=175;K.F%(>O+^0"A6:Q^CP !U)HL-?1@>0Y.Q.[=J>[>G4
M+Z:&!]1(8L'<(9$$<^U!W1*MS+@G0*8&=4YR.BB,%@_0(G?%:Z]9D%1F!T2>
M9)P HI)?3!2/WJ>0*?1>%,]-FHN2*9!0"A45V.TE24Y_Q<':@V MI\L=$JED
M>'ST@M6R63_U;[MM!O?MZZK;MCTZ>GBC[HZV+VB)X[6]FEIP_*-/5Y,\2/U+
M-IA_Z5_.&_\\]>[5OC]FZZ?Y:C/XVG9=N^Q?['ILVZ[)XS(?\C1X;F8/AR^+
MYK';?HSY\WKW2MWN2]>^[%\7'!_>6;S]#U!+ P04    " #"@59.7%0,"K(!
M  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3;6^;,!#^*Y9_
M0$U(MJ41(#6=IDYJI:C3ML\.'&#5+]0VH?OW.QO"6(?V!=\=]SSWW/F<#<:^
MN!; DS<EM<MIZWUW8,R5+2CN;DP'&O_4QBKNT;4-<YT%7D60DBQ-DH],<:%I
MD<78R1:9Z;T4&DZ6N%XI;G\=09HAIQMZ#3R+IO4AP(JLXPU\ _^].UGTV,Q2
M"07:":.)A3JG=YO#<1?R8\(/ 8-;V"1T<C;F)3A?JYPF01!(*'U@X'A<X!ZD
M#$0HXW7BI'/) %S:5_8OL7?LY<P=W!OY4U2^S>F>D@IJWDO_;(8'F/KY0,G4
M_"-<0&)Z4((U2B-=_)*R=]ZHB06E*/XVGD+'<YCXK[!U0#H!TG< -A:*RC]S
MSXO,FH'8<?8=#U>\.:0XFS($XRCB/Q3O,'HI-OM]QBZ!:,HYCCGI,F?.8,@^
METC72AS3?^#I.GR[JG ;X=N_%-ZN$^Q6"7:18/??%E=R;I-W1=ABI@IL$[?)
MD=+T.F[R(CHO[%T:[^1/^KCM3]PV0CMR-AYO-LZ_-L8#2DEN<(5:?&"S(Z'V
MP?R$MAW7;'2\Z:87Q.9G7/P&4$L#!!0    ( ,*!5D[(B-P.M $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3VVZ<,!#]%<L?$"\L3=(5
M(&531:G42JM4;9^],( 57XAMEO3O.S:$TI;VQ?:,YYPY,Q[GH['/K@/PY%5)
M[0K:>=\?&'-5!XJ[*].#QIO&6,4]FK9EKK? ZPA2DJ6[W3537&A:YM%WLF5N
M!B^%AI,E;E"*VQ]'D&8L:$+?'$^B[7QPL#+O>0M?P'_M3Q8MMK#40H%VPFAB
MH2GH77(X9B$^!GP3,+K5F81*SL8\!^-C7=!=$ 02*A\8.&X7N <I Q'*>)DY
MZ9(R -?G-_:'6#O6<N8.[HW\+FK?%?26DAH:/DC_9,9'F.MY1\E<_">X@,3P
MH 1S5$:ZN))J<-ZHF06E*/XZ[4+'?9QNLIL9M@U(9T"Z &YC'C8EBLH_<,_+
MW)J1V*GW/0]/G!Q2[$T5G+$5\0[%._1>RN1]DK-+()ICCE-,NHY9(ABR+RG2
MK13']"]XN@W?;RK<1_C^-X7_(,@V";)(D/VWQ*V8_1])V*JG"FP;I\F1R@PZ
M3O+*NPSL71K?Y%?X-.V?N6V%=N1L/+YL[']CC >4LKO"$>KP@RV&A,:'XPV>
M[31FD^%-/_\@MGSC\B=02P,$%     @ PH%63I! 36>Q 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL?5/;;IPP$/T5RQ\0[[(D35: E$T4
MM5(KK5*U>?;" %9L#[7-DOY];<-2E*"\X)GAG#,7C[,!S:MM 1QY4U+;G+;.
M=7O&;-F"XO8*.]#^3XU&<>==TS#;&>!5)"G)DLWFABDN-"VR&#N:(L/>2:'A
M:(CME>+F[P$D#CG=TDO@632M"P%69!UOX">X7]W1>(_-*I50H*U 30S4.;W?
M[@]IP$? ;P&#7=@D=')"? W.MRJGFU 02"A=4.#^.,,#2!F$?!E_)DTZIPS$
MI7U1?XJ]^UY.W,(#RA=1N3:GMY144/->NF<<OL+4SS4E4_/?X0S2PT,E/D>)
MTL8O*7OK4$TJOA3%W\93Z'@.D_Z%MDY()D+RCL#&1+'R1^YXD1D<B!EGW_%P
MQ=M]XF=3AF <1?SGB[<^>BZV=VG&SD%HPAQ&3++$S CFU><4R5J*0_*!GJS3
M=ZL5[B)]M\Q^>[<ND*X*I%$@_;3%-<SUNR1L,5,%IHG;9$F)O8Z;O(C."WN?
MQ#OY#Q^W_0<WC="6G-#YFXWSKQ$=^%(V5WZ%6O_ 9D="[8+YQ=MF7+/1<=A-
M+XC-S[CX!U!+ P04    " #"@59.R::F;[4!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q]4]MNVS ,_15!'U#%3MIF@6V@Z3!TP H$'=8]
M*S9M"]7%E>2X_?M1LNMYF[$72:1X#@\I*AN,?7$M@"=O2FJ7T];[[L"8*UM0
MW%V9#C3>U,8J[M&T#7.=!5Y%D)(LW6QNF.)"TR*+OI,M,M-[*32<+'&]4MR^
M'T&:(:<)_7 \B:;UP<&*K.,-? ?_HSM9M-C,4@D%V@FCB84ZIW?)X;@+\3'@
M6<#@%F<2*CD;\Q*,KU5.-T$02"A]8."X7> >I Q$*.-UXJ1SR@!<GC_8O\3:
ML98S=W!OY$]1^3:G>THJJ'DO_9,9'F"JYYJ2J?AO< &)X4$)YBB-='$E9>^\
M41,+2E'\;=R%COLPWEPG$VP=D$Z = ;L8QXV)HK*/W//B\R:@=BQ]QT/3YP<
M4NQ-&9RQ%?$.Q3OT7HKDTTW&+H%HBCF.,>DR9HY@R#ZG2-=2'--_X.DZ?+NJ
M<!OAVS\4WJX3[%8)=I%@]]\2UV+V?R5ABYXJL$V<)D=*T^LXR0OO/+!W:7R3
MW^'CM#]RVPCMR-EX?-G8_]H8#RAE<X4CU.('FPT)M0_'6SS;<<Q&PYMN^D%L
M_L;%+U!+ P04    " #"@59.8&[ C[0!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q]4]MNW" 0_17$!P0ONVV3E6TIFZIJI59:I6KZS-IC
M&P48%_ Z_?L"=ERKL?H"S'#.F0M#/J)]=AV )R]:&5?0SOO^R)BK.M#"W6 /
M)MPT:+7PP;0M<[T%42>25HQGV7NFA32TS)/O;,L<!Z^D@;,E;M!:V-\G4#@6
M=$=?'8^R[7QTL#+O10O?P?_HSS98;%&II0;C)!IBH2GH_>YX.D1\ CQ)&-WJ
M3&(E%\3G:'RI"YK%A$!!Y:.""-L5'D"I*!32^#5KTB5D)*[/K^J?4NVAEHMP
M\(#JIZQ]5]!;2FIHQ*#\(XZ?8:[G'25S\5_A"BK 8R8A1H7*I954@_.H9Y60
MBA8OTRY-VL?I9L]GVC:!SP2^$&Y3'#8%2IE_%%Z4N<61V*GWO8A/O#ORT)LJ
M.E,KTEU(W@7OM=S=W>7L&H5FS&G"\#5F0;"@OH3@6R%._ V=;]/WFQGN$WV_
MIF?9ML!A4^"0! [_+?$MAF?_%LE6/=5@VS1-CE0XF#3)*^\RL/?I$=E?^#3M
MWX1MI7'D@CZ\;.I_@^@AI)+=A!'JP@=;# 6-C\</X6RG,9L,C_W\@]CRC<L_
M4$L#!!0    ( ,*!5DZNT]PZM $  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;'U386_<( S]*X@?4!(NW:I3$JG7:MJD33IUVOJ92YP$%4(&
MY-+]^QF29MD6[0M@X_?\;$P^&?OB.@!/7K7J74$[[X<C8Z[J0 MW8P;H\:8Q
M5@N/IFV9&RR(.H*T8CQ)WC$M9$_+//K.MLS-Z)7LX6R)&[46]N<)E)D*FM(W
MQY-L.Q\<K,P'T<)7\-^&LT6+K2RUU- [:7IBH2GH?7H\92$^!GR7,+G-F81*
M+L:\!.-37= D" (%E0\, K<K/(!2@0AE_%@XZ9HR +?G-_8/L7:LY2(</!CU
M+&O?%?2.DAH:,2K_9*:/L-1S2\E2_&>X@L+PH 1S5$:YN))J=-[HA06E:/$Z
M[[*/^S3?9.D"VP?P!<!7P%W,P^9$4?FC\*+,K9F(G7L_B/#$Z9%C;ZK@C*V(
M=RC>H?=:\H3G[!J(EIC3',,W,>D:P9!]3<'W4ISX/W"^#S_L*CQ$^.$/A8=]
M@FR7((L$V7]+W(O)_DK"-CW58-LX38Y49NSC)&^\Z\#>\_@FO\/G:?\B;"M[
M1R[&X\O&_C?&>$ IR0V.4(<?;#44-#X<W^/9SF,V&]X,RP]BZS<N?P%02P,$
M%     @ PH%63MMT>X6U 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL?5-A;]P@#/TKB!]0<ES:JTY)I%ZK:I,VZ=1IVV<N<1)4B#,@E^[?
M#TB:95NT+X"-W_.S,=F(YM6V (Z\:=79G+;.]4?&;-F"%O8&>^C\38U&"^=-
MTS#;&Q!5!&G%>)+<,2UD1XLL^LZFR'!P2G9P-L0.6@OS\P0*QYSNZ+OC13:M
M"PY69+UHX NXK_W9>(LM+)74T%F)'3%0Y_1A=SRE(3X&?),PVM69A$HNB*_!
M^%CE- F"0$'I H/PVQ4>0:E Y&7\F#GIDC( U^=W]N=8NZ_E(BP\HOHN*]?F
M])Z2"FHQ*/>"XP>8Z[FE9"[^$UQ!^?"@Q.<H4=FXDG*P#O7,XJ5H\3;MLHO[
M.-T<TAFV#> S@"^ ^YB'38FB\B?A1)$9'(F9>M^+\,2[(_>]*8,SMB+>>?'6
M>Z\%3VXS=@U$<\QIBN&KF-T2P3S[DH)OI3CQ?^!\&[[?5+B/\/T?"N^V"=)-
M@C02I/\M<2OF\%<2MNJI!M/$:;*DQ*&+D[SR+@/[P..;_ Z?IOVS,(WL++F@
M\R\;^U\C.O!2DAL_0JW_8(NAH';A>/!G,XW99#CLYQ_$EF]<_ )02P,$%
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M_QMC/*"4Y Y'J,,/MAH*&A^.;_!LYS&;#6^&Y0>Q]1N7OP!02P,$%     @
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MQ >$-;O9K%:VI6RJ*I5::96H[3-KCR\*, [@=?KW >RX5F/U!9CAG#,7AG1
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MWVLV)%0N'._\V8Q#-AH.N^G_L/D3Y^]02P,$%     @ PH%63IU;KL:T 0
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M\>'X'L]V'K/9\&98?A!;OW'Y%U!+ P04    " #"@59.U\'0YZP"   3"P
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M\OW+04HC[%ZR.VNQD^U0QTDM#L8-YW:L^C:MGQC9#2TH&?O@S5]02P,$%
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M'F\VSK\RQ@.6DMSA"C7XP&9'0>6#^8"V'==L=+SIIA?$YF><_P%02P,$%
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MZ/S+QO[7B Z\E.3&CU#K/]AB2*A=.'[V9S.-V60X[.<?Q)9O7/P#4$L#!!0
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MV=C_5FL'/I7DQH]0[S_8:@AH73A^\F<SC]EL.#TL/XBLW[CZ U!+ P04
M" #"@59.!'"SL?4!  #+!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6QU5-N.FS 0_17D#U@#N9&((&VV6K52*T5;M7UVR'#1VIBU3=C^?6U#**6S
M+]@SG,N,P9/V4KWJ"L $[X(W^D@J8]H#I3JO0##](%MH[)M"*L&,#55)=:N
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M%!?A_5[CR0=OB&&B)IB("J<F1A:6S2B&B!H3$9=-C><,K!V&K!H?M+AD)M"
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MN[<6=E_::IO>R)CM7PLY_Q]02P,$%     @ PH%63C.';0Q- @  L0@  !D
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MF_K#2Y7ONE\A_--/(=/_ 5!+ P04    " #"@59.]<IM?C$#  "Y#   &0
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MQC.[\:;3Y^D\,KH=BJ[_ U!+ P04    " #"@59.V3N\*2@#  !^#@  &0
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M<&R4?">[UU2]-WU%U#>D. [57C"6G*O?4$L#!!0    ( ,*!5DY/W-KV40,
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MM[_S_N,VT439H+LLPCBZK9N^N/R1512@V52VUO)9(6PQ'$]0V,L#?: ^D+U
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ML7@OF]ZK&7!V4&VEU_:VT_]02P,$%     @ PH%63A[,A0[5 @  ] L  !D
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M+:6"R.##;[)8>SG"M9N";(5:IG+-FD&FV0A:FQDM: ?%V3]02P,$%     @
MPH%63@30!^_Q 0  *P4  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
MC53;CILP$/T5Q >LB8$$18"TV=6JE5HIVJKMLT,F@-;&U#9A^_?UA; HN%5Y
MP)[AS#DS@SWYR,6;; !4\,YH)XNP4:K?(R2K!AB1#[R'3G^Y<,&(TJ:HD>P%
MD+,-8A3A*-HB1MHN+'/K.XHRYX.B;0='$<B!,2)^'X#RL0@WX<WQVM:-,@Y4
MYCVIX1NH[_U1: O-+.>602=;W@4"+D7XN-D?,H.W@!\MC'*Q#TPE)\[?C/'Y
M7(2120@H5,HP$+U<X0DH-40ZC5\39SA+FL#E_L;^8FO7M9R(A"=.?[9GU11A
M%@9GN)"!JE<^?H*IGC0,IN*_P!6HAIM,M$;%J;3OH!JDXFQBT:DP\N[6MK/K
M./'?POP!> K <P!VM3@AF_DS4:3,!1\#X7K?$_.+-WNL>U,9IVV%_::3E]I[
M+=-DDZ.K(9HP!X?!"\P' FGV60+[) YX%1['D9\@]N886X)X09!L_Y)!XB5(
M+$&R),BRNR(=9F<QG2MR$[G'+Y5ZI=*55)K@.ZET)87_J;3U*FT]2K&?8.<E
MV/U_6S,O0;;*($[2NUK7F'3U\]'BL#(0M;VF,JCXT-D1L?#.D^ 1V\/^ 7=C
MY"L1==O)X,25OC+V8%\X5Z!3B1YTWQL]N6:#PD69[4[OA;N_SE"\GT83FN=C
M^0=02P,$%     @ PH%63HD)5%_$ @  +PH  !D   !X;"]W;W)K<VAE971S
M+W-H965T-34N>&ULC59M<Z(P$/XK##^@)$!X<=29VE>M-]-IY^X^IQJ5*1".
M1.W]^TM"1 RYRA=(EN=Y=I==PHZ/M/YD.T*X\U7D)9NX.\ZKD>>QU8X4F-W0
MBI3BR8;6!>9B6V\]5M4$KQ6IR#T?@,@K<%:ZT[&RO=;3,=WS/"O):^VP?5'@
M^N^,Y/0X<:%[,KQEVQV7!F\ZKO"6O!/^LWJMQ<YK5=9904J6T=*IR6;BWL+1
M,I9X!?B5D2/KK!V9R0>EGW(S7T]<( ,B.5EQJ8#%[4#N2)Y+(1'&'ZWIMBXE
ML;L^J3^JW$4N'YB1.YK_SM9\-W$3UUF3#=[G_(T>GXG.![F.3GY)#B07<!F)
M\+&B.5-79[5GG!9:1812X*_FGI7J?M3Z)YJ=X&N"WQ*$[^\(@28$9T+X+2'4
MA' H 6D"&DJ(-"$:2H@U(1Y*2#0A&4I(-2$=2H#@5#EPID3?4]IBP\%>3N6&
MOD'QFL92G7J/.9Z.:WITZN9;J[#\I.%(L(2XM*K>5P]%MS)A/4Q1&(Z]@U32
MF%F#\3N8((*7F$4?<T9X(H0V#M\:Q\SO\?U+#W=]1! 9F/L^QLCEP:827&(>
M+1AT"7FRR1BNGFT80V=NPT3&J[WZ:EZN![SL0Y+(7J# WBB!$@BZKS;Z3XE#
MNT*H%,)N"(G1:0TD5I"R2=5/(F"V@@V&@C0VNJ$/@TD$@>'TP:(&@QBF1E=8
MU,3/+C9B>[+ D(\@,)JC#TM38(8V[Z,2D"1&G@L+"@6);_312Q\6(C^,#;6E
M)8$4ABBTUQK9:XUZM48ALBM$=H5H>+_%=H7X:K\MXEZN1IU>KB*6?00" !B1
M>IT#N2#U5HT>S%G1?<EEEAUK.]W<^O) -^PS.)I#BWTAIJ%F>#G+-Z/4#UQO
MLY(Y'Y2+'XDZZS>4<B)B!S>B3CLQO;6;G&RX7,9B73<S3+/AM-+CF=?.B--_
M4$L#!!0    ( ,*!5DX+,N-3QP(  # *   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;(U6[7*B,!1]%88'*"00/AQUIO93Z\YTNK.[OU.-RA0(2Z)V
MWWZ3$!%#:ODCR?6<DWNY![CC(ZT_V(X0[GP6><DF[H[S:N1Y;+4C!68WM"*E
M^&=#ZP)SL:VW'JMJ@M>*5.0>]/W(*W!6NM.QBKW6TS'=\SPKR6OML'U1X/K?
MC.3T.'&!>PJ\9=L=EP%O.J[PEOPD_%?U6HN=UZJLLX*4+*.E4Y/-Q+T%HV4L
M\0KP.R-'UED[LI)W2C_D9KZ>N+Y,B.1DQ:4"%I<#N2-Y+H5$&G^UIML>*8G=
M]4G]4=4N:GG'C-S1_$^VYKN)F[C.FFSP/N=O]/A,=#W(=73Q2W(@N8#+3,09
M*YHS]>NL]HS30JN(5 K\V5RS4EV/6O]$LQ.@)L"6(,Z^1@@T(3@3PJN$4!/"
MH02D"6@H(=*$:"@AUH1X*"'1A&0H(=6$="@!^*?.^6=*=)W2-AL,/N74;@ -
MBM<82SGU'G,\'=?TZ-3-LU9A^4B#D6 )<1E5WE=_"K<R$3U,41B-O8-4TIA9
M@X$=3!"!2\RBCSDC/)%"FP>TYC&#/3Z\/.&NCP@B W/?QX27B >;2G")>;1@
MT"7DR29C'/5LPQ@Z<QO&N/V+;V_-R_<)+_N0)+(W*+ ;)5 "0??61E^T.+0K
MA$HA[*:0&$YK(+&"E$VI,(E\TPHV& K2V'!#'P:2"/C&H0\6-1#$(#5<85$3
M'[O8R.W) D,0 =\P1Q^6IKZ9VKR/2OPD,>I<6% H2*#AHY<^+$0PC VUI:6
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M#1E]MMGM3;Z]'!1FUW9?$_N]'MZ?#@=M=1K?#8>7%]3+?P%02P,$%     @
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M4)]\ A 0ZI-"AL#R?8^"Z:4,P<40A8 +NT88T.2$X;*)H+IIEQHT+(O@?C\
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M8,7,HKL^R$2LG%D!,F&1XLO)LR%"\'+7#'$HY<*UO04JTLIG!X.+.+CXHB$
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MJ5\S]<[[&=XO).N&^TDP7I+F_P!02P,$%     @ PH%63M'-O/&[ @  S@H
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ME6-F6KB9"-KVUQ,:[LC\+U!+ P04    " #"@59.&./DRQX%  #R&@  &0
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MJ[\5$&I4SJR!T)V T^@]W\L %K5G%=48B_H+6-08BQIAT5U%M<0BAPE'GG5
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M=];U\&X@:-O?3X+ADE3\ U!+ P04    " #"@59.7KE<1?T"   C"P  &0
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MA0@*F46M76JFMBJ$%6,$WZ<(L#>R+U3TF7,9@,PPC6)+,H21*+GA,K[Q#<"
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M#D>EM#3IT+UIZVQ.D].DDD=MAYD9=\.1:IAHU8['Q60ZLV[^ U!+ P04
M" #"@59.&=+\W^4"  #J"@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX
M;6R55FUOFS 0_BN([RL^;/,2)9&:M-,F;5*U:=MGFC@)*N ,G*3[][.!4F(?
M5?LE8.>YYYZ[\YF;7V3]U!R$4-YS653-PC\H=9P%0;,YB#)K;N115/J?G:S+
M3.EEO0^:8RVR;6M4%D%(2!2465[YRWF[]U OY_*DBKP2#[77G,HRJ_^M1"$O
M"Q_\EXT?^?Z@S$:PG!^SO?@IU*_C0ZU7P<"RS4M1-;FLO%KL%OXMS.XA-08M
MXG<N+LWHW3.A/$KY9!9?MPN?&$6B$!ME*#+].(NU* K#I'7\[4G]P:<Q'+^_
ML']N@]?!/&:-6,OB3[Y5AX6?^-Y6[+)3H7[(RQ?1!\1]KX_^FSB+0L.-$NUC
M(XNF_?4VIT;)LF?14LKLN7OF5?N\]/PO9KA!V!N$@P%$;QK0WH"^&K W#5AO
MP-YKP'L#;AD$7>QM,N\RE2WGM;QX=7<>CIDY=C#CNEP;L]E6I_U/Y[/1N^=E
MS,)Y<#9$/6;58<(1!@9$H-D'%R'F8A4ZYI:#M8N@_!IRYT*2Z!IR[T(X"7&A
M%,T%;0GH6"A)<0*&$K"6@%TEDUK)[#!QBZDZ)XP!@)42%T9P)1Q5PETE-+:4
M=!@^<L$3 +LV+HI!DO($5Q.A:B(D+\Q2$SE^/M&()(18>A!<" 3(1'IB5%#L
M5#IF'"=(4(($B<@ZCZO$41I')++C05 IM5OP+G&.0P3)Z'!V'>"BDB2B$Z5*
MT<!2)##[X*2.&Q:1J0( P>\=@CB:4 H35Q>\OXJ 7DVW$")]8E>H!_&KY+/I
M@/'+!2@2<&J[HHXK(.&T*_P: N0>XE,4^/T!_ .YQ9L>D*YW<^NV,^-T.F"\
MG2%& I[X1@'>T)!\(&"\=0#K':?";O-0Y"P%H^]W*>I].TPUWD:>*F6^<:/=
M86"[#<WWW]I?P6S=C5VO--T4^#VK]WG5>(]2Z>FBG0%V4BJA59(;79"#'CR'
M12%VRKS&^KWNIJ]NH>2QGRR#8;Q=_@=02P,$%     @ PH%63@2W(7!I @
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MX)-0RTRNV3@XQHV@PS03P3R8RW]02P,$%     @ PH%63F',[,_N P  _A$
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MU[]6>N:"EIV*M%+B]_::5_K:=/I7FIF .@+J"3#XE.!V!/>#X'U*\#J"-R*
MMA2=S18+G,2,-A9K'V^-U;\(/GLR_50MZK#U/1D/EZN7) P6,;@HH0ZS;C%H
M@($] DCU?@MDVF*-)G1TN\%FBG#]6\AV"HD"LPG76*>K^>ZPSM Q"WA& 4\+
M>#<"<!14B_$UIFKK6 31J-@I" ;>N-PI*$">'YD-^T;#OL$P,@L$1H%@?F2A
M42"<$5DX)[(IR!#9%(1"/[@3660T'!D,NV:!A5%@,3\RZ)C?1V=&:!UH6*LS
MBNPQ9&N 0,>Y9_=.^X &N]X="6-[6$'T'Z&97V[HS@G-?1S:0\C6 ''=:#'V
M"P;]MR3LI,\V;J7T7 G5Q@:K_?FY0JI_C];7ZES5??U#ICV4?V!VRBMN[:F0
MIX/NX4=*!9$NG2?I+Y/? ?VD($>AAJ$<L_8P;">"UMU!#_JOC>0?4$L#!!0
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M/FQ7N+?]/],;WK3#=6#CG2S^ %!+ P04    " #"@59.DKN2;.8$  !W'@
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MH%7U&*!)R6,BF&0!2+;,$P(S*-(9=F &!=H#B1TV<)Y0W=0\D9AI29E6VG?
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M^Z;[VOU6=7T5>KUHRO/PFC>^O6M>_P]02P,$%     @ PH%63CLY=T=2 @
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MFG/;INQ"LK9OP<'P'9#_!5!+ P04    " #"@59.(?IX9C<%  #*&0  &0
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M"#O.M-#1<H/?<T,8=?CH:.9 7WZVAHXV ?P^ 9^NYPW3:G>YTUCCI/$Y"+G
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M(X8!@Z,RW53W17>8=@/%F_ZBX VWE?P_4$L#!!0    ( ,*!5DX*@V+J6N
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MC+XEG2[.]G .<%?Q\L)E8.Q0T6-T1"3(H7LEM+TX'/T# BER#K0+:8AER6,
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M>@,W72\_GZ>P(EI]\SS?7OUJ=A*C-%60M!3CHN9PM.+KN8<Q,KS)?-?T"6Q
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M]*+6&DJ(>@=-:4>T)56+U/ON12FE/.'7*S8<MIIP?H%+ ^_^B&49X.S/#KZ
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MY!$.$^4X(Y2(,3K1< E'HJ?L*[4$#,C+'RD*E[")X^G@_S&.3IN+Z#C/$3@
M"E!,"B!H@*D@!&-&G2)<C =VA"PLAQ AYO!03,A1KSM)04!T[M$WNS)&I>1+
M)6'.3"O(16-!SMK3 V5SP,:9QN$1PM-I8>TH%&ZI)'H=#<EN.I"1Q>8H3G9M
MT*%RJ:#FRG+D6ZDBIM5.H5BU=TBMHO1(%5QBA2#1M>)[NP\%+]2.,9+8>8"3
M+0685"&/4)Z2+,G?+2G9WG=%;'ND7,> "*,4B/DL8;QN?&17!4>4%)_(3H1
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M[6S,",7J*/2+MNY8.MU:(8YO1!:5EOS7FC&N7F"5S7Z-B>'(;([JPPZR/]I
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MEV42X.SRQ>JZU.<'U@Q'-*'F;+<NW?E=A3,\QLV(,PT3DSXS-RAP"";U%71
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M&1OTC2&#*KL[WL*7@,G!G\>]WA5*"?C'KUAI@N8ZW^9E6K%F)*ZS#5"&+-^
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MJ.:M)49P8VEW/_@XM*D1FDHSZNXL%']Q]Y%CQ 3$_"T74.22^I67F@*[&L]
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M/DHX"<G^'\M&'V)<&2Q;%;/8"Z\R,6H6@Z4!N%X7.6I%EBQ2\>$X@B-K %8
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M"$[0-BF$Q',P%#0-:[[X^[[<^11,C%]]F\OU-M^#K%#D5Y1'^6PV,_<EHLC
M8RS=?3'_EI+-+$M@\?O<DI6H,H$=N$,0,!>8L9^LF+('Q'SIC$H+0N?*DBT+
ML;V@\ /0ZIKW*#\:A9S1G27V_LE;B@Q_0/F-(>WJHZ_F6Y23I7^B(?S\ZZM/
M'0E!G[Q]?WD)[;[ZV+G\\_G'5RYU9+]S%QTBOUX+!L>*0'(9DM*&K'WN8%.L
MI3'5L.6=\.O^KB"D*78@A]T 63CK9;U)3X"7^PSA/>G!3WWQ8\H;!AMFXY,F
M:)$-4JT'O:< AG4TAE_FY@1@,TC:0 '!4]@T;=IOQ(>=@GCW?3ZGHZ(96NO'
MC@#:>FSOVRQ[./,P!F9C<*-X6;#@I(7[K9I65%-T;I,M%=:.-R=?B8<FM3^;
M9%.X2_NS03::PBX:];(1&!HO<4#+;Q9B&M%C9@B*,\V&^<BXBH_OJ3LIE2_$
M(V@SL8,<P<P&]-\>_%?'$"^B>R>3J<&ZYP$N0Z\[HM7H=?O3\!3$KVJ?\.5^
M3B\/9^;E#QL4BZCWUTP%*B#5U,V*1&DS;C7T,75STP'+C&]YO$?@\V=N@I\G
MMON^#L0CJ^3*N9KP,*=JD,W&4\3"&XX(7@G^06&$ B&"ULAL2^$=!"/C"#U]
M_PO60F.2&T*-+!,,;B^+8GM#%=/OO"_C@I6#K/.V^Z';.?'/4.LQ1\  3N.L
MQV5-OX%1,K?<28XE@\A3.>!B!S/N9\/1E*Z%RH=8'=H6]_,EK;,"J4VZ_BL6
M9B0"=L,OTE<; $@D\W(9<&,/036V@SD5A/8:$2@X!ORP*^'0C%4I=K3XX9[J
MF+(WOG RLN1=EPX9(9Q0Z@(GE_CJ#7CK$NX[Q^<ZB>YXDSW_CJJPBR0+FGG,
M9Y@UP:*]/G_SL?/7\[>?7W7>O3J__/SQ%?.>T?T>H+L:A$P)(JO[R[O"3>G$
MER4(0EC2AX[G1;[CGE?K)W9!R<6:D>7!IE+A_0A6LK?H">GD\E_%D6W+TU3'
MSN1.BA RU1$SN>>$C>D)K$R.NXSIF(YA99)13*:];#";>D:F&EJ<"IM20*H4
MK3DZ+9;1VIG)G,S&V6R&/TV1I6J0(HH[9I%B-J0Z#J0JYU$=]Y%[3AB/GL!\
M9*8.R8Z.XCSB40PHYZ?O"8\.+1*3%06<1>T722=SB(7Y@Q[]"H1Y;^JK/DW1
MIV_7!M4??9;K? :@0,9;I'N@1QKFV 9]"U&(>7L-.DTRZLA.A=4 .P2POQ%J
MO$-]T_0=ZA4F9,#&ITRW]L5CFZV;'(KXZZXB7XE6:AHF/?4T_>_]9L?E"4H\
MS"7!OLM+@O@4/%&!=D>/@9[4Y1K4,\X"VKJ2K6"';Z4''O1FN5V<,>FHH@R5
M<(U0G29_@<(T5YCQ0I:%+<*G.@9+E4)3Q=@PL*LP1<:\26%15 K@;I6QTMO?
M,*_FQ@"4:-)2\#:-3>K"N:.)*>CK%%PV(\=J/!K5F*VKP@B96M3=YQQNY!6O
MY+_8K5.S2:OK$>W :G*6(D9=U["J94C)L"BD<!,GIR0HY$QRB8+?2ZY*B7R_
MO DIE:F:$8B?\0XZ]XA6A.VV%?EBF[$(Z\$C'XLKMRF("$!R6J_!$ 9C82M8
MK-1I==+29+BJ.-,<GNKP--1,'^'(>]%*,/&\44R0I920L)<VL=_&[!=!Z:7,
M$01"A/=;50A<O'_W[HU0U1(N<(F.5%_HH_33RW6X6V'/(%N'QKL)[9"<]Q0B
MO?2>6YN+]&&SPF"UV]Q<-"AHEQS8G(*"P=M4]7"W23]8C&#--I0TFAT77#MO
MGP0M7""9XJ3"TK%<2Y248]1:Z:@9WC8%AP,9VK->:ZAL:O2\Q())N."/1,ZF
M<BM!>L;.)@"R_Q,1L=773.5%&J4#2YW +"T8O);OV(](M$)'5\D^=W7>/TQ#
MCHYML;R[VF_+PC&2&2-M9B;#Y<LM,>B.8H$J5TOGT]7WI/9QBE0RF#NA\,]7
M!5+0O"ZNMG;O=3(;J?JBS%2E"&%!,L7/?2]6WP@;8(=9.R@MKL21KAO7S^#N
M^X8(FSA7Q:#H,$:GV4Z,OP=J[1GAT$@%/$YPP,#M]YX'2K5("(* @/_&J+#0
M3?$O[(11GJE&DTK]WMR''CS"@<$^$^TH>47%29A:#Q=>4@\NNTX&7MJ:3_T8
MYK'@+H8^76%@2#>A\I*1_\;A%Q#^!T8*9(;MV5'I)DD2I6N#0'O8.E>W)R5V
M^3.M7_TVAYL'K_]K1A4W99.4.D<7B+N3)>.^M'D Y!:@&6+U;TNL(3<%9:;P
M_.C'+)<2GJO,17+LN0U#]?E$G!_^%!,L ;\_ES%76T:W&-R %AD40?W'".>?
M8Z;T_%A,?Q>X8T5#^):J>T]_)^N_\_!06T[C<8E0]Q4L4GI#3M>"9)D?4E4I
MLAD3XE-:/?!1IPT()_-JOUPM*-*!OA4X4%\ZER@:$,\7N;:"L9&\GTOQ,,SR
MG,1GC@'405I\>D8AQ,+VN3>JQ;'*(;XBB8V%6HFPRC#*0O5",Y?I6A!)*CED
M+D1R8T]B5..+-%DN$EF91=*(:;/0.BWFNWGGFFY$@C+>D/S!?'_\ R6D;Q5+
M5)L472EH4FY*RZ(AXHB]=CHG^!,="GZ7S[6&K\L$O9 V$2O&Q[B'8G.NFG(>
MY*-?5*AD8O8B52QMAW[H],GG\4-G-.QUWCIUTY#-Q*- Q_ULAD:Y&/1-MD ^
MS*:#26<VG"*)4[ (0?_]'XVWDD)->$#.=INS<K_<R9O.NS#,1H/>(\<^G+EV
M6@Y\,JMD\E>W53A+4^T?/QP_\@,%:<:$Z\&N#HU64M2[]+T0H5_#>/$^DOOJ
MWFT5;,\.5L&T#3I4]@%9',C1DQ/-,'+VD*,M&_=[G;_JA6:>S;/Q.(<MV8?&
M\JPW&H.R?\5_E["**<'J$[GPR2 ;C0:.G]9,%V[J;#HBKU$V&XR(XBOO#QCL
MA[S\E.L@&GXUQ'/GO=?IW="JP)51C2J(RU5B1(Q?D8WKDBBO'LRADO2D9:ME
MI<&]QE4\!$$1D[8VG>-#6Z2R]B7MF5(!\:M]F+'DF0U1.^XADQNL"Z4Q]K-9
MCW[;A_V"^@3\., ?IWWV9C$Z(I)\3(?!HCOE&OW'TXGP+7W@]!5Q-\U][/ED
M!$]AHM2GR*BH&@(G4Z*B.VV2P'R84=0U/32WN+A:@7<?=%%56><FJ8RNHM_X
M)YC<X<W:W<!J143MARV2@:EW*!EN^&O,4=ULMVR+L#?:]GNY)EP1-LJMZN:5
M;05TX<QR:.'0AHR0N5,C1"MKYA!*-0<J>I5X2M%=15W?B^7I\1<E7R6Y4 ]T
M0(==Q-KHPC9"I&(^6YP(B1_]Z#U1=.)4W]I<H:Z 7_N^8?!0.,HKWX1R,8<%
M0$EK7I0]F,8K:E%>9>P.S$JW@/[S5LQSAG0!;0+7V58=!?5S QKRM@P=9LLU
MB$G2A>[1[?(@.J3IK!+M5C#">A8 [5AV;U6_<1CW2)0-D@C+X'5$\\J8TD/"
M'9_0N55[EP6HSKOE/DQW?*(W-14FB%/"9*TWG02KA,;KX4WBQ7;^?4TP5UTD
MM56Y$;\R=W%<\E#N,&6,TK:NV*9-A&\$<<?_T?RM=*<I:$XKYVOV4:2SE%]
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M;]]<,)GGP3%E1OVG[SMQ'R8%M.$_=%8_^[%)CC/1!*=ODLV .?U4?-3&;@W
M$A-C<=+) R;&I:.<H=(X6:[4P954Z72TLJXKD-S?[3XH%G9UV^\U.I)'S3KL
MHS2[MD0$E<A9-Y388V&9/W>,B]5^;YCL.*(_Z%8^?WX+3071??S('4.P^?M4
MRLG#L/5<WZWL_2Y)MD#4+4M)@^6-^BMO90NJ6A)P88*Y/-(7GA#D[9SH3Y%&
M\3/E\>!V<_Z29<SDFGZ*B^AJ"U>\BF+<+TM7!%UH=#?D N#]NO'EOM^_P.P_
MG&&5VX)J$)>+)8@AR<@L"Y=)JSPR-_OUM00;V*<)!M>R]*>-$9'9(J"<$AF
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M:RJ@?W/E^2:LI&F[:G(948X<5F3)2V9H&51>8%A\3IB!&E,Y-TD:%APY52)
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M0^U?9G)"%8%S.H.0*K1%<5YB9NIV?JEA?=H&,X"I:@<FP:5(N:('33R5CG)
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MC][,!UD/.A.^"A,Q'.;12(..OJ\+HL&<T6R-LWS4"YH=9/F$%F.6#?JIKKE
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MY[>WV^+6&;7-5)DE&BD+_Q+J?SI9Y'U^K#0G=99*9#]42LI?(%=(6<:EYGC
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M@Q+D/.1",K!WJ)3<!<T2LWG# 3NT A&1_-\T0(&_J_9AQB(!+L(^5DQB >X
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MLE+$"-U8MV\<L:!" J5;1E?VC*=\L&'/CDPWM3J,<"&;VK:"_5RUTT>!;F0
M":4]H ^M(PH*I!26_%H/FLF-\X\0:.WEIM"$F40;SY_#(:%YZ"(K(1,L^S(>
M[%Q10'%J<"3)<O-4HG!,4"G!M)$0E F.&H8NHS6T;(PIO3-?M1_ICG:= CO'
M'(D+@:'H3+WJUAQ.S6V0M]6L]K:L?Y N*,A:J"^57@YOQJ;I\*W$*:F;<9WV
M %H=%07=?*8DXPS;Q3Q9T#NP8!2@K@[(A20/6L^T2JP=6$*PQE*1>-OS2Z)B
MB6O5M5.='LKL'R'S:^]SACF6B&Y#Z]Y_R[O\GXEG9W^/W/RJC(%?D=&\-(\
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M\;=7=S%GZD%8]X(-L\F46"<!23EM'B$09HXIL3I\FN4-X5.#$+ /_[5R$WX
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M]26ORUO#PD<XTC1*TC"A=]G6]:5?=Z,^:Q[6=\?8O6/X_C=02P,$%     @
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M:VT!UY;OM05@6[[8%I!M^69;@+;EJVT!VY;OM@5P6[[<%M!M^79;@+?EZRU
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M.P*](U_O"/2.?+TCT#OR]8Y [\C7.P*]XPIG!=%A0;[>$>@=^7I'H'?DZYV
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M<F]P<R]A<' N>&UL4$L! A0#%     @ PH%63B%D"';N    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ PH%6
M3IE<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #"@59..X1!;,X"   T"P  &
M@ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ PH%6
M3@@!?(S(!   VA<  !@              ( !^PL  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( ,*!5DY5*X"-+@(  "\'   8
M      "  ?D0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #"@59.0WA-[&<$  #]$P  &               @ %=$P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ PH%63DL=&==A @  3@<  !@
M             ( !^A<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ,*!5DZPMSMH P(  ($%   8              "  9$:  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #"@59.&!8#IML$  !J
M%P  &               @ '*'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ PH%63D<2<TA7!P  OR@  !@              ( !VR$
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,*!5DY<5 P*
ML@$  -(#   8              "  6@I  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #"@59.R(C<#K0!  #2 P  &0
M@ %0*P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,*!
M5DZ00$UGL0$  -(#   9              "  3LM  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ PH%63LFFIF^U 0  T@,  !D
M         ( !(R\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #"@59.8&[ C[0!  #2 P  &0              @ $/,0  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,*!5DZNT]PZM $  -(#
M   9              "  ?HR  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ PH%63MMT>X6U 0  T@,  !D              ( !Y30
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #"@59.7??Q
M&;4!  #2 P  &0              @ '1-@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ,*!5DYS@,1?L@$  -(#   9
M  "  ;TX  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MPH%63M 6Q^BU 0  T@,  !D              ( !ICH  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #"@59.-V:?\[4!  #0 P  &0
M            @ &2/   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ,*!5DZ=6Z[&M $  -(#   9              "  7X^  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ PH%63M?!T.>L @
M$PL  !D              ( !:4   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #"@59.F8?&'<,!   W!   &0              @ %,
M0P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,*!5DX_
MO)P$W0$   $%   9              "  49%  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ PH%63B*="9VU 0  T@,  !D
M     ( !6D<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*!5DZ">X9=W@$   $%   9              "
M 6M1  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ PH%6
M3EQDPNC# 0  -P0  !D              ( !@%,  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #"@59.Z3J/4+8!  #2 P  &0
M        @ %Z50  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ,*!5D[,X;)<T@$  )P$   9              "  6=7  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ PH%63O4)*IBV 0  T@,
M !D              ( !<%D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #"@59.V;[&P) #  #R$   &0              @ %=6P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,*!5DYSOPX'
M, 0  $X4   9              "  21?  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ PH%63M>7KPM.!@  (B(  !D
M ( !BV,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #"
M@59.,X=M#$T"  "Q"   &0              @ $0:@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,*!5DZ/XYMQY ,  +@1   9
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M970T,BYX;6Q02P$"% ,4    " #"@59.V3N\*2@#  !^#@  &0
M    @ 'I@   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ,*!5DY/W-KV40,  -8/   9              "  4B$  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ PH%63JC >*K+ @  .0H  !D
M             ( !T(<  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #"@59.2?0T:QX#  !"#@  &0              @ '2B@  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,*!5DX==/\<Q0(
M !(*   9              "  2>.  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ PH%63M5:=C@< @  " 8  !D              ( !
M(Y$  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #"@59.
MR^#$YQ0"  #8!0  &0              @ %VDP  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,*!5DZ9IN!$70(  #L(   9
M      "  <&5  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ PH%63CZXO@CI @  YPH  !D              ( !59@  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #"@59.'LR%#M4"  #T"P
M&0              @ %UFP  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( ,*!5DX V!#6R0(  #0*   9              "  8&>  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ PH%63@30!^_Q
M 0  *P4  !D              ( !@:$  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #"@59.B0E47\0"   O"@  &0
M@ &IHP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,*!
M5DX+,N-3QP(  # *   9              "  :2F  !X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ PH%63O.R9Y@Y @  V08  !D
M         ( !HJD  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " #"@59.*396/E8$  "L%@  &0              @ $2K   >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,*!5DY^^X6IW@(  (@+
M   9              "  9^P  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ PH%63K5/X%?& P  5!(  !D              ( !M+,
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #"@59.C[K,
MC.L!  #S!   &0              @ &QMP  >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( ,*!5DZOW..?IP(  # )   9
M  "  =.Y  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MPH%63M'-O/&[ @  S@H  !D              ( !L;P  'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " #"@59.NN&=TD8"   O!P  &0
M            @ &COP  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( ,*!5DX8X^3+'@4  /(:   9              "  2#"  !X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ PH%63NQ$/BY3 @
M3@<  !D              ( !=<<  'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " #"@59.$%'<92D"  !-!@  &0              @ '_
MR0  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,*!5DXQ
MRO^\F@(  &\*   9              "  5_,  !X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ PH%63EWIEKSY @  , L  !D
M     ( !,,\  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*!5DX9TOS?Y0(  .H*   9              "
M 2C>  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ PH%6
M3@2W(7!I @  I <  !D              ( !1.$  'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " #"@59.8<SLS^X#  #^$0  &0
M        @ 'DXP  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( ,*!5DZ2:PT290(  'D(   9              "  0GH  !X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ PH%63G<:;=*D 0  GP,
M !D              ( !I>H  'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    " #"@59.DKN2;.8$  !W'@  &0              @ & [
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,*!5DX[.7='
M4@(  +4'   9              "  9WQ  !X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ PH%63KD!)CJ$ @  0@D  !D
M ( !)O0  'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " #"
M@59.M47@B$P"  #L!@  &0              @ 'A]@  >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( ,*!5DXS>M7=/0(  $@'   9
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MZ.8! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #"@59.G\";JS\&  #G.
M#P              @ %KZ0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MPH%63@,'MU"@ @  1S,  !H              ( !U^\! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ PX%63EOL=<DV @  S#$  !,
M             ( !K_(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %\
,7P +&@  %O4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>341</ContextCount>
  <ElementCount>413</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>106</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Commitments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Condensed Consolidated Balance Sheet) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Condensed Consolidated Balance Sheet) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Consolidated Statements of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606AndTopic842OnConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Impact of Adoption of Topic 606 and Topic 842 on the Consolidated Statements of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2401406 - Disclosure - Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues (Revenues by Disaggregated Category) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues (Net Product Revenues Disaggregated by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Significant Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Geographic Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues (Changes in Contract Assets and Liabilities under Topic 606) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details</Role>
      <ShortName>Revenues (Changes in Contract Assets and Liabilities under Topic 606) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails</Role>
      <ShortName>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2403410 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Other Collaborations, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2403411 - Disclosure - Collaboration Agreements (Collaboration Revenues - Daiichi Sankyo) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesDaiichiSankyoDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Daiichi Sankyo) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2403412 - Disclosure - Collaboration Agreements (Daiichi Sankyo, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Daiichi Sankyo, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2403413 - Disclosure - Collaboration Agreements (Collaboration Revenues - Merck) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesMerckDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Merck) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2403415 - Disclosure - Collaboration Agreements (Collaboration Revenues - BMS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesBmsDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - BMS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments (Summary by Security Type) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Cash and Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsGrossUnrealizedLossesDetails</Role>
      <ShortName>Cash and Investments (Gross Unrealized Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2405406 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments (Summary by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails</Role>
      <ShortName>Inventory (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Stock-based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails</Role>
      <ShortName>Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Stock-based Compensation (Summary of All Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation (Summary of All Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Stock-based Compensation (Summary of All RSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails</Role>
      <ShortName>Stock-based Compensation (Summary of All RSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Net Income (Loss) Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Commitments (Leases Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsLeasesNarrativeDetails</Role>
      <ShortName>Commitments (Leases Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsBalanceSheetClassificationOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments (Balance Sheet Classification of Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Commitments (Components of Lease Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Commitments (Components of Lease Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Commitments (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Commitments (Letters of Credit and Restricted Cash Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsLettersOfCreditAndRestrictedCashNarrativeDetails</Role>
      <ShortName>Commitments (Letters of Credit and Restricted Cash Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="exel-20181228.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - exel-20181228.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - exel-20181228.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>exel-20181228.xml</File>
    <File>exel-20181228.xsd</File>
    <File>exel-20181228_cal.xml</File>
    <File>exel-20181228_def.xml</File>
    <File>exel-20181228_lab.xml</File>
    <File>exel-20181228_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0000939767-19-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-19-000042-xbrl.zip
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MBGE=5%CP.GT@>ESD\\76<U>*J2NDY]S)H\J(;V3H-63H"$HDB-^I&=U2W'#
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M/<5 <Z&MQ''!:.U)'"=&ZQ2(]9IJ?DPL O\] 3VO%F5K UJ)?3+6Q"2>!*E
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MF$O'C Q)"-/3X Z[4GH%QE3,)=KL8\"'F_U&.<\D21+F-*).)8 PF-8)F5"
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M4PX[AIAQSG&4R!B=UCR>%S HUJ0J,=423U6SP0YLPD G32XGW._AW=J)*PI
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M(PEF<'H2VG]!@B8&T00#.A8L9O<%51R>CINK0E";F$J"$G&1!*T+0RY2E)G
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M%RU:3";9B*A'M 1?LY<!@!LO ",>,PS_0SI6>#.2X3!> ,2M+]=>)L]=@)C
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MTFN,N?'8*FF<32Q!DK$02EM\5PQ=!(F?:W=LD1K/>. 8^R  L_ND4+[:&GM
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M@)IWWI%B6X%)'G H29\B2K&M'(72 /<^N0-I>!]C:> V(<D]CQ<R24Q0XI*
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MO6(M5K=-B8B36[I7VY'D.%",#.5(6!NT -AN)_B"D5 ^K4#!T5ES-JPA_LL
M#"=<H-Q)B0SF5GA#@G38, "&UN.D5"QJ@Y,&S=*]],XD+" &,Z6#BB4NK6(R
MAA(L]XA95*X[)S4BC?0=!>  @$$(!F28:,\E4>#HFX1HJBTS!-S_QEP=+=*
M=>)!F&C[8MZ3583R(LS)K:;,E4O@"")>*:+YRI5G>6*9PBPQ!FL#:DF$:?1!
M*UN^\/280S_';,JEL(7MQD*CA :=2"#VF,X"?BV?8SIB4WX2=C<QG$LGB),
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M$!7KO9/I3$"V,=)!E"FI,B]T"\F&"(/G"_T R4M:QI*[GY0M61N":C8IQFX
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MFD23&6>VDEP.8!P'A+E5%[?;<OT\3N*/"#)5*TJA-DV7#+%5#B1;J:KJG%.
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MN;V9GE__='/QPT LC F\X:OE8S#64M)@(UIK9+F3LZV;,[G0N/LZMP<_CQ=
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M::\!,QM26=$3JDPO7&ZV=+(Q_:AL+.>L'4%GD@O(^N_(66/9"1#%U6K!R,Q
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MK']*JD"Q4NKG3<(<+ .PV/HP%?Z5Q'9B8U%U2M58PB#S/9VG1=]C\=(]U3@
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M3,:+?OHX?D19HX ^9_("'H%*#6O2R4?7VQ7B\.MAVG=2=@1^]CL.2"XHV=#
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M%WH890^O.&8H1GR6C645?/"*^'27A!&[F"VY?>.]/<I5']]53I$C: XB&7Z
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MD*1)D=C/98M=FE0FV3V%@JX)_]OU_.9O;R?7ZPK&Q1%N_MG7Y,1&C<WWR%I
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M3!94X0$?]W0<'?]L(>;"-JDV@Q&(FDPC69ZM3J6?!Z>-/NK9B@4^("!"5-E
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MS7 X_AKC%0\1$,]1K@7)*5"0MUS"?\0"'F.IV3"O4F!RA$+]JJ =7AA-'[H
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M\L. LN&4B@:Q$/"&UB\N'@\DSY$:Y1B\<BMS1*GA*"@EE,PED=SY.,"UD:<
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M]I$A]<%AT#R!6["G8\<\Y9AP-,>.Y\Z1YA!9)KM7:K@E2EMG2#$+%B/O%0E
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M"VL"6)A<68P(Y2N>B>-ZFG93M_#9QC>[S4.ZGM_I%$?"@:F=@Z"(+BG1SH+
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MZ2IZ ZI&-"Q +"4!8^DE ;N]?JGC^X9)+8.5%H7<&;<*]1O>#/43LB'0<[I
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MR%W'J/#(6N&Y$:"9P(XD"\24%-XTHG71,-K%$^@(8D\.(@2CP6%"(@@$RER
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MG&YTH%:QY/0/@.LD#V8EA;08)LN,)FS,7:S_1L%RY:$Q_*'.<27MFBP0ZV*
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MR7<[BQI%%^.^KD&^5A[=/1S!LKO7V,]/  X;J;[SD'&;9Q"2(62%:1%*Z6,
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M<J"#X(3K^PO\)4(RS+GSV7#'TEX[#LDF$40[0(74ET'VB^CI+F6SI#R@GW:
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M+6AK"VZ(RH<3.+P<9EI!.X=,G=YCR S2TD;.<Z1HXTF#.1$8$,M&Q[+X,AE
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M2S"="H"+$^=NEVVJY*B#! +TKGZP2(!<@&3/'UG76+]*WW/#N8KE4H4+P(_
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M5B5676?5#5:,N6YG,,3G^0L+8 1;U.D0X$#1O<^>:X9&P+PH&O-X4.6E7'M
MLIZ"N->&6.>K)XGCB..(XXY%N!<9WSRAUH/RIVQD94<RMEPSM<?TGVM(I-).
MRJN;?J5'VL/N2.MW2JL':DK>#MDHT@X-T Z]=D?K#T@[D'8@[4#:81.$0==Z
M8](.!XP!GM/^Y,;R#9APX$L<:([)5MPQ2D9\KB+$6ANH*%T?:YU^>V\!W)5(
MC0&2HMA5";&K9LIDOPL>\_[PN222))(DDB69R8&F=_8OW""1+,/1S7%2=W!&
M_NRO(M@GVKXSNFD5V1B[EP<5T/>1!8M?>2A9'Z!'/*P(WFJ3,K6IJJ)H5\T-
M+,GND[+;[8VU=KLBV"2279)=DMWJ0L'=OM8=5H0JT5#9I5S2G5CO&DM#)U&R
M.&64'E)UUH98)VMSB..(XXCC:DLXRBC-/>*#90C'%]NC6WL^'Q_AA\LMY 7J
M_;0!JI$^9AFL+?*%KB*9\,1G;IEVWA)4$1:ODU<_[FCZJ+0=^;DXYK2I)@G:
M48+& VW0+:UFE02(!*AA M0?:)W1SN6W31&@*AO=G9/#^D7X0&%C+C,,3?!:
M;7>Y$/A(X=V#,WLJGFRG<D_VH)D?-=(OW;'6;Y?6[7PK%<]%\5 (YA '30V5
MQ9$V+,]7)E$D4211?+'_(JDZZNB=ZOGQ7 2R!*S <_*]/P5 :F84GL[6W-WN
M5N]N'Q>WL]KN=]JH?[ LKG-1'A02(^':K9A!&[</EF?5N)(&$D,2PYW$L-,N
M;Z=*0GBPZ/99%1Q]=0-N[^IATV;XY0YMMZ?U>Q29HLA4G:QK0X51;W>U7GF0
M5"2,)(S5N[I-%=;^0&L?L!KWW&5Y_W3D_CE5_BC_MVQ@VVHZR]:E8.W0T'8[
M4_.<^L2.^EUMU"DM:^WI5K%UX2Z*D->X.HKT&NFU_:C7ZW>TWK"BP"?I-=)K
MI-=(KQU!K^EC7>OU]T>(([U6O%G]4385+[P^\W=F7GOV3M]L."\;S&?[HE]V
M>LMLR_GQWNR$3S V&\[_OX+_'B7ALQJPKQ.A@$[9":SW:&?;%GY[*W1)R6>V
MI*ZJ 37,^CG2\D@.&"Y>WDX@>U3"$!?Z:[:WIL&4MKVFOEUS5"8)OR]=AP5S
MP;CI+N5AI3ME7]VE9;!!>\"XCY__R9V0>RNF:PP;TVKJ!MMV#1[?LO1<0PC3
M9U//73 W7$\R7'(O<(3G:\QR##O$-67A$BZ&J6 =$$Q ^ 'H,[ARA=5 <.5$
M! ]".'!' ((FC"#D-KYH"61?,5O5O2N@<N^)FB(?9_( 3\%_<?1P0V@'.(K
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MGO([1AU]^),?/1++,M""*?,CS1R^P0T#9O 0]*L9>JAXX3E 7U>>8, ]B,<
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M2(>!W\I^]:!RYI8QESW1L16]6=P0G8PT&>F7$W*;/=YL3U*R/<:UN\Z*#JI
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M@*>/T90CR<)C1OBDN66;2CH2G6--F&@_'LCSV$8&,:[D?K9107BIN-@#KS#
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M,NJW.@?R*5![5#R;?OM@'E(F "(-NPI%G*E^J9H-#Q#5J)[[#G'J"&[+4AT
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M24A)2$FE[HFT4@SU53'4+0K<E,.J&SHHOT2TMS\K4(WU*:X=X+;4W#'Q]BF
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M._W!]>7Y9>]JT+J\LCNMBW<_KBQ.GM!/%.#?M+8/]BC0;(,"N+KZ2YBYJ=E
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MZ:($SK>6GKI(!T4\GQ/QI'XFU5D1*BR]#P%GJBM-T2ZJR4_0>0C0V1MTK<&
ML).PD["3L).P\UD;-.VVU6M1/Y.=>_W;]3/)S8MZ'RR-G'H?[$T%_(K=3I.G
MW@<5MQ,7PZ7>!P7U/NB5&IDGGJ7BWB]E6>I]0*Q8)5:DW@?$DQ7B2>I]4'S4
M9T]Z'U20<E1&]\'&R%:[5_YAC+I$ O<(DRJG2@F "(!VDNA>";X@%"(4(A3:
M%Q0B,XB.M+V8>:B; )UEH],V=-KF%2)B#P96M[WU9A>)!XD'B<?!BP>%S:F;
MP'[9;;7WC/9(^O97E=52VNS>P&HTRZ^Y0Y)&DD:21I)&T;Z7<0]U$]A'NY.J
M]U# A$0L7]VGV2VL.R-)%TD721=)5W6CF?6KK;7GW02J(JJ4^$%!E\JIQCH*
M6FO0M@8M"KJ0I)&DE:S2V@VK;3=(TBB\^0+NH?K\E--(49+***@Z1TE:5KO
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MQ:.1=*0>,O^FFZHG/#N3T3A1GDL48$!!&;BIW CNC&$^4ZPY"U1%KK?R$W<
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MQ)YUP&'B&T<&U558X45IBP$<P"1044*$E5>N=!)\HJRNRGKYN2D5X&8E,AG
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MZ,6P3QF/E8RB6W:_N'J65> (VD&LIBHF_"'\V9!4;0W:;<(?PA_"'\*?M\C
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MUK?L?F'-& [BV YIP:?9"O.:'N]$2+MEM%M6),?]LI18S=T_8]-IM2K:H"J
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M/JT8ZTNS _Y!1L>$S^%&S43ZJ@EP/'[G,[L)'_QHK(7DIZP(P(IL/;Z"2[4
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M$%!2:$!/!,F[1["!P^J?:^6)$P1U>@UXB0HYG#+PPB[A].#]K 7Q,9-RQII
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MCIS+#! #Q##3?J=Z'0T5),4H'Q=1.5N<HH(H&$Z;0^)["$.!#  T@,OJYP7
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M\WSU=P-9OX93V*3?P.[^DDR]A;()\&6OPY@GZ15YHC[@&@WZY#8,\LF;X\X
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MC'G^:(QKH+<&[<5V)13%5BM8J.2[-2\I;EP)T0"O@$*;:HP::,F:]"T68W@
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M#K@1/&$#2!N([Q:!+ (U(]"@YPZZMBC<(I!%((M +X% 9V=N9WU79FX$2U@
ML@!D 6A; &C8<8=#>XK6:JAH=R-"]E9.6U>RQ74E9UUW8$O5GX/YK2UEP6'[
MP.%TL#;7S(*#!0<+#CL##L-C]^S,6@X6'"PX6'"H#W$R<$].U];I<U? P6;9
MW(][-N_.R(V(ZME [],(TS]UC_NV6/39V,/:.!: + "9+E/7[0YMKHT%( M
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MTM2+K\44P,VY#?.)\[.(X=\"**E([2?3J4C]$.;PEZ;3Q:>OE[_\\O'BR/E
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M',GP(?X<OL1D'0X:-_RX#H/DV%2CN_S>!O_%J\3!T9]*,_+G:R1C[V-:1'Q
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MR4@W:'\_-]P3+Q*2/75.CGE.JH[;I"!D]5-9$+X'U6&'7)IT ?HKB4+VEJ_
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M$U6)LQ$CCW$25E)VN)&%^RU'TTUY\= HW*\,%NN[KC42:(:M]>1ME@ T  U
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M F;ALC[IBRR\U<JXA>:/:7(?1.4@:9[%LS=*_V/Q3KGV&3J7%3<!?):<%N;
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M+/$"&I()G;!D%_]9*\NV&JZK=>V-@U1;7[@5GFH)GNI6(@WER($VH UH ]J
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M]%BGA5?#^NYQC?6X:06\,+^"Z$$VNK=AR4)2B_:..S S3AS7S+PX\E(W=^/
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MO+"GS5D(H?2OE9D@]!D+[6B\::*4&)C_^SA"T8X3BH@M&EM'!&5^KFP7@MB
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M-68KY,S2K.UGCBU7P\VR;64HRO-N>44>A7K>OQR<\=J':%%?%W&0\@'W+&?
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M$"M99$SICYC,1AX7.+'(LR*.G8EI\N1\#&H@^N/@8+4K#Z>#T5:06X].<S>
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M"QM.F2?43 D;>IG')4Z?%[4ZFN\W@?YR CTC["F>H5]_^"]02P,$%     @
MPX%63MN.*U7++0  Z.L! !4   !E>&5L+3(P,3@Q,C(X7V-A;"YX;6SM?5F3
M&SEV[KM_A6[[&=/8%X?'CEH[%.[NDB6UQ_<I VL5;[.8-4E24OG7WP.2M7-)
M,C=*XXF>4A690!X<?#@;@'/^]=^_W8[??8G5=%1._OH3^0O^Z5V<^#*,)M=_
M_>F/3^CDT]G[]S_]^[_]T[_^'X3^^_3CK^_.2S^_C9/9N[,JVED,[[Z.9C?O
M_A;B],]WJ2IOW_VMK/X<?;$(+1N]6_PR'DW^_)?\P]EI?/=M.OJ7J;^)M_;7
MTMO9XMTWL]G=O_S\\]>O7__RS57COY35]<\48_;S8ZN-3^2_T,-C*'^$"$6,
M_.7;-/ST#D8XF2[>7>,E#X]_>_/\5[9XFAAC?EY\^_CH=+3N0>B6_/S?O_WZ
M:3%.-)I,9W;BXT__]D_OWBW9497C^#&F=_G?/SZ^?]%)_!;'HV^CZ5]\>?MS
M?N#G,SN].9F$]Y,O<3K+$S % A;]W%0Q_?6GW +&3C2A5.>1__/F%K/[N_C7
MGZ:CV[LQC/CG]DCZI2JGTS\F@(SQZ']B^!7^BM/S.+.C\0'DUNFMLZ'\;JL*
MH/DE'DS^IAXZ(_EC].7$C\:CQ9*Z2OF)_/^+O\]A08[S(]#@(SQ>C3PLW?S=
MP:-KX66=,>+3_/;65O>G]V?E9%99/YO;\6]V-J]&L_N#![Q'I]T/[%/TBQ=_
MAC<U']&6WCH;RF?KQO$ HE^V:XN\<CRVKJP66#ZYKF*L)V&W-^N6N T?_Q8K
M_^?>PJN]5_0XZ(_Q2YS,XV?[9PRVQ9%NZ[?_X4U/;VNKT$:]#C"T<SL:^9O1
M)SOY\[[L8)#;^A]@N+_$"7P7?6VMVT+? PSS_=TT3CH8XKI^!QC>0OQU,+QU
M_78[O!?+HR6=4:O/;H>5K85)95]\V]+H]NFZXT'FQ=#)$&MWW.T KV8WL7KQ
MW?X^6>.>NQWBQ_+>CF?W#P+@CTEX1=?CHW\;S6Y^F3:4.DU?URTS/LWB[?1^
M$JOK^RY@O6_WW0ZVIO=3IW'7A&8CN(L)V:/GUH9X>SNJ&3M[^VC[1)S:<0X)
M?KJ)<78VMM/I*(W\*ISR:[33^.O(NM%X-!O5#Z*UTGO[0X5?[\K)0O@N7W[Q
M[2Y.IO4AM&]/[0]A\;(#5%#-#KH@>#:+%;#IK(IA-'L3C6LTE,.Z;G^0JP@<
M8/@J7=W%_-;)=?/%<TBW[0^NKI;8T* U@B;3<CP*>;?GN5"I0=B.AET3^,%6
MP)6;. /!-SZ8VK6]=$#ZIQG\7!JHBVCZY;C\NA>/MW;0-<$@EJMX Y(85OW[
M"3P?\W[-P>1O[VZ8P1P,IT/[[GB8*\$&WQXZF+<]=$SRIUGI_[PIQ^"Y3/-.
M4]YZ ;-F-#MT!#L[;&E #]OFH"HO)C-XS?M)*JO;!?-VT5ZG;4MD7MI1]5]V
M/(^_@:Z;5_6V0;8VZI*PO+<>YN-XE1Z_AE]'$Y#=(SL^F4YCWJQ8/!^N)A_S
M+E<%>OS43D=U;8*NW]LE>^J9#S6:MD3D4MI]MM]V$[7FT?:)>.Y*/'Z\<B=.
MXP3DP*PF2AIUVO[ ]K7L:S1MG\BG1002-U:P5)8+!Z3<_J9[TWZ['-[KDQ+/
M'CJ995TTGY75_64$%63'CU]^!!WUN?P]SIX]WH09G5'1)>ORX1]?7D_R\1_X
M:K5^&O&A7I?M#ZJ>,-[8H#6"OH!H@HG>3<BK!]LFX&E&'C^J/:VUN^B/Z#,[
M]K0%RE_TTS;Y=3&X]O&6B'F4)0NO)U:?;L#SV472UD9=$I:U^7RV$IG9?O.@
M1LY'XSFX$6L;U,1P)R_KDA'[FA1[==(EX1_*&: 9S/+Q_8*5\/;%YTM7_+:<
M+#S )J,ZZ U=#KG>,J_1M"4BKZIK"_IVN?\S":MCA^![CT -YTT)<&V]+^>3
M'&3] %ZZ'^TFOU&G0P[L8CH;W>8PQ!_3F.;C7P$N@)0/57D7J]G]A[%=.OI_
MGX_NLBM6$YD#D#(D$]_?WED_NTHGH;Q;RLO/Y=W(2RRAB\6OFM.KR5DY"=GQ
M"IN"NUURMR,:OP^V[P@7'@??]R-R2,;OJWY;?<F0 ^]4'1R36JBGM%OHNJ5!
M/FB)YPIB%_7;VG1(UKZ+9Y\^.B3[R4E<]VV#L>S5<8<#K ?YW2U;(O$_Y[::
MQ6I\_QC)/[<S^\?$SL,(=,0N.FLV[X?81\'P^,GZ!C51U,W;^F%%/93MU4E+
MA#\<Q-Q%V^OG6G[]B0>YM@B*+S88\]W?CW$:JR]Q985.+\OJF8(Y UOINJP6
M9V/.1].%MLE-3\;C\NOB^9JHZHV EAEV=F,GUV!G3AYN J[;8%B<KGTP//=D
M2.,7M#S@W^,,I'"8^]GCQ9K1U%Y?5_%ZX:S<K[[=<Y@'=MORX!XO1-V_>/L*
M9'6#TH?UUM%07K'QEUA>5_;N9N0_QFLP' \<TGZ]]C.TYU)A/IV5M[%J9W2[
M.VYY@/74U/JG6R)E$:<\M8M0Q&W>L*YU.F5[JTY)V]>PWZ^73DE_LL&SUO(9
M=!?PHO(^QO4-]CLPW>E+>V+,L[,UCU3F&/6BR0=[OXC7G'RU59A>3._N0$?.
M;Q<!GZPH_Q9'US<POI,OL;+7\;&ONK;)41#7+:,?C'; PL?I?&6$U=5W3?KL
M;5B+)ZX6;&]]>+O[[G28]=1%G;:=DOD*Z;]4H$_!L7J"?*/YV+?WC4/U=NSG
MXT6?O\+?J\?SN [.RK-\5_PVBV"GAZ[>5C]%SB,EF8X'2D )O&#\ZNV+W$C)
M3MTBD]%\BJZMO?LY3\C/<3R;/GRRF"*$R2K5TC^O/B[.HYNM4HIDG^X+$),1
MEYTX"U!Z0>V'<CI:KB$_O\U,67[\0#LTC..__@1T%BWV7@@;J O&(FU90$YH
M@Q+7"DG)*4O!$<->!6P6ZK*L5O,X)/^R3SB:S,OY=/U8?XW3Z6=P( G]#9Z\
MF;;%V8;O+8QRDFK&$+:<(BQT0DQKB;CC00K/#5:F#L^?K9Z3RK\K*W"#__H3
M^>G=UX4T6/RZ[,56_LVB>IGV:_7$S],LV'./:#2+MP_M<SJS@;%7'O<, ?^^
M@Q7Q,-ZKZM=R<AVKOE;$CO<6P9DH#*6(1H41Q](A8CVPGQ$=7? $TW3XBJ#_
MNR(&F*'C6!'K1]NR4BU$<E8X[5%B+"&O4P0J94!&$J&<B#:$6O@]1IGQ6E;V
MIC8+$[P*3#L42"(H1NZ19MXBEW"(S%B/J?\1]>1^<.I4,1XP!\>Q[O>5=[VI
MOD)PG"*(=F0)YLA$ZE$45,'D"D$)93HJ_B/JN@%1W<(</*'Z7W]>Y[IVXM-N
MC\=V[5&WEM>T1X=[#8TO"7Q#\;,GM\B 1OT6Q$?NM(DH64&1(D"W<-$B22F1
MVG(AC!W./%B1_WIJ9V> OOO1Y'H1/]K!FYWM"T83)]$:\*:\1%$1AKCD#@DM
MK5 D$$\:F/C]*/,>45#VP^.^E/5+KIS-J^K9@;<UF%K[?*&)8U@[@CQ/"7&-
M/6(&''3*B HI""IIK74TI.H<#D-M\708S/P.NFA/V#PU*; 7*LHH$-%"(L*U
M15Y*@72B\"GSC&-\.'+8/Q1R&K%U$#MJ[X3E/5HLKVW9)ROWI<V[!?5UNRB$
MA;4NDD7$"(N$\6"&@QN'N!,!/O<FQ%JNQQ"<>,I#E5,RCB97D_A_HZT>-[@.
MYL^NCD&K&DM!M2+I@&L\)'"&P3] C 69!+-6)W+LEDLW$"D'YG-?FJCNP$[2
M+%8PKL\W53F_OKD$SRT/<=HF2'>^HW!.)J881H&;@!AV'FGP;I&,SAJ>5'#V
MZ ,,1X77+E@^K![<6>:BE@)\>S@A?]+,3LF'EU]-RZO8SVU9S7* YZR<SA9Y
MA-8LJD'H*"[.S[5B](0Q8(KBIZ=8F NF^:DX%>KD1!Z/:CV I8=V523L$J6<
M@'F8-*R('$;60:&D* ?WP@;CCU9]'CF.=LBS#J9F*(W[:BA/FY.OCOW\8D>3
MTYC*?'__V^$HKM=_(0)ER:J(5%(228$5<HKFLP(T@5^M=60--.TS:*,>56V[
MJ-D/HIWQ_=AQFW<KNL3MB_Z+B)-A8!_!*")%!,PD)(0E2,',$9F<QZK!QNHP
M%N)1PK8IVX_#P3G.(,20H;A!P=<B9_O"UX^]+3>$&/R^+-.^YVDWK@?Q78?Q
M5 N!+T\4EF=GEY>G6)&STTNF8=9 ])S0"X%K^:4_J/=5GS?'))2[ ._339'1
MU(_+G/^X$[BN>4_!U#DV[.)4$')&^>F%/I7T@JE+>4;IJ3EM$![X[H7PW@ ]
MAAD:)+BY[BY7RT>DZA2Y[>65AY>C[9^\W35D!Z-I8^G7X2C:7:=U.-JV%U8=
MCJ[-U5"'HVES"=->:-JC]F@O].Q?+;0?LO:L\-D+47L7Y>R%JG9*9O9"ZF$%
M+GLA;3 C9>\:DVU3M:&*9&>O:5STL<D6^&.A/#!1EVG4XK+FX<-+[S?Y5KM;
M%IJ8DPO!#/@!%^?X@N.+<R8NV>7IQ=F)EI=JN&WF]?4!UXUU1XN"$Z6YEPEQ
M(02RR5#$F.!()ZTP\4HEV>"\9@]ABS;GL>R*9WV%?S=0O/L8^/:&!3;>),TE
M(L(X1)22*/F8[ZIY&W!TAEMWK"AI=3;K(>1PM@T,E%IGOW>V+52D.J1$4;"2
M(4H"182IB'PT04COB)/Q<+CTL^W9(UP:<:XOQ#R7K744SMKGB[P::'(<!8T%
M4D)1%&/RB%&N G;,1-L@2MY#$+)#==,6QP9%Q&Y5LZU905B^I,HBXLD29'"T
M".L848J>26--4+;!3F$_BJ:%>:R#C,-9-BA :JF8'2T+2XV4"1L8J0$68@WB
M&/.$**?"&L.9%T=_KJ8GF#3BVL$[9"\UW:.LA ^NW'AT;3?D!JG=MI#L!!-,
MS"635)U=2D'5)28 ^//S2VG4Y2&^6:VQ[$O_,YJ95@PSPMFI.C\[(>+DA)T#
MS5RQ,W9RJ>FQ"K8.9J5LGU\M8?7I_9M569UFA:8DTWO)U?G%Y1DG5&-X-Z/L
M\DR=731)/='[;!\R)W5F^#!6M3[16U52S9:%!L&==XY/Y(4P8/QAJ<Y@#.R"
M"BIA.,>JCGJ<[H.Y=?",[Z%UUHDSP4XU/=&&\S/,&%74G'!@R*4 ;7S*3QOD
M#NQ]3ML4V,U9U<>YA:<(]?/ZV MF;,LQW>.-Y 4M^<S?%DOX\9DB"(LEE@0Y
MS0+"00CD5& H N2-S*?QY8 )1%^B;<>@WCY<)*RM,H(AKIQ',@B-HA )6:NM
MXX01IX[6/FHX5UN#1 <RIR\7[[]L-<H[;75F_<VSQ2+U!4T$!1H"4H8)%'52
M.3X:H@W12-P@K-R/&]?.I+?!F[[F_-,<" 4REZ5<MTSXRP<+12VU@@9P.O,X
M,(S-* 9X%LQB8Q.FL8'3SOJYQ-7.=#?F3+\*=!GA'&@;^]<XF\4J5S:N8AC-
MWARH'(BLIUOKC_4[7\7U&^UWMV5A3*<Q;MAV>"@9<;XU74+=+@H>J'0!R.#,
M<R2,)@CSP!&L#AP-H]J2 >V3NL/X'6;G\]<X_A)W)F$]M,N"&.V9Y!0I33RR
M"I@DDPI(<XRMH\81??3I5KN!13D8A_M2GG6'E/->?/Y:M@"_54_Y4F2^2R01
MPR*B2 W8CPX;)#2WT0HC#3[:\_]'B;K#&7N48(,7MZ$''OLJ=&0B2B40,V ;
M =L%(LYXL&]T")Q@(VF#4P#]W#\]/L =R-ICA-QE.=^6#GK?K@H-)K32"=C
MG0$/.3F4P$I')H &8($;*1N$[/@_)N .Y.Q1X@V<A+;P!ET5RDHMN:4(?+^(
M*(\*$06^FQ)!Y ->3,<& D[\@^+M,,X>&]X6J<Q:!-V+_@JKO1)"P@),W"/'
M83W2".:NH\0GS:E6MM;IY/7(D_]XR&O*WG[C,7U<;IA,R_$H+"K3/CO@/V H
MXRFJ<C()B^)\-^48\#K--VJW'D7<U;203!/P$3%*2AB4+%A27%B!M(/_,1E!
MZ-0R'#J*M[XA^/W$C^>Y9OF'G#@"UNYL5HW<?)9A\;G,VZPY_6XY!E*NWT\
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M@HGT!)W='%G9U?F'@^[_[9_^/U!+ P04    " ##@59.9=IY6_"&   ]W08
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M_^3-]6WE+;31J"<@S::3R>AF<IG.OMSG'1"Y;_P3D/MG-@N_9:/*NVX+8Y^
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M\;^6\\5*X?%Y\3[[%G3@F,X;M.$/13X+'T=K=6B__GC4. DA#G'B)0G*M%-
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ML1!V@NL@EL(R)S$;/[U,N.[ZMWVT1'EK#4"$X:"Q2!BV"@]*7##B]4O6=98
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MF^7M<KJJ[>:NKK+1XE.1ABW\V?U0>]Z>YH,G&EFF=5A0&.(&:DZX"V81%K%
MM+.N4D7&@2%WZ(R_V< )E0!A8"DWWG ?5G3ES1HQX%R#Z\=:/OGO4SA^N*&P
M1X3[C!>H9D!D\WC!\Y[,\RVM$BF,(@@;;!4/E#(!!"V)1J2!9M/QN7]?O,[;
M@JY3V_%Q9CM/9K>V2Y!S"G-@!?)&:8 %!G)- Y-&@@'[ NIR8SM'&^%QGKP=
MGH_@)"P]"2O5^%_+^6+ON=N!'@F&2 ?CSEE$J=1$"4G+79*1H(@/QSYIR)<=
M2W S/'H+U]],<^[SXGWV[8G-4>2S\''T<$YP*'G[F'$2Y1FPP,%@LA.-'(5P
ML[TQ;D7]^@ =>^Y[WM7[ +<O08OG5X]VZ\%3O6W-$P$\#B\?X)YXA1W0"K$U
M95PB/U!MH&,NOKS^N#W@7I-H#$J9. .).-%NM*'_,I:/C/>W_W47G5>A/0'R
MH&A4ZI^H8*-+JY7'@%"MJ!8!UY)V@P9X*U8S%K[<33H :0@"PO[_]KZLN8T<
M6_-]?DP/]N5E(K#Z.JZWL:NZ8YXR:#(EL8MBZI*4J]2_?@ RDY(ED4SF"JK<
MU5%E2XE,X#L'P-D/0*T89#\^(]81@Z2)=7F"D*8)8JY:.]4M1-?>X@8'8Y"F
M( W%(.>+9B<$VV8OS&)H#N!$8N0)90YAPF"%#B&N.0N='W=X"1+N("BGRX,G
M\Q6:OC+#L4FF]TZ%$\" <*!S2?>V:NIHVB)SWVS1F@M;H?R+'U\BE:2<_E;8
M<!SV,Y/%-,X[G_V^#*0J;YAW]_-9=$>_7^X6H_.K8I57WNS3U6@:OS2CA@&)
M%(D5\+P+?T"J,NP)3>6@+%BWVU[?#/&\@,U0Z [%@W8>9KS*P^1UOODSSY='
MEZ26,W6UR5>UN;&+UV=&"&($08Y[MG4@$(LJY)0@S5.<>^S=.S!?CH#S8*=D
ML=RL)M/-O^:;&W._WA2W^6K;I_Q3OC'WJU5^M"I.C=$9!SIL0 R$\@ 81I@2
M 13B('.">MB\RVAOY]Z(L1K= YH"(WTJEM-6O/3X@@RB:%<05@O#-:/4J"C=
M$!> YAR+!%N-)\I.C3$=BJ.^YM-\_F-;%*G68?3J\QE7  B,)>5<$2<QU%*4
MT$EG://8\MXR,4<-%6L/X>BASF'F36*<P[ , *ZT@P!0:8R.(B7%U4H14LWK
M=?>6SCDBLW2(Y&#)W6'"DVAAWN8D[GJ&7?V^SK=GXA&F.3HN0XCIF+M!*8#0
M 8(1J@"4G-OFFEUOZ9XC<DV74(XIVWR83[[/%_/-0S,I^?GP3&)$##;<8NV-
MPY)'#'8K5T"@YD</>X-,U .B2?!28T'YE3=D@FC*O 426VZ-0(+AR@ZHJ&_!
M4?SOQE&-01WL7MO<!,%^.EW=Y[-JUO-\??IH.CXP8Y#IL(,P%9K&S&]H:>57
M4YJVD(?$&V2A3K%L7.YD?[_&BCOS931/;6_:]9Z;7V&'FB,S)JT$,9+42LF"
M1L )V7._!2WJ;,HWQ _]@#F<UKT)N.:SJI!R8.@=1OG,!LI-Y\=5\%.#,Z^4
M8H+[(- IPQ&2P#\>H-*VB)@#;XB'>@/TTO-+]VFEWZJ(]_7GJW*SA=_^2C ]
MSH>6(T*Y@XHSXY V!$L*D;!*20=XO=V7&'(])Y@JPH'1#@-'- K(:4-EB1AA
M4 R93])W@FEMYN@VP?0\A(=,,+V0M!8"@/*$2(,T<P 2R""H $18)ML?>2B^
M:976<AZXEY2[8+&P" O'*!7""@NP$M7*E$*)%KSJF8IUDAB: ?>66"/)<+F$
M.2*]K(7NTEJ<8@9227E$#2N-N6'EVBDQ(,%"UNU(V"BMY3R04F"0[M):%+76
M(4:YYX)R#DE N5J[)_6*VB20UM('@S0%J;%U\%F$Y?'0RB>Z]XE"R:W>FAFN
M*9 .6LFE,UY(9BN]@^+PE_1"-#IAD.&A2S?ROY]L*&L\Y51QS6(4D[%4[^]X
M$_XV9'W"2U",!D$Y71[L+_L$4L:<55 J+J1'W"O-*X2<]8DW!.J;+;I*0VF&
M\B]^?(E4DNK=6V'#<=CO$C)1!#4  6T<0 Y1)A#@U;UE&&=#%MWK.Q.E-I/T
MD8ER'LY_UWP]*0S#4F,)/78^$ D(4J)DM5?-HSK3RXMJRHV#H=N0!VN5G_NR
M*F;WT\WGU;=\]6,^/=8#Y+5',PZX@2BH7T'4-M8**4&E]EG':7/S1MHE%\Y5
M,CK";P!.6,>PA=T$UT=K2QY\/M,!&0LT0\0J@K@RD='+-0%*5)H"?WL2O:1U
M9^"\#<(G)5DG0N^N3)O%8K%K)'G,[77HT0QCCB@''B)(-=$"(>#V%Q(T":6I
M=H1VT2D@PX4G;F\M']!X+63;_35=W,]BV.5ZG8?_SWZ;_'4Z-NB<MP7I600@
M!2<:6&=C\O9>6'+ R@2UE/%#@WH$>"C&^Y8OPCNOW^7+?!5 #)K5[#;0<+U9
M[:#[ZRYVOCC":_5>D"'(B30B3((1 %78:GB_>JUE@D7@1F2O7C =/!FQG.8Q
M!\B+9S,,B1'(,L60%,@QBFUU1SN&_9"5WM+GD[;P#6<DWN2K?+TY?9H\>S+S
MDF,>;F88SDL@F*,<PG(]'CK9/&(GY<SEINS0#KRAF.%3L2PJOGV_G(;[\C1;
M'!R3F; LISUV84U4 *D=K\0Y[SEM[F1/.4FY*8-T!>-PYT:<XX=BO:XDK?GR
M/LS],3%B9X3;/1>$K'S]<;XL5O/-0[47PN7Y\UMB.O_FX6.^N2G";W[D96C=
MT3-IL%ED8:MB805Q-.Q='UO(D\JMXV,OX<;LG'*Z=//S+E7"#+M!PLK*?:R#
MQ'AU-)7MP(A,".^!@DP#X $AD NQ7Q_DOGG#L92SJMLQ7EL0![MP\\TCCQ^[
M9)\^ER%J@"9".8>] RK\F^!J+9JW.(E2SI%N?+&V@&XH-JAR+0,:WVXFJUQ/
MUO/I$79X]?G,QW*KWB&CL(V5*0$%>Q;77C8/BTXY5;HI6W0!X5CL8>>+^TT^
M.X-!RA%9T#:$I9XY@@6PUH3KLO2!*J"L:5Y=(>E4Z*YXI!F*:>8_?YJL=A:K
MYOG+A\I!G)Y.-8D/1U*0&[\KPU1Y1J"FEB(*,168",BP(4(3[5@M)N]^K8>2
MAAN])T,,:8\X@A1+AV LYL!V:U22ZD'[U[^:(SP ]8KA\!LR WB0")(@#5M#
MM(\E(IATDAJ&R^4KX%I$&O64O]LSD4\%C)P'UV7$#7@B$0XW8A!ZC7,*$6!=
MM28K +ZP@)':)*H50- ,G+=!^,L(&!F6WIT%C-S>AL,NR+%?5ODZWT8L?IRL
M_L@WZW\5X2+Y<S[+3\61U'U#IA5' ('P/X^MBYW, *_6A(49M%%@F_"2VK0I
MAL"I,>VK!=J@MOS(9W'U9O*]^,\DBN7S[\?)7FMP1GS07L-*+-)$64R#%EN*
M3DI#(1-*>^V!XGU -%A6]"A%7"A&S@$B@P8L86#7<'Y6XI&.VO* [)*0$#@$
MEI=4F$-R8*WUAEAD4:Q%:OU^QUAB29IR8L]4K%.AHQEP;XDUDI(D+X C1KI\
MCE6+@*)=28YJ?.:$Y)PZ#7FXTS7%P')0K9U(-FA]GQ85%VJ3\)R2' U!2H%!
M.BSJ0ZBD) A]"C&-+7>"^6KMQHKF##)LS98^&*0I2"DP2'=%?8 QC&+E,5.4
M(V60DV2/+&I1(6S8FBV]G" -04JW$D$_U5F("=J>9M C$>YR$?.0*^Q-^'GS
M3EX])4X.J_$, FJZ+-=C*V## 18(0JR=9,@K(BI[1KCF=>(J5-]LT5E/X$8H
M_^+'ET@EJ;>]%38<A_TNH1B+)@ KKA$ RDE-F08,5<AYHA)4$?MGDCZ*L9R'
M<Y].S:_YNNJI<"2"X=E3&;<(>FZDIXC&=K36[;5D8X!NGE=R?N)10E)<>Z0&
MHO11M_6+Y[(P9<H=\XPJ$I/,@^I;.7HM=AJD*3RUHL;K%&V%QV72-BE!9#R2
MCG,@[^WD!V__$R,R8S$G MI83]AHQ"1QU45C:1N37B\1""WH<N (;H?'P)Z@
M59!1KH]=Q4>?SP26""-)H'!&&N+#LDP9MHDP@<W[M)V?[)G0I=PE9H-9<Q]G
M&6,S/A7+R>-/MI+L9+K-X#MMUSWO39GT'"EH/-;$.JJ]M]96>'@N$JUAU1&-
MGYM[!\'N%T\E)6)<!BMU%@RYKP#U(W\RQS_GFYOW=^N\?D6M8\,S'X0S1Q"F
M&G*NL1! E9>NQF%2"85!]DZO _6W.H2O,3-\G"^"X%0L\\_?_YU/MW-Z70HY
M\G1FE#70"PTI!1I)J:.)I9PK)BT2(,_/T$](!ND.L0ZI>U!1//I\9J7S6F#$
M-/->2<$Q5M5\#<,T30FA$PH<IV8K?-*G:U*W=#KD[(B,[J/R\T6LB3>=YG>;
M:$C^+V..7[_'QF0,6,FP-UI(XQ%B%A-<S=M;/JB#Z?B=VQ'^13_(]&GJ^3CY
M=[&JJB(>"BQ__<$,Q#QY$<T8S$,4UJ,KLY<./R'-VW^>7Y$DH8NV$[#Z)/FG
MR6U0*WZ:XE&#[<'G,QSXE@:Y4#D%@]Q)D26^6I,(OTCS'FY+H*(_:-X&V9.Z
MII.@=D<W]+O%Y*_BVVW0S?X[/'PB1_#5AS,""*?>"X.M,!0BRI&L9NH)2*S:
M= >(%QU#TIAXG^[CUXJK*D-MOGS,3MSE)!ZBY.F1F5=:4V(LL59BAQGQO!(H
MJ)4HH=K0 Y>$Z!R[H6RENXE_OMI7D/VV*R9QM#[8H3$94D9  Q60E% %F$5[
MA81BUX(_.@^K'XX_ND9M,,[(-V:RO@D<_6,^RV?ZX?=U/GN_W-5"W"H<07<)
M=#I:U[G^2[*P?,4H"U*O@!8 IR70%0H.@^9%9CJ/N!^!=_J"<2AF^AKK/BWS
M657D*FBKNZBU?&8#S:9'2U6>'IQQ$G1<Z"@W7"H1MI,2^\,5H185BCHO#ST\
M\W0.7WL+WI?)P_;HBU-ZM;3<L<<SSR"&V!$-".4ZS-7Y_6PAI<V];)V7>AY8
M"ND&L*%%CZ_Y7;':1"/(&;+'RT$9-!8#R*5@"F O'/:\DM69,[9YY=K.2R:/
M)WRTAFTHYGA7%+,_YXO%^]N[R7P59WJB:.WK S(F,</$!?&*4.010VYO5&6$
MM6@WTGDYX^&9HA/(&E\&WR;AL"HCRK\$32E&PLW7V[1#7ZR"J'-[MRG/L4,7
MQ!FOR#P'F'-GB4' @("6-*Q:E:8LH3+& U\:_8'8"6M4<XD5MJ=!9-D4W_/=
MM59.M@YSG'Q)9@*G@R P6P,M\Y8[SRI#79"D5?,Z99V7,QZ1/;J&L3&#E)\+
M]UGQ,%EL'CXO@X849WJ(&0X.R)0CC!A.F<(XJ-Z>$T'V+ U%BXB=SHL4#TSY
MKC!K3.6HWBX#V@\?)\O[J\ET<[\*NN\VV>AK?ATUF/ [=7<7M.+)XA#ESWI)
M9E2,P69,(,^$I5AA3ZN560V:!_7 2[=P]HGC(X>D5+2Z^N_/<]T7JRXG//R\
MMO[B/F<5[OR[?+5Y"#.*75#NGHI@ WVN@X+AW>@AU>2^+"(MGLSPPY%JXO4'
M9YQ3%'8@41HHJH %T"' L!!(2V!<K?3"?E;^;7J3S^X7^>>K@\LX5&7\W%=D
MG %#',!  ZJI]EH97J) H/!#NGI?+3#>!T&?MWKL!ZM):L7$OU4)2^_RXGHU
MN;L)I]SB2$#0P><SA:WUUAOAI 30*TR\*8'@6( AF>:LQO3=4[KH'JX^0T1*
MT]/3&1X-$3GX?&:!@09KX1Q&&EL,#"/5FH#B*-W(H [H5/2'T-N@?G(!0JD0
MO2/]3"TFM_EL8B:+>5 #EO/)\4BA X]GACLHL=+,*&,E(9;2_6R]&):,IV.%
M.D"]Z!R4H:SR!R\L_1"SR$[D\M88G0&$'!7,>.V<YHQ*J??K#I@T=^+T5":Z
M]TN]/_!&9YHX[Y-UIVJ,#C*W09Q;'U"UVG-HJ8#EN@5@*-%$G5XH6Y=K6J/W
M]^&>I,2(2V&:CD2,#_EDG=\4B]G[VVA9W*6IZOOY8A8C6?Q]N#&C(3),TL__
MBG]:F^+V[GZ3K_:3CG:UXFKSYV1U(I*YCV]E2!@2("+ 6:P]0+&A=H43I6W<
M"UT+-[U0OT@+WZ$.+9O?K?+I?&O7/7(Z/7TL8\Y1C8B,*5K6*&H\IY7AB&.5
M4&SU -:P%L@,5V4BG\2 FLG";8OP5&@<H?>A(9E3D.I8U\E1+HB1*JQN#Q-O
MD2[16SGR'FG?$4K-G<N'EJ9FLRV^L4["MC+"5;XZ6#7@O+=D3#,+I,8Z* ;4
M K0MZ;5;F]*T13>EWNJ-]\ !_0/7NZ?Q-6?62]WPZ6_?NH>+84NLMA8YQAD#
M0?>55G(69 >E++=_$P\7@]IH"IW G$-I7+C#*A0$PVS(RD!M/5RU"=K4PW4>
M5D-ZN!(TF,7J.]HK[(FT"!D'M60E6$$69D.*C?T8S&IS0P.#V7G@O1V3A]?4
M4Q.VJR:< >;B/]6ZL52)]PCHE+(-;!_-T/O[<,_%&LS&9)IQF.55F\S)LHA'
M1F7(*&@H!I &I5T;P(-RM9<.)&F>B3>JP:LV]8J^D&JLSC8WB-8POX5/06D9
M\]QAB,+]+.A^QTCDF\?+#F^X:$'M?M :Z@QXS?)Z\@@X/"C&_EK',1>6(Z:!
MEU[1/5\#=DFFC Y.@,Z :NY#V57>+%8/^W6=<(0<&I!1H947WC$+J/($:<5$
M!4(XSIIGR72>9MW[=N\*I*%VN2F6ZZ 6;VNYOE\&6*X#(Y[>Y\>&98)+HJ#4
M"CGNO.,(:E\Q, 6HN7.K\T3L(79ZAU"-KBN\6QW/MCT^,#.&(:"T5=QSX['W
MS,ARM=H!,V@=[,ZLV4WM7IUB-9AWZVF1B$=?7/CS(B^S5=1ML=J4R2L'UWC,
M&];1)S)AC"6Q:F*0I:$',HC5U8&KF6Z1^#^F]ZPIMXV$ZN@GUJ=7"YO5&999
MSH&G3#"A8_=C;A'?KQ0 EE#EH3%/J_.1&L79UGMVW/^]GZR"FK=X\//E9!D+
MO-G)9O+[<G(_FV\>B]D,_^5]]N#^)Z\/&-OA>*@90-E^8'K@UT][$7RHX9KL
M\C,9LM1K1) G $.H$.=8V2# Z2 34EROEW/?3LP.%ES?W=G5QS)M)40@2-I$
M4NV4-,)5R$(&Y9#VPJ..T7'8Z: +=23\DTLG+ MN?EY]RU<_YM-#'M5#C\;*
M9UB&R\Q+RXQ3C'/!JN438X<L5-O0?3H\)Q2=8MIGKEE5CC6:8G<37!_--3OX
M?(:-A28(3B16\.648D%DN28DH4DXT[ =B5[2NC-PW@;ADW)V)D+OSCQ7^Z.K
MJ-^?JWHTP]8ZAZ61B@JHJ&2*P&J6 M&$0N\[0OM QZV&@/2Y/9NUX@Z35C1H
MG(&!N8XN>D%P-7]D=/-&((/E!HYZ5[>#<R!V.+.GLV#.*HV)P88Z9@FA>Y;&
MGLI$FWBVHL;1YL[-\+A,VB9W\XY#TG%.[?;]NF-F != 42L@(1YI9BN11$)M
MD^_779LN-?MUGX?'4/;V;_DBO//Z7;[,5Y-%=![,;@/DZ\WNDHJ5()?KHR:C
M6B_(*"18"4,H-0 2*(QZM(@HQ!-J&).60:@/=(?BK;*JJ _0FF(9ICS=_&N^
MN:E:\+B_IHO[F!NJUNL\_'_VV^2O(XS6X&T9]8:8L/&L(PQI38S7HL(%M\G.
M[<USF 37]0]U[ZZC$[Z4WKU()81#?.*Q.4CTDRTC8<(]%'3,7$\6L6'DVA>K
M)Q4G3;BAKHM5>/[S557Q-PY5BT7QY_;YCCU(M82/?TX6]U6=S$"\Q?SJ8=?U
M<CN].,]%L;Y?Y<=<0XW>DP%I+.9!;190(\L$ EIM,PR)("SHXIWY?CK%X9 K
MY^QW9%A@I8"U#E&E85 U@87E^A%EL'EX14<>FIZI6@R#6])I;(\+WY\! 8+R
M%%G7R&2K]X*,8*TX]L9!@JRRBA N2\@PH"ZYDHX],D4Q (!#"7K')W\R)ZG.
M\(P+#ZQ!@GK,M/;.6HZJE7M&;)J6H+[(>Q;WM$+P[\1#25F<+HEUNG((W4Q6
MU_GWR?2/.(>];/J\3<D)5]$Y+\D8DL1:@26PP!N*%!/5>8VUM DYD?HA6#$0
M<HUY8K]*_]B\UZSRH,6M?9ZO)\N9*<+$@BHZ7V_B<Z>*E#9Z7<:@B?T[@4-0
M(LT(%I!6XJ0QNGE.;&^6A/[X9!@,.^&8TNOZ-7#UYDC66ZUQF;<>JB#'&<RX
M"\J%T[0"BUB)FF=']19'/ P/= #68.;N7;>CS?UJ^;/)XV2BU(F1F?2: 6FM
M5XZ&A6/#:'4<$A_4S\;,T5OJ7"_,T0]<0[''QS*%^_WR.#A?B\4B,/Z?D]5K
MS4U;O"TC '+NC 7 4,MH4"2I*7&A2)N$Y)%AS#+#89F&HE.:;!MK.N7X3#BN
M$:8TB&)08HN9]Y4Z$.LKMFATU==QU"N%SU)ZFF'86%XY/IE]5;S?BFU[\*@S
MJN_KK5/FD"33_(T9C-W%P]ENC-!*6HP(8M6:%>'-@S)ZDW.'X)MA4>V;DZ([
M*%[/[Y?F?K4*T'W)5_/B8)ON=F_-M++80,^HX&$_>2JL<.7:F0<T(<__8%1N
MP%7=H#L<9WT)LUMUS%=/WIDY:)QE#'EN@%!22^5LM>X8/YO..7497-4<VS3D
M)IO/=I49FGNI'E^1"8,%\ A"3P/&&CNOJ_N!48::*W.]:?KI2$^-8>P])J0*
MF# W,6PF'J5E<$N,8]F&0'R83[[/%]M8BM^7@6"_%7?S:=AM8Z?4EC-_'U<]
M6:B[N\5\NDOOW^Y8LZL($ /"KJ[RZ2X:J +H9")M^Y=G!CG%F%10*^V">L>5
M#TSEE8%6,^YKA1 DAMRI5-EV+\X8YLHBC)G32!CGI?6H1$QB/*C?X6A:[)#,
M\7H4VC ()QV><3X$)\(UFKTP(PHHPX37PED,+;4:L!)293 >,F+_K 2=H3BI
M& 'EH<2O\Q=STF??])69<-1QJPB@DIN8Y4:9JQ"*S432C@7IFRU:<V$KE'_Q
MXTNDDHPK>2ML. [[F<EBNJO"M544RAOFW?U\%O6A]\O=8G1^5:SR2HLX78RQ
M\4LS03GDF@81BRF-N/6<5$*6@EX/&<1;4V/MGR&>UV\<"MVA>-#.PXQ7>9B\
MSC=_YOGRZ)*B%_9J\ZC3GN3&+EX?B(6P0!80@ 0'-OQ)5\32SH($_0F#\^4(
M. _%H8])D-'4^"G_LW0-SY?77U;%,OQQ6F8W'==7SGI/QA'S#B O@&/*!@E=
M8;Y7./6@1<LO04WI$]RA&"V&P7Z^4K/B+N)Q\FA[[?$,2 B1AU@Z)\)^=1YH
M7*W,8J;3UBIZHF+1&W!OB362%/ 3YHB1;J/]^K]M)LO99#5;_WXW"P)A>)X
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M"9;  :FM!LYA8DQ%#0N];:$[OB5W7EI42%X4</]S/]\\O%^N-ZO[;;[#MLG
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M5.W4R:;&,Z/SK,Z6+$L^R[+<,?:9TGA*2N/@VTP75*D.4<\,Q_R/Q3+F.1;
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MWML&=K7I[\SHH%=G/QR#-WZOD N6)3/$45)(%Q7"P:JK+'IZ]7@LV2+B/5E
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M]WI/=?J8='#X3NM/":<SW:;5O/ +2(B0R+<(AK[E HI#._)("PF;U!JF[AJ
M3"COSW$^5Y&D,&!I?+E+V* G+O?LZ7\R:,*>\WA[K#7561!EQAL6G_WCH?E
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MI?&WI&R_3D[$U$=.3.9F#9J<$#*HI]E?CBK*,MJCF]J"LPQEU>=>-M%#+KG
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MUF4U=D[YWU=9=N6%INV8V ,193"  R&-3-\) L\V"0FE#KO0#$5[;TZ%GK<
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M$1,CZQMCX[^,)#*C_]K6.O1$8IX5CU?85[[O^0%*(A39/DI"/[3CI,?L)4Y
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MN5K.T 4T3  ^YT7VJ<D>ZE5B1="UJ1M12&**O,3U45\#<2'[:O0<0-S4?-,
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MWL=Z4.IK+5*WJ3QEV_*QK>D43.GO=EM.X?-O^9:I?ED,UU!9@1,D,7*Q$]#
M<9G"H[ W#2UJ"RT<:#5H6G\/,-OJ_0$HV".5NNQ#$\TB&CT#PY*B?41N?()<
M)1W7Q;+4Q2K3LZUZO8H.UD5O61%BY60VT$SJ$M*#;I=*@XU0(H'$FTW.FV&Z
M%06!7 1]UXU(["#;03$)X9#%((UBH4?L#9DVG%0.@('F_&(@"@*99MX R.6<
M$]SK3#\&@B"1B.8-AEI*TAX4L>PD3=6I/&6.\P5D+(/.E9.T6XDLQN99F]VZ
M0>7#0U:M\W2;_[-MR;U%GZ5*E$004R^P[(3-MB+:6XQH&(FGK)%V#.>G'AUX
M T]"!,<R*9!V)B11+L><Y$\EFXPE4B)U3$BH6IX80:Q81CC/P"GYU\3; K1>
MER>E_E8E>P?03<DO)'[*C@ZU_)DW]Y^*IZRHTGTEC>*8)M")^3T0;N):*.B-
MQS3$XF]OZ#-I6-M? 'UQVHY#!3U6V:MH]) MH/GS\"PG_V(4J^0"C5S+WOHS
M.><C+OTY<']792K,2USY(\++J;RAG]@%I! #3KVY[\< 9Z+3 [X,\ZE@,Y6V
M7=(LZW?"KH(8AV$2A%%HH3@,'0HIZLQY;FQA\87H,4;,3PS:I<%\CPW<9C+U
MJ5$$BDT))N%.>C[0TG: !1BNX;C 5/3)300FH5%Y%J!"I_ ,X)3K9X;_H]E:
M@'!K<:/4W(HD=WVREM1F@R^W[1:E^W++&*O)/W9Y\QS?U$V5KIN59P4>#"(O
M(OPRN#9'8#OP X=]$WE0>">A%F,&=PP.^-IC2D<(_S_0801_#2BGWA4HPMRY
MW7]:F5_(+C^]/KW>S6> ,>E.V>X17+D(D019'K6M"#M6R"R1P8@?P43JZ*G<
M1QL>'1TZ7+?M5O+!,%F>)%5*/T6J<O01.V8UIS4N(BYRA"U,123!GY(+%0Y$
M=2%>K_DEX'EQU[Z&R$],__&X8899! ,K&F9Q/F$BY$"(7<]APP,$DT&38N3[
M1$8N]%@TO3G@Z@_ \?QB17+ZH8E/,5F9GDHYM3G@ WN H$,XL"M=!M(C1$+,
MG=$GO<PO0[8T^U2:;*N*@Y]NJ,7/QI4%OR,B_I[7J\"'-$!A&$?0I<2%KH.B
MO4T'VDIC(25+AD6MGW <0+&Y!X.E.D)2(U-RP&2<1SE%DZ;0[##J/79$1E6C
M6%V&6FGRY=282P-#HNKTRA0N']*\6$$20,=Q,:4N\OPPB.C>5A(XB=0,3<W"
MQ&H$_NIP2<J1(GMB,F2>N''R\S%G1O3G75K.Z,XX&I>A-R-]*'4V+#E]X7L^
M^DL AF?L@PA%%DJ@3]G<,;"Q;0U3R<3SK%!&6^0_W?C>"@ZHJ[7*28D"46(R
M8I8C.0DYIF>FR=<;.LY(ASIURY"-$?A+78U(LB*TWP)\F>:;3P5*'_,FW?8V
MPP1[V E"W[,29/NQ&X7N7J("2VCSK1Y+IBM A]WP'-TO>0%Z?)(%H7%T"A:"
M)F-2L@!TDL2YZC[GB#I7[]%"\#(D29,OK^L[&AF2*%[O'OBYA&SSI;G/*CZ>
MJK+[K*CSI^Q3L2X?AE,*-(+$"T/L)R&R0QO9;A(.]JGO"FTQU6_5M(0=@((6
M*7@!%7PN:\G+3C42+ESAGH%K29'[@CZ!N&FJ_&;7M#?]-"63NZJ=G\U5W19C
M[7R%6S/S"U$__7Z]K70;84Y4%;]F#9M,9AN25D5>W-6#,4Q0@&S/IS[!26Q'
MU(E[8RBQJ"LC@8HF)M0[G-WFZUQP6]]8YL2T; +2Y(1K  0&1#/)U?O$G-&F
MD4PN0XC&.E%J;5V*"VJ?F<E/[,N:3481"OW0METV$<4)QH@Z@Z'83QRE533Q
MCY]N5Q''!%I0J@MG$J1)KI:9X4M.522I,KM MB=$9%5,GKUE*,D8!TZM?ZER
M(:H@;!Q496F=X:S[WT_%VRV17\OMEI85O]U\Y=E>@#R:(-?'Q$N". G\ 04A
M@2<C+[IM&]:> 2[X:0#\,W]F[_W-Q!PWZ(%+ZI/VD(B)UYS1D%,V X$PHGZ2
MC)Z11E.Q689N&O.NG*:%*R\#MM>$UU]V3<VW8K'1XBHDD)ESG 2S^:A'(HK1
M,!-%MF.'J\?VC4&6'JI&>EU0WIQ,'WZ-3+@[)RG[YSH#:0-NLKN\X,-F?DJC
M^T#P$^O:=8O\9^5E1 6BI5<4S;*KOKAXT;W*4U^ (VRS+32^84ELS5&=W&5(
MG!Y73J]$CN5'?,+Y6C"9J&YWW.)E6;6OVQP58*_+WQD]9=$PJMB'WGTJV+ K
MJYL5X5>UAKX30Q(B0F/?BO!^+(LB)"]S$P%;@"!./8/3P>O96=^D@5N&'$SM
M])O9Y0R<"X^/NMIQ_I21V]MLW7RY_3W[=MBU?EGEQ3I_W&;#>\M?;N--V3ZJ
MLJ+0M5PO0;%K6S3$U*+([@%A2*C47DV#,(SOF.APM&^4G#GY\5-\]<?/X/?R
M;\,9D(L7#R;]S_\!'=OYW]T&I1>OTO]T73[F:Q#:\.=_ Y\>'JOR*>N>>FS*
MLV]!'L&1',H9;!." [UE- ?)8> >-.A0M^^E9-^.F\4>.9]"=]C;AM.CGWB@
MJ,SRN6&D^= M(ZM,X>CK(>A4W(IFC]^SIEO:Y9LJF(W8\MPH0I$?A=2-+0?3
MO8W(@W)/5\E]MDRW5GJ*BL%A?9;CF;:3OJ#A3+]3HVL974D1>ZFCP2C,R#[5
M]2[;X%W%^UPW[6@GA(B_5E35K+M]N>V^;G(VHKO*UNQ7FSRK5[;'WQA-H,6W
MNB,KH;:'!E")+3=D,@S%='F? 6^G72S[K;OZ2=V.?7C]*6N:[?[ZD/4!/BC*
M)JO5:U2FHR>Z;KF8P,FN<?( =<A!![T?PQRJ7@?\/'9''H"#"S/,J97I_F@N
M;3Z.RY#HJ9Q];^X\%<<CDP!_<CK[&)/O.-!S8T*"D,80!;Y%@@&3XQ&I-5VS
M2):; K3(OJYXC5+]&4*E3_1;\#^0YHN1+2_YFH.X:,77[:N8X!MA6,N@__W'
MIU<QQ1A9CA>X; X2V59L4VM XCJAT&-U)NW/I>V[@C5;D'7;1=A\FBD\+YCQ
M]X>Z7WADGWC/MYL\L@\T-=97#9J& ?X$\=(_JN^JRS=M=?D8]@7@91$68UI6
MMUG>[*J%*/TYKE6']",CMVA5U^.AS.!="YLZ1NPG@)"0^MAR(-]!3FTG\8)D
MV(Y$;,^7O!])N_D?1+_U#=15PS1^=#Y!A+0/R7\XP3[#M.)X?&38%BW76AR4
M&'EKX5++<+L]6[B*$A=2'+ D$;@TB1+_L%>4^(CJJ*'(F)M+C-D7WU+^#D4#
MLN_\@2.^2]O(@%F0=@WC8_V,ZQ\.MQ@7(9M'G*D.:^4(7[0L*CDD,VA5X4K'
M&+6SZV/7A5X4N$F"_1#9?A0,%V61" 5(UY!4S-J,HK<7._:S7@ UCC0%R1X_
ML-3/L_9QY'*4[L"8XGA0CNU%ZYR*/Q*C/16FQ._9^N]=W;3[%Z_+$[?GM%I[
M\WJT^95/.NN\R:ZRZBE?9QW@K]FZO"O:3VFQKYP049@X#K$2DM @(I;G#;!=
MUY6[M'UNL(8UMFT$_2QQ?81>]JZON4,J)L6SXS2GY$>N\5W!KRX@ X<+R,Y5
M!O9>@M[-88/JD:-3WUMF-F)G,LEB&LLR$M%RZ'AS =M2@.D[EHH3V_&L)+9"
MEY($X<3R]O,++W*'\UJDV(BEL5'&9$3K)2YA]3HZ@945&\G#J#_,$4I1HI?1
MX?6X(G.$4HZ?B8]0LF8"L4U<:"%,;#L(?"?<3_G#B,AVR8E@S=AY_]_!R3$!
M6X8(3.VTF8.3<IP+/<;,T3SR04=<;.BN*MJ%M/[N,0R3R&'295M^%./0IQX)
M*72Q%T+?\2D4?HQYC!'#$\<]G';A]S;_?GXA43.!YZ=[DW(G-TW;HP(,%CB0
M^.$%A)H)E'B.>2HBU9YC_HC0OXU\D?F,]^_D"FV$+>!%9BUNE)H;DMS0[\OM
M+9O6[>WVMA".,/6A%R1![#I>S$QC"OT0(]>W(9+:UZ-FP; V=Z#:+3J/XF^\
MCR1-K )GGB\Y/>ZI.JC(/#?!ODO+F;'H.!J7,;0<Z4.ILV')R<IE5;(93O-\
MR9H2%[.]U3_J[':W_9S?9BOHA8'C)3ZE 5.P. I<0GM!XY>929WSU&'/L.20
MNLD?V@NH=RTFL,V?9 _I:*%53(:F9E1.E 9T%Z#%UXZP]P@O0(<1<)#3JI0
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MXY'(AE:"D.MA"_9(/4+M:%7PS?#,WN@,8A2FD$9%G4:]\4BB2#VX +IUX[(
MS7T&MMP'7K/F_TCWGH"Z<Z7=1+X]>*,EYYB-^J@$-'^D=6>CO4>OT]'G(?('
MKT#O%O_N9X&@3YF<QD1&/E--T@X6G;:F84 LATT8C;&+!T[D!#'FCP'9%G^1
M$89..%A#883[Q0-2;,8M'7QD1W[I8( D+#K]B:0??-5 E,A%=U9Q+P17#>18
M$5HU0'SWXDU9I?QZ^Z,=.;^EW_.'W4.W*$BV^1U_9>NVK'#VE&W+]OAV6FR^
M9G>[+:?^^;=\F]5-662L:WM>;"?43Q A 4&>ZT>Q9?LD0A%TD14*+Q[,@,UP
M%:%'#M(6.LAZ[.UQP<T!?;N[O=KC_[_MO6MSW#B6+?K]_ I^N7&K(^0>OD 2
M\^%$X$'4]5R[[&.[N^-$Q8T,*D5)/)5*:I*9*GM^_07XR$P],@6   FY)F)B
MVN52"6NO#:Z]-[ !>'=[ Q06H>?PK,0F@^-.5<OP'AESW ]ZX0VN[@SR\F-7
MTR>N/ECE?7PKKE;8=G#<Y7J[#Z,_Y?X8T?) CB@#BYM-V9+S]Y';$.9)/[4;
M,:-['=B4F-/ZVHV/3"'=>!$-JS=?ZA_%2ARN^[1NCT_^0WP;Y-&G@88O8Y%#
MGNUD-(^",,-YS&A&R( K8%$HG6!,@F;&E&(SV"'6E9KVU/-YT5&(.=-X4B*A
M<,Z):BG$J3R!6^!].?9?=VJ]M<)[;(:'G/6?0I;@G!_'Y05V_2F7 YB@]%34
MG]1=#L3Y:>VMY_HPY&)YL]DNQ%&;[AS/^NI_[8I5=?U#=!$ONYMM#@]EM4=K
M%U$6(>13FH< X0"2S*=!>ZM;G(4@";!,S#8_JN78_#4GWO"8S847A.]\>.'M
M+6A+@X,-WF#$HT?I6CLD3Y]8\,KY^#NO0]3BK'U?R"RI<L:.EE/Y/SU=2E6F
M] 5]MN>6>778HEVU[0FMMH]QP+"_.P:)(JV]/J;YQG\7^EXUBSC"*(T8R8,X
MI(BB.$YA/WCD@SQ7:=,R-.2\BGITC5.WKM:A]P1\[W=A@.)!/E..D-O^GL$'
M1D5T#/U6-J3D"#VS/V78(VYL5YDVJK8ZBTTJ)ZWOBFJ]2#/F4Q)F@$4)QBRG
M- V'H5D22QUO,3J@FZKY>X?>J&3*>L"$8%H@?Q*Y?)7W&;2R@Z2ME(JN> LZ
MJ6J2DDIJ\26WX7];;&[*RV+YAQAO?Q,MJS>?.0'WV_[ZC?Z=H"2$,:59!'WJ
M,P)"E&1#>AMA2.4?"30[K/UF_P%L^V4>[NL5J^H=X.&*'Y5M6K/4RVRVS\:Z
MXC[Z$>'H$>'L&>$Z;^H99EYE[WLV#^@M7YOUA.16M0I')W>AK1#MP,*S)<-J
MZY-4(2CM8R ?<KBCD6S*JXJ#*,N&:S"I.0C4-%6S%3\W0 D(\B'P\S" (4[B
M* M #R4F!,O?3F\+@.5 ]6E[*W:/>L!>C_C?!.0V<)'ZW7WQPSO 5M!,:SZ1
MB%LNN$,M@NT1MSKYU",7GH!],?CD\R.?Z 0T:\Y1"&TN.$DOR%EUEES,TR3O
M5/2S[0L'XJ!U$^L)Y[9F;.3A6)RY^,)C];9L^C$990&*LY!$29K3*,TQ&(K$
MF,)0ZK"VF9$L1[L>C*9,ZG&G&*RLTS8F*O7@O![=V+BC1ZAF@+%.K(E(HDRP
M>JQXB0>9H#"*/\?4?YPMIV3> $/2%\&+=IW^1KU'#X3THT*&$Q]2RE .^/ 1
M2<!08<4LR:0:7$V-95W36V2*5Z:/Y4]N=V%*ZA0W%MK>P>$BTL>/B"FKCJ$[
MP\^3=6;GP!3-;FP:&+/FZ1W:1EDRV>#WH5J7[[?E7;/P(>$:V;84XI#R07V,
M!@Q)%D/337[R([O?Z"=L\5IC+'3[*;CHO#3.[QVC.["F'#-YZ]^>VY'M?^H^
M>CLM@!JV:;0!ZC(HFRM^K!_:#N[WZ_,[QL<W,\=^D*8YH;Y/ $T I3D@/1(0
M8B*U:VMS_#G4>+!#O+TBT8(QXO)_*QZ3RUCG=I8!<;;B)RL9KP;99[)@FZYS
M(S.V:F$]W8=@LB&Q?PITD>4I#B, (@P#&-$H86QHA@2$I8'Z[?9FQE7Y^/7O
MNN_ >,76N]Q?>U]?>]TO--E]*$VWG-Q.S['1[/>$J%[T9Q==:C_LN=3N/U3U
MA1N*:=@FI0Y$/<:D=K3.#XRNKKI++[_5GX=+==%ET[[AN0@@2D"<181D&$$:
MA7&8#&A0G"+IO2Z+&"QGMWM W67$Y96XB[@[W']77)4\;_IWA0T=F[Z0V#MS
MQ UJLOJB@J+'"CH@][[5WL%COP_H5?;<;+I(83?.$5?I[=-9=9G<+IX^?Z?V
M]R;PB ,[?U-864\[S\W'2E[#M!L$[]>/[I!>8$0C$K $9"F/XPQD-,M[1 GS
M 3$=+W5QV&[H[R]Y5ZDH)J'?7(B<@GF+85*T3W2[FN_73^[D=\A=YL/E%&Z;
M(&3JN,]HV#S!X\C0.=8[;R=\CK94(X2:8==.&#UZMF>1!R2G21*RE/@9@ABB
MG YXLAC*OX9G%87ULE.\E]4%4)463+O,VXB?MDB?*GH>OVSFC*-L1DY;#ILZ
M;DHYSE+4/.+06,S4\<M;C)A:=HZ*E_K,&KI'8__TPR(C4>:S, @8X#4NCG*&
MAUVS!"1AJ/'>C[&QI3[VT8_X]*<CNTV4Y7"8:-F=%O&JIMF51C>Q5,@WL8]E
MFO!)M[+VX%W:S3HPJKVAI>&4M["GI6.6VL4:NKR9W>]':1X2E <@)Q$-<9I'
M.![&#@%3?I#&S*CJN_W*S],<[?67_$-]?9?_#6\VR]+]%CY,99NT-IO5&)/]
M) _-FI^N27UW7ZZ;%LJ7;O^4U,VV^7I;;$HLWN ;POFW\OL6<X+^6(1QC&#N
MQR'SDX1D.&!AW#V[PQ $5.DXCFTLMELKMQS$N^ZMPF/X:OF-=8?(I3TN^4(M
M&SKJ3^<*>HS=Z\%[+?H+K\7?.VR?J/XN;/!:(R;NF1Q)^1E)GLJ9;HCU9-;6
M\WPR:@+_>5/S+&+[XS/_2+8\K.3_N:O:ETT. \,4IR@B89H$(*$D]&,6]4^G
MX2QC2E?E&AC.MDSWE9)0AP%M6QCMH:H)M@F"Y31Y8F[59'< =^&U\!XSVM\/
M[LVFK:]3=T8^#?+NAD*:-*BV-D<5SXWOE?58>X\>>\(_GHDO$KWMG^[;DO?3
M;BMN*Q$/A!XWOOL9#5&:^"P'29*&,44P9EE$XQC@/)2[0&1FB+;U5$!6/:0^
MD[/D=/8-^$EQ@? HT7V4$!_9Y%W^>"DA]EK#+KS>-/Z'@W&SGC"RXZ0S46#F
M6>%&Y)B;A*<'_UWPR0P1ZK==>Z\!B2#%#!+(XBS-$?7S"/8X"41)J'XR:GJ,
MZNNJ&J>H>G1>?21>3T]4;6]+[T=9;+Q?JK77M$'M;V]6TCKRIU$S14?_=$*F
M:K\]#=/RQ%3R]2O_P:W8GV\_XE\W==,L  JQ[T.: 9IF$$',,!J09BR,%P_E
MYK*>*K_60:@B7\?&2$M7"XKG8V]6E5Y@U:(NC?'ASZ%,HQ@PK$WCO2&M3F+S
MY7W;3T)W&ZZ%W9!=<=K^RQY2_KW<+"L.=Q$E<1[B) P "/(0I&$ DP%(E*;Y
MT)TC*3[F 6BTZ*AIRQZ*E+I,QKMDE3X3X;-7X(,]C;@&1*TCTE!$4&;^G.#;
M<Z,C>F[1P*=R;9O+J7)%7HA?E]5VMRGWP6/! M^/H<\@R),H2OT4!?F %! ?
M*<KU# BMZWD/:I2>S^&Y:99EK;EL]HAP9-EL,<&\<RQ6"6.F@B-194X&#%<)
MX[TQ55S*O]]7_?/Q>Z04)BA)<7NE+$EP"J*,#DAIP(A&D_\<,*<Y#] BFS,^
M:7EPFOADS6NSQZ<CR]YJ?'K!.1;CTYBI\'/$IU$,&(Y/X[TQWQ9A'/N 8I:%
MP ]]$#$*PJ#'26&41:J'*:9'.,'!BQ/;@V7WI__>&YS,QS^'=HVPW_K>H)HG
MILNKV_4HT2/:XT19"B,2H"B,TQ2%+$J"85V*XCCWI]T95,=G?5_P")+0*EHN
MV[<NO"BX\(2&S)EB*SMSJ@3;IA=GWQ 0=EUXG65O*S@]<XS5U%IW$OP<P6F$
M_<;3ZG&>F"&I_E=9W=QNRRO$);NX*8=ME,^;:EF*!L+KOH$P2#!)X@A A)D?
MIQ',?3 8$C$@=2N2P_ M=Y0/,+T>YW['TVN1SM9J;LS[D[>AS^%X)UK4+[Q7
M)I/&';9NQ$QU[TY3\9F>:C]'U+5)D+V:T8XO'8O;"P(0Q&F>AGDN&OTSGZ3I
M/NN(PGF[Z$<A=[.W_HK/G&+3B,M-N@)UXOK4V+QP*HP;G0QO(W;_E %[_B@M
M/9/^4J%9GI5YXK&BUXP%X4:I!?RL!8!F((X1"4(:A 2PE"1XL(!D*#&\YCLA
M\DE/B5B/KU.ZW%",==37YN-L(QMH.XL/[1AO+=J:\^B8B#O#O'HC47<.9E0C
M[VS>FRSZ[L^*R!D!$Y^%E$5)B/,TX@E%,!P<I13Z:.( ;!;\5#NRKD1APZZ?
M*!#/Y_,98_$+)[I^MG"LY%>;$=G.!/M)@K(E<DS'99L^G"PTOW#JX;P9$0&8
M A+X/D8Q04D0#?5]'J5Q-G%P-@W?>GA^?#AN]O!LW/T3!>@Y_3YCB'[QB-W/
M%J05?6LS3-N:9C])H+9&C^E0;=>/$];1SXZ G#4CRX#OLP0A$N"$9DF2DN'X
M8IX!A(TV@$T-WG+[U_$9P=G#M'''3U9'S^?S62OI%TX:_FQA6M&W=JMI.]/L
M)PG3UN@Q7U';]*-K'5\AC?,P@"0*,/)3$J4D(P-Z2/(Y#T6.PNW<44F%\/W?
M/3N33(TW(JQ3LS)3SXZ:UV8XC7D6/<4L\-,LP#X"+$:04,(&])C$;+8SFJ-0
MNW%R<^XF66-S8)HFV3F</U^3[*,#GV^KMC'CQVG.AQJ923]'P#7.BKVSI :]
MIA1P+U]'?ZF<+GPI[XI*G*(@];H]I;8K5M_*S5VXB!*?%U\D#(,H3J,H(  ,
M%SGDU ^4'MYT$?_49TSW2+TCJ)[ NA?>IT7/L\BM$:(=8UTE7#L&_6V$[O/G
M6TY/PAG"^+3^?2VD.SK;' KOKC+T4JAW%>ND8?]TTG+*DF#AAT%*4 QPQOPT
M0MA/XN&*#(:20.=>),<LL%Y_*X7^UXKU:4.^E1DS3<B?>ZJX6JW_+"%?P[\6
M0[[-V?9SA'RK#!D.^?:].<,.Y7L.N%HWU?*?Q6I7+H*8P_5)% '$LBP-LD.7
M,LOCF,QT990B2LM5.[JYV;1WCWM[7%X+S&J-/H^_IUDXG\;5CM3;3R;-VUH:
M/^FI:7:?-6>'0\%R7A[L[3"/\LP,M>YCO,$B2I/83WE!SC*<0,8P](>CLRQ!
M6E?]S@/4>N5Z)OPY6Z<J>WOR<M2FFQVI.N</?%9<-4T!J3L_' I],Q-AKQP<
MYQO9X)<7&U%C-I_+30OL2RG(KU95![R_0'3!$ISB)(E2%ODT"/G8?I1%043"
MC) P5]J2-32DY7KLM]T=+\/Y]/YWM?ABBE"Y6#$#EVJZ/P 4YQ4Z<?<>8YSM
MEEHYZL[HL&'NW=!4TT;55N>KFM;]@]<4?(#J<K<MKP8D'^JF0:N6]O+J6_VY
MV&RK977/\:QOOI;+W:;:5F7#:Y5JN4C##&>\^J ,)B"(PSC-_ %6!G*J]DZK
M=3A27_681UE_*[=>M5[6=SPQ'S![V]J[/T;M-7O8:DIJWUUR&NN&G[34]Q%T
M;Z_%OPCT?_/0L<\>6> =3+CP6B.FU>:QE)]1[<F\Z8:>3V=N/=-7HQ8#N&2]
M;Q6KA?)05"N1:W^K>;I^5Z_;A\1OZQ5W2H^"(I '20!0&,$P0RD+4C*@H %@
M*HFOZ;%M9\ '=?]EU0I&)_)B'88+QK)%[34"MG==;[Q+ =I;/_NO]GW^:O)O
MW%-R:C^GD]3$7?CG?<]T+^@#7.&?#K!WC'@6+5<D](QTVW*-&TIMS;IZF@D^
M62Y.JY7XCQ8!AC!$/#8 B&!"*,9[8!1@&D^6C<L"LIZ/HZO_LVNV[9HI%X"U
MJ]FYM .MY^=&/3=?AMZ;\69R]!ZOG2Q=U:=NJ/^4!IO+U/6X-I^K#SA( '.<
M)5$"*8(!2:+4W^,(:9S:R=9E1W<L7[_J8,^1L4O[RW3.;L-5]K/V6?1=F50C
MF;NJ@]Q0;XOV:6?O>DS*:O.39M7NE=-/U^VB_G$'3X^"5LV2:\MN4[[?EG?-
M?J&?8@1"G,<I"_.<I0FB63B R_G?JPCV1) LJS@MU_5=M=;8>9S*)7*:[* W
MU(3ZV7&&S@1Q$5!GQ'$#IBN;FF98/Z/D$[O5#7F?VNAZUD_)3B#H%I-@F&8L
M!TD$HIB!*(LP90.&A/^O6D.DV;$G.YWWKN@5I>ETA"O*H^3\N,]_)QKAJK7X
M@?M=6_B_NLS>7K+3_6K%FW4,^])LH##O1(OQ8):5=B4F#6B\FD?>EI0KVJ:I
MV#H,CA+F/D0\ W)8.5XDV(>,T1"G24HCEF=Y1 <T<:AV^XHM#)9S\./$KI?D
MH?=XMWXH&Z$"7[[^H_'XSWCYU\^?N3RONQ6T]J"660$VX;,14CRQN\R(<@_Z
MI4S]@-L!=7Z=7%6=-N@NAQ7;I)4RVFV<U9'I]2D\BYA%:9"%)/:C*$E@#/(P
MZU'D-(X4G](Q/;J3*;80\78MO'HHC[9#7TB])5;,C2??^IX>E7Y/XF*K"?@L
MB^:*;*HGX:/]XK"HF[!.+A$WQ*+N(9LN[4<^#B+*",D"&$,_3L6)UGZL/$CR
M,6=JY$:8?$-R+Y,7_3*&"S>IO\B=PKD/-:[=^/Y&VO#*J0X=1G2_I6&;"S-$
M4Y+E04@8_WH)91$81HM@HO0LD>X8<WY/0V[BXA?U^@;Q6,;=_*J4K7CEN])C
MY;4OJ_S./XE/]^*T(Q_L0UGP>5D5E]6J38/WVP<P3FA,,P(@BX(L3A@+TR!@
M84A@EJ295+@R-)3MY9\!H+<2"+W5 :+DEJPI2L^G\#.PJ9:Q'XALP7E'Z&1V
M2*U0>E4O=Z)>;_=I7:+V$;"I*'XB_\+L5M2#,,Q:29<CX@5E-\S@O )OVIC:
MRBQ32Z1>'O<'V6TV8CDK2"EA$*84\F@3)QDAA V#1CB,5/*ID4-9EOL>AG=?
M;]K>#9YBK797W=K/I^TMSZ&6_4\<!0*UM9VQ7,LMY4Q(\Z@X<+%7J1\77H]N
MV@3U/%-G\E1#%+N1KIHRIK8R#;63UT^7J^JFC:+[(2.:YSE$.4)1%OH)ACCH
MAX0^0E*'.(T,]':5S S/ROFL78K'9;,';*^KF 4NM1-9NYR:26-5N-7)89]Q
M()?!ZE/G7/XZPI33V>M8?D;FKK]Q%OIQJ9\CGR?-*.9CIG$"4IKNQ\W]Q$#Z
MJC":9=W_4*]OWO'_[FZO_/7U\[4+(RFK"L6CLE9+[)I+7 \ G<A=#W#4TU<-
MKIW.8'7LD4MBM9D:E<<>C0JS+$=I" FB2<[2B)(XZD=%$:+!Z%168:PWI&K&
MZ!V1P5IBUEP2*Z%H=D@UD,I:(M=\-JL>-A03VK.!P#2'#J>U.M;(9+;:+(U,
M;A=!'B"?PCS(0A"F,,K3-!]&2Z,T6FSK;;$:E=*^.H:2Y._A2'\XW\1_XM6G
M]]^,Y+"O,SDJ<S5*HJE\U8D<53TSE>;2Z7Q4W@JY+%21E5&YYX)'G3#F&6W$
M?S..<$J28,AS$0A8+",[XT9X&Z(SDL41B:51 DVEDY.09B!Q-$J>Z7314HJH
MFAA*<^1P.BAO@TP2J,B(E *S:EVLE^<: 4@8!P&.,H10'#*:H#C/AD$I _+%
M__BA+-?^>X#C6K ,4"JAR].RJ2;0!R(-M6 9H%1!M:>E5D^^1U(L)^6O$G%*
MT\TQZ("X&S2FMC++=.3^**J0B 0!0AE-0X)]F(8TCO=1A5*IZY"T?_EDDE[O
M,77W1N^JU=6[;?VNV57;3N]U]$B%1A51M\2@KHQK9=A:).G(M"6RQ@JSL8SZ
M!4-?%5X-3ER26AWX+XJK-@^R"Z?=2.7+;6=1EI&$AHA$(4U1E$#H^_V0&.=R
MQQ>,#/1V>\#,\"RWMCH9Q3HZ7+K2QWJ.I3.+K4;(=6/%U8PIM87)9T"[CK::
M_"1# <*1GXB74/(<1VDXC JIV@-\8\=Z0_O^QN@=H5J6F#4E7'/U,;W"E:I\
M:;#LL(+I6",C8MHLC=*Q18 13/(X":,(I8%/,?:'? ^'H=K6M=X(D^PA79]>
MM30@5Z^S.$*DC!)H1IH<D"-5$9)FT6'ID;=!1G 4&5';JD;KJ^-!F\.H)$II
M@H,0X9!F(06,@N0@;BQ0W[36'VL2Z9$7',6MPY-VO[J).)XQ!Y9!3%KSXL:B
M*98TFCSV0S]>G$E9FE.8\+&9>" @CC*_[VI#04Y#W88/S=$<^WIL<2JQ(CTY
MG6IA_&D7 P?HC5RV-D.M=I/(!!2;:1A1IEJG?>1E-N1:248RZ5(<,&+/Z183
M(TS)%FO[]V-8O?E:K,JCA[W*R^W'8MO_T[^J[6VU_K0N_W=9;%A1;?Y9K';E
M(J=I0L(<!1$C49Z )(\ C5+DIV&4)A2IW35J&8S*5ZEU]6B'D']_U=JKUZ7W
M@\/CDY+'ED:Q^K/M%KDRT2%_J 4B <\[?AYQ;\F[ZWKSKN&V7'@]_A\71V\L
MBHM@OW(/KLK]O_8H_S<7WI^MC1XWTA-67GC"3J\U=-HJ=9Q3SI2S$WG;C;IW
M*F/K6;XH.S$ 76_+#<?T[793[VYN6?70PFL.^")>X_MB13%+8A3'L;B6;L 7
MH!#;"0?C<4T7&0J!]1 <MAUD[UI</"W^QE*<,. ZLR%C6I_-'CTZMXO@T1OL
M"8O;2-*X'TI>=9:!J&)N0KRM &/0;LU88YIY,V'G\$^+&*(D8!%@2>P3'_L0
M^O00]5*DLG5D;-!)%J6J]JD9L3K0>,4S$7))+ [_I*T%&N2_A4]=QRRE+UF;
M-]D/M7MM]NN61S(Q%?<=T0D$-,]]&D4XS+,@#1$A?L 'B@(<APF03!ET?[V]
M!*!_G'D/:;:W/$]0<^83&TNF&U_4:"MJLU-,[7OYO*FO=LOMQU*\-+$(DB2-
M$A*'(,Y"E)$P(Z ?@]=P&*JT;:G]9LM-6N(N^OL.D+<I'\KU3G[+T<SG\8B.
M,Q^%'FUN? J:V&L3$T=MVG_IY\#AM5F? >S'**0H]4G$:,Y@/PQ-XTBI85'Y
MEUN>_ ,>Q0>ZU3F2BZ%6Z5$+G@.4V8+F4R[."(,V;6YH@S[\VM#TT;S6)O]^
M7ZZ;H_$8)3#)$AHQ!B.0I6$<[\<#!$B=>AL_BF7-..S9ECTR1?48P9^<C$Q#
MG9J>'%@;0,VF+"?I.2,QXREU0VL,V''J9IN1S,BJ#ZF;[:?K7^OZJD'KJZ_E
MYJ%:ELW7>G6UB'$(:9AE+/>CG$"((AKV ^81I$HGPT8,8UE_!#)QD.)&8/,:
MCDA-?L80**<_$W&G)D #;2VL;HV_!^9]/<>A%0DZS= 9#3) JQLB9,*0VOB4
M4RV3FI+_["T?C?*T:U7?BR6)7@,7(6 D"M(8L(QE68;B!$7#F RS5*UF&C.2
M]0*J ]>]O7N IUI/C2)3MKB:BD?52NN(PB-D0Z(T==EUAJ6S-9@)=MW0)T.V
M/*O.S#&DH%+;S6[9=2V0VV)S4S8+'$4^SFE.,< @R1 C,!B&\H':4J;6 /8U
MZ8#)^V53+NN'<O/C;]ZRQ:<L31H,2BN27?*4A>B(MQ[/Y.KSC)'SHJ-/H#-:
M,\*$YQ(SE@_M1: %"E.?\5\;D(3%S$\A _$P#LH"I?U]]=\^R49^_6SI9^:5
M"Y45"VD*W?@P1N!_;85"D0GE3Z+;I_Q0-\TBHGGL$_Y+,S_!E 0QC/QAI##(
MB=9'H?#[+7\6[Q\]8BV<.'PC]5KWBF\5]A370RT1I[L2.K G $W\L/<+E,AH
MB0:!CJF)C@6G]$2;#5E%^:U>UX\'ZR5LO\8:P@PRR,2A;,J5#(?,'_: &8M
MK-:J/7X\E<]&JP6[N_FJZK^</@S_[<);EUO%;1@#Y,K)S[2LJHG1,;:]'O7P
M_C;;#LVKC)W1*G-LNZ%<!NVI;<U+U49$7M3S2J4;L_V@%S3)J<^SL1 PE@:8
M)/Y^^8-1C)1VCG5^O^4EB0%2+UQJ0J7%EYPTV:9*38SV+'5P+KIK#J?NU7S&
MR!FQ&<.?&_(RRH)G_9ECV9 NM<3O/JE?"X0("XE/6((0)C!@P,^[04,_C4FF
MU(<R;BC;S2@"79O]*%9;(PF4++RFXTZQ!FNSR+/)S\3UV%FFSI5F9BAV0XQ,
M&?.T8#/)T>C:;9$$+!2+L7&:T8B7B0RF_C >BE.HLB:D/\HT"Z8ZU=JT)85.
M*2%-KAN?E0$[9$L'16;4SBZ)E1;&K2/UF@^\$Q>K[!<;<7E=;\KNY[X5W\OF
M8[6NQ='=(2E!ZZO'OR7_SQW_UQ_+[6W-_\W^A-X"^A'( ,M3!!/&$3-_:*OG
MW&=8ZL8Y%W%/NA1\V9HU?/E;8=@<9ZXF8?YL?>">_]W0)">9>?&\F6,8E73S
M7V5U<[LMK] #1WQ3_K83!X<^77^]+3BX3[MMLRW65]PB7#35<L$"R$B$L2_Z
MXAC.HI@.VAW$2:[4M69V9,M55(?*VS7=ZPK<7_>[MBC@><H^>^F$C;O>:\2/
M7WB7 KKW"_\/VK^8>@M'B>$S&F7'4VZHC"7;ZBGFNI$OG5:K'?_;9U 6) V2
M"$:(0Z&4@0CZ@ TH_) HG>HS/;:37_M59XUSW_LIEM6_^-'^<OJ;'V^=W%=O
MB$7YRNB!YP_U9GC5Y)NX8&*11 E-(Y!BC+,04))%/F-91&,0\:%RJ?=%QXU@
M?4.E![5_K\?[O04F^0+F2/ID=U=L,Z>ZOZ),FJ7:[ 5>SE918WAT0Y5&VO"L
M,AG/B*S"X&(E+C7_>EN6VP^"15[XH.]5LZ @CG,&*$@P\Z.84!J!83B<AT1%
M9+0'L:PS/2ZO!>8-R+S?!39%J='G44YM)J%037#TV+.B.:?8.2,[HPEU0WG&
MFU$;GFCC]8?6=T6U7F"6Q)1"EN4LYY43I3&BPX!9G(Q6(,EA9M*@#IT!%9)E
M4U^'+!!I1HE>XW R+>J **J1(JWNZI&J(1**I,6-:M55E4U_&5/[,)*?96G"
M<@"BG 7,W^=>6.U56O7?/E6UI5=<*;"D5EC9(4BOJ*K$C28=FIG*J3T;$J64
M.G-NB,<(_"=**%TFY)YI$OT/XAE4\0HJ:IIR.PP6I0G* LC2+ XS$&:\:$/]
M8$$&,B:C%R.'F$HT7GBY>K5_&;9H$:L\):1/Z7EQF9!--87I*#L\IMO!>EUL
MC'*G\O;2)!QJ/KBDR:7D.TNG+']!D0U1Y<*+2N.-J(U.'\T5] _5NGR_+>^:
M!0$Y#EG$H@0R"#'&, N'@0C_H];RN?ROGTR8?Q>8O!:4[KJY FF*B^9V^-)<
M,9>CRNYJ^9X0F:5R=?;<2O!T##BU2*[+A;*"?"G^_%CP+[(J5LV"YOS7D@A%
M/D@12I%/D[U:12F,M$1$:03+.L*Q>'<#&$WY4&-,44&LD:6][28HVT.Z\'[=
MU&>>E+.K)L?DR B*%IF.:8J>#:=D900CRLKRKWKSQ_OUYTV]+)MF 3 +?$01
M"%(?X BS!"7[1(A7L5K2HC:$96T18$2Y>-_!T5071=84Y<4>8=KZ,M#6@YI7
M81[Q(R,Q>H0ZIC&:1IP2F3&<**L,J]95<UM>M?=H+O(PQ%E*4HI0E(8A]4D<
M](.%>9 E6BJC-H1EE1G ='?I:HJ,(FF*(F./+VV1V;/68II78Q[1(Z,Q>GPZ
MIC&:1IS2F#&<*&M,.UL640)($%'F)PGS_=B/:3*T"H0$L%#MD)72KU;2%,V#
MCYI2(LF-HH28IT5;.N:4BG9L&8E0X\LQ:5 $?TH2=#A0+VHVU;:D]9_K!1\D
M2/*4Q S'A$9IDB?9,% 2(Z5&'HU?/]F"ZY\"TKLKCDFWHI&G3+6:L<*6[G+K
MOUXGRG+Q,M A5;@H<^>8:F@8<+)@T>1"5CV^+GFFLEN5GZY)O>+_HA9',1]*
MM-GPF=2^"RA> /B-$W#B7W_C?VJ*97M^L^V;_E9^WV).RQ^+B.(XS*,TQ2!B
M819F%#"?^I0Q7G0E *C(T)PX+>O98)IX3N.1<=[^U;!_K/G4/?Z7]=I#-YNR
M5'\<8%:'RXGH6_&UFAJ?=O.Q8>VS!=RT=\M3/^(=6]>?./&$@5YKX<3;:19]
M=294N#!#W(@Y3C!1N_?]RD7![BGQQ>'F@.[D#_8AR%$$(I"G048@#//<3Z(L
M"QDB82IU?:+FKYX@=^[@J!WPTR7JO.!/P)%ZQBQ)SQDU;<KEWV_JAW_KS!-:
M&O5_%BH:':GHRP2\('PCF9I7J\:"KXW,%DU%:(_B$$I1 I(\# + HI2E#*7]
M&#B/@-0;+WJ_>4(]4#B$I\F2HAH8)TA?#+2/V(W0@A/GZ<;1Y)@2J&$_)00:
M#"CK0'\ AD4XRP+J!SC._ !A#))D&"5DB5YJ(/F[)]0"I<-PVEPIZH$%FO05
M8<11MQ&:</)<VUBR'-,%5?2GE$&+!:FS*.B/8K,NOMV6F^*^W&VK9?-A>_7W
MOK6:8)HS_OL3&-$0D"R/\F$\$N=8:@%^_"B6]:+#YAV#N_ $/(4C%.-8/*\?
MTQ*HIB0GN=,YAS*.1(6C*).1J7<:902I<@=2SMG_@B:;X\R!8REF[*A-SR;-
M;.[#OH<] P$@(,T3ZI,T@@#&"1P&2L-$JJ]\Q*^?,*?[H'HZ90QKBJF='<+T
MLSL9KNQD>!_.'$LQ0)MC>9Z& :=2/5TN9'=*:7FY_5HN=YMJ6Y4->BBJE5A_
M8O7F:[$JOY3%JOJO\NI7GFZV3YA!FJ5AFK  QCD)THQ@3E0'@O+ZU%?9_#0\
MM&7-$3B&&Q_KM==PB(W8]*KVKFJ\8K#AW76]>2=^1&T7T[0SSLN5 WY0DS(!
MU#L@O?#0,[XOO &OUSELAF<3U?@\LQ]HR3%N;/'9,JZ>9'*;%-E_K#<]# 'A
M<]U4HCX8K@H=_ID'@(PE(&<(Y12!G.8^@63 !G. S6FO*426);D#]%2$^5=?
MK+W=W@1/:+9WWX,V*<C&'&="I^?PF07Y/ICA"3N\ ?B%=_#VWAB7=%V2?VVY
M-^W?MQ %C-NL%!SL,*[T>MVWVV+]K;R[KS?%YL?[N_NBVK1% <=S'ON"A@01
M'P4A9CB/LRS(\+!O1 .H%BPL0[$<)5KT[[8<_KOM@-^K]@9XR]MB<R-R^?4+
M^;O7[.W2>#O/HOOD0H9#GE.+%2\Z[8"]C0T7GD1$F>&%/FV^S\2&B1SI1E"8
MRMB77@"<BF/9,- ]!708ECW\5CVK6G >A#!-$L9'3!&%,?:9GV0,TP0AB)7$
MWLB EB5]7^/?B!J_7XT1F>&R;K;>7?MNTE%-H*;<9AB7T^?)R593X0[>(X5E
M_WSWVWL75EEDJ#LCJ$:9=T,VS9I46YRI:A)(^$?]["VT9V.G?I! ',4^S6 0
M(\8!L+W\ K65:3,COF41-,2YG I.3[>:# I\[WI"CQ"ZH()2U)V10;/4NZ&#
MAFVJ;4Y6A=:LEP;^].>:"\=M=?^YY%-WO2UNR@7.XC#*0@HA#@#+PBABH!\Z
M)PQ)":'1 2WK('E1[KQZ0"K>9^NA*G0?&6/[O 3.1K2Z GH?GRK@A;='Z7V>
ME62%;J\YR-9K_#)"NEP+F"0II[K!3'/J0&.8<9-JBW-0Y;+Y89CA\6'\8WB.
MN'V-\+9>78E&M3@*?#]E$4D2BC/,*!B:37)(8ZE#[B;'LQQ#<+DNKZME5:R.
MXD;5(_8N?WAX52S_^%(O__!^N1-OEHN5R=.IGCW:):+)#(PKKNWN&1X0>OB'
M-V#TCD#.0+#*%?;3$ZT72/;4[A$?!Y$!_=AK[:78.!5!#'/I0  Q;5%M;^8I
MA(\OY:K8EE>?B\WVQ_%Y=E(TM^TS]ON2Z&.QYB'LZH"L!;U@C,8ARBA)HY F
M80;I_CQ;GI-0ZK[(:9!8#CFLJ#;>0[':=6LV''5[2<9Q)\M=!_Q1_%&01/N^
MDHA&3KE)+4[UT+T6^Z/[22X\ =_C^(_7@[S>@D?1K#7"*:<I1#BGG*<7^R9P
MHEQ\',OEJ<@YF8\<B*G3V5K/\15,&(>['RCY#WZLU^6/C\7FCW++=NNK18S#
MS(\1"Q(:^!PG!C[:)PUQ)O4J_,P0W8S<HC%U>UL>_<6'ZC]WU940F-9"KS/1
M$S9.&#%&3(4)XO\TLV"NQ.#"&^SC?WBKLV#"A&*:V3!WIJ$[*Z9)1$[ZP%:&
M,M[I/T'J8H $DSF-*9^,2G;0U4/5B*OIR[+Y7%17"YK'$8G"$.,LQ0!R( SW
M8S.?1/+OI1H;T78JPG%XU_7&*WI@7E-N'JHE_]M[#L_;UD97#M0)'Y$A6.7:
M7, ?8'JM+P3068@V$(2M$FX^IBH0/RXP/N5%-<YI\^IPV-*W228*C61,^I9P
ML5:.BZ:\(O7=?<F'%Z,?W=B*?QQ^Y'/QH[V4[<]B<R4JP'^* A US>[NOL7\
MI6K^8)NR');DOW#+%@%-:(H Q3#CI7\,4 @S3-.<4IPS2/+%0[FYK*5O"Y\=
MK\H7?VR:_ ?/4;V[YK .NZ\;#DSQ,O#9>9*]$GQVH/9B9@O\W:5 [AU;]^C2
M[\M^N[?_N=Y$K[7QPFL76EHSO2,[+SQAJ2=,/6P@?SDW2>Q<$6[;=V>Z-MV9
M-VYT?#K$Q]-+P]U!-E]HS+_?ETL>YVGU4%V5ZZL6-Q;O$T*4YQ@@ L)4W(@U
MX"990&<,C5IXK8?& 8WWHRI7DD6&._3,$1&M^]&9B#A8ZNTGR1L/B"^Y;JJ
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M?DW+ZW*SX3EM\1TU3;EMQ/)45YVL5O6?!6=T@7 (TY3Y-(F3+ X(2.!0A^
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MTMIE'D6Z0_'5@G'2^\L&.#09"Y_M<_M!A B!+. H6( 0(ED\0*$Y@&9ZI$8
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M2D",TCB*^W&3A&'Y6V2-C&;YN^Y.##VTH-0?XS7#IT0>,SF5:AK1P1,/L@\
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M97H/3?K##8FU8]JI;D7S_$FU,9X<G^ZZ/K-/UX.F[V&P(/']((\A2&.&\CP
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M!%M04./<3J.A K;#*BK@F=)1)0^]0255LV^,EFHP:4--&?\8%GD<$T RD!-
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MX:'%4# (2YU7&B*WN8W[3ZAT-!Y:A!@HJ0$G'MB=[!I),K%"FEV0HL;])]5
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M0$F1)MX &V]D0) SM\,"2B.:G(0<H1_190BO2]R'W[%L=%7 _68<8TYKI43
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MO(PH0OYLT;F*W809PWN!<?BVM<&>&>[T#F)$E+43BZ -0XPR)GX[^OEY-KH
MA\Z')8Z8> UU\-VUQP4N$C2Z[&6$3L.@O.U/3:/;Z'IS'5[RNLE5JO:<,$IX
M ['E"@GOC;>[ZC6! 0B52C=[W>0Z9 5Y;3U11 /N+=.8.$YA@6P\6#"M);IG
M-G:_R55-?2]KDPM!HQCT4D!JC+022;XKLP8](6!BU!R2'.52H"NI8_J;7,!Z
M:(/KJ+AB'!IMF5$%'DQ,K5!G0TXTW.2JAG4GFUQ;:ZW^!M>#Y@G&P!,& ,&>
M(VH%Q<85TFA,)W;)6F>Z+KNY51_ZU_CC<4</(*Z4=$!9!XE3FG*TJW:&8I"W
M"8E'Z"./:'4>4(L_3P0H;H!3%^N:4X>DXYIS4N"B@)Q8":9A*-5"!*B:FD87
M =I>1?8: 2KC<TLA&;8(&RUI6+JQL K<);5;3:$OM=/^&@$ZM XQ#9"40!FG
M #.,245\@:Q7>F*I5CVSL?L(4#7UO:P($&?.2HPA8=9P%NPD0PO9C*/H]<K?
MULA1*@)431W3CP!I2\+W#VD07C$*".5ZCP<2?&(S9T-.-#T$7PGK3B) +5[Y
MZX77,H!%'42&$TX4%WMIS-1N4>E,UW6N_*T&_6L$Z+BC9X%!VC"@'-3,&V<8
MPCLD+;6R"8E_C@A0W=5Y0"W^/!$@[!RC!#C)(:'(64)P,4^$E8XWR0$:X10]
M#*5:B !54].0$:!'E5?^C"M@!/,U^E/JX@$*)*(Q09>;8&(Z@$!1!@=!(4NE
MW[]&?PYF02NF@(<F2&=! %E"7]3^09SIB259],S&'@ZY5U+?RXK^$(P$X9AX
MK D@VGI)BYHI2%KV>LB]-7*4NPFUDCJF'_VQ&$)%L=*4.!T,=XJD*_ @CDWD
M[%]+G&@8_:F&]4LK@>B4$$H+1H#RF%L.S!Y%[+#\R?.!2NN^20G$:BKH\G#R
MASC4$Z?<][]/.,,$ L@U1,8)%KP?@[R/F^U  E.N\M-/'7^INCXV@;]SRAR=
MDIX\D<1A!J9[RH)?#AC#3,K=N)TA:")F54U=/=5T+<RZU/6[V??%U<W526T_
M>B:1C# C,:/>*Z)EK*<999> ..X"]R>F[ZH:R]K![76CX,290*&M1IP+IP&W
MT%A/BRL#B&>XR3;^3W)4O:8C-Z 66[?!=Q^GNLIN5ANW7'Q9!&0NLMRFW])E
M=AT?F:W./Z1?;I:1/K?O%LMTO<E6Z2&:=_2F!#%G!->> (X%M$!@P@N,C#(3
M.Q,R#+W*F/F]J7!$-/_K.EOY1;[>?)P=#"+W\=I$QJO.N=;086HH\MMZ]1XI
M#H0)=E<38V.$/LD4/X F^JS]-;Q/\WD8TMG%A^QVMMS<GJW^3$_R^&B#Q D5
M(,2>:.6L9\9(2L*(N74.*:J:A.5&:&P,S\"V-#'DUNR;U;=TE<\>_?9UA[;2
MGAB(;G2P3)&R3E@NL ?TKA8'IHB"4K='ON[0'C+^A5)84V6Y#3,O !I)R7;(
M,D44G99-V3,;N]^AK::^VBOH?@$_^_SOZ7P[JL,QY!-/A]7>.2.]II("#1 .
MX]L5[\$<L:E5W1U2V5G;RFB1.$=KH9Y\/I'(:"4\LY0"(0 2'-IBO-C[B<09
M6]'8:>W7PK.V_NUB/<^^I?GM^SR+ SB]M7GXZ40Q@(/,2@A$%53:T*(0+.;&
M\(G<'=V2OK*V\:RO^WMO4!WT!I\A0[GF"6"(:66P1<PSA)G09E?T-4CE89/B
MN2,*"G3!CDX KDT7=7Z^B/C/E@V)4[FCQ& C*,;2*60@,LKQHN(]%EZJB6PA
M=$"AKJ&N'_*YJS-MLJNK-(]F_,[H/\V<TZT2&KAOM!0V%GF!.DR61?5)+#V7
M36A")DV35G%]66FF@')LJ0($0LG"2JO<WFJ3Q( FG!G1ZC0BIZ=-=4P_S101
M;J#V+M8DA\HAP* L\ @_GTBZ3DN<:)AF6@WKUO?^XF&G72BZ7H+I#QT$1\);
MY;5 "G,%L,; %-^F\MQ.[!1;9_HNL^76%/S7#*+C.U.,6QZL&HYX,$N)8$#%
M9)@[)*%#34XIC<C\'^$:/: 6:T^O?UT'2+=.SMY&?C^[W8[ZV(1ZHDD"!;=&
M><@AX0@BQCPJ_"%- 7R]Q*(%A6>=Z*(V@XJ$B=U[[PXD/]@;]H\2*0Y[TRH
M'9Z)#_RU"MI^U,'ZV:M6>AQ"@H4,,X)"D@@9+^Y%AA0>H\' 3<P#&I[AX]5M
MDVA.C$*\62TVBSL9TD*\$Z&<8TT2%E8JKAF7'!@5[PD3?@<KP0K8)OL)(USO
MAV=D>[H8-(TG%GI^3>*IGS;!+'1"2D.1%A+;,&%PM4T 8\0PXTI5O7U-XCED
M?SLF.& *JNTA1J&I=;9 5CO]FL33A(W=)_%44]^P23Q*>4LMMH@8@+5A-!@
MWF/*G>;$@8E<53H&99=(XJFFC.&3>("E'D%G"--::FL!5FXW7BD=FPAY6M%8
MJ22>:GC6=UC?*;]8QM)8\WEZO0E3:OK_&G,ZB'RJ36(H(9XPQPWAF$MF*4#;
M<7O/K>(3*4G0DNZR;E#M*R!\9_4OU?7U<C'?:NM]FB^R<W-S%;W. (B[N C(
M;&?*;3+!,_NL]3I,*+?,8 :#JZH84X)*P^_P9N&;Q$T.SXTP##&"A:M7?8V7
MS4>7RJ9=!E^<8:^IE\B8,&5[S039(628)A,K\]LUC1JSMI96^N*M7831!ICG
MJ4XW?Z=I<4G('S?!=PH_?;.Z$T?'8WQIF!K415#II^QZ,6> /9MVT$;W"?8*
M22MB 07A(8$ZS#9WZU>8<!@5??+Y6YI_SD;'Z*H4RP;74F\9-.?_?K/>;-<U
MG^5_IG\' RD>3@VFTOL\6X6_SG>KWFGCHE(_"2$.<>(E"9:64R#>VDKO%$&0
M HV*M(TPD#PBFZ)+-?6<7WB>79],3#WU>.(%"*!1[;$! H9I(,"XDXQB;B9V
MD5A'6C^<.-@$Z-YFO;W\'^.!^UE^OO[K^GRV2</S!,CGLP7+M$^\"YZEY<%:
M"JN.<! C(^]F?(65X=,L15E3_4_GJ0X ?EGYSTI)J)'3F A(C-'6X?T,SR1N
M$O(;4<[\")?(-M0Q_?QGBZV%G&,,+%<0.P"A+/! !$TL@[4A)QJ7V:V"=>OY
MSRU?LVT899Q QP)>'$?@J-M)8RWAO1;CZL-;[4S;=2[:K@9^S6FLY8*Z2FOC
M!'*0*6,!L 0B7XR90]O$5J?CFVI&L!(V@;]SRI0NJ L9-A!A(@D$0DI  ]OO
MQ^TF4OB@IJZ.%-2MAEF7NGZW6#U?4/?A,XG \5XC!Z'#P"@%PO^*L3L0W(.)
MZ;NJQK)V<.M4Y]6+* ,KA6/0$VVH,,)#!8NQ>^DG4L*@%9TWP*VV1;FK/?=I
MD>:G,J:>/):$43"$L *."P\\$\X5LYA#GC99\-EXM#JB!;\%+33ER":\]G1R
MU \/)L0JZ:D2QE$NK+*.H<*8=<K*B=3%:J:< QJNC6!M'<=TTF4<^VD/\LEC
MB9 ,2<\IP0H3Y9V#E.Q&YZ$A$XDQ-%5-UAJ"M?6[VY ]K=U'#R7 .R*X@Q9J
M9P"5V'!:C,S+1D='1[1RMZG;)OC5UNS'=)ZMSD\K]N$SB3<8!;$"R\+Z8ST%
MGK!B7!;Z*54$:DFO#>#KUAC_]RPO[G@]MOM_^,'$4H=B8%1PK"U00GE2V!_>
M2-+D6 4?#PE&9,"UHH<NV?3G["K@\VB(1ZV]D\\G@AH&N<=<4TH01<(K4<@D
MJ)Q(X96F"LW:A[+V&O+'<O8]^WBUV%S^[_#P,S7H#CZ<.*$Q(19K[H@"'E$-
M]-U(*3#&3>3\0TO:REJ&\[4"RO%CO<9(9!UFV%O&@"&*65 @:3ULXH**\1!S
M1"O="+38^@;K@Z(!;V.!@75V<5_Q[WV:7V3Y54PSO<MRK;K_6JWWA&NGF&$&
M:$>U"(XC :S 0G,[L2.QP]"HS,YMIVIK6L2G9.&>?8$8!C0B$@") 6$$,\+4
M;D^;0F;MZ_U#+9.J&?[-S[L6+W:S?)4>G;&./)X0KV/V*?34AI5!2N9P(3(T
M4+^6&6F9+>WHX;6L4[G2/P8HZHATQCD,-11<JV*FA@J2B25V#L_N\>JV_CQ[
MZ!JY(,>]@?#@XK@:GT-;_2?0<"(@#?,'=EX9PJ4V!1Z:-+IB8(2I6\-S?2#%
MU:]/UMX%@]PK +52$"NJ%13,:%2,F%O=I#3""),&AJ=:6YIH([FD1&))8@UR
M AE) /7"!<D$IL6H!%--#GV/<$]B>'[4Q[ZO>./N$.^'-(97XU&X>Z?Z['.8
M.[=J/A%(+-4^<0P0[!S7 &+(-"=6XT)V;QL= AMAA'!0WG6IF/K35%!=:'PY
M6YT_-#/O9=^-+CT/_SW;7 85?4@75Y]O@JKBKR_BZKV.EZ'.;Z*B=_/NT2FO
MF]<EWCB#..:*<H*0 0"P7<(114C")OOZ\I7&!Z;/4>BQOZV?U;:X8"S67VQ[
MO5W,/B^6B\WMR;V<$^T2HKCV#B/I*(%(&*9UL>P@Q52CZ^_ *VF/[,NTIY%[
M]O5?M';[23WVCEZKUE:J$ZJ@#1K5A EC5+P CP #&!8"2T@Q+!7S[P:_EUZU
M5G$D99BUM1&$TS!KH^!QW2&+!),3R8L=B(W=5ZVMIK[ZL94\NUAL/E[.\F "
M1S?L6!+?B:<3:JPR@$O"F.?$(&.P+<;*X-1V@X=4=M:V,EHDSNF#&<>>3X)7
MA1FS AI#Y?9(/,"[\6)DU)2JE3;5V&GMU\*S/?V?/9>T=[Q%HHVR@EO,#"6.
M,TN8 L68/3!-_,;Q<Z"JWDZRH"ZF[?'@T]]911[L6R02,&,,=PZ+\"5 KAGP
MQ9@M;G2F;T09('WPH"ZF+?(@/%YU1GC0)J'*2LN1]8&N80FDAHH]#I;:)NO"
MB/([>N%";53[BNRT4PS+0"<\<(93RRU7P9"R?"<;,;!1S9@1S1XC,D/;5$=?
M5!NN&!9SPB"+"(3<4<N@UUH4>!#[]&[VEVKDM,2)AL6PJF'=>JYV+*CT1[H*
M?TOGE_4+8CWI(N&4,8"-5I(*&B9LS'PA%36>3Z183><Z+UL2JQG\G9#*SA:+
M -O'V>KK[3-F=L5N$N2U4Q!(IIVTEB)A#2VDLTHT">*,</4<G%S-5= )P=ZE
M^?QK?6(]:)X(AZBSPCG *,#8,0-)(4VT-:=AP(^&4/6A[X1(^MW'^C3:-TZP
MYX(8+S0SX1NPBCI31.2I1KP)B4:8!STXB>H"/^2Q7X(-AX'7DFL:Z X=A7@_
M:T+4I*3;"-.'>Z%(&T"/M>Q$O #7,AO\#0V0T/$67+:3@EGFFEP)/\)E:011
M@E;T\#+*3GB'D =22B$ -_$>F?VZRYR>>-F)T@HM57:B&I0_TN-EP-B"_"]I
MWOY0NIRS=P123&(=:N8X!YR28I()!HEO4C)AA';?2&;INO!W3IG2Y9P-55QB
M*["02F@@J=]+S4'XV70FX!JZ.E+.N1IFW9IU54O[NN#I$H4Y"V(#CY%46A9C
ME] U2MX=H;ZK:NQH:=]JN'6J\\HEO)%Q2'"&-).$Q4)75A2>*;> -3FC-:)
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MP:F[8;KOU^EJ?:IFP.,'$RP<L,'HA@Y";+V*A9X+:1#C37(/IEY"JBJO6M%
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MX" 4 5A)1A"44D IV$Y&*HEJ$ET?X;HY*+U:T\)K"OOQL'5TD0)^(ABT$,"
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M-N !Y<22J1IRHN%N836L.SF]>&?$U3^^^+!]PCQ36!%#:%A%@*<8*+V3QUF
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MK-GZ,BZ"X0_W'S>+;[/E=EG<F%F>WX9EZ]]FRY-;::7:)X3@L&@*I3%6'CC
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MK(,G6B4*!G?6$0>D9)#$N@K,[N2DFI.)U83NBU8-81Z,3L\N?T=:)![%L 0
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M; C9XID2BB]T*<LW6%U!6NYZ>;ZXNOVCKF\>^WN?Z\G^H/9=@P+12%HDA'<
M.R.EPA9MI'18%NIJ4XPX'6C[Q35R1]"66_KF5?Q=*5W61F,ZJ5==3#9X[%WD
M]HP+B'J#(2?4"Y\ZH1"FFG,'Y[7/N0<<H/WIGD9=HEML^U5-XCN__5%-(QJ3
M^.7JYFX\'2<D%N,?U6%*M7M!T-20N-]$F&' I&!:H093YYS,V:8-,-B\>V[U
M G-!<[5* UK.4DO0[Z/9M[VEHUY[/&B,@7;664TU94)Y(V$C&:!91W\##"/O
MQ3CE@GHVK_H8;SHHQ(&/(D##//& 2T^;\S*G!,Q)XCN^>TKOD7;=$R47T>(L
M:16?_LK3 5M'@(DB","T-9!(#!JY$'3F0F,R.]QOG0QFP63V^NG';EC=+HE]
M_]B I)!>>H8PMG%B:.1!<XGB/<[:L!^])OVH9E_KM[-E[QK<TB58UM^\BJ':
M&^/SXNE@F;,@6M*X'_ \'=.#[3[ 6ZTNK6U#=WK>483E=&Q+<^;P9NK9DT$R
M[ 'BFO/4Z0E;96 3,^0C6CD'.^UWY,5K]/9.F=/@+1I(NQ.$0W&T.P<&I8Q'
M!AC/E-+1T?<4;$PU IR8LBDH;YA%G<)\=D?H% <H,.A1VC,2+FS<0@(O.6AD
M5"2K=O@ Z]/V1Z6N$"Y;4BSY^\WEW7BZC-_^$("MJ]MZ5CTJ=O7G>%JG5H:-
M[573FZ=O214>%S__K!;?4\7=-GTK"WY%D"#NG:EW7,FX^8U;7]#$244B"0TS
MF#[ TX0.'?SA*JGL9(F2;>:TKJ;5[;A5$;ZG(P+@BC+E!00DBF>1EEHT\D5+
MDQ,I/=Q6#9US,1?78DOU2247 (+">VF0DQ)#1RQ@Y&$.N)RMP@";*'1Y$I$!
M8RE*N-%L&FUGJDO?-.(:7^^AQJO/!V*9!X)# $S<&BN>^B,ULC%(<O)PAEQK
M,9\B7<!Y+JK8\62YV-MI=,>((&5<406@PFNHB9..,[MU01W(2;N4OQ1=3@.T
M%&'^5:7B>=6-^A$=LV_5AV4*%K^Z77WY_&JYF"]&TQ2-=\CF'/6>X*'T!FL-
M4A2-UP)'2[O! A+FLG+.P46SJT^<S\RYS41Y(<KQK-OUIF!2D4>)503%6D^Q
M!$W$/(( F:R@\ $>O_?/NXZ0/FO^^*J,7NIU&O6QWF/:N#^X?MBKG;/HRLN/
M.Z[4RN[Q@43G5C!)I"-Q!;(JV@<+&64H_M 0T:KQ6L_R'YEJCHUQVL3M' 32
M(L#3PMI(1*7("3,;\NSN1LO[$\^/@[;42O)0.67NZ]F'ZF]U?9W*848+]'%6
M3^,?K]>S?$=V^DGO"<IJ;C7D!D!)/.<2$-I@04A6A_0AT^Q((M3E("Y%MR_Q
MMUW=JIOZ?F]"Z[['@V"$4:VX4U$<H+TU"&XD4\KEN;[#(T]/6J\[![J8Q=K*
M_SFY2J/9S?RO^^22Q.<9D <YU6I\4-1%*X^$L)@@)ZT1NC'ZRE!Z82DA>>I_
M;J=Z '@(Y"*9Y-J.#]X@A:3R/'H/W')(!-TBF]H@%0E+N3QRG0KP$,C% ,JT
M7)OQ07)&"8=2KQK\0<5Y*GVPEIU+EA-;,, PE8*6ZS2 B]>!6.]>4F&Z>MK"
M<=\[+C J/#.<*RFP=UA@9.362B.1<WT_0$O5D:/>):3%KCV>?NK.PE-[GP_"
M,8$0MMYC0RAGTF]ETPSI2ST^R-/S\]N/#I MEXA]=U=/5V<G!U>O%\^&='XB
M@=&"^CBA&+00-/-+$P(N;".7J=>7E;NST"QWOG0S3KH935+KGG?339.?P[[.
MOG&!:TLL8IQ&7\Y JK#D>(L: SF%0P:X+'7+G"Z1+>@Y+^^6DW3OL*OL;AOO
MN=T[@I<BE4NQ5',#.300:]Y@D"YB+LN#[IA=/:%<+M5ZW?JNB4$X2*O7!P1O
MG6$&$NJILUI!Z9':2&<T\*VNAMY.NG6W'.H$TN+[KO>GU=^+'V\XY1#BN&1;
M;:WQJ)%*49USH3Y 8]/U#NM4' O&,,]2WTQ;K?_Y;OKRHO%3/9GX>O;W:+8O
MRNS(-P4""3/$:Y.*7A+-E&;-38!QCEU8FF0.(5X&._<(]!EV9L>$ ^T;%K@3
M44J$HHO(.7'26].LV 8B6'2_=E_-QG4*0IDM^JY&WP\;=N_G<H$OM_(]!R*"
MM:X\^&K'LM3:,Y4KK%>5>)HDE;VK91>_(#A$%>04*>&X<5[1N-9L#8&1.64J
MCMXL7AIMSZ*B8C9TO9-)Y:%N;ZOKQ=7ML^OW\?1Z?#^)X'Y<J?7A'F*?A3WY
MI<$+###11F$(/+<>>--<:UCA_(75 "MF>4LI9-CY3UXH0+"4)CK>W&,%D/5;
M623)R6X?9"V64O3*0;EHQ81!-IT5-*$=MX504.&LTL1N9YB&/"<,Y_CTX8LQ
M>66U4M0?7;=QMZLJ?6M[O7:G'W=]7_]Y,8XB/70'/.2'GOSB  F@7FL!TC&8
M =I#8A[0REJVVV<?7QR'BRKES!3^C]%D6?7 X';O#10A0;"*VN!>"<,H<*S!
M"I&L+C+'IT9?.H%[T<D@3'"3^ENMVG'&=6=T8*MTPMN"\M8:@ C#T<N2,"Y1
M'C2X8,1SJI<.,$=[$,:V$TT,P<)V1= ]+PN.>VH!$ND.RT.D"=.-!APD-">@
M;H!)X4.PI9TH8A &]%"US,.#@]18>,OBG&38:ZGI \".&I]U*S3 M/%!V,=3
MD!^".3R1;@]C [48"R(9UMI2;B"5K D <-*PG)/W(2:+#\':G0+\&7)-O]0[
MPM!64^;K<VO]J8K@S<>+:M-;9BWPI^JZ_C9=O64E^]YPPGY_=4#<>*$1<D [
M[9ET@#1) 0YCG)4O-L"0Q%)4'YC>WO+MO=40$: 5X-@[;:Q^2 UU1.(L8WST
M]='Z'M1-;RZ"I1WB_OOR_NG-</QZ8:'# ACK(&2,(KYUF[C,LJM'WTM=%FO/
MHJ$B=6IL?;U,:X::1F4M5H+=UK.[)]OY(TK2[.C-O>^W["DQTWIL@();QU-!
M_I34886 DAL,?:JZZ0AO%1KZFO68-^9C7EW_MV_UC_]^4XW7EB/^X;G!B#_:
M?FU*MGQ%HN>/!,,1]IYHZE*M-N&T,V[SX1QZ>"%MYGM09-T)H.W6D*-9H.+G
MW*1/\I/1:U[(BV>"Y4H!C1@7"C% J:2"-I]-)& 9/!B03]PO#W(0[8D(C:P?
MF^70CA:'[,*39X,S0F,@$*4$ >^X=Z810P F+J250AD#D8-LSP3QX_GU:/)_
MJM',QY^\=D&YY^D $116<DL=,9@[0IR1C2A0JIPDOP&ET)0A21ZV16BRYG%[
MHCQZ/E 7%T;*,3(*0@R<)D@TXB"-<@J\#RA,J"153D>W)[)\F8W2SN3SS[NO
M]60'09X\$[P$FFKI#&.>0\H@AF3+<4-SKH('%'?3+RER$.V)"&L!/U7?5LU[
MIXL/H[M=SL=KCP:LTD&,99 1X3U5Q)*MZ<,VJQ'N@*)9^J5%!\#VR@X3A9Z-
M)N_BUOZ?_U7]W$N/9\\&G+[="*.$5@AI+ZQO2"XI CDG3@.*("G!CSQD>R6(
M'T^JF8D.\[=ZMI\>3YX,\84N2NV0D(Y:Y^-JB!H1$LDO(WRC!#ER<.V5&NZN
MFGU+K>)G]=^+[^E*:33=3Y%71P2!&23:6X(0<A+"Z$09@Q%&"%I-8$ZDSY!"
M+4IPI0N >^7,Y[O19**7\_&T>C7E9L>3 5@LD=042"[C"NFMPBG1$U,1Y:(X
MBR._S$EI/K#]<N-[-9FT,2./'XP"0 ZP(%!2IQWP(B*2!) "0F1@UFWM+W-V
MFHUK3\0PR]GLR:',_C/478\'XPEB# #((R1"&PMD<]@G/;)9"?F_S#EJ1^CV
MNY\Y+AZDW<! @>'4  ,(QAX(S3 &&P&CBY[5\N[XN_6W2I_.<>Z52/^*IO!_
M3>N_IY^KT;R>5C>K,,+7HCP/C@G&I J7BB EF)866^P:M)2U6>WPX"]SZMHE
MQ+TRY^/RZV1\[2?UZ+6@AE>?"P 9P!3S L?U-K4M,@QOB6]A%D-^F2/87%C[
M79C6B^>GZCY%#*WJ9B]VWM_L&Q*@1PHC[J&#3E+,B'&L$0I3E]58[!<[E^T$
MX5YI\Q_U9!GU-%N? NWGR[-G@U.,0Q1Y;PRT"EJ;+J8:,9#,2F'YQ0YH\Z M
M$LKG1^/9*E+[S[@R+F?5D][VQ=O*;;_&QMW"I$X?-&_136[?L$ QMB"N[U 8
M2+GGDE"E+7?6ZK@M]:UV^N6D_1+1UO'7_?M(<;?C F2 :4ZQYU%N:6C<B=M&
M7@]LULG&<*9OMZJO^P/X?+/X\_7WZF8YJ:YNMW\=_SB>CJ;7X]%$S>?58KYY
M_N9J^BGEOL\V?5GG-I6(G5R6(6!">L6=,-A$GD4"4*:\BS886(BE:A7$TK.T
M:Z7$U>C]>/1U/%F5(GA%1?&!#_5T]D1CAQI1=O8[@K>0"@%$W&M;0"!7<37<
MX(BASMN7OC$#TYI2NPQ,8664RG[96IEWTXC4VL7:WR9GQXB@I>3: T:C<\TC
MUM RN)&/:($OK./)&7CQG)F=Z*$4S[[,1M-YU&!":IV'&%%XM,@]"#%/<?[S
MU__J8#.>+G]-<!S%_2&PG'MIK$02J<9F4(I83N7Z(3(ZET_/&VF>3Q6E2/UG
M/:U^_CF:_;M:^.7TYG"+A-<'!*R9@G'+&EU3@J*3JN(*U4BGB;JT%IMG(4;=
M@R9*)D%7LP3 Q]%]-6O58.K%\X$J*1B&%JOH!''ID/!@*YNT.5'  [I''Q3+
MNE!$.9+-[NO9:%'I.B'6U%=K0;8]XP(&4@&&/':820^$T+3Q;I@3(L>T#>A>
M?F"DZTXAI<CWU^<OLY73_#,B]T?]HYI-$Q0'R;=W7(#24*6B=ZTUQE!RX65C
MS1FT(.> ;4"W^H,B7Y<**6;Y4E')VW'4?@+%5O?U?'R8>GM&!2FE$9 APXQ-
MSK*A:&WA(8 1R)RLS@'% PR*>-VIH]C12W.$H'\^.@SVL^K_+JOI]<]#QS"'
M1P<,D18.&X<YIBD/%FG73#>"P87U+![ D4SG.BG.Q=>^^^"I2XO104% L'9
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M_0<Q4>C&[!(,94Z/LS?B0^?3J#M\2_'HKU2"HOXV'?_7ZBYF$S.RSQ+M&!&
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M+.6::&]-=#V0)(UT )J<O2O_50ET"K)GX\T?L[C!/H8WJP$!2:T5!L ) 0B
M6%O0@(6(M3GW.>)HWA3+_.^7-Z<@>SD9G*DGM?$ (F"())!Z1INE&U&O<A@E
M3\STOP!.90-]-H(=F6F>DI\QE4@8HX0!0@/!C5.BD0Q3D-6.#_RJ5NEX8,]
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MUP;MG&'06<4@X=Y*9*AKD+(@J['O /?V_?*T=_C+$_5E=;4GE:-/X.A1;PS
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M;C(<EBRG/L\ M^<#H]AI2CA?",*'T6PV2O6Q+BFT0"(%&23(6".4L'$MD4(
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M!QXB2#71 B'@MF80F@O)>NQ(4W6G8/Y.#%]'!EF."(VF6'%F'-*&8-F<33G
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M%(?JB!//#]!ZQ;J+VE$_JD??^/=X\?W=?=14ZWI2^X8'']=\1Q"F&G*NL1!
M;>RQQO&C+L3GZ5W7.ZI/=0C]R43Z<SR)ZW$]K:Z^_F?<Y:5O>GUQV_-T,,H:
MZ(6&E *-I-1I([KY5DRR4F8&E(Y:9FGK#N<..;%SJ[3W^6"E\ZES%M/,>R4%
MQU@UWVL8OJ0PX5R-[=?^27B>K'_WI_+C22K'='U=W2_2*=#_,&;_BK)O3&#
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M8"\<]KS91S-GVI4"NKP[J^[<K6S(2Q'KC[J^^7L\F;R[NQ^-9^E+#U2@?'U
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M.'H]6[8?9O1UZC5?S8$DN-,&#$0!99CP.G(#0TNM!FQ#'64P'DD)@KZAM!B
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MA4:BC [DHNB("\/A+DUZIQ_CV%>#K<55LCH.:VC=;MNH3=R4<1+_,@Z+MWT
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M5/[7__AO4$L! A0#%     @ PX%63M_N\6;?M0( ^@\P !$
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M !4              ( !C:<$ &5X96PM,C Q.#$R,CA?<')E+GAM;%!+!08
1    !@ & (H!  !$<04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
